,nct_id,primaryOutcomes,secondaryOutcomes,startDate,status,study_type,phases,otherOutcomes
0,NCT01814735,"Changes in fasting blood glucose, lipids, and blood pressure",Feasibility and cultural appropriateness,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1,NCT02058160,Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2,NCT01275820,Glucose blood level,Dosage of Insulin,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
3,NCT03878758,Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators,Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Force),2019-02-07,COMPLETED,INTERVENTIONAL,['NA'],Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
4,NCT04407819,prevalence of sarcopenia in patients with T2D and in the control group,fat mass,2018-03-20,COMPLETED,OBSERVATIONAL,['NA'],
5,NCT00520065,Positive area under the curve (AUC) for plasma glucose and mean glucose level,Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6,NCT03741660,change in systolic blood pressure,change in apoB:ApoA-1,1991-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
7,NCT01302327,beta cell function,,2011-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8,NCT05123963,Change in glucose control.,Change in plasma cytokine levels,2021-09-15,RECRUITING,INTERVENTIONAL,['NA'],
9,NCT00849576,Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.,"The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.",2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10,NCT03761446,Mitochondrial Respiration,Physical function,2019-03-18,RECRUITING,INTERVENTIONAL,['NA'],
11,NCT00973830,Diabetes knowledge,Change in HbA1c reading,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
12,NCT02644590,"blood pressure monitoring , pre and post treatment with melatonin",,2016-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
13,NCT01784289,Measure of blood Interleukin 7,Count of blood lymphocytes T,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
14,NCT04853537,gestational diabetes,any associated comorbidities questionnaires,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],
15,NCT01293318,Association between copeptin level and severity of pancreatitis (according to Atlanta classification),"Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection",2011-03,COMPLETED,OBSERVATIONAL,['NA'],
16,NCT04019938,Serum Cystatin C,Bone mineral density,2019-07-04,UNKNOWN,OBSERVATIONAL,['NA'],
17,NCT02220296,Incidence of adverse events,"t1/2, the terminal half-life of insulin 338",2014-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
18,NCT04812262,Number of participants with clinically significant abnormalities in 12-lead ECGs,Number of participants with antidrug antibodies (ADAs),2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE1'],
19,NCT00674986,Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12,Glycemic Variability Pre and Post-Prandial Excursions at Each Meal,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
20,NCT06020664,Proportion of subjects with complete wound closure during the 12 weeks of the Treatment Phase,Changes in Wound-Q Health-Related Quality of Life outcome during the 12 weeks of the Treatment Phase as measured by changes in the subject response to the Wound-Q Health-Related Quality of Life scale,2023-08-16,SUSPENDED,INTERVENTIONAL,['PHASE1'],
21,NCT03859193,Change in nutritional knowledge,Patient Satisfaction with Care,2019-09-27,COMPLETED,INTERVENTIONAL,['NA'],
22,NCT06171412,Mean hours per week CGM worn,Mean count Barriers to Device Use,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
23,NCT05574023,Less time spent in hypoglycaemia using Predictive Alarm vs Alarm on Threshold,Better glycemic metrics using Predictive Alarm vs Alarm on Threshold,2021-05-10,COMPLETED,INTERVENTIONAL,['NA'],
24,NCT01932866,Change in abdominal circumference,Change in diabetes risk score,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
25,NCT02562326,Pharmacokinetics: AUClis 0-30min,Local tolerability,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
26,NCT01051102,Area under the Glucose Infusion Rate curve after a single dose,Area under the insulin aspart concentration-time curve after a single dose,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
27,NCT00889668,Clarke Error Grid,User Satisfaction,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
28,NCT00287456,,,2006-02-02,WITHDRAWN,INTERVENTIONAL,['NA'],
29,NCT06035367,Value of absolute photoacoustic signal on the participant arm,assess the tolerability of the investigational device by a usability questionnaire,2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],
30,NCT05399446,Change in Eating Disorder Symptoms,Change over time in Diabetes-Related Quality of Life,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
31,NCT01337440,the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA),change from baseline in autonomic nerve function,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
32,NCT05671679,Percentage of time with sensor glucose in the target range,Percentage of postprandial time with sensor glucose in hypoglycaemia,2023-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
33,NCT03474601,Treatment outcome of pituitary diseases,Complications of pituitary disease,2015-03-15,RECRUITING,OBSERVATIONAL,['NA'],
34,NCT05872009,Number of neonates with adverse neonatal outcome,Percentage of participants with pathological placenta histology findings in case and control groups,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
35,NCT04527107,"Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the study",Incidence of systemic and ocular adverse events (AEs) and serious adverse events (SAEs),2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
36,NCT05647083,Means of diabetic foot risk score,,2022-09-09,RECRUITING,INTERVENTIONAL,['NA'],
37,NCT01237119,Liver Histological improvement,NAFLD Activity Score,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
38,NCT04064996,Pain assessment With Visual Analog Scale,Albumin levels,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
39,NCT05473767,Change in postpartum weight retention,Change in physical activity,2022-11-18,RECRUITING,INTERVENTIONAL,['NA'],
40,NCT02081989,glucose uptake into peripheral skeletal muscle,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
41,NCT06269419,Urinary creatinine ACR,,2024-02-25,RECRUITING,OBSERVATIONAL,['NA'],
42,NCT02774876,Area under the curve of sensor glucose levels,Coefficient of variation of glucose levels,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
43,NCT04155996,Data collection - Sleep hours,Data collection - Medical treatment information,2019-01-20,TERMINATED,OBSERVATIONAL,['NA'],
44,NCT04075110,Visceral Adiposity Index,leukotriene B4,2019-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
45,NCT01689142,Change from baseline in HbA1c,Number of patients with various types of hypoglycemia events,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
46,NCT03686436,measuring visual acuity by snellen chart,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
47,NCT03901248,"Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages",Change in HbA1c,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
48,NCT00395148,Metabolic parameters,,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
49,NCT01765894,"Glucose homeostasis in controls, type 2 diabetics without medication and type 2 diabetics in metformin treatment.",IL-6 and incretins,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
50,NCT05260931,Ventricular sphericity indices,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
51,NCT03251079,Safety Endpoint,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],
52,NCT02661165,The self-management Interviews to identify if and how patients' spirituality influences their diet and exercise.,,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
53,NCT01263132,Mean Neuropathic Pain Score at Visit 6 (Week 4),Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
54,NCT03802877,Recruitment,Completion of evaluation procedures,2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Breastfeeding
55,NCT04358263,Percentage of time in hypoglycemic ranges,Changes in glycated haemoglobin (HbA1c),2018-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
56,NCT00206349,,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
57,NCT01169090,Change in HbA1c from baseline to Week 16.,Change from baseline in Fasting Plasma Glucose (FPG),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
58,NCT00359775,Impact on Family measured by the Impact of Family Scale.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
59,NCT00499707,Change from baseline in hemoglobin A1c (HbA1c) at week 32.,"Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks",2003-10-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
60,NCT00859755,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Assess the excretion of the study drug and metabolites in urine following dosing.,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
61,NCT05801614,non diabetic HbA1c,Changes in Insulin secretion,2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],
62,NCT01244152,Weight change,Hemoglobin A1C,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
63,NCT03786146,Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers.,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
64,NCT05417841,HbA1c,Time Above Range,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
65,NCT05446493,Serum YKL-40 and platelets indices in erectile dysfunction,Effect of tadalafil on Erectile dysfucntion patients,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
66,NCT01473953,Number of Treatment Emergent Adverse Events (TEAEs),Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
67,NCT03557541,type 2 diabetes new onset,HOMA-B (homeostasis model assessment B cell function),2014-05,COMPLETED,INTERVENTIONAL,['NA'],
68,NCT00054925,Change in Weight,,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
69,NCT05753436,Heart Rate,Serum Ferritin,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
70,NCT05007977,Change in glucagon between euglycemia and hypoglycemia,Change in cortisol between euglycemia and hypoglycemia,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Symptom score during hypoglycemia
71,NCT04019821,Postprandial Glycemia,Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L),2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
72,NCT00628056,The primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
73,NCT03343366,Glycated Hemoglobin (HbA1c),HOMA-IR,2018-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
74,NCT05476016,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes, included suspected de novo DM diagnosis based on HbA1c",2022-08-29,COMPLETED,INTERVENTIONAL,['NA'],
75,NCT03341312,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
76,NCT01403961,Compare incidence of immediate post surgery complications in diabetic patients with HbA1c > 7 and patients with HbA1c ≤ 7,,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
77,NCT00379652,"Potential outcomes for the future intervention include systolic blood pressure, diastolic blood pressure, and hemoglobin A1c",,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
78,NCT04786340,"Incidence of Treatment Emergent Adverse Events as assessed by dermal assessment (Draize score 0.0-4.0) score of skin erythema, edema pruritus and dryness score) of the dosing area",Neuropathy Total Symptom Score-6 (NTSS-6),2020-11-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
79,NCT01104701,Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population,Number of Chemistry Laboratory Values of Potential Clinical Importance Observed During Treatment Period - ITT Population,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
80,NCT03513939,"To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch",Proportion of participants with a reduction in HbA1c >1mg%,2019-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
81,NCT02020850,Toe-Brachial Index,Ankle-Brachial Index,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
82,NCT00529191,Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus,HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
83,NCT04616391,Between group TIR difference,Between group difference in the Diabetes Quality of Life (QoL) questionnaire score,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA'],Number of Severe Hyperglycemia episodes
84,NCT00687999,"Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy",,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
85,NCT02657213,Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia,Study of average cost per patient for each therapeutic strategy supported from the point of view of society,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
86,NCT03542370,Blood Pressure - Systolic Blood Pressure (randomized and non-randomized controlled trials),Inflammation - C-Reactive Protein (randomized and non-randomized controlled trials),2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
87,NCT03751735,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,,2017-01-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
88,NCT05951270,Apple polyphenols and glucose homeostasis in prediabetics,Apple polyphenols and fecal microbiota composition,2022-01-14,TERMINATED,INTERVENTIONAL,['NA'],
89,NCT05988957,Describe CGM data use,Describe overall experience of receiving a NFA during CGM initiation,2023-08-01,COMPLETED,OBSERVATIONAL,['NA'],
90,NCT02246400,Change in measure of Health-related quality of life from baseline to 6-months follow up.,Body weight,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
91,NCT05385575,Number of participants with abnormal clinically significant electrocardiogram (ECG),The efficacy of KN056 by analyzing HbA1c (Glycosylated hemoglobin) changes,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
92,NCT01510223,Gastric emptying by 13C octanoic acid breath test,Food intake by buffet meal,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
93,NCT04007640,fibroinflammatory lesions at histology in obese patients,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,2019-06-18,RECRUITING,INTERVENTIONAL,['NA'],
94,NCT00676767,Glycemic Response,,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
95,NCT02977130,Glycated hemoglobin (HbA1c),,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
96,NCT06246175,Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to Infinity (AUC0-inf),Incidence and severity of adverse events,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],
97,NCT05223556,Accuracy in the diagnosis of referral retinal lesions,Satisfaction of participants as measured by questionnaire,2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],
98,NCT04021602,Duration of Breastfeeding,Edinburgh Postnatal Depression Scale (EPDS),2019-09-18,COMPLETED,INTERVENTIONAL,['NA'],
99,NCT05215210,change in fasting plasma glucose concentrations,change in HOMA-B levels,2022-03-23,COMPLETED,INTERVENTIONAL,['NA'],change in creatinine
100,NCT01510522,Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6,Rate of reported adverse events,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
101,NCT04979130,Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups,Differences between treatment groups in plasma hs-CRP,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Exploratory: determine the effect of semaglutide as compared to placebo on intestinal microbiota in relation to changes in intestinal permeability and inflammatory markers
102,NCT03915990,the diagnostic value of Umbilical artery Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,he diagnostic value of MCA Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
103,NCT03338010,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®),Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year),2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
104,NCT03307486,Occurrence of type 2 DM after GDM,Fetal weight at birth vs eating habits,2015-09-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
105,NCT01835431,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L),2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
106,NCT05415683,Data Collection,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA'],
107,NCT00760578,Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test,Change From Baseline in HDL,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
108,NCT01570946,Progression to diabetes,Improvements in Quality of Life,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
109,NCT00755287,Absolute change from baseline in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies",2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
110,NCT01022619,apnea-hypopnea index,growth and development during the 1st year of life,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
111,NCT03137316,intact parathyroid level,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],
112,NCT02123901,Change from baseline in vascular reactivity,Change from baseline in blood chemistry,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
113,NCT03681054,Child: Neonatal body fat%,Percentage of participants on GDM medication,2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
114,NCT02459561,HbA1c reduced by 20%,To estimate the cost-effectiveness of the EndoBarrier device compared with conventional treatment.,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
115,NCT02772679,Survival of Tregs,"Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
116,NCT02309424,Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC),Number of participants with adverse events,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
117,NCT01418911,,,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],
118,NCT00855608,The main outcome measure will be visual acuity improvement (3 lines),central foveal thickness and angiographic lesion size,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
119,NCT02455414,Change in regional brain volume,Change in disease severity score,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
120,NCT06330233,Electrophysiological examination of the peroneal nerve of the lower limb,infrared thermography testing,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
121,NCT00108524,Change From Baseline in Body Weight at 48 Weeks,Change From Baseline in Blood Sugar at 48 Weeks,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
122,NCT02178501,Change from Baseline in endothelial function status 3 months,Change from Baseline in glycometabolic control at 3 months,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Safety Measures
123,NCT01332149,Change From Baseline in Mean Pain Score at Endpoint,Change From Baseline in HADS Depression Total Score at Endpoint,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
124,NCT04487678,Change in venous blood pH,Gastro-intestinal distress symptoms via a questionnaire,2023-08,WITHDRAWN,INTERVENTIONAL,['NA'],
125,NCT02068989,Percentage of Subjects with an HbA1c greater than or equal to 6.5%,,2013-02,TERMINATED,OBSERVATIONAL,['NA'],
126,NCT00992641,Glucose metabolism,Transcriptomics and metabolomics data,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
127,NCT05567692,Type 2 diabetes incidence in Descendance population,Study of interactions between risk factors on type 2 diabetes incidence,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],
128,NCT01499108,Change in ambulatory blood pressure,Washout analysis,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
129,NCT03618420,Glomerular Filtration Rate (GFR),Renal Oxygenation,2018-10-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
130,NCT05663606,TIR,HbA1c,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
131,NCT01783210,Gestational diabetes mellitus.,Mode and timing of delivery,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],
132,NCT05372809,Incidence of index ulcers closed,Wound infection,2022-04-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of adverse events of the index ulcer
133,NCT04404556,Barriers to Diabetes Adherence questionnaire - Youth report Time Pressure/Planning Subscale,Type 1 Diabetes and Life -Parent Report,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
134,NCT01196533,Comparison of the TensorTip Accuracy Against Hospital Periodical Readings.,,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
135,NCT00928876,"to determine the effect of Interleukin-1 receptor antagonist on insulin sensitivity, as derived from glucose infusion rate measured by euglycemic hyperinsulinemic clamp",systemic inflammation,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
136,NCT06185348,Body mass index (BMI) variation after 6 months of treatment with hybrid closed loop (HCL),description of metabolic parameters at 24 months,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
137,NCT00846300,Change in blood pressure,,2001-08,COMPLETED,INTERVENTIONAL,['NA'],
138,NCT02392117,Change in the number of any hypoglycaemic episodes,"Change from baseline in HR-QoL (health-related quality of life) questionnaire scores (PROs (patient reported outcome): SF-36 (short form 36), and DTSQ(Diabetes Treatment Satisfaction Questionnaire ))",2015-03-16,COMPLETED,OBSERVATIONAL,['NA'],
139,NCT02212951,Post-standardized meal glucose exposure (AUC),Draize injection site erythema and edema scoring,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
140,NCT06130215,Time above Range (>180mg/dl and >250mg/dl),Diabetic Ketoacidosis,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],Ped Quality of Life Survey
141,NCT01165983,Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside,"Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL",2009-11,COMPLETED,INTERVENTIONAL,['NA'],
142,NCT05115747,Mean changes in the glycosylated hemoglobin level (HbA1c) at six months.,Mean changes in the health-related quality of life at six months.,2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
143,NCT02899390,Body weight change,Change in the Perceived Stress Scale (PSS) -14 score,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
144,NCT00700765,Major hypoglycaemic events,Variability in fasting blood glucose (FBG) and average plasma glucose level,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
145,NCT03297879,The change of HbA1c,,2013-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
146,NCT00316537,Assessment of ulcer size as determined by weekly ulcer tracings,"Assessment for complete wound closure. ""Complete wound closure"" will be defined as full epithelialization of the wound with the absence of drainage and lack of dressing requirement for an interval of at least 2 weeks.",2006-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
147,NCT00481286,Change in systolic blood pressure; change in Hemoglobin A1C; change in low density lipoprotein,"Attainment of benchmark levels for SBP, A1C, LDL; self-management performance (self-report); completion of group clinic",2007-04,COMPLETED,INTERVENTIONAL,['NA'],
148,NCT01778556,Total Body Insulin Sensitivity,Endogenous Rate of Appearance of Palmitate,2013-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
149,NCT05275400,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ),2022-03-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
150,NCT01039324,Emergency department encounter rates among patients in the study population.,Provider satisfaction among providers with contact with patients for whom intervention was appropriate.,2009-12,COMPLETED,INTERVENTIONAL,['NA'],
151,NCT06271382,Ankle Brachial Index,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
152,NCT00657605,Change in Weight,Change in Glucose Levels,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
153,NCT01743014,Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy,Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
154,NCT02789722,Evaluation of transcriptome analysis.,Clinical evaluation: weight.,2016-08-15,COMPLETED,INTERVENTIONAL,['NA'],
155,NCT01657474,Mean time to healing,Percent change in wound area,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
156,NCT03378271,Accuracy of CGM and FGM,The evaluation of patients preferences and experience of the two glucose monitoring systems.,2016-05-05,COMPLETED,INTERVENTIONAL,['NA'],
157,NCT01068730,Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax),Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
158,NCT00698932,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
159,NCT01774500,"Combined hospital admission, seizure recurrence, or death at day 7",Recurrence of seizure,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
160,NCT03248401,Change of carotid artery atherosclerosis,Change of carotid artery atherosclerosis 3,2016-09-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Body composition
161,NCT03524404,Program engagement,,2018-03-28,COMPLETED,INTERVENTIONAL,['NA'],
162,NCT00679042,Number of Subjects Reaching the Efficacy Goal,Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score,2007-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
163,NCT05897372,urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline,incidence of symptomatic hypotension,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
164,NCT03220425,The change in the level of glycosylated haemoglobin(HbA1c),,2001-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
165,NCT06167616,LADA,Type 2 diabetes,2010-09-01,COMPLETED,OBSERVATIONAL,['NA'],
166,NCT06043843,Compare first incidence rate of hypoglycaemia or severe hypoglycemia between intervention and control groups in Ramadan,Compare the weight changes after Ramadan as compared to pre-Ramadan weight,2021-02-16,RECRUITING,INTERVENTIONAL,['NA'],
167,NCT04646746,Postprandial glycemic response,Postprandial GIP (Glucose-dependent insulinotropic polypeptide) response,2021-02-08,COMPLETED,INTERVENTIONAL,['NA'],
168,NCT05575206,Insulin secretion capacity,Glucose tolerance status,2023-09-15,RECRUITING,OBSERVATIONAL,['NA'],
169,NCT05887271,Change in the distance walked during 6 minute walk test (6MWT),Exploratory outcome: change in fibroinflammatory biomarker panel,2023-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
170,NCT03403556,Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C),Mean change from baseline to week 24 in HOMA-B,2018-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
171,NCT00106340,Time to HbA1c >8%,Change from baseline in body weight at 5 years,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
172,NCT03040414,Non-inferiority for Percent of Time <54 mg/dL (3.0 mmol/L) During the Entire 24-hour Period.,Key Safety Outcome 3) Number of Severe Hypoglycemia Events,2019-06-03,COMPLETED,INTERVENTIONAL,['NA'],Human Factors and Diabetes Technology Attitude and Human Factors Questionnaires
173,NCT05820295,Number of emergency department visits or hospital admissions,"Efficiency, as measured by the total number of care-coordinator hours used",2023-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
174,NCT01334034,Number of adverse events,Area under the glucose infusion rate-time curve,2011-04-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
175,NCT04905485,Difference in VIOME's Type 2 diabetes risk score,,2021-05-21,UNKNOWN,INTERVENTIONAL,['NA'],
176,NCT01597843,Registration for MHV,,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
177,NCT00832390,Change From Baseline in A1C at Week 24,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
178,NCT05866497,CAVI measurements,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA'],
179,NCT03435328,salivary volume,Eight-item visual analogue scale xerostomia questionnaire,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
180,NCT03826290,Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period,Cost of diabetes medications prescribed,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],User opinions of the diabetes dashboard
181,NCT00923975,Number of Participants Out of 50 Rated Successful (<=3) by Healthcare Professionals When Participants Performed Specific Software Tasks,Number of Participants Out of 50 Who Rated Their Satisfaction With The Following as Good to Excellent (>=3),2009-06,COMPLETED,INTERVENTIONAL,['NA'],
182,NCT02119754,Clinical Response,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
183,NCT00240422,Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment.,Changes from screening in ECG at the end of the study,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
184,NCT05407233,Change in Pain assessment,Analyze cost-utility,2019-10-14,COMPLETED,INTERVENTIONAL,['NA'],
185,NCT03579797,Eye health management,,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
186,NCT02874612,Evidence of a correlation between negative diabetes health outcomes and psychosocial functioning over a 1 year period,Number of participating rating themselves as having diabetes quality of life as assessed by the PedsQL Diabetes 3.2 measure,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
187,NCT00342992,Cancer,Causes of mortality,1995-03-03,COMPLETED,OBSERVATIONAL,['NA'],
188,NCT02666807,Change from Baseline in NF-KB at 10 weeks,Change from Baseline in insulin (µlU/ml) at 10 weeks,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
189,NCT04050098,bioequivalence study,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
190,NCT03845868,Incidence of cardiovascular diseases,,2013-04-16,RECRUITING,OBSERVATIONAL,['NA'],
191,NCT00541450,Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,2008-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
192,NCT05849701,Wound volume,Wound volume,2022-03-10,COMPLETED,INTERVENTIONAL,['NA'],
193,NCT00760292,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],
194,NCT02709629,Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire,Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
195,NCT00569959,LDL-Cholesterol,Other lipid parameters,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
196,NCT03116009,Large for gestational age or macrosomia,Glycemic control,2017-03-19,TERMINATED,INTERVENTIONAL,['PHASE3'],
197,NCT00775684,Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL),PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
198,NCT01696266,Incidence of any hypoglycaemic event,Incidence of probable symptomatic hypoglycaemic events,2012-09-05,COMPLETED,OBSERVATIONAL,['NA'],
199,NCT00370084,Gastric emptying assessment,"Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution",2005-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
200,NCT02663661,Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.,Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.,2016-03-16,COMPLETED,INTERVENTIONAL,['NA'],
201,NCT04082000,Adverse Events (AEs) and Serious Adverse Events (SAEs),Improvement in sleep disturbance,2019-04-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
202,NCT04981808,CGM time in range,Time above CGM range,2021-08-18,COMPLETED,INTERVENTIONAL,['NA'],Health-related quality of life
203,NCT01187576,"to examine whether an extended multi-professional PAR intervention, based on SDT, is effective in increasing and maintaining the self-reported physical activity level in patients with newly diagnosed type 2 diabetes or hypertension or both.",,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],
204,NCT04207853,plantar pressure,,2019-08-08,UNKNOWN,INTERVENTIONAL,['NA'],
205,NCT05986253,Postprandial blood glucose area under the curve (AUC),Postprandial serum insulin concentration,2023-08-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
206,NCT01024244,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
207,NCT06181227,Safety of AVD-104,Treatment effect - vision,2023-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
208,NCT01774968,Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c),Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
209,NCT04972175,Incidence of adverse event,,2021-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
210,NCT04591015,Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days,"Knowledge, Attitudes and Practice Toward COVID-19 Survey - Change From Baseline to 180 Days",2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
211,NCT04714411,Clostridioides difficile Infection,,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],
212,NCT02228122,A measure of the presence/absence of biofilms in over five weeks when exposed to Aquacel Ag+ Extra dressing.,Size of the wound and an indicator of healing,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
213,NCT04940897,Measure incidence of adverse events,,2021-10-25,COMPLETED,INTERVENTIONAL,['NA'],
214,NCT02730741,Compare number of treated patients who have had diarrhoea in the verum group and in the placebo group between Visit 2 and Visit 5. Diarrhoea evaluated using the Bristol stool scale (types 5 to 7),,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
215,NCT04700436,"Triglyceride (TG) change rate (percent, %)",Electrocardiogram (12-lead ECG),2020-01-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
216,NCT01820273,changes in incretines in the bariatric patient,Diabetes control,2013-04,WITHDRAWN,OBSERVATIONAL,['NA'],
217,NCT01712594,Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits,Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits,2013-05,COMPLETED,INTERVENTIONAL,['NA'],All descriptive endpoints stratified by the accuracy of the sensor based on mean absolute relative difference (MARD) overnight
218,NCT05703152,Change from baseline in quality of life on the short form-36 questionnaire (SF-36) at 8 weeks,Body Mass Index (BMI) measurement,2022-10-31,COMPLETED,INTERVENTIONAL,['NA'],
219,NCT03415139,Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis).,,2019-03-12,RECRUITING,OBSERVATIONAL,['NA'],
220,NCT03742219,Triglycerides,24 hour dietary recall,2017-06-05,TERMINATED,INTERVENTIONAL,['NA'],
221,NCT00638872,reduction of ulcer rate,safety and tolerability of the compound,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
222,NCT01951651,Hepatic Fat Content,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
223,NCT01265537,Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection,eGFR at 6 Months,2011-06-24,COMPLETED,INTERVENTIONAL,['NA'],
224,NCT04489043,Oral glucose tolerance test (OGTT),Anthropometric measures,2019-09-05,UNKNOWN,INTERVENTIONAL,['NA'],
225,NCT02536248,Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period,Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
226,NCT01079637,treatment failure rate,Foot temperature,2010-05,TERMINATED,INTERVENTIONAL,['NA'],
227,NCT03908606,clinical attachment level,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],
228,NCT03172247,Combined endpoint of diabetic hospitalized patients,,2016-12-01,COMPLETED,OBSERVATIONAL,['NA'],
229,NCT03062592,Blood glucose,c-peptid,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
230,NCT02866539,Number of pre-diabetes achieving euglycemic status,,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
231,NCT04313088,Proportion of days with improved bowel movements,Nocturnal diarrhea,2022-07-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
232,NCT02748434,Blood glucose levels,,2016-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
233,NCT05718375,Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
234,NCT05556291,Change from baseline in bodyweight & BMI,Percentage of patients who discontinued investigational drug due to adverse events,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
235,NCT03950245,iAUC glucose,Beta-cell glucose sensitivity (β-GS),2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
236,NCT06140030,Anxiety Symptoms,Glycemic control,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
237,NCT04847778,Number of daily insulin injections irregularities,Change in Insulin Treatment Satisfaction Questionnaire (ITSQ-change) Score.,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
238,NCT05446753,Change in cardiovascular health risk indicators,Change in body composition,2022-06-17,RECRUITING,INTERVENTIONAL,['NA'],
239,NCT03720080,Adjustments of basal rate insulin infusion 670G,,2019-05-16,TERMINATED,OBSERVATIONAL,['NA'],
240,NCT00458133,Hemoglobin A1C,"metabolic measures, including serum cholesterol and triglycerides",2007-04,COMPLETED,INTERVENTIONAL,['NA'],
241,NCT02850224,Number of participants with improved health-related quality of life as assessed by the PEDsQL.,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
242,NCT05481021,Identify any self-reported stressors associated with burnout,To compare any change in presence of burnout from previous cross-sectional study (5 years ago),2022-07-05,COMPLETED,OBSERVATIONAL,['NA'],
243,NCT00129792,weight loss,Cortisol levels,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
244,NCT00961025,To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects,To evaluate the safety and tolerance of DA-1229,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
245,NCT05281029,Change from Baseline of HbA1c at 24 weeks,The rate of subjects who reached the target value of less than 7% (reasonable HbA1c goal) of HbA1c.,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA'],
246,NCT02947828,Presence of painful diabetic polyneuropathy,,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
247,NCT03648554,Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone),Weight,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
248,NCT02883829,"Changes in attitudes, beliefs, and intentions about alcohol",,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],
249,NCT05533996,Diagnosis of gestational diabetes (GDM),Labor dystocia,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
250,NCT02230137,HbA1c level,Satisfaction survey,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
251,NCT03071016,To record the mean change in HbA1C from baseline,To record the change in blood pressure,2017-03-04,COMPLETED,OBSERVATIONAL,['NA'],
252,NCT02009995,Testing of Strength,EuroQOL EQ-5D questionnaire,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
253,NCT01317979,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],
254,NCT03341559,Perfusion in lower extremities,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA'],
255,NCT03415880,The effect of a LiPA intervention program on increasing carotid distensibility in patients with type 2 diabetes.,The effect of a LiPA intervention program on microvascular function,2018-11-08,COMPLETED,INTERVENTIONAL,['NA'],
256,NCT02587741,The incidence of diabetic retinopathy,oxidative stress,2015-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Metabolic indices
257,NCT01775059,Safety endpoint,Accuracy endpoint,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy endpoint
258,NCT02001766,Glucose metabolism,,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
259,NCT04299763,HbA1c,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
260,NCT00567047,• Pharmacokinetic measures,• Safety and tolerability measures,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
261,NCT01381887,Plasma concentrations of glucose,Adverse events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
262,NCT04539769,Diabetes remission rate,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
263,NCT02581488,Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.,Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to Closure for Ulcers Achieving Closure by End of Follow-up
264,NCT05983120,Determining the effect of SCLT-based education on Quality of Life,Determination of Body Mass Index (BMI),2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],
265,NCT06189417,Mean and proportion increase in glycemic control,Acceptability of a community-based club intervention led by Health Extension Workers,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
266,NCT03254446,Change in Joint British Society recommendations on the prevention of cardiovascular disease 3rd iteration (JBS3) risk score,Change in HbA1c,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety profile of TRC150094
267,NCT00555217,"A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death","A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.",2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
268,NCT00473733,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],
269,NCT01838122,Prevalence of HbA1C in both arms of the cohort of subjects,,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],
270,NCT02839174,Hemoglobin A1C,patient-physician relationship,2016-09,COMPLETED,OBSERVATIONAL,['NA'],
271,NCT01268696,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],
272,NCT00916188,"Insulin Sensitivity, oxidative Stress, lipid Profile",,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
273,NCT01515384,Pancreatic uptake and clearance of 18F-AV-133 tracer as determined by SUVR,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
274,NCT01561976,Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)],Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),2012-01-30,COMPLETED,INTERVENTIONAL,['NA'],
275,NCT04175665,Change in HbA1c,Proportion of patients who achieve weight loss ≥10%,2020-01-06,COMPLETED,OBSERVATIONAL,['NA'],Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use)
276,NCT04228822,Dyslipidemia,Glucose variability,2020-11-10,COMPLETED,INTERVENTIONAL,['NA'],
277,NCT04784650,"Presence of foot problems (no = 0, yes = 1)",Indication of peripheral arterial disease (PAD),2021-01-31,COMPLETED,INTERVENTIONAL,['NA'],
278,NCT01578980,Percent Time of Active CTR,Frequency of Unplanned System Resets or Restarts,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
279,NCT02818322,time of ulcer healing,,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
280,NCT01357876,"To investigate the relationship between the glucose lowering action of metformin and lipid metabolism including, but not limited to, fasting lipids and prandial TGs",To measure sparse metformin profiles on the days when the PD endpoints are measured,2010-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
281,NCT00870831,OGTT will be performed every 6 months for 5 years in subjects with a functioning Islet Transplant,The OGTT reflects the function of the Islet transplant and could be used as an indication of Islet Transplant function,2000-10,TERMINATED,OBSERVATIONAL,['NA'],
282,NCT03164785,Change in urine albumin creatine ratio (ACR).,Incidence of Treatment-Emergent Adverse Events,2017-07-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
283,NCT04141241,hs-CRP (high-sensitivity C-reactive protein),Body Temperature,2016-03-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
284,NCT01161797,glucose variability,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
285,NCT03204552,Change in BMI,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA'],
286,NCT00105846,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
287,NCT03460964,Glucose measurements,Acceptability of sensor,2018-05-01,TERMINATED,INTERVENTIONAL,['NA'],
288,NCT02421198,Change in percentage overweight,Waist circumference,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
289,NCT02320461,Myocardial infarction (Incident cases),,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],
290,NCT02868788,change in plasma dipeptidyl peptidase IV enzyme level from baseline,change in plasma incretin level from baseline,2016-06-14,UNKNOWN,INTERVENTIONAL,['NA'],
291,NCT01844479,Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking,Gait Speed Variability Dual Task,2012-12,COMPLETED,INTERVENTIONAL,['NA'],Sudomotor Function
292,NCT03704389,Diabetes overtreatment in the elderly,,2019-01-17,COMPLETED,INTERVENTIONAL,['NA'],
293,NCT05134025,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise.",,2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the maximum iG concentration
294,NCT04877730,Time in Range (TIR) 70-180 mg/dL From Breakfast Time + 5 Hours,Units of Insulin Injected Between 2 Hours Before and 5 Hours After Dinner,2021-05-21,COMPLETED,INTERVENTIONAL,['NA'],
295,NCT03689530,Change in Body Weight at 6 Months,Change in Controlled Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Controlled),2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
296,NCT05433584,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in the IWQOL-Lite-CT - Physical Functioning Domain,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
297,NCT05908708,Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system,Sleep quality as assessed by a questionnaire,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],
298,NCT05459285,Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞),Elimination constants (λz),2022-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
299,NCT01926457,Umbilical Cord C-Peptide >90th percentile,Return to prepregnancy weight,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Diagnosis of Preeclampsia
300,NCT05778370,Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus,,2023-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
301,NCT05261373,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from blood pressure,2022-03-10,RECRUITING,INTERVENTIONAL,['NA'],
302,NCT03865901,Negative predictive value (NPV) and positive predictive value (PPV) of the Mellitus GCD59 ELISA for gestational diabetes mellitus screening,Sensitivity and specificity of the GCD59 ELISA to that of glucose load test (GLT) using two or more abnormal oral glucose tolerance test (OGTT) results,2019-05,WITHDRAWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of the GCD59 ELISA across relevant subgroups
303,NCT01736124,Diabetes Self-management,Prospective Memory,2015-04-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
304,NCT02853630,Changes in Insulin secretion rate,Number of participant treated related to adverse event,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
305,NCT02477163,Changes in the value of laboratory investigations,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
306,NCT02989142,"prevalence of participants with at least one of the following four complications: pregnancy-induced hypertension, gestational diabetes mellitus, caesarean section, large-for-gestational age baby",Number of women who gave at least 6 months breast feeding,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
307,NCT01496339,Glycosylated hemoglobin (HbA1c),The random glucose level,2012-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
308,NCT01219803,HbA1c,"Ins(0h,1h,2h),blood lipids",2010-08,UNKNOWN,INTERVENTIONAL,['NA'],
309,NCT00082316,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
310,NCT04328896,CGM-Tele-monitoring effects on hypoglycemia,CGM - Tele-monitoring effects on HbA1c,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
311,NCT01812122,Cardiovascular disease risk factor,hypoglycemic index,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
312,NCT03529903,Change in Physical Activity,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA'],
313,NCT00901472,Improvement in glucose tolerance,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
314,NCT02784275,Change of Body Weight From Baseline,Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline,2016-06-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
315,NCT00294723,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156,Hypoglycaemic Episodes,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
316,NCT02496390,Improvement in Homeostasis model assessment [HOMA] score.,Modulation of lipid and hormone metabolism,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
317,NCT03456271,fracture,,2017-07-01,TERMINATED,OBSERVATIONAL,['NA'],
318,NCT02765399,Change in ApoCIII Level,Mean Fractional Catabolic Rate of VLDL2-apoB100,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
319,NCT05602441,Change in glycated haemoglobin from baseline to 12 months post intervention,Change in diabetes distress measured by Diabetes Distress - Screening Scale 17 (DDS-17) from baseline,2021-01-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
320,NCT05803421,"Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]",Pharmacokinetics (PK): Plasma Serum Concentrations of Orforglipron,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE3'],
321,NCT01994746,Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir,Time to Maximum Change From Baseline Concentration (Tmax) of Glucose,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
322,NCT06240273,Fasting glucose level will be assessed before and after the trial.,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
323,NCT05939271,- What is the incident amputation rate in persons with and without DM in the Netherlands in the period 2011-2020?,"- Does the presence of a formal multidisciplinary foot clinic / team in a hospital make a difference, especially when comparing previous and actual macrovascular complication rates?",2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
324,NCT02003677,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,2013-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
325,NCT03917784,Matsuda index,total bilirubin,2019-02-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],
326,NCT02701257,Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus,PG AUC in the 3.5 Hours Following the Meal,2016-03,TERMINATED,INTERVENTIONAL,['NA'],
327,NCT04127890,Weight loss,,2017-03-07,COMPLETED,INTERVENTIONAL,['NA'],
328,NCT04664764,to compare the effectiveness of insulin degludec to insulin glargine and NPH,,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],
329,NCT01759823,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
330,NCT04605991,Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12,Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
331,NCT00382564,,,2006-09-25,COMPLETED,OBSERVATIONAL,['NA'],
332,NCT00789711,"Number of all (Major/Minor/Nocturnal) hypoglycaemic events, reported as serious adverse drug reactions.",Number of major (including nocturnal) hypoglycaemic events,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
333,NCT00785005,,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
334,NCT03107208,Rate of Rebound Hyperglycemia,Evaluation of CGM and POC Glucose Monitoring During DKA Treatment in Children.,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
335,NCT00424762,Peak Oxygen Uptake (VO2),Percentage of Patients Developing New or Worsening Peripheral Edema,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
336,NCT02292290,Composite,HbA1c only,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
337,NCT03528031,Visceral adiposity,24-hour diet recall,2018-06-19,COMPLETED,INTERVENTIONAL,['NA'],
338,NCT04999189,Change in blood pressure,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
339,NCT01947855,Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
340,NCT01594281,Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS),Number of PRP Laser Spots Until EOCS,2012-12-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
341,NCT02768818,Glucose metabolism changes,Admission to Neonatal Intensive Care Unit (NICU),2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
342,NCT03970889,Change in the number of missed meal boluses,Positive predictive value of a Klue meal alert,2018-10-12,COMPLETED,INTERVENTIONAL,['NA'],
343,NCT03226990,pressure areas,denture retention,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
344,NCT04613076,Depression change,Proportion of participants with change in glycosylated hemoglobin,2019-09-03,COMPLETED,INTERVENTIONAL,['NA'],Utilization of health care services
345,NCT02261194,Change in depressive symptoms,Change in life space,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
346,NCT01105923,Intervention acceptance,Quality improvement based on problem list accuracy/completion,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],
347,NCT03965013,Number of treatment-emergent adverse events,Maximum observed serum NNC0268-0965 concentration after a single dose,2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
348,NCT05076955,Healing Rate,Wound Closure,2021-03-31,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
349,NCT01117350,Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period,Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
350,NCT01051011,Glycemic control assessed by HbA1c,"Meal tolerance test (in a subset of patients): Glucose, insulin, C-peptide, glucagon values",2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
351,NCT05335629,Effect on ST2 (suppression of tumerogenicity 2) level in the acute phase after myocardial infarction,Echocardiographic changes due to intervention,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],
352,NCT06169982,Pharmacokinetics (PK): Area under the concentration curve during one dosing interval at steady state (AUCss) of LY3209590,"PK: Total amount of glucose infused during one dosing interval at steady state (Gtot,SS) of LY3209590",2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
353,NCT03443180,Change in the plasma-induced transcriptional assay,Leukocyte analyses,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
354,NCT05791942,MyChart letter opened,Completion rate of one screening/test,2023-03-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
355,NCT02278939,Count of Participants Who Completed the Study,Change in Body Mass Index (BMI),2014-11,COMPLETED,INTERVENTIONAL,['NA'],
356,NCT03804970,Proportion of scheduled eye care visits attended over 1 year,Visual acuity in the better seeing eye.,2019-08-15,COMPLETED,INTERVENTIONAL,['NA'],
357,NCT01455142,Maximum observed serum insulin aspart concentration,Maximum glucose infusion rate,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
358,NCT05271045,serum HbA1c (mg/dL),TAC (mg/dL),2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
359,NCT06334133,Change in incidence of Level 2 or Level 3 hypoglycemia,To assess the incidence of adverse events,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],11-item/Short Form Hypoglycemia Fear Scale
360,NCT05338567,Validation of the accuracy of the predicted length of the small intestine,Building prediction formulas through machine deep learning,2019-10-02,RECRUITING,OBSERVATIONAL,['NA'],
361,NCT05639478,Change From Baseline of the Foot and Ankle range of motion at 12-week,Implementation at 12 weeks,2023-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
362,NCT04738591,Glycated Hemoglobin (HbA1C),Retention rate,2020-12-30,COMPLETED,INTERVENTIONAL,['NA'],International Physical Activity Questionnaire (IPAQ)
363,NCT00534105,Cholesterol,LDL,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
364,NCT05129735,Improvement of quality of life score from baseline to 12-weeks,Improvement in LDL cholesterol levels from baseline to 12-weeks,2022-09-15,UNKNOWN,INTERVENTIONAL,['NA'],
365,NCT00322621,Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint,Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
366,NCT00969007,5% weight loss,,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
367,NCT05431140,Diabetes Treatment Satisfaction Questionnaire (DTSQc),Time spent by the HCP,2022-06-20,RECRUITING,OBSERVATIONAL,['NA'],
368,NCT01432938,Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin,Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
369,NCT06085703,Change of olfactory brain activation by fMRI,Change of metabolism,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
370,NCT03821675,Change in Wound Size in Response to Electrical Stimulation Therapy,Change in Tissue Oxygen Saturation in Response to Electrical Stimulation,2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],Change From Baseline in Skin Perfusion in Response to Electrical Stimulation
371,NCT05992974,Number of participants with gestational diabetes,,2023-08-31,RECRUITING,OBSERVATIONAL,['NA'],
372,NCT02515461,Changes in glomerulus basal lamina assessed using transmission electron microscopy.,Protein concentration in urine,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
373,NCT01535495,Area of retinal neovascularization on fundus photography,Early Treatment Diabetic Retinopathy Study visual acuity in study and fellow eye,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
374,NCT00947726,Decrease transepidermal water loss and foot dryness in study subjects.,,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
375,NCT02465411,HbA1c in venous sample,Number of self-reported severe hypoglycaemic events per year,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
376,NCT04144374,Omadacycline Tissue Penetration.,Omadacycline Area Under the Curve (AUC) in Tissue,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
377,NCT01951729,Insulin secretion rates during each treatment.,Plasma pancreatic polypeptide levels during each treatment.,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma xenin-25 levels during each treatment.
378,NCT06230276,Difference in an area under the curve of a glucose concentration change 4 hours after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems.,Difference in CGM parameters after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems using insulin aspart.,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],
379,NCT06105931,Change in triglycerides from baseline to 1 year,,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
380,NCT01634464,"Long-term evidence of early human programming of obesity measured biochemical perinatal biomarkers, and the offspring growth and development.",,2007-03,UNKNOWN,OBSERVATIONAL,['NA'],
381,NCT01725815,Health Related Quality of Life (HRQOL),Medication Adherence,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
382,NCT00145925,Composite of new or substantially worsening nephropathy or microvascular eye disease.,"Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.",2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
383,NCT01752803,Hb A1c,inflammatory markers,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Lipoproteins
384,NCT03387826,Platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods,"VerifyNow P2Y12 assay % inhibition, using the TRAP-induced response at the end of the 2 study periods",2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
385,NCT02061488,"Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)",Assessment of glucose values during the night (glycemia and interstitial glucose values),2014-03,COMPLETED,INTERVENTIONAL,['NA'],
386,NCT01909687,Analysis of system accuracy,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
387,NCT03851848,Talocrural joint dorsiflexion ROM will be measured using a universal goniometer,Foot plantar pressure distribution (FPP) will be measured using Platform Pedography system,2019-03-03,UNKNOWN,INTERVENTIONAL,['NA'],
388,NCT02587780,Blood glucose response,Body fat percentage,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],
389,NCT00693511,Insulin sensitivity,Change in visceral abdominal adipose tissue,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
390,NCT05762653,Degree of impairment of exocrine pancreatic function,Factors associated with pancreatic fibrosis,2022-02-03,RECRUITING,OBSERVATIONAL,['NA'],
391,NCT00976937,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
392,NCT05878444,Presence of our bacteria in feces,Adverse effect,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
393,NCT02716519,Target Ulcer Complications,"During the post-acute phase, weekly surgical procedures for target ulcer treatment",2016-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
394,NCT04291391,Differences between groups in circulating C-reactive protein (CRP) at Week 4,Change from Baseline in Phospholipids Classes Quantifications in Red Blood Cells at Week 4 and Differences Between Groups at Baseline and Week 4.,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
395,NCT00414999,"Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.",Systemic pharmacokinetics (Part B only),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
396,NCT06254014,HbA1c,blood pressure,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
397,NCT02942069,Blood glucose response measured with CGM,,2016-12,COMPLETED,OBSERVATIONAL,['NA'],
398,NCT00740519,Incidence of serious adverse drug reactions including major hypoglycaemic events,HCP time used on titration training,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
399,NCT05516966,Incidence of Adverse Events (Safety and Tolerability),Immunogenicity: anti-HRS9531 antibody,2022-10-12,RECRUITING,INTERVENTIONAL,['PHASE1'],
400,NCT00306436,composite criteria reflecting a good glycemic and arterial pressure status. Success defined by all measurements of HbA1c < 6.5% and of systolic (diastolic) pressure <=135 (85) mmHg if proteinuria is < 1g/24h or <= 125 (75) if proteinuria is => 1g/24h,,2006-05,UNKNOWN,INTERVENTIONAL,['NA'],
401,NCT02302599,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D,safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
402,NCT02298556,Absolute change in systolic blood pressure,Blood pressure variability (daily or hourly) in home blood pressure measurement,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
403,NCT02801448,Delta-HbA1c,Delta-fasting blood glucose,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
404,NCT05654805,change in insulin resistance (Matsuda),change in IGF-1 and its binding proteins,2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],change in faecal excretion of BCAA metabolites
405,NCT00933998,Epidermal Nerve Density Count,,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
406,NCT05448105,User Experience - Acceptance,Change in Diabetes Readiness for Change,2022-12-22,COMPLETED,INTERVENTIONAL,['NA'],
407,NCT02195856,Hepatic perfusion,Plasma incretin concentration,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
408,NCT02358096,Mean change of log transformed urinary albumin to creatinine ratio (UACR) from baseline to end of treatment,Proportion of subjects with either >30% or >40% or >50% reduction in AER from baseline to end of treatment,2015-03-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
409,NCT00787605,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),Evaluate the Safety and Tolerability,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
410,NCT02188186,Change of HbA1c,Lipid profile,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Body composition
411,NCT03135015,Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours,ISSI-2 Index of Beta-cell Function,2017-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Effect of Capsules vs. Tablets
412,NCT00376181,Change from Baseline in Glycosylated Hemoglobin.,Change from Baseline in Systolic Blood Pressure,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
413,NCT06199440,Primary Outcome,Secondary Outcome,2022-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
414,NCT01270061,HIV testing rate,Linkage to care,2012-04,WITHDRAWN,INTERVENTIONAL,['NA'],
415,NCT00911482,Spillover of free fatty acids from chylomicrons,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
416,NCT02924064,The Changes in HbA1c at Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
417,NCT01675271,VO2max,mental health,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
418,NCT01869933,Ocular Safety and Tolerability,Systemic Safety and Tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
419,NCT01004757,myocardial diastolic function,"triglycerides, insulin resistance",2008-02,UNKNOWN,INTERVENTIONAL,['NA'],
420,NCT01244971,Glycemic control,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
421,NCT00660998,Sexual Encounter Profile Question 3,Safety and Tolerability,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
422,NCT04581421,Liverfat,Insulin clearance determined during steady state insulin infusion,2020-12-03,COMPLETED,INTERVENTIONAL,['NA'],
423,NCT03993145,Adherence,Changes in HbA1c,2020-02-07,COMPLETED,INTERVENTIONAL,['NA'],Participant satisfaction
424,NCT04253613,IL-10 level in GCF,,2013-01-15,COMPLETED,OBSERVATIONAL,['NA'],
425,NCT02546401,Area Under Curve (AUC) of glycemia,Area Under Curve (AUC) during 4H after a high-fat meal,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
426,NCT05762120,Weight Loss,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],
427,NCT03604419,The change from baseline value of HbA1c will be compared between treatments,"The change from baseline value of Fasting Plasma Glucose at Weeks 2, 4, 8, and 12",2018-06-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
428,NCT04475380,Target lesion failure (TLF) at 2-year follow up in all-comers,Clinically indicated target lesion revascularization,2018-09-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
429,NCT00877890,Change in HbA1c From Baseline to Week 24,Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
430,NCT02589626,Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,2015-10-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
431,NCT06011512,"Proportion of participants developing diabetes mellitus during the study period, measured in changes of HbA1c.",Duration and cumulative glucocorticoid dosage,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
432,NCT00121355,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
433,NCT04617405,"Association between the level, content and bioactivity of exosomes in serum and plasma Versus Insulin sensitivity at five times during pregnancy.",Association between the body weight Versus Insulin sensitivity at five times during pregnancy.,2021-01-11,RECRUITING,OBSERVATIONAL,['NA'],
434,NCT01474772,DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period),Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period),2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
435,NCT00955903,Change in Abdominal Fat Mass,Weight Change/Maintenance,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
436,NCT04232995,Berg Balance Scale,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA'],
437,NCT05369065,Device success,Change of anti-hypertensive medications,2022-01-27,RECRUITING,INTERVENTIONAL,['PHASE1'],
438,NCT01022762,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
439,NCT05404178,Diabetic Foot Self-Care Questionnaire,Foot Care Behavior Scale,2022-06-10,COMPLETED,OBSERVATIONAL,['NA'],
440,NCT00539409,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect Metabolic Integrity in patients with Diabetes Mellitus. Monitor results of QOL questionnaires, Hgb A1C levels, medications to see if patients complications improve",,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
441,NCT01151293,,,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
442,NCT05752929,Number of paticipants with Glicemic control,Number of participants with hypoglycemia,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
443,NCT04184947,3 point major adverse cardiovascular events (4P-MACE),Revascularization,2014-03-01,COMPLETED,OBSERVATIONAL,['NA'],Occurrence of adverse events
444,NCT00964587,HbA1C,Barriers to Self-Management,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
445,NCT00606112,"Safety and Tolerance of a single intravenous dose of trodusquemine (MSI-1436) in obese, type 2 diabetics",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
446,NCT00741585,"To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.","To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment.",2008-09-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
447,NCT02942914,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics: Average Glucose from 8-Point Glucose Profiles in Participants with T2DM treated with Placebo or LY3209590,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
448,NCT03230266,"Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not : collection of biological and device samples (blood, catheters, insulin)",Associated conditions related to the patient and to infused insulin,2017-06-02,TERMINATED,INTERVENTIONAL,['NA'],
449,NCT04964713,major adverse cardiovascular events,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
450,NCT02290600,"Accuracy of continuous glucose sensor output by individualizing sensor bias in subjects with type 1 diabetes, assessed by quantifying the improvement in CGM accuracy as measured by MARD (mean absolute relative difference).",Continuous Glucose Monitor sensor failure,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
451,NCT03644199,Glucose levels,Evaluation of gastric emptying,2011-03-30,WITHDRAWN,INTERVENTIONAL,['NA'],
452,NCT05651490,Change in HbA1c over 18 months,Cost-effectiveness of PST-D,2020-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
453,NCT01658579,Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]),Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
454,NCT01407289,Mean blood glucose,Number of glucose measurements in hyperglycaemic ranges,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
455,NCT06169033,Area under curve (AUC) of the T2DM remission prediction model after 1 year,Area under curve (AUC) of the T2DM relapse model,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],
456,NCT02173457,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who discontinue the trial due to hyperglycemia,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
457,NCT05081817,Difference in glucose measurement,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
458,NCT03506711,Change in coronary cross sectional area (mm2),,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
459,NCT01574365,Adverse event collection and assessment,Profile of Pharmacokinetics,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
460,NCT02779556,Hemoglobin A1C (HbA1C),Diabetes Knowledge (0-13),2016-11-07,COMPLETED,INTERVENTIONAL,['NA'],
461,NCT02729246,Change from Baseline of beta cell function,Change from Baseline of beta cell function,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
462,NCT01159184,,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
463,NCT00101764,,,2005-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
464,NCT01939782,"Metabolic Clock Gene Expression in Peripheral Blood Cells(PBC),",Serum Cortisol,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
465,NCT01288898,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
466,NCT02748330,P2Y12 reaction unit (PRU),Non-coronary artery bypass graft (CABG) related major or minor or minimal bleeding,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
467,NCT00000542,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
468,NCT02126605,Percent agreement between DAD alerts and glucose readings,"Psychosocial variables (quality of life, fear of hypo-/hyperglycemia, diabetes distress, self-efficacy, and DAD experiences)",2014-07,UNKNOWN,OBSERVATIONAL,['NA'],
469,NCT04217161,Blood glucose measurement,Hypoglycemia events,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
470,NCT00816608,The development of diabetes,DM complication,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
471,NCT04865809,Change in BOP - Bleeding on Probing (percentage),,2021-05-12,COMPLETED,INTERVENTIONAL,['NA'],
472,NCT02760017,fasting glucose levels,Plasma endothelin-1 levels,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
473,NCT03818711,Glycemic control (A1C),Quality of Parental Involvement,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
474,NCT01935349,The proportion of HT/ DM patients who have achieved the target blood pressure.,"GOPC consultation, SOPC, A&E and hospital attendance rates in the past 12 months.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
475,NCT03235362,"YHR1705, YHR1706 Css, max",,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
476,NCT01500005,arterial stiffness,blood pressure holter,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
477,NCT04935671,Depression,Tryptophan,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
478,NCT04348565,Self-efficacy level in diabetes management,Quality of life Measurement,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
479,NCT04170998,Change from baseline in HbA1c (%) After 24 weeks,Change from baseline in 7-point SMBG After 24 weeks,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
480,NCT03209258,Shift ('improvement') in functional recovery (death or disability) defined by the modified Rankin Scale (mRS),Residence,2017-12-12,COMPLETED,INTERVENTIONAL,['NA'],
481,NCT05480657,Efficacy - Insulin independence,Efficacy - Durability of insulin independence - long term,2022-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
482,NCT05951621,2-h postprandial plasma glucose,"Self-Rating Anxiety Scale, SAS",2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Maternal and infant complications during childbirth
483,NCT00791661,Number of Participants Who Discontinued Treatment Due to an Adverse Event,24-hour Weighted Mean Glucose (WMG) Concentration,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
484,NCT02954692,Mean change from baseline in HbA1c,Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores,2016-11-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
485,NCT01512108,Incidence of Treatment Emergent Adverse Events (AEs),Change in FPG From Baseline to Week 52,2012-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
486,NCT01115257,,,2001-10,COMPLETED,INTERVENTIONAL,['NA'],
487,NCT01144338,Primary Safety Outcome MACE Events,Secondary Efficacy Outcome Hospitalization for HF,2010-06-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
488,NCT04711083,correlation between nocturnal oxygen desaturation and glycemic control,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],
489,NCT02344433,Accuracy of family members identified (defined as the agreement of first and second degree relatives identified by both the tool (VICKY or MFHP) and the genetic counselor),Family and provider communication (Communication of family health history with family members and health care providers),2016-11,COMPLETED,INTERVENTIONAL,['NA'],
490,NCT04459936,Responders (Dichotomised: responder/non-responder),Serum Urate,2020-11-24,WITHDRAWN,INTERVENTIONAL,['NA'],Hospitalisation
491,NCT00965302,Diabetes remission,c-reactive protein,2009-08,TERMINATED,INTERVENTIONAL,['NA'],
492,NCT01846767,Peak Delta over baseline in 13CO2 breath enrichment,Per cent dose recovered,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Diabetes classifications and measures of insulin resistance
493,NCT01267448,"The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.",The number of fold increase in beta cell function in the 2 arms.,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
494,NCT00087516,Change From Baseline in A1C at Week 24,Change From Baseline in 2-hr PMG at Week 104,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
495,NCT03420040,Change in fasting blood glucose between baseline to week 4,,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA'],
496,NCT01984827,ECG Analysis,Proportion of Participants with Adverse Events,2019-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
497,NCT04055428,Change in energy expenditure after natriuretic peptide augmentation,Impact of Natriuretic Peptide Genotype on Study Endpoints,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Metabolomic Profile
498,NCT03462420,Change of shoulder performance from baseline to 6 weeks after physiotherapy,Physical activity level,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],
499,NCT00449930,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting,2007-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
500,NCT05248776,Efficacy in lowering plasma glucose during the Oral Glucose Tolerance Test (OGTT) after 2 weeks of CPL207280 treatment,CPL207280 concentration immediately prior to dosing (Ctrough),2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
501,NCT01846377,Change in fasting insulin from baseline to immediate post intervention (approximately 3 months post baseline assessment) and 2-months post intervention (approximately 5 months post baseline assessment),Change in Fruit and Vegetable Intake,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Change in Moderate to Vigorous Physical Activity
502,NCT04281069,glycaemia,Hemoglobin A1c,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],systolic and diastolic blood pressure
503,NCT01063868,Number of Subjects With Treatment-emergent Adverse Events (TEAE),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
504,NCT05823337,five-day second hour postprandial glucose average,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
505,NCT01883037,Does HemoCue Glucose 201 RT provide lab-quality results in the analysis of glucose values during oral glucose tolerance tests?,Is HemoCue Glucose 201 RT method cost saving relative to the traditional laboratory method for analysing glucose values taken during oral glucose tolerance tests?,2013-06,COMPLETED,OBSERVATIONAL,['NA'],2. To see if the HemoCue Glucose 201 RT offers sufficient advantages to make it a viable alternative to conventional testing
506,NCT02795559,Serum acetate response,Post-lunch ghrelin response,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
507,NCT02104466,Change from baseline in average weekly pain on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at week 12,Patient satisfaction,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Use of medications at baseline and throughout 12-week intervention period
508,NCT05808699,Sensitivity and Specificity Corrected for Enrichment,"Observed Sensitivity and Specificity, Level II",2023-03-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Precision substudy
509,NCT03664583,Mental Health Using the Short-Form 12 Health Survey Version 2 (SF-12v2) - Mental Component Summary score.,Collaboration Using the Partnership Self-Assessment Tool (PSAT),2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
510,NCT00225849,"Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)",Severe side-effects that lead to interruption of the study medication.,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
511,NCT01588639,Occurrence rate of serious adverse drug reactions including severe hypoglycaemic events,Number and ratio of missed injections,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
512,NCT03835923,Change in HbA1c,"Number of the combined endpoint ""4P-MACE""",2019-02-12,COMPLETED,INTERVENTIONAL,['NA'],
513,NCT02150824,The percentage of patients with drug- related adverse events,Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
514,NCT03646916,Post-operative blood sugar,,2020-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
515,NCT03744975,Plasma cGMP Response,Renal response,2018-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
516,NCT02240680,Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.,Change From Baseline in Fasting Plasma Glucose (FPG),2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
517,NCT02906930,Change in HbA1c,PGI-C Item: Scores of the Two Individual Items (Used for Validation of the IWQOL Questionnaire),2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
518,NCT01990092,Change in plasma methylmalonic acid (MMA) levels,Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6 questionnaire (NTSS-6),2013-11,UNKNOWN,INTERVENTIONAL,['NA'],
519,NCT05791201,Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT),Part C: Change in HbA1c values,2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
520,NCT02338193,Change in Body Weight,First Phase Insulin Secretion (IGI/HOMA-IR),2015-09-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
521,NCT02200965,Assessment of change in completion of nine key care processes in diabetes,Assessment of change in surrogate markers that define hard outcomes in diabetes,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
522,NCT03750695,Percent Change in Endothelial Function,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA'],
523,NCT00232362,annular tissue Doppler velocity,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
524,NCT05754424,Area under the glucose infusion rate-time curve of insulin aspart,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
525,NCT06112418,The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.,The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.,2024-03-06,RECRUITING,INTERVENTIONAL,['NA'],The safety objective is to assess harm with the 2 prevention strategies
526,NCT04201912,Toll like receptor 2 activity,Toll like receptor 4 activity,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
527,NCT03731637,Determine sensitivity and specificity of serum CA 19-9 in pre-symptomatic pancreatic ductal adenocarcinoma in subjects with new-onset hyperglycemia and diabetes,,2018-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
528,NCT04237493,Hyperglycemia,Hyperosmolar hyperglycemic state,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
529,NCT02287506,Time to optimum treatment following diagnosis.,Mean glycaemic control,2015-08-28,TERMINATED,INTERVENTIONAL,['NA'],
530,NCT05017571,Change in Homeostatic model assessment of insulin resistance (HOMA-IR),Change in Matsuda Index,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
531,NCT02612675,Area under the blood glucose curve (AUC 0-240),,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
532,NCT02520050,Absolute and relative change in HbA1c,Absolute and relative change in energy intake,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
533,NCT03696810,LOR ratios,Retinal Thickness,2018-10-30,COMPLETED,INTERVENTIONAL,['NA'],
534,NCT04141891,Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention),Occurrence of self-reported crashes,2019-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
535,NCT02363907,Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device,,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
536,NCT03235219,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S),2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
537,NCT02829268,Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests,Changes in Neurological Functions in Participants Assessed by the Wolfram Unified Rating Scale (WURS),2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
538,NCT00797212,Number of AST Results Within +/- 15mg/dL or +/- 20% of Fingerstick (FS)Blood Glucose Results,Percentage of Participant Ratings for Overall Testing Experience With This Meter,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
539,NCT04007133,Compliance rate with statin measured by the Girerd test,Compliance rate with statin according to risk factors,2018-01-31,TERMINATED,OBSERVATIONAL,['NA'],
540,NCT02294175,"Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed),With Phenylethyl Alcohol (PEA) Plating","Satisfaction: Wound Pain, Day 8",2015-01,COMPLETED,INTERVENTIONAL,['NA'],
541,NCT00437606,AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.,"AEs, laboratory parameters.",2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
542,NCT03457168,New-onset CKD,Cardiac events,2019-02-01,RECRUITING,INTERVENTIONAL,['NA'],
543,NCT06315725,"Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.",Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumptionT1D on AP following beverage consumption,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
544,NCT00713830,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
545,NCT00999856,demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement,duty of care,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
546,NCT05268237,"Incidence, nature and severity of adverse events",Serum concentration of liraglutide,2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
547,NCT00907114,center subfield mean thickness using Stratus OCT measured in microns,"macular volume using Stratus OCT, measured in cubic millimeters",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
548,NCT05322304,neuropsychological function,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
549,NCT04092023,Glycemic control,QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19),2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
550,NCT01292018,Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months,Control of dyslipidemia by all commercial available brands hypolipidemics drugs,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
551,NCT00285194,"-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.","-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for >30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;",2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
552,NCT02431234,Serum RANKL concentrations,,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
553,NCT02958956,Number of 10 Most Common Cancers Associated Cases,Number of 10 Most Common Cancer Cases By Dose of Pioglitazone,1997-01-01,COMPLETED,OBSERVATIONAL,['NA'],
554,NCT04817228,Change from baseline in wound biofilm presence before and after treatment,,2021-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
555,NCT05046015,Change from Baseline in Overall Dry Skin Score,Skin barrier,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Cracks/ Fissures
556,NCT03462017,Change in Flow Mediated Dilation (FMD),Assessment of PK parameter: AUC0-24,2018-03-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
557,NCT01990638,left ventricular diastolic function,exercise capacity,2004-11,COMPLETED,OBSERVATIONAL,['NA'],
558,NCT02327754,Change from baseline in urine albumin creatinine ratio,"sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC",na,COMPLETED,INTERVENTIONAL,['PHASE2'],
559,NCT02820558,Stage A Safety: Side effects reported for entire cohort,C-Peptide Levels (large cohort),2016-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],sP Longevity
560,NCT01798238,Glycosylated hemoglobin,Glycosylated hemoglobin <6.5% subject percent,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
561,NCT02208921,The proportion of T2DM patients with Chronic Kidney Disease (CKD),Frequency of patients with HbA1C less than 7% in T2DM patients with and without CKD,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
562,NCT01577719,Effectiveness of a 6 month culturally-specific multi-media intervention on Heart Health Risk,Change in the MI risk score and clinical events,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
563,NCT00074633,,,2000-01,COMPLETED,INTERVENTIONAL,['NA'],
564,NCT02035891,The incidence of overt nephropathy,Death from any cause,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],
565,NCT02695706,Skin acceptability through the self perception of patients.,Instrumental Performance Measures,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
566,NCT00921570,Flow mediated dilatation,"TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure",2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
567,NCT02818192,Change in albumin excretion over time.,Change in estimated glomerular filtration rate (eGFR) over time.,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
568,NCT01455441,HbA1c,Myocardial echocardiography,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
569,NCT00698126,Number of major hypoglycaemic events reported as serious adverse drug reactions,Quality of Life (QoL),2007-10,COMPLETED,OBSERVATIONAL,['NA'],
570,NCT06236672,change in HbA1c (%),,2023-02-15,COMPLETED,OBSERVATIONAL,['NA'],
571,NCT01487811,Maximum drug concentration of the two formulations (Cmax),Frequency of adverse events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
572,NCT04021251,Validation of predictive algorithms for determining blood glucose levels,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA'],
573,NCT05658991,Retinal function amplitude,Retinal function latency.,2022-12-11,RECRUITING,INTERVENTIONAL,['NA'],
574,NCT05744856,The acceptability of the self-care intervention,Self-care of GDM,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],Costs
575,NCT00711217,Wound healing,Clinical outcome data,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
576,NCT00228878,Researchers will assess whether pulsatile IV insulin therapy can successfully reverse the abnormal underlying metabolism in diabetic patients to the point of improving their quality of life.,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
577,NCT00413348,Change in inflammatory response to E. coli endotoxin injection,,2006-11,UNKNOWN,INTERVENTIONAL,['NA'],
578,NCT01372852,"plasma adiponectin concentration, isoform distribution and activity.",,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],
579,NCT04791787,Hepatic Fat Content,Fructosamine level,2020-11-25,COMPLETED,INTERVENTIONAL,['NA'],
580,NCT03144050,Clinical risk category,Ulcer incidence,2017-04-14,UNKNOWN,OBSERVATIONAL,['NA'],
581,NCT01975428,Participant Perceptions of Utility of Monitoring,Total Health Care Utilization and Costs.,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
582,NCT04043260,Percentage of readings below 54 mg/dl,Change in HbA1C post study treatment,2019-11-27,COMPLETED,INTERVENTIONAL,['NA'],
583,NCT03189407,Change in estimated glomerular filtration rate,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
584,NCT01828970,Mean plasma glucose level measured 3 times just before the first hemodialysis session,Deaths and major cardiovascular events,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
585,NCT02800044,accuracy,acceptability,2017-03-14,TERMINATED,INTERVENTIONAL,['NA'],
586,NCT00849563,Percentage of weight loss,Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR),2009-04,COMPLETED,INTERVENTIONAL,['NA'],
587,NCT00005140,,,1977-09,COMPLETED,OBSERVATIONAL,['NA'],
588,NCT01781884,C-peptide value,HbA1C level,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],Daily dosage of insulin (units/kg).
589,NCT01764373,Change in aerobic fitness,Change in pain experienced,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
590,NCT02130505,Postprandial change in leukocyte activation,Correlation between acute glycemia and leukocyte activation,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
591,NCT00964184,HbA1C,insulin,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
592,NCT00703209,"To determine if nerve decompression of lower extremities in patients suffering from painful symptomatic diabetic neuropathy with chronic nerve compression, has a significant impact on alleviation of pain, and improvement in quality of life.","To measure changes in quality of life. This includes medication changes, pain relief, restoration of sensation, etc.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],
593,NCT06031389,Detection of intestinal flora difference between intervention group and control group with diabetic nephropathy by bacterial 16srDNA sequencing,Statistical analysis of the degree of proteinuria relief in intervention group and control group.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
594,NCT02266030,Coronary artery stenosis,Lipid metabolism,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Heart rate
595,NCT01506895,Change from baseline in Spectral Domain Optical Coherance Tomography,Plasma concentration versus time curve (AUC) of study drug,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
596,NCT04954313,Association between changes in oral health and changes in systemic health (Flow-mediated dilation),Impact of treatment on triglycerides,2021-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
597,NCT01999374,Duration of sustained islet allograft function,,2013-03,RECRUITING,OBSERVATIONAL,['NA'],
598,NCT05379686,Percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise,Coefficient of variation in PG concentrations,2022-09-21,RECRUITING,INTERVENTIONAL,['NA'],
599,NCT01306110,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
600,NCT04569630,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycemia warning system (HEADWIND) in detecting hypoglycemia (blood glucose < 3.9 and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Perceived working alliance with IVA,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
601,NCT04976426,multidimensional network biomarkers,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
602,NCT06062069,Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline,Change in insulin doses from baseline when comparing CT-868 to placebo.,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time in hyperglycemia as per CGM metrics.
603,NCT01521520,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
604,NCT03349684,Absolute change in the levels of glycosylated hemoglobin (HbA1c),Number of participants with adverse events,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
605,NCT04697485,Change in NT-proBNP,Compliance,2021-01-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
606,NCT03208751,Change in VO2peak in ml/kg/min,Change in max. Watts/kg bodyweight,2011-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
607,NCT02977598,"Atherogenic index of plasma (AIP) values compared with glucose metabolism parameters like HbA1c, Fasting Plasma Glucose and 2-hour plasma glucose levels.",,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
608,NCT02176278,Attainment of at least 3 treatment targets,Incidence of all-diabetes related endpoints,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Changes in albuminuria
609,NCT01111955,Lowering of fasting plasma glucose (FPG) throughout the study to see if there is a decrease from baseline,"Pharmacodynamics (measuring daily glucose, glucose AUC, HbA1c, lipid profiles, HPA markers, free testosterone, and SHBG)",2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
610,NCT02257190,Glycemic control,Insulin sensitivity,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
611,NCT01908348,Endothelial function,,2013-07-18,COMPLETED,INTERVENTIONAL,['NA'],
612,NCT03785275,Beta cell mass,Beta cell mass vs. beta cell function,2017-12-06,TERMINATED,OBSERVATIONAL,['NA'],
613,NCT06222775,Glycated hemoglobin,Changes in Medication cholesterol,2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],
614,NCT01038648,1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT,1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin.,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
615,NCT04104243,Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program,Compare change in hemoglobin A1c over 6 months,2021-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
616,NCT01077570,Number of serious adverse drug reactions (SADRs) including major hypoglycaemic (low blood sugar) events,Change in postprandial blood glucose (PBG),2010-03,COMPLETED,OBSERVATIONAL,['NA'],
617,NCT01552603,Mean Percent of Time in Target Blood Glucose Range,Mean Deviation From Target Blood Glucose,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
618,NCT01217476,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares",Relative Wound Area Regression of 40% or More at 6 Week,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
619,NCT01996995,complete cure of the target nail,Change surface healthy target nail / all clinically infected toes patients free of hyperkeratosis,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
620,NCT06002997,Number of pregnant women with Periodontal disease,Percantage of HbA1C (Glycosylated haemoglobin),2012-05-03,COMPLETED,OBSERVATIONAL,['NA'],
621,NCT03002116,Mean foot tissue temperature,,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
622,NCT02480465,The mean percent change of HbA1c,"Safety evaluation - physical examination, vital sign, laboratory, adverse event",2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
623,NCT00529815,This study will determine if a real-time continuous glucose monitoring system is a more effective method of improving glycemic control in patients with type 2 diabetes than is episodic self blood glucose monitoring in the both the short- and long-term.,"The results of this study could also provide information on the impact of the two methods of glycemic monitoring on number of hypoglycemic and hyperglycemic events, and quality of life.",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
624,NCT05219812,Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention,Number of participants with treatment emergent adverse events (TEAE),2022-02-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
625,NCT02081014,Serious Adverse Events,Glucose Tmax (Post-insulin),2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
626,NCT01137812,Change in HbA1c From Baseline to Week 52,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
627,NCT01364298,Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84,Number of Participants With Adverse Events (AEs),2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
628,NCT00427986,"Retinal thickness estimated by the fast protocol of the StratusOCT (0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 min).","Side effects during the three-hour examination period, to evaluate if caused by galactose per se or by an increase in intracapillary osmotic pressure.",2007-01,TERMINATED,INTERVENTIONAL,['NA'],
629,NCT02695082,Incidence of Acute Kidney injury (AKI),,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
630,NCT01294423,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Body Weight,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
631,NCT02169570,Change in chest X-ray,Change in Random Blood Sugar (RBS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
632,NCT06117358,Prevalence of Pre-Diabetes in Overweight and Obese children and adolescents in Assiut governorate,,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
633,NCT04176276,Urine expression of miR-25,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],
634,NCT04810676,Cmax of CKD-383,CL/F of CKD-383,2021-04-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
635,NCT00442845,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
636,NCT01148238,T-reg,"HLA, anti-GAD, anti-IA2, white blood count, CRP, fasting C-peptide, HbA1c",2012-08,WITHDRAWN,OBSERVATIONAL,['NA'],
637,NCT05257460,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on continuous glucose monitoring (CGM),Total bolus insulin dose (units/day),2022-01-25,COMPLETED,INTERVENTIONAL,['NA'],Utility evaluation is the frequency and duration of use of the closed-loop system at home
638,NCT03631108,Iris Vessel Geometric Characteristics,,2018-10,UNKNOWN,OBSERVATIONAL,['NA'],
639,NCT05944549,Percent weight loss,Change in food security as assessed by the National Health Interview Survey(NHIS) Food Insecurity Screener,2023-05-12,RECRUITING,INTERVENTIONAL,['NA'],
640,NCT01005069,Reduction of venous Fasting Plasma Glucose from baseline,Change in lipid profile from baseline,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
641,NCT06251895,SII,readmission,2021-08-01,COMPLETED,OBSERVATIONAL,['NA'],
642,NCT02322268,Glycemic control,Lipid profile,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
643,NCT05038137,Assess feasibility and adherence to time period of eating recommendations in both study groups.,Continuous Glucose Monitor (CGM) derived metrics,2022-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
644,NCT00845156,Insulin Resistance,,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
645,NCT00466362,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],
646,NCT02150889,Differences in insulin sensitivity between groups,Differences in fitness level between groups,2014-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Differences in body composition between groups
647,NCT01962701,Fetal plasma copeptin concentration,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
648,NCT05398783,Mean difference and limits of agreement between measured and predicted BSA,,2022-10-25,RECRUITING,OBSERVATIONAL,['NA'],
649,NCT01463449,Low grade inflammation in adipose tissue after weight loss induced by gastric bypass,Quantity of fat in the liver,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
650,NCT01610219,Change in Dietary Intake,Change in Parent BMI,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
651,NCT05147324,Change in percent time in range,Change in hemoglobin A1c percentage,2021-12-13,COMPLETED,INTERVENTIONAL,['NA'],
652,NCT05481944,Left ventricular myocardial longitudinal strain measured by MRI (%),Epicardial fat volume measured from ECG gated Dixon MRI images,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
653,NCT00485056,The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function.,E/E' measured by TDI (a non-invasive measure of preload).,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
654,NCT00398853,Insulin Sensitivity as assessed with hyperinsulinemic-euglycemic clamps,"body weight and fat distribution, myocellular and intrahepatic lipid content as assessed with MRS scans",2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
655,NCT05979077,Participant Tool and Workflow Survey,To evaluate the impact of a patient-facing EHR-enabled questionnaire on glycemic control and visit efficiency.,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
656,NCT03466177,Retinal biomarkers for AD: receiver operating characteristic (ROC),Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more,2018-03-01,RECRUITING,OBSERVATIONAL,['NA'],
657,NCT00922389,Adverse events and laboratory parameters,Trans Cutaneous partial pressure of Oxygen: TCpO2,2009-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
658,NCT03345004,Change in Stimulated C-peptide During a MMTT,Change in Body Mass Index (BMI),2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
659,NCT01487109,To assess the change in urinary albumin to creatinine ratio,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
660,NCT05333822,blood glucose improvement in type 2 diabetic patients by continuous glucose monitoring.,insulin C-peptide gastric emptying,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
661,NCT01444443,Number of hypoglycemic events,Time spent in euglycemia (3.9-8.0 mmol/l); mean blood glucose level; LBGI,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
662,NCT04634214,Severity of COVID 19 among people with and without diabetes,Length of hospital stay,2020-11-16,UNKNOWN,OBSERVATIONAL,['NA'],
663,NCT01276288,Urinary Sodium Excretion Over 24-hour run-in Periods,"Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
664,NCT00678990,Safety,,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],
665,NCT00642538,AUC 0-240 min post-prandial serum glucose,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
666,NCT01183013,Change From Baseline in HbA1c After 30 Weeks of Treatment.,Incidence of Rescue Therapy During the First 30 Weeks of Treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
667,NCT00546702,Change of HbA1c.,"Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
668,NCT05933161,Estimated average glucose (eAG) values based on fructosamine lab values,Number of hypoglycemic unawareness episodes,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],
669,NCT03551925,Change in Adherence to Refills and Medication Scale (Seven-item) (ARMS-7) Score,Change in Blood pressure,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
670,NCT04501991,Lipid profile,,2020-03-11,COMPLETED,OBSERVATIONAL,['NA'],
671,NCT04141475,change of LVEF between before and after 12 weeks of treatment,,2020-11-24,TERMINATED,INTERVENTIONAL,['NA'],
672,NCT00908921,Change in glycosylated hemoglobin (HbA1c) rate,Percentage of patients achieving HbA1c <7.0,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
673,NCT02551640,Differences in the change in physical activity levels between control and intervention groups as measured by daily physical activity measured by the Gear Fit device provided to participants in both groups,Differences in the change in C-reactive protein between control and intervention groups,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
674,NCT01903044,"Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions",Survival without amputation,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
675,NCT01000922,To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments,"To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
676,NCT02765347,HbA1c,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
677,NCT01137903,Number of healing patients,Quality of life,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],
678,NCT01002547,"Liver Histology (Kleiner's et al Criteria, Hepatology 2005)",LDL-cholesterol,2010-06-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
679,NCT02627534,Probing Depth,Clinical Attachment Level,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Gingival Recession
680,NCT02681497,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
681,NCT02148523,Statin Adherence,Morisky Medication Adherence Scale (MMAS),2014-01,COMPLETED,INTERVENTIONAL,['NA'],
682,NCT04938843,Glycemic control,Liver fat function test GGT,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA'],
683,NCT02316665,change in mean nocturnal glycemia,Change in mean heart rate after intervention,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
684,NCT03496597,surface of the central retinal avascular zone,,2018-02-23,UNKNOWN,OBSERVATIONAL,['NA'],
685,NCT05143827,60-min glucose,AUC glucose 180 min,2021-11-20,RECRUITING,INTERVENTIONAL,['NA'],
686,NCT02302443,Incidence and severity of treatment emergent adverse events,Area under the concentration-time curve (AUC) of HM12470 following a single dose,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
687,NCT01806727,Predicted Cardiovascular Risk,Predicted Cardiovascular Risk,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Health Costs
688,NCT04530292,Measurement of HbA1c (%) one year after the discovery of diabetes.,Percentage of time spent wearing the sensor for patients with Freestyle sensor,2020-09-28,COMPLETED,INTERVENTIONAL,['NA'],
689,NCT03447275,The difference in serum vitamin B6 concentrations between cases and controls,The difference in serum and urine vitamin B6 vitamers between patients with advanced global vascular risk versus those with a low vascular risk,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
690,NCT01908530,Difference to the Venous Blood Glucose MARD,Acceptability Questionnaire,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
691,NCT06170515,HbA1c Performance,Type of errors as displayed,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
692,NCT05768191,To compare improvements from baseline in patient HbA1c when aggressively treated with insulin human isophane plus rapid acting human insulin vs treatment with Premix human insulin,"correlation between patient QoL and glucose variability as measured by CGMS (baseline, week 16 and week 32)",2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
693,NCT03104829,HbA1C,Diabetic self-care behavior score,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
694,NCT03175120,Change in HbA1c,Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
695,NCT00381719,Reduction in Daily Pain Score,Quality of Life questionnaires,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
696,NCT03154073,Insulin Sensitivity Index (μmol·kg^-1·min^-1·pM^-1),Change in 24-hour Glycemic Control (glucose AUC),2017-07-20,COMPLETED,INTERVENTIONAL,['NA'],
697,NCT02934737,Markers of progression of diabetes,,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
698,NCT00946972,"Adverse events, laboratory values, vital signs, ECGs",Incretin levels,2009-07,TERMINATED,INTERVENTIONAL,['PHASE1'],
699,NCT06310980,Time in range,DIDS,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
700,NCT00729079,The primary outcome measure is weight loss with a goal of 7% of initial weight.,;Fat intake less than 25% and saturated fat less than 10% Fiber intake of at least 25 grams per day;Fasting blood sugar < 100 mg/dL; Absence of tobacco use,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
701,NCT03372824,Glycated albumin reference interval in pregnancy,Admission to neonatal intensive care unit,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
702,NCT02580591,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD)),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,2015-12-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
703,NCT02212522,Genetic and environmental risk factors of T1D predisposition,"Undertake a prospective research of G and E risk factors of ""death in bed"" syndrome in diabetic adolescents",2004-11,UNKNOWN,OBSERVATIONAL,['NA'],
704,NCT02690467,Fructosamine levels,Number of episodes of insulin leakage at injection site,2016-09-06,UNKNOWN,INTERVENTIONAL,['NA'],
705,NCT00034788,Time to complete ulcer healing.,Incidence of complete ulcer healing and reduction in total ulcer area at end of study. Incidence of adverse events throughout study.,2000-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
706,NCT04920279,Validity of the Turkish Version of Activities-specific Balance Confidence Scale in Patients With Diagnosis of the Diabetes Mellitus Before.,,2018-06-11,COMPLETED,OBSERVATIONAL,['NA'],
707,NCT02098395,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
708,NCT01035879,Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch,Evaluate the effect of MBX-2982 on additional glycemic parameters.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
709,NCT02411825,Number of adverse events,Change from baseline in HbA1c,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
710,NCT01972113,Change in beta-cell function,"Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)",2013-09,UNKNOWN,INTERVENTIONAL,['NA'],
711,NCT01393808,Changes in urinary albumin excretion from baseline at 4 month.,Ambulatory and 24-hour blood pressure profile.,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
712,NCT04311853,Implementation of new evidence-based nutrition practice guidelines,Improved health outcomes,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
713,NCT01346033,Validation of SCOUT DS algorithm for detecting known type 2 diabetes,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
714,NCT01140932,ERG,Retinal Vessel Caliber,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
715,NCT01315756,"Improved glycemic control, HbA1c","Lipids, self-care, lifestyle changes, complications, quality of life.",2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
716,NCT00167284,Lipids,Patient and physician barriers to diabetes care,2001-10,COMPLETED,INTERVENTIONAL,['NA'],
717,NCT05415644,The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-∞),Adverse events,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
718,NCT05888688,Volumetric quadriceps skeletal muscle mass (cm^3),Sarcopenia assessment,2023-12-06,RECRUITING,OBSERVATIONAL,['NA'],quadriceps musculoskeletal Biopsy Analysis
719,NCT02806739,Number of Participants With Adverse Events That Are Related to Treatment,Effects of Soy Intake on C-reactive Protein (CRP),2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
720,NCT03216564,Urinary albumin creatinine ratio (ACR) measured biochemically,Blood pressure,2017-05-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Patient Reported Outcome: Quality of life
721,NCT02831361,changes from baseline HbA1c at week 25,Changes of HOMA-β at week 25,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Changes of Triglyceride at week 25
722,NCT02435329,Impaired endothelial function in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as measured by:,Impaired bone metabolism in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as assessed by:,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
723,NCT04882332,Correlation between Metformin Usage Index and Vitamin B12 status among Egyptian patients with type 2 diabetes,,2021-05-05,UNKNOWN,OBSERVATIONAL,['NA'],
724,NCT00955201,Peroneal Nerve Conduction Velocity,Short Form-36V: Mental Component Score,2010-01-14,COMPLETED,INTERVENTIONAL,['NA'],Age
725,NCT01512680,Difference between HbA1c at Month 12 and Month 0 > 0.5%,"Better score at surveys of quality of life (SF-6D, DQOL) and auto-management",2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
726,NCT02152371,Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c),Rate of Hypoglycemic Events up to 28 Weeks,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
727,NCT03033433,Stage 2: Number of Participants with Adverse events and Serious adverse events that are related to treatment,Stage2: Change from baseline in biomarker( serum fructosamine) testing results.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
728,NCT06107153,Change in hemoglobin A1c,Hypoglycemia,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
729,NCT02505893,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),72-hour Continuous Glucose Monitoring,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
730,NCT05549570,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",2017-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
731,NCT02010541,Glycaemic control,knowledge on diet and diabetes management,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],Quality of Life measures
732,NCT00337298,Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer,24 hour ambulatory blood pressure (mmHg),2006-07,COMPLETED,INTERVENTIONAL,['NA'],
733,NCT02368600,Proportion of subjects developed GDM,Proportion of neonates born with macrosomia,2015-04-21,COMPLETED,INTERVENTIONAL,['NA'],
734,NCT06172166,Continuity of care,Diabetic Ketoacidosis,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
735,NCT01813799,Difference in average 24-h pain intensity (Likert scale) between before and after IP administration,Average daily dose of acetaminophen,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
736,NCT02373059,Patient Involvement Questionnaire,Patient Medication Adherence Questionnaire,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
737,NCT02204527,Ambulatory Blood pressure monitoring,,2015-10,TERMINATED,INTERVENTIONAL,['NA'],
738,NCT00331448,,,2000-06,UNKNOWN,OBSERVATIONAL,['NA'],
739,NCT02683902,Weight loss,"Weight, waist circumference and total body fat loss after 3 and 6 month of end of intervention",2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
740,NCT03717909,Visual acuity (VA),Pancreatic beta cell reserve - glycated haemoglobin or equivalent,2018-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],PMBC - Biomarker 2
741,NCT02264951,plasma GIP,plasma CCK,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
742,NCT02967211,Change in HbA1c (percentage %),Change in fasting plasma glucose,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
743,NCT01041144,HbA1c,PP2hr Lipid profile,na,COMPLETED,INTERVENTIONAL,['NA'],
744,NCT05347030,The change in the value of 2-hour blood glucose from baseline at the end of the 12-week treatment,The change from baseline of blood pressure,2022-10-06,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Adverse Events
745,NCT03147274,Change from baseline self-care adherence at 12 months,Change from baseline hemoglobin A1c at 12 months,2017-05-03,COMPLETED,INTERVENTIONAL,['NA'],
746,NCT00660907,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Body Weight Reduction of at Least 5%,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
747,NCT02152891,Change in rate of EMS Calls,,2015-11-01,COMPLETED,INTERVENTIONAL,['NA'],
748,NCT03663322,Fasting glucose,A1C,2018-11-15,UNKNOWN,INTERVENTIONAL,['NA'],
749,NCT01107171,Hemoglobin A1c (HbA1c),"The rate of adverse events,the blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests",2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
750,NCT00655603,Glucose turn-over,"The inhibitory effect of GLP-1 on glucagon, and the role of this in its anti-diabetic potential, measured by looking at glucose turn-over.",2008-03,UNKNOWN,INTERVENTIONAL,['NA'],
751,NCT01739205,Weight loss,Inflammation,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Other outcomes
752,NCT03440203,Activities of daily living,,2017-05-11,COMPLETED,OBSERVATIONAL,['NA'],
753,NCT05596760,EHR documentation of Goals of Care discussions,Anxiety and depression (HADS),2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
754,NCT01807377,HDL cholesterol,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
755,NCT01924312,Brain T2 hyperintensity volume on MRI,Total brain volume,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
756,NCT02312427,Serum BNP level with and without DPP-4 inhibitor use.,"Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)",2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
757,NCT00591227,Hospital Length of Stay,Frequency of Hypoglycemia During Emergency Room Therapy With Insulin,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
758,NCT04799925,Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
759,NCT01222429,"indices of renal function (serum creatinine, microalbumin)",,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
760,NCT05661799,Change in amount of physical activity assessed by the French Version of GPAQ,Progressive medical data assessed by a specific form for the study,2021-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
761,NCT01633086,Neuopathic Pain Scale,the likelihood of reusing the nitric oxide gel recorded,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
762,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol,Change in FPG From Baseline to Week 78,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
763,NCT00523042,"Changes in lung function, chest X-rays, or asthma exacerbation frequency",Preprandial insulin doses,2007-08-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
764,NCT01240980,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
765,NCT05286892,Perceived Competence Scale,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA'],
766,NCT02837094,To examine the risk of C19A3 GNP administration in terms of general safety and induction of hypersensitivity.,To study the immune responses to C19A3 GNP generated in the draining (axillary) lymph node.,2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
767,NCT03207711,frequency of eating in response to cravings (primary mechanistic outcome),Perceived Stress (secondary mechanistic outcome),2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
768,NCT06150209,Time Closure in Diabetic foot ulcers Managed with Vendaje,Reduction of wound volume in diabetic foot ulcers treated with Vendaje,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
769,NCT00682903,"The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the ""fonctional"" insulin therapy",,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
770,NCT05607576,Post radiation Dexcom G6 transmitter functional duration,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
771,NCT03515421,Marketing Claims Evaluation questionnaire.,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA'],
772,NCT02456051,Pancreatic cancer diagnosis,Mortality,2015-04,TERMINATED,OBSERVATIONAL,['NA'],
773,NCT04696640,Change in hemoglobin A1c (HbA1c),Remote patient monitoring survey,2021-06-03,COMPLETED,INTERVENTIONAL,['NA'],
774,NCT01571817,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
775,NCT01857973,Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform),Percentage of Time in Euglycemic Range - Phase 7,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
776,NCT04739215,"Main Structural Objective: Changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL)",Changes in high sensitivity troponin T (pg/mL),2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
777,NCT02639988,Time to the addition of a new treatment for type 2 diabetes in months,Proportion of patients with increased HOMA-IR between 2 visits in %,2016-04-13,SUSPENDED,OBSERVATIONAL,['NA'],
778,NCT04909580,Decisional Conflict,Genetic Counselling Satisfaction Scale (modified version),2013-09-05,COMPLETED,INTERVENTIONAL,['NA'],
779,NCT05755321,Characterization of neural progenitors cells,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
780,NCT02748980,The coronary microcirculation dysfunction is measured by index of microcirculatory resistance,,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],
781,NCT05758545,Complete wound healing,Quality of life survey,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],
782,NCT00763074,,,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
783,NCT04894916,User Experience,Change in Medication Adherence,2021-06-12,COMPLETED,INTERVENTIONAL,['NA'],
784,NCT04573335,All-cause mortality,COVID-19 illness,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
785,NCT01498731,Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.,Length of hospital stay,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
786,NCT00653341,Percentage of subjects reaching target HbA1c = or < 7% at endpoint and not experiencing symptomatic nocturnal hypoglycemia,"Safety data (Adverse events, vital signs, laboratory values, etc.)",2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
787,NCT02553382,Change in HbA1c,Change in 24h ambulatory systolic blood pressure,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Change in Hs-CRP
788,NCT00362011,Hemoglobin A1c,"compliance (plasma fatty-acids, returned supplements, diet records, body weight).",2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
789,NCT05623189,Primary Endpoint,Endpoint 28,2022-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
790,NCT02755064,Relationship between gastric emptying and glycemia,Number of subjects with delayed gastric emptying,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
791,NCT05454891,Glucose Area Under Curve [AUC],Percentage of time between 70-140 mg/dL,2022-07-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
792,NCT05089942,Efficacy of Recombinant Human Insulin Patch ZJSRM2021,Pain assessment of Recombinant Human Insulin Patch ZJSRM2021,2021-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
793,NCT03522311,Visual acuity measurement,Presence of postoperative vitreous hemorrhage,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Presence of postoperative retinal detachment
794,NCT01282567,Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
795,NCT04558827,Effectiveness of Intervention: Changes in Insulin Dosage,Feasibility: Percent of day compliant with Carbohydrate target,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
796,NCT02389335,"Roles of interferon gamma, interleukin-2, tumor necrotizan factor alpha in the pathogenesis of type 1 diabetes",,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
797,NCT04958356,"Number of participants with confirmed positivity for at least one diabetes-associated autoantibody (insulin autoantibodies and antibodies to GAD65, islet antigen 2 and zinc transporter 8) or confirmed positivity for tissue transglutaminase antibodies",,2018-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
798,NCT00603590,Systolic Blood Pressure,LDL Cholesterol,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
799,NCT04304430,Combined categorized endpoint,Proportion of patients attaining blood pressure target,2018-10-18,COMPLETED,OBSERVATIONAL,['NA'],
800,NCT02994316,Interest of copeptin dosage as a severity marker in children under the age of 16 with diabatic ketoacidosis,Correlation between plasma copeptin levels and other markers used in management of diabatic ketoacidosis in the first 36 hours after diagnosis- Plasma copeptin levels at diagnosis of diabate mellitus type 1 without ketoacidosis in children,2016-10-03,COMPLETED,INTERVENTIONAL,['NA'],
801,NCT05606913,HbA1c change from baseline at week 28,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
802,NCT02742662,Change in body weight in kg,Change in plasma triglycerides,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
803,NCT05799976,Care gap order rate,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Care gap completion rate
804,NCT00481117,"Safety labs, ECGs, vital signs, adverse events.",Pharmacodynamics (lab samples) and Pharmacokinetics (lab samples),2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
805,NCT00156078,Mean pain score,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
806,NCT03380416,Liver fat content,Biochemical parameters,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],
807,NCT01724502,Protein Concentration of Mitochondria,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
808,NCT04991142,Feasibility of measuring meal quantity and composition using CGMs,Feasibility of measuring impact of gut microbiota on estimations of meal composition using CGMs,2021-09-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
809,NCT02617160,Percentage of glucose readings within range of 70-180 mg/dl,Percentage of glucose readings below 50 mg/dl,2016-05,TERMINATED,INTERVENTIONAL,['NA'],Device Satisfaction
810,NCT02597309,Reduction in insulin recuirement,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
811,NCT01480804,change in hemoglobin A1c,"Change in clinical, functional and psycho social tests and questionnaires",2006-11,COMPLETED,INTERVENTIONAL,['NA'],
812,NCT02123628,Primary outcome measure was the proportion of patients of each group with remission of diabetic foot osteomyelitis at the end of follow-up.,tolerance to treatment in each group of patients,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
813,NCT01169818,Change (decrease) in mean hemoglobin glycosylated (HbA1c) level,PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions),2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
814,NCT02103595,Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS),Insulin set replacement pattern,2013-11-01,COMPLETED,INTERVENTIONAL,['NA'],
815,NCT02439684,The specificity of the use of HbA1c,DM risk,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
816,NCT01832077,cost-effectiveness,Cost-effectiveness of van,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
817,NCT02105324,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5,Percentage of Participants Using Pramlintide During the Usual Care Period,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
818,NCT04427982,DES Score,,2020-09-03,COMPLETED,INTERVENTIONAL,['NA'],Glycated Hemoglobin (A1c)
819,NCT05725889,"Finger tap, visual and auditory reaction test data within 10 seconds",,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],
820,NCT00254254,Number of adverse events,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
821,NCT03984058,Recruitment Yield as assessed by number of participants enrolled from electronic medical records (EMR),Adherence to Pap Therapy as assessed by the ResMed AirView Remote Monitoring system,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
822,NCT05088616,Change in A1c (from baseline to 90 days and 180 days),Change in identity and level of cultural connectedness (using part of Multigroup Ethnic Identity Measure survey questions) (from baseline to 90 days and 180 days),2021-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
823,NCT05795439,HbA1C,Diet Acceptability,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],
824,NCT03254381,Number of exercise classes attended at trial completion (6 months),Change in blood glucose levels as measured by finger prick glucose test,2017-11-02,COMPLETED,INTERVENTIONAL,['NA'],
825,NCT05589155,Long term change in diabetes via fasting blood glucose,Quality of Life after using mHealth apps assessed by World Health Organization Quality of Life BREF questionnaire,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
826,NCT02312596,Percent of wounds healed,Quality of Life score,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
827,NCT05038020,To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.,To Evaluate the Changes From Baseline in the Workplace Productivity and Activity Impairment General Health (WPAI-GH) Questionnaire.,2021-08-17,TERMINATED,INTERVENTIONAL,['PHASE2'],
828,NCT05409235,Proportion of participants who have improved by ≥ 2 steps from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores,Time to administration of rescue therapy,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
829,NCT04135365,"Cognitive Function: Behavior Rating Inventory of Executive Function, Second Edition",Imaging,2021-01-18,COMPLETED,OBSERVATIONAL,['NA'],
830,NCT03903042,Image Quality of Aurora camera,Outcome of artificial intelligence algorithm,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
831,NCT03407833,Ability to establish organoid cultures,,2018-02-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
832,NCT00883038,Insulin resistance,Visceral to subcutaneous fatty tissue ratio,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
833,NCT03978884,Proportion of Subjects achieving Target Blood Pressure,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
834,NCT01779089,Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline,Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos,2009-02,UNKNOWN,INTERVENTIONAL,['NA'],Safety
835,NCT02183350,Assessment of tolerability by investigator on a 4-point scale,Change in plasma glucose levels,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
836,NCT02087293,Discontinuation of mediation,Adverse drug reaction awareness,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],Call metrics
837,NCT04208295,Autonomic adrenergic measure,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
838,NCT05404295,The efficacy of UCB-PL in ulcer healing by assessing the change in ulcer size.,,2019-06-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
839,NCT01645891,Complete (100%) wound closure defined as complete re-epithelialization without drainage,Total Bates-Jensen Wound Assessment Tool Score,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
840,NCT05146869,Change from baseline in active glucagon-like peptide1 concentration,Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.,2021-12-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
841,NCT05296759,Pittsburgh sleep quality index,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
842,NCT00541697,Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment,Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment,2005-01-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
843,NCT04533646,Time in Target,Hypoglycemia duration,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
844,NCT05809843,The measurements of retinal and choriocapillary vessel density in type 1 diabetic patients undergoing artificial pancreas device,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA'],
845,NCT06148649,Change from baseline of HbA1c at week 12,Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs),2023-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
846,NCT05338125,Electrophysiological properties,Endocrine deficiencies,2020-12-10,TERMINATED,INTERVENTIONAL,['NA'],
847,NCT06219590,Numerical rating pain scale,,2023-10-28,RECRUITING,INTERVENTIONAL,['NA'],
848,NCT00929539,Change in glycosylated hemoglobin (HbA1c) levels,Safety and tolerability data,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
849,NCT04593693,"Goal of therapy: The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft",Evaluate overall satisfaction from clinicians,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],Determine performance satisfaction of dressing components on periwound
850,NCT02159378,Serum fructosamine rate,,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
851,NCT01591525,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],
852,NCT01375738,Blood sugar stabilization after gastrectomy,,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
853,NCT00464854,Achievement of a fasting blood glucose of 130 mg/dl and a mean daily glucose level of 180 mg/dl during hospitalization,Hypoglycemia of < 60 mg% (symptomatic and asymptomatic),2005-07,TERMINATED,INTERVENTIONAL,['NA'],
854,NCT00790556,Mean Change From Baseline in Hepatic Glucose Production (HGP) at Day 14,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Hepatic Glucose Production (HGP) at Baseline
855,NCT00256867,Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy,Number of of Participants With Laboratory Evaluations of Potential Clinical Concern at Any Time Post-baseline,2005-08-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
856,NCT03865394,Changes in wound size,Record of adverse events,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
857,NCT05666843,Cardiometabolic risk profile (DIAL risk score),Skeletal muscle fat infiltration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
858,NCT03226210,The primary endpoint was the between-group difference of MAGE,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
859,NCT01097551,Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit),"Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.",2011-01,COMPLETED,OBSERVATIONAL,['NA'],
860,NCT00976391,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26,"Change From Baseline in Body Weight at Weeks 36, 48 and 52",2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
861,NCT06078683,Changes in maximal exercise performance,Change in Cardiac function after acute ingestion of KE or placebo,2023-06-06,RECRUITING,INTERVENTIONAL,['NA'],Change in stiffness
862,NCT00885118,Change From Baseline in 8-point Glucose,"CLR,ss",2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
863,NCT04702477,Intervention Attendance,Program satisfaction and barriers for attending sessions,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
864,NCT02734667,Time Spent in Hypoglycemia (< 70 mg/dL),C-peptide,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
865,NCT05856877,"Comparison of the blood-brain-barrier permeability in different age, weight, sex and metabolic risk groups",,2023-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
866,NCT02182830,Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks,Change From Baseline in Trough Seated DBP (mmHg) at Week 24,2014-07-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
867,NCT01592539,,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
868,NCT01046422,Fasting Plasma Glucose Improvement,Lipid profiles,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
869,NCT02776722,Chronic glycemic outcome - fasting insulin,,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
870,NCT01689090,Diameter changes of retinal vessels,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
871,NCT04269655,Percentage time in severe hyperglycemia of interstitial glucose values,Hospital readmission rate,2020-02-25,TERMINATED,INTERVENTIONAL,['NA'],CGM Satisfaction
872,NCT01134107,Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use,Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline to 12 Weeks Endpoint for Each Treatment in Blood Pressure
873,NCT00493727,This research will test the possibility the Mucomyst given by mouth for a month will decrease oxidative stress and slow the disease.,Reduction of proteinuria,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
874,NCT01699763,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),2012-10,COMPLETED,INTERVENTIONAL,['NA'],
875,NCT00753896,Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events,Change in Blood Pressure From Baseline to Week 52,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
876,NCT04966754,Rate of mortality,Quality of life,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
877,NCT01432405,Hepatic Fat,Plasma Adipocytokines,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
878,NCT04050553,Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL,Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
879,NCT04530617,Rate of hospitalizations and oxygen use,,2020-10-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
880,NCT01488734,25OH Vitamin D level,Markers of inflammation and metabolic control,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
881,NCT03981627,ΔAUCPG(0-4h),Safety and tolerability (Adverse Events recording),2019-06-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
882,NCT00633425,Change in interstitial glucose levels between the observation and maintenance phases.,HbA1c and fasting blood glucose levels.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
883,NCT03463941,Health Educators' Perceptions of Feasibility as Measured by Semi-structured Interviews,Goal Attainment as Measured by Days Per Week That Participants Exercised for 30 Minutes or More,2019-01-05,COMPLETED,INTERVENTIONAL,['NA'],
884,NCT00814008,retinal blood flow after 1 hour of insulin clamp,"Mean blood velocities in ophthalmic artery, posterior ciliary arteries and central retinal artery after 1 hour of insulin clamp",1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
885,NCT01488877,Number of Participants With Confirmed and Severe Hyperkalemia,Change From Baseline in Sitting Pulse Rate at Day 15,2012-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
886,NCT00507494,proteinuria,"efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema",2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
887,NCT02811172,Collection of samples: mother's milk,Bioactive peptides,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
888,NCT04783376,Capillary blood glucose levels six hours after the test meals.,assessment of serum triglyceride level three hours after the test meal following each intervention,2021-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
889,NCT03575988,"pulmonary function parameters(diffusing capacity for carbon monoxide of lung/unit volume,DLCO/VA,%)","Vascular endothelial function(endothelin-1,ET-1,μmol /L)",2018-07-03,UNKNOWN,OBSERVATIONAL,['NA'],"Serum lipid(Triglycerides,TG(mg/dl))"
890,NCT00044460,Change in HbA1c from baseline to Week 24.,Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
891,NCT05149625,Hemoglobin A1c (HbA1c),"Fasting, postprandial plasma glucose",2022-11-27,RECRUITING,INTERVENTIONAL,['NA'],
892,NCT00566475,hemoglobin A1c,"glucose levels, hypoglycemia, quality of life, satisfaction",2007-01,COMPLETED,INTERVENTIONAL,['NA'],
893,NCT03840343,Adverse Events,Kidney Function,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE1'],
894,NCT02844660,Study Safety Measurement,Cost effectiveness of treatment,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
895,NCT04207541,Proportion of insulin initiation,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
896,NCT01241370,"Comparison of retinal microvascular endothelial function in obese insulin sensitive, insulin-resistant and type 2 diabetic subjects with retinal microvascular endothelial function in lean healthy control subjects.",Comparison of the Oral Glucose Tolerance Test (OGTT) in the different subject groups with skin and retinal endothelial function.,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
897,NCT00596297,Intra- and postoperative intra-ocular bleeding,Visual acuity,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
898,NCT01054300,Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin,,2010-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
899,NCT02945540,Measuring patient satisfaction at childbirth by a questionnaire on satisfaction of hospital care,Neonatal blood glucose measurement,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
900,NCT04917471,Percentage recovery of left ventricular function,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],
901,NCT06269120,Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%,Change in high sensitive C-reactive protein (hsCRP),2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
902,NCT02156336,Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.,Occurrence of Serious Adverse Events after randomization,2014-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
903,NCT00515632,"HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.","Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin",2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
904,NCT01850615,Change From Baseline in HbA1c,Number of Adverse Events,2013-09-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
905,NCT01653392,Infant Outcomes,,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
906,NCT02605889,Improvement of blood postprandial glucose levels,Improvement of Nursing Diagnoses,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
907,NCT02031341,"Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow;",,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
908,NCT00495469,Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12,Number of Participants With Abnormal Hematology Value of PCI at Any Time on Therapy,2007-08-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
909,NCT04550520,Maximal increase in copeptin level,Maximal Change in oxytocin,2020-09-28,COMPLETED,INTERVENTIONAL,['NA'],
910,NCT02529982,Change in pancreatic B-cell function,Waist circumference,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
911,NCT00524875,early post-vitrectomy vitreous hemorrhage,Visual improvement,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
912,NCT00543751,,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
913,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
914,NCT02898766,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
915,NCT02916576,System accuracy criteria (see description),,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
916,NCT06246799,Number of subjects failing to achieving HbA1c <6.5% Long-term,Change in body weight,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
917,NCT01756703,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
918,NCT02839226,"comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases",Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
919,NCT01722240,HbA1c (%),Body Weight,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
920,NCT02681874,Increase in Healthy Food Dietary Patterns,Improvement in Parental Feeding Behaviors,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
921,NCT03324971,Change in Hemoglobin A1c,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA'],
922,NCT01136096,Exercise behavior,Exercise behavior,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
923,NCT06048510,Incidence of GDM diagnosed during pregnancy.,Neonatal morbidity 4,2023-12-18,RECRUITING,INTERVENTIONAL,['NA'],
924,NCT00600730,fMRi scans,,na,WITHDRAWN,INTERVENTIONAL,['NA'],
925,NCT02600338,Mean arterial pressure,,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
926,NCT02981069,Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug.,Change in Plasma Insulin Concentration,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
927,NCT02933424,Change in body composition,Meal challenge,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
928,NCT00835861,Blood Glucose Measurements,Number of Babies With Adverse Neonatal Outcomes,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
929,NCT00773279,HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®,"Hypoglycaemic Episodes, Number of Events Per Subject Day",2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
930,NCT06173934,Characteristics of gastric emptying(the gastric half-emptying time ) in patients with type 1 diabetes.,The blood glucose,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],
931,NCT01646047,Changes in visual function,Changes in retinal structure,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
932,NCT03396146,Measurement of pancreatic polypeptide for calculating the area under the curve,Measurement of fecal elastase level,2018-06-14,COMPLETED,INTERVENTIONAL,['NA'],
933,NCT02895750,Efficacy of once daily Metformin XR on 24-h blood glucose control,Tolerability of Metformin XR in mild to moderate (CKD) 2,2017-08-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
934,NCT01517919,"Changes in clinical, self-care and diabetes-related quality of life from baseline","Changes in clinical, self-care and diabetes-related quality of life from baseline",2010-01,COMPLETED,INTERVENTIONAL,['NA'],
935,NCT01483781,Change in hematology laboratory analytes,Change in percent Hemoglobin A1c (HbA1c),2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
936,NCT02523001,uAQP2,Cholesterolemia,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
937,NCT02059005,Change in Substance Use Rates From Baseline,Number of Hospitalizations and Use of Emergency Services,2014-11-18,COMPLETED,INTERVENTIONAL,['NA'],
938,NCT01476345,Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus,Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
939,NCT02068027,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
940,NCT02916706,Change in HbA1c From Baseline to Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
941,NCT00988182,"Blood glucose, Insulin, Subjective appetite",Physical comfort,na,COMPLETED,INTERVENTIONAL,['NA'],
942,NCT01565096,Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min),Drug related adverse events,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
943,NCT04816890,Body weight change from baseline to week 16 of treatment,Hypoglycaemic episodes,2021-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
944,NCT02204397,Safety and tolerability,Composite C-Peptide efficacy according to specific parameters,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
945,NCT01578096,Hemoglobin A1c,Diabetes specific distress,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
946,NCT03889977,Changes in blood triglycerides,Changes in substances that react with thiobarbituric acid (TBARS),2019-02-11,COMPLETED,INTERVENTIONAL,['NA'],
947,NCT01989975,Subject Experience After Using the Carelink Connect Device,Number of Participants With Investigational Device Deficiencies,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
948,NCT06301022,serum potassium,,2022-12-15,RECRUITING,OBSERVATIONAL,['NA'],
949,NCT03675269,Change in wound size,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['NA'],
950,NCT00371007,"HbA1c, safety and tolerability",Plasma glucose,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
951,NCT02022111,Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors,Cost Utility in the Treatment Arm and Usual Care Arms,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
952,NCT05769868,Ejection Intraventricular Pressure Difference (EIVPD) measure,Matrix metalloproteinase-1 (MMP-1),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE3'],
953,NCT05869734,Sleep efficiency,Self-management of urologic health,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],
954,NCT03800901,Change in the percentage of evidence-based diagnostic and treatment decisions made in the simulations.,Impact of available CME and ABIM MOC on retention rate,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],
955,NCT01447121,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Study Staff Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method When Testing Subject Blood Glucose (BG),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
956,NCT05773209,Changes in subfoveal choroidal thickness,Changes in DR grading,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
957,NCT01804803,Changes in HbA1c from baseline value,"Subgroup analyses of changes in HbA1c from baseline according to patients' age (<45 yrs, >45yrs), type of diabetes (type 1, type 2), and diabetes duration (<5 yrs, >5 yrs)",2013-09-09,COMPLETED,INTERVENTIONAL,['NA'],
958,NCT02691429,ocular inflammation,complications of the posterior segment,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
959,NCT04031417,Hypoxia and low humidity on the endothelial function in healthy volunteers and patients with type 2 diabetes using Wilcoxon signed rank test,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
960,NCT00251953,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
961,NCT06063109,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Pharmacokinetics - PTF,2023-10-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
962,NCT01927562,Changed in Mixed Meal Tolerance From Baseline to 3 Months,,2013-07-13,COMPLETED,INTERVENTIONAL,['NA'],
963,NCT00005479,,,1996-09,COMPLETED,OBSERVATIONAL,['NA'],
964,NCT00491543,Pharmacokinetics,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
965,NCT05144737,Change in body mass index over a 6-month period,Change in resting metabolism over a 12-month period,2021-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in pain severity over the 12-month period
966,NCT03751813,lower blood stress markers via venous draw,,2019-03-21,TERMINATED,INTERVENTIONAL,['NA'],
967,NCT00494884,Change from baseline in HbA1c,Change in systolic and diastolic blood pressure,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
968,NCT04161131,Hemoglobin A1c (HbA1c),Frequency of Blood Glucose Monitoring,2019-12-09,COMPLETED,INTERVENTIONAL,['NA'],
969,NCT01023906,Sensory/hedonic rating,Genetic Variation,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
970,NCT01076075,Number of Participants Discontinuing Study Drug Due to An Adverse Event,Change From Baseline in Fasting Plasma Glucose at Week 24,2010-06-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
971,NCT05290506,change from baseline in insulin sensitivity/resistance index after 12-week treatment,change from baseline in beta-cell function after 12-week treatment,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
972,NCT06203860,"Time to first occurrence of major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure (HF).",Cost-effectiveness ratio of implementing a Cardio-Metabolic Clinic,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
973,NCT04187443,Treatment-emergent adverse events,Average mean change in best corrected visual acuity,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],
974,NCT02796534,"Prevalence of obstructive sleep apnea syndrome by oxymetry, confirmed by polysomnography",Incidence of new cardiovascular events and changes in microangiopathic complications of diabetes patients depending on the presence of sleep apnea syndrome and to the adherence to CPAP treatment in case of sleep apnea syndrome treated,2016-07-28,COMPLETED,OBSERVATIONAL,['NA'],
975,NCT00005116,,,na,COMPLETED,INTERVENTIONAL,['NA'],
976,NCT01536600,Change in HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),2004-09,COMPLETED,OBSERVATIONAL,['NA'],
977,NCT03417466,Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values),Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values,2018-06-28,COMPLETED,INTERVENTIONAL,['NA'],
978,NCT04621929,New kidney stone formation (mm2) as determined by non-contrast CT scan,Change in urinary uric acid parameters,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],
979,NCT00732147,Endogenous glucose production,Endogenous VLDL-Triglyceride production,2009-04,WITHDRAWN,INTERVENTIONAL,['NA'],
980,NCT01631084,Incidence of all diabetes-related clinical endpoints,Proportions of patients with improved control of risk factors,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
981,NCT00907374,Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio,Endothelial Dysfunction,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
982,NCT02427464,Number of Participants With Treatment-emergent Adverse Events.,Participants With at Least a 50 Percent Reduction in Average 24-hour Pain Score From Baseline to Day 180,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
983,NCT05999110,Change in Respiratory Compensation Point (RCP - VO2),Change medical appointments number related with Knee Osteoarthritis,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
984,NCT03552523,Average Time Spent With CGMG Less Than 54 mg/dl,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA'],
985,NCT00141986,change in 25(OH)D from baseline,changes in urine calcium:creatinine ratio,2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
986,NCT01552499,The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of care,Mean time to complete healing,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
987,NCT01412905,,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
988,NCT05439226,HbA1C,Metabolomics,2022-07-05,RECRUITING,INTERVENTIONAL,['NA'],
989,NCT01527747,Change in fasting and postprandial triglyceride concentrations,Changes in glycemia,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE4'],
990,NCT04998032,HbA1c,salvage treatment,2021-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
991,NCT00198471,Vitreous detachment,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
992,NCT05881447,Incidence of cardiovascular- and non-classic risk factors of CKD:,Assessment of Hypertension incidence,2023-06-21,RECRUITING,OBSERVATIONAL,['NA'],
993,NCT02995629,Perceived patient pain assessment,Time of treatment,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
994,NCT01508949,Change in weight,Adverse events,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
995,NCT01301521,Water-soluble Cinnamon,,2013-06-11,COMPLETED,INTERVENTIONAL,['NA'],
996,NCT02834689,Mean 24 hour glucose levels (mmol/l),Time spent above 10 mmol/l glucose,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],
997,NCT01165944,HgA1c,Continuous glucose monitoring,2009-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
998,NCT03626623,Number of Wounds With Wound Closure,Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs,2019-05-21,TERMINATED,INTERVENTIONAL,['NA'],
999,NCT03665974,Pre-pregnancy BMI,,2013-01-05,COMPLETED,OBSERVATIONAL,['NA'],
1000,NCT03550066,Acceptance of Health Message,Diabetes Prevention Behavior: Intention,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1001,NCT01142297,Implant Stability Quotient (ISQ),Clinical Success of Implants,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
1002,NCT05735873,Change from Baseline to 12 weeks in Numeric Pain Rating Scale,Change from Baseline to 12 weeks in diastolic blood pressure,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1003,NCT02887898,Change in HbA1c,Change in treatment satisfaction,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Adherences to bolus calculator use
1004,NCT06099067,3-point MACE,,2020-05-15,COMPLETED,OBSERVATIONAL,['NA'],
1005,NCT01627899,Change in A1C From Baseline to Week 24,Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks,2012-10-01,TERMINATED,INTERVENTIONAL,['NA'],
1006,NCT03962296,The change(Improvement)in the hard exduates,The change of total macular volum(TMV),2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
1007,NCT02546063,Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring,User satisfaction,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
1008,NCT02994095,PACIC score,,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
1009,NCT04932213,Change from baseline in pupillary diameter,Change from baseline in central corneal thickness (CCT),2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1010,NCT01217463,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition",Relative Wound Area Regression of 40% or More at 6 Week,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1011,NCT05661474,the proportion of patients complete responders,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1012,NCT03530930,Change From Baseline in Visual Analogue Scale for Pain,Patient global assessment of osteoarthritis,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
1013,NCT06003400,Change in wound size between V1 and the last treatment,,2023-03-29,RECRUITING,INTERVENTIONAL,['NA'],
1014,NCT05263232,average 24h blood glucose levels,Culturing human primary myotubes to assess circadian reporter characteristics,2022-03-16,COMPLETED,INTERVENTIONAL,['NA'],mRNA in peripheral blood mononuclear cells (PBMC) of markers involved in the molecular clock
1015,NCT02117154,Area Under The Curve for Glucose excursion,"Measurement of HbA1c, fructosamine, Glycated albumin levels",2013-06,COMPLETED,OBSERVATIONAL,['NA'],
1016,NCT04582448,"AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1017,NCT02829177,Improved Albuminuria,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1018,NCT06218147,Percent of glucose time in range assessed by using continuous glucose monitor,Amount of fasting blood glucose,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],
1019,NCT01498913,Body weight,Adverse events,2001-08-30,COMPLETED,OBSERVATIONAL,['NA'],
1020,NCT01500798,Measured GFR assessed by plasma clearance of Tc99m-DTPA,Circulating endothelial cell assessments,2012-01-31,TERMINATED,INTERVENTIONAL,['PHASE1'],
1021,NCT01917669,Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?,Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?,2013-10,WITHDRAWN,OBSERVATIONAL,['NA'],"What component of peripheral metabolic dysregulation (HbA1c (%), adiponectin (ug/mL), cholesterol (mg/dL)) is associated with changes in calcium responses (nM) in skin fibroblasts?"
1022,NCT02784236,To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
1023,NCT01202266,Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145,Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
1024,NCT04866264,Subjective effectiveness questionnaire of eNutrition Optimizer,systolic and diastolic blood pressure,2021-11-11,RECRUITING,INTERVENTIONAL,['NA'],
1025,NCT02952352,Weight,Stages of Change for weight loss,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
1026,NCT00162305,To assess the safety and tolerability of multiple oral doses of BMS-512148 administered alone or concomitantly with metformin in diabetic subjects,To identify potential biomarkers in both urine and blood,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1027,NCT00489879,"HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profiles","exercise time during one week, self reported change in dietary habit, fat consumption ratio",2007-07,COMPLETED,INTERVENTIONAL,['NA'],
1028,NCT05144802,Assess accuracy of interstitial glucose values measured respectively by FreeStyle® Libre and Dexcom® G6 compared to blood glucose values in standardized hypoxemia conditions in patients with diabetes and in healthy volunteers.,Tolerability of acute hypoxia,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],
1029,NCT03440502,the incidence of complete failure of spinal block.,determine the effect of DM on the other spinal block criteria,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
1030,NCT06188572,Ferrans&Powers Quality of Life Index Diabetes Version,,2023-05-01,COMPLETED,OBSERVATIONAL,['NA'],
1031,NCT01902316,measurement of the amount of plasma peptides,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
1032,NCT04051229,Blood collection_insulin follow up 2,VO2 peak,2019-10-29,TERMINATED,INTERVENTIONAL,['NA'],
1033,NCT05498974,PAID,Metabolomics,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
1034,NCT01960231,fasting and post glucose load glucose level,fasting and post glucose load c-peptide,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],glucose metabolism measured by CGMS
1035,NCT02228642,Prevalence of Hypoglycemia Associated Autonomic Failure in the inpatient setting as assessed by hypoglycemia symptom scores,Measures of cognitive function following a hypoglycemic event,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Measure of cognitive function
1036,NCT00818077,Glycemic Response to the Fixed Meal,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
1037,NCT00935467,Evidence of steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,To assess the safety and tolerability of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1038,NCT02560090,Change of Self-management Success Measured by Diabetes Self-Management Assessment Survey Tool from Baseline to Study Completion,Change of Diet Measured By a 24-item Introduction to the Lifestyle Survey from Baseline to Study Completion,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1039,NCT01588366,Change From Baseline to Day 28 in Hepatic Glycogen Content,Change From Baseline to Day 29 in Insulin Response to an Arginine Stimulation Test (AST) (Part A),2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1040,NCT02723539,Proportion of participants who are clinically cured,Proportion of participants who are microbiologically cured,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1041,NCT04263675,Study the mechanisms linked to the effect of breastfeeding on the growth of children in women who have had GDM.,"Associate level of hormones related to satiety and energy metabolism (i.e. endocannabinoids, ghrelin, leptin) in the human milk of women with or without GDM and the growth of the child.",2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1042,NCT05130593,Palatability of Bar,Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.,2021-10-25,COMPLETED,OBSERVATIONAL,['NA'],
1043,NCT00021801,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1044,NCT03404895,Number of days to ulcer healing,Total number of subjects with minor and major amputations,2018-04-13,RECRUITING,INTERVENTIONAL,['NA'],
1045,NCT05330208,Incidence of reaction of the injection sites,Immunogenicity,2022-04-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1046,NCT01536639,HbA1c (glycosylated haemoglobin),Adverse events,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
1047,NCT02480244,Change in BMI,Change in blood pressure,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
1048,NCT04528212,Sirtuin1 (SIRT1) (ng/ml),Triglyceride (mg/dl),2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1049,NCT01189890,Number of Participants Discontinuing Study Treatment Due to An AE,LS Mean Change From Baseline in Participant Body Weight at Week 30,2010-08-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
1050,NCT05038046,Change from Baseline in Nerve Conduction Velocity at 3 months,heart rate variability,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1051,NCT02950181,Observing Cerebral oximetry readings when patients present to the pediatric emergency department,,2014-07-29,TERMINATED,INTERVENTIONAL,['NA'],
1052,NCT06132126,Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters,Part A and Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC),2023-11-17,RECRUITING,INTERVENTIONAL,['PHASE1'],
1053,NCT00469833,Insulin Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,HbA1c Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
1054,NCT01512979,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in FPG by Visit Over Time,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1055,NCT02501850,Change in blood levels of Lipoprotein (a) (Lp(a)),,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1056,NCT00521690,"Incidence of serious adverse events, including major hypoglycaemic events",Incidence of hypoglycaemic episodes,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1057,NCT01516242,Patient satisfaction with NovoPen® 4 insulin delivery system,Hypoglycaemia,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
1058,NCT03814512,Change in Total Sleep Time,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA'],
1059,NCT02911311,The primary outcome is mean visual acuity change(BCVA),change of central retinal thickness,2019-10-12,UNKNOWN,INTERVENTIONAL,['NA'],
1060,NCT02274207,Days to patient discharge,Rate of adverse event,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1061,NCT00485758,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1062,NCT01278160,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline,Number of Treatment Emergent Hypoglycaemic Episodes,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1063,NCT05174507,Number of symptomatic hypoglycemia,Change in RNA sequencing (RNAseq) in peripheral PBMC,2022-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1064,NCT03767790,Time in target glucose range,Unanticipated adverse device effects (UADE),2019-01-03,COMPLETED,INTERVENTIONAL,['NA'],Device Issues
1065,NCT00516074,Change in Mean 24-hour Heart Rate From Baseline to Endpoint,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1066,NCT03384758,rHb,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
1067,NCT03078725,Failure rate,incidence of medication side effects,2017-06-20,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
1068,NCT01997281,Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal,AUC of Plasma Total GLP-1 Levels After Lunch,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
1069,NCT03394352,Continuous Glucose Monitor metrics,,2018-01-17,COMPLETED,INTERVENTIONAL,['NA'],
1070,NCT04876274,HbA1C,Score of Simplified True / False Version of Diabetes Knowledge Scale,2020-07-14,COMPLETED,INTERVENTIONAL,['NA'],Score of Newest Vital Sign
1071,NCT00269061,Changes in interstitial fluid volume in the lower extremities as measured by MRI.,"Assessments of other indicators of fluid volume changes, including labwork evaluation, fluid compartment volume measurement, direct measurement of the calf.",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1072,NCT00960453,"To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1073,NCT00445627,evaluate phenotype of T2DM,,2007-06-18,COMPLETED,OBSERVATIONAL,['NA'],
1074,NCT01462227,Glucose Infusion Rate (mg/kg.Min),Norepinephrine (pg/mL),2011-08,COMPLETED,INTERVENTIONAL,['NA'],
1075,NCT01340664,Change in HbA1c From Baseline to Week 18,Percentage of Patients With HbA1c <7% at Week 18,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1076,NCT03014908,Metabolic phenotype of type 1 diabetes mellitus,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
1077,NCT03281512,Diabetes,Overweight,1989-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1078,NCT00853801,Providers improve their ability to diagnose and treat metabolic syndrome/pre-diabetes.,Assess changes in insulin resistance using the HOMA-IR index and in vascular inflammation status using C-Reactive protein in the intervention and control groups.,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
1079,NCT03152084,Change in 24-hour Sodium Excretion From Baseline to Start of Treatment,Number of Patients With AEs and SAEs,2017-07-12,TERMINATED,INTERVENTIONAL,['PHASE4'],
1080,NCT00843388,"albuminuria, expected decrease","plasma renin, angiotensin, aldosteron",2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1081,NCT00264394,Reduction in total cholesterol in the entire SHCS population,"The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)",2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1082,NCT02313428,Wound Closure,Quality of Life for subjects- SF-36,2020-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1083,NCT00041405,,,2001-07,COMPLETED,OBSERVATIONAL,['NA'],
1084,NCT01930188,Change in HbA1c (Glycosylated Haemoglobin) From Baseline,Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no),2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1085,NCT01726829,The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl,Artificial Pancreas Satisfaction Questionnaire,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
1086,NCT00570739,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks,Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1087,NCT05594563,Number of participants with treatment-related adverse events as assessed by CTCAE v5,"Biomarkers of β cell stress at 3, 6, 9, and 12 months after treatment.",2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
1088,NCT03144505,"Changes from baseline HbA1c at 3, 6, 9 and 12 months",Changes from baseline quality of Life at 12 months,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
1089,NCT04245267,Glycemic control after the program,"Health-related Quality of Life perception assessed by EQ-5D Indexed score (0-1, higher score means better Quality of life perception)",2017-01-07,UNKNOWN,INTERVENTIONAL,['NA'],Blood pressure of the patients who attended the program compared with patients attended in primary care units (wait-list)
1090,NCT04600622,Average Feasibility Score,Change in Family and Friend Involvement in Diabetes score,2021-06-17,COMPLETED,INTERVENTIONAL,['NA'],
1091,NCT06206525,Clinical significant hypoglycemia,Clinical significant hyperglycemia,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1092,NCT00982371,"1 Tesla peripheral MRI assessment at non dominant distal radius: Trabecular bone micro-architecture parameters Tb.Th, Tb.Sp, Tb.N, BV/TV, bone CSA, marrow space","Calcium, vitamin D and vitamin K dietary intakes; TUG (sec); grip strength; DXA assessment of hip, lumbar spine, total body; physical activity",2008-09,COMPLETED,OBSERVATIONAL,['NA'],
1093,NCT00815178,Maximum inspiratory pressure,autonomic modulation assessed by heart rate variability,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
1094,NCT05353790,Changes in Kidney function markers,Changes in Cognitive Function-6,2021-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1095,NCT05022875,Change in Hypoglycemic Events,Change in Diabetes Knowledge Questionnaire score over time,2021-04-23,UNKNOWN,INTERVENTIONAL,['NA'],
1096,NCT00536549,"HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles",three day diary meals and seven day physical activity diary,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
1097,NCT04115592,Postprandial glucose,Postprandial insulin,2019-02-20,COMPLETED,INTERVENTIONAL,['NA'],
1098,NCT01195090,The Percentages of Patient Achieving an A1C <7%,Baseline High-density Lipoprotein Cholesterol (HDL-C),2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1099,NCT02236962,brown adipose tissue activity,,2012-04,UNKNOWN,INTERVENTIONAL,['NA'],
1100,NCT01983917,Change of diabetic retinopathy risk factors,Motivation for adhering to treatment recommendations and follow-up,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],
1101,NCT00964262,To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1102,NCT06275971,Time within the target range of 100-180 mg/dL,Mortality within 30 days of surgery,2022-11-24,RECRUITING,INTERVENTIONAL,['NA'],
1103,NCT01099956,Increase of Interleukine 6 in group DTI versus control group,"Increase of others cytokines (IL1-beta, l'IL-4, l'IL-10 and TNF alpha) and increase of High sensitivity CRP in group DTI versus control group",2010-04,COMPLETED,OBSERVATIONAL,['NA'],
1104,NCT01778049,Change From Baseline of HbA1c After 24 Weeks of Treatment.,Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1105,NCT01285934,C-peptide,Stimulated C-peptide levels during mixed meal tolerance test,2009-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1106,NCT03563313,Time in Target Range,BMI,2018-06-28,COMPLETED,INTERVENTIONAL,['NA'],Any Adverse Event Rate Per 100 Person-years
1107,NCT05975242,Spanish-language Diabetes Self-Efficacy Scale (DSES-S),Weight,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],Mobile Device Proficiency Questionnaire (MDPQ)
1108,NCT00515099,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
1109,NCT00907075,"Average percent deviations from the assigned eating system score for full days, meals, and snacks for each group during each evaluation period throughout the intervention (days 23-28 and days 51-56).",Change in dietary macronutrient composition from baseline to end of treatment.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
1110,NCT02713477,Measurement of plasma glucose concentrations,Measurement of anti-insulin antibodies,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1111,NCT06202950,Glycemic control form,,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1112,NCT03651466,"Incidence, nature and severity of Adverse events",Pharmacokinetics(PK) variables,2017-08-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
1113,NCT02234973,mean HbA1C of patients with diabetes (A1C ≥ 8.0% at baseline),,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
1114,NCT00993096,Area (AUC) under the glucose infusion rate curve,Area (AUC) under the insulin aspart concentration time curve,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1115,NCT03274089,Hemoglobin A1c,Health-related quality of life questionnaire,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],
1116,NCT02890836,Early preterm delivery (Danish),Chronic hypertension,2016-02,COMPLETED,OBSERVATIONAL,['NA'],Body mass index (BMI)
1117,NCT03956797,Incidence of Anesthesia-Related Adverse Events,Pain of Intravitreal Injection (Follow-Up): VAS,2019-04-15,COMPLETED,INTERVENTIONAL,['NA'],
1118,NCT00063674,,,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1119,NCT01591902,Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.,Change from baseline in HbA1c by intensification of concomitant diabetic treatment,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
1120,NCT04009642,The difference in myocardial FA extraction fraction (%) between T2D patients and non-diabetic controls at rest.,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA'],
1121,NCT01120444,Blood Glucose,Insulin levels,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1122,NCT00670683,Incidence of adverse events,Clinical laboratory abnormality,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
1123,NCT00740922,The primary objective of this study is to retrospectively evaluate the safety of sterile becaplermin gel vs. sterile placebo gel treatment 12 months or more after the last dose was administered.,The secondary objective of the trial was to evaluate recurrence of the Target Ulcer if it had healed in the previous trial.,1999-07,COMPLETED,OBSERVATIONAL,['NA'],
1124,NCT05291975,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Neuropathic Pain Symptom Inventory (NPSI),2022-02-17,RECRUITING,INTERVENTIONAL,['NA'],
1125,NCT00728377,Gestational diabetes diagnosis assessed through glucose tolerance test.,Adoption and maintenance of exercise during pregnancy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
1126,NCT05795582,Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo,,2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],
1127,NCT00529048,Progress in Incretin effect in patients with T2DM compared with healthy subjects,GIP and GLP-1 responscurvs,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
1128,NCT02449213,Insulin resistance,glycated hemoglobin (HbA1c),2016-03-11,COMPLETED,OBSERVATIONAL,['NA'],
1129,NCT01186354,Accurate understanding of genetic risk information,Impact on behavior change,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
1130,NCT03556605,"Change in A1c from baseline at 12 weeks in intervention group compared to control group. At this point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks.",,2018-07-30,UNKNOWN,INTERVENTIONAL,['NA'],
1131,NCT00530023,Change in A1C From Baseline to Week 15,Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1132,NCT01981031,End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure),Number of Adverse Events,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1133,NCT05411640,Australian type 2 diabetes risk assessment tool (AUSDRISK),Borg rating of perceived exertion (RPE),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1134,NCT00687284,Change in glycaemic control as measured by HbA1c.,Change in waist and hip perimeter,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
1135,NCT03588000,absolute change in % HbA1c from baseline to 12 months,change in blood glucose from baseline to 24 month,2018-11-23,COMPLETED,INTERVENTIONAL,['NA'],change in health economics indexes from baseline to 24 months
1136,NCT01835964,Change Between Pre and Post Challenge Glucose Variability,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
1137,NCT03597815,Apnea-Hypopnea Index,CPAP compliance,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
1138,NCT04403945,the comparison of the density of total length of the small perfusd vessels(PDV) in the acquisition window between the 3 groups,Correlation comparison: The correlation between SDF vascular parameters and the clinical data of the subjects was compared,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],
1139,NCT01353469,Change in HbA1c from baseline to the end of treatment,Change in fasting plasma glucose from baseline to the end of treatment,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1140,NCT02962921,Left ventricle ejection fraction (%),Time needed to exert insulin effect on myocardial function (hour),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],A' (centimeters)
1141,NCT02847390,Hyperglycemia,,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
1142,NCT02711059,quality of life - self estimation protocol,cognition,2015-10,WITHDRAWN,INTERVENTIONAL,['NA'],
1143,NCT01880476,Changes from baseline in the Summary of Diabetes Self-Care Activities questionnaire,Changes from baseline in number of hypoglycemic events per week (blood glucose <4.0 mmol/L),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Partnership and collaboration questionnaire
1144,NCT02250066,Incidence of Diabetes in 322 Subjects with Prediabetes,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
1145,NCT01170442,Area under the curve of HA1C.,incidence of hypercalciuria,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
1146,NCT04651816,Subject Retention,Opinions about PSH DPP program,2021-05-25,COMPLETED,INTERVENTIONAL,['NA'],
1147,NCT02227849,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Change in Blood Pressure,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1148,NCT01302145,"Safety assessed by incidence of adverse events, vital signs, 12-lead ECG and glucose monitoring",Pharmacokinetics assessed by metformin plasma concentration change,2009-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
1149,NCT04146155,Initial and absolute claudication distance,Changes from baseline in HbA1c,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1150,NCT04430582,Assessment of working memory,Assessment of psychomotor speed,2020-08-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1151,NCT02499107,Food Intake,subjective appetite,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
1152,NCT04952324,carriers of the MTHFR gene mutation have higher serum homocysteine concentrations in the blood,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1153,NCT03466567,"Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide","Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide",2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
1154,NCT04304963,LIG optimum detection of hypoglycemia,Secondary outcome 10,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
1155,NCT05577169,Acceptability of intervention in the study population.,"Hemoglobin A1c (HbA1c, %)",2022-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Child and Adolescent Social Support Scale (CASSS) questionnaire
1156,NCT05751525,IQ score,"Hyperactivity, emotional problems, conduct problems, peer relationships, prosocial behaviour.",2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],
1157,NCT04088552,Change in abdominal circumference,Change in knowledge regarding hypertension,2020-03-07,COMPLETED,INTERVENTIONAL,['NA'],
1158,NCT05552859,Difference in the mean change from baseline to Week 24 in HbA1c level (Gla-300 vs IDeg-100),"Number of participants with adverse events (AEs)) and serious adverse events (SAEs), including adverse events of special interest (AESIs)",2022-12-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
1159,NCT01729403,Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate),Safety: Incidence of adverse events,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1160,NCT02897219,Change from baseline in HbA1c,Safety assessed by laboratory tests: Urinalysis,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
1161,NCT05629403,HOMA-IR,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1162,NCT02517866,Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12,"Change From Baseline in DBP at Week 12 in ""Treatment-Naïve"" Participants",2015-07-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
1163,NCT03656341,Manchester Foot Pain and Disability INdex,Foot Health Score,2018-09-27,COMPLETED,INTERVENTIONAL,['NA'],
1164,NCT05310526,food intake of 400g of vegetables per day,Professionals' perception regarding the incorporation of MAC guidelines into practice (implementation component),2022-11-01,COMPLETED,INTERVENTIONAL,['NA'],
1165,NCT02681185,HbA1c,Survey of Quality of Life,2018-03-01,TERMINATED,INTERVENTIONAL,['NA'],
1166,NCT03752840,Pinhole visual acuity (logMAR) in people aged 60 years and older,Cost-effectiveness of the screening intervention,2019-04-21,RECRUITING,INTERVENTIONAL,['NA'],"Bilateral presenting blindness in people aged 60 years and older, defined as presenting visual acuity worse than Snellen 20/400 (Metric Snellen worse than 6/120; logMAR worse than 1.3) in the better-seeing eye"
1167,NCT03983551,Change in urinary albumin-to-creatinine ratio,Change in systolic blood pressure,2016-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1168,NCT02697201,Effects of lipid infusion on mitochondrial fission,Insulin sensitivity,2016-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1169,NCT05806723,change in testosterone level after atorvastatin treatment,change in DHEAS levels after atorvastatin treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],change in vitamin D level after atorvastatin treatment
1170,NCT04071626,"Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange",Serum Ketone Bodies (Betahydroxybutyrate),2020-03-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
1171,NCT00106366,HbA1c,Glucose profiles,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1172,NCT01263496,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1173,NCT02703350,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1174,NCT00325624,A1c,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1175,NCT03560375,Change in body weight,Change in frailty syndrome,2018-05-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1176,NCT03578991,Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).,The Resource Utilization in Dementia (RUD).,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
1177,NCT00689026,The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.,,2008-05,TERMINATED,INTERVENTIONAL,['NA'],
1178,NCT05621551,Hs-Troponin-I,Hs-Troponin-I,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Length of in-hospital time
1179,NCT02273050,Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue,Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1180,NCT03146208,Role of endothelial bio markers in patients with coronary artery disease,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
1181,NCT02361606,Youth satisfaction of the program. (Questionnaire regarding the degree that the session was helpful.),"Change in glycemic control. (HbaA1c levels, obtained from medical records)",2009-03,COMPLETED,INTERVENTIONAL,['NA'],Youth expectations of the program. (Questionnaire regarding the expectations of the possible benefits of the program.)
1182,NCT01919788,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue.",Metabolism,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
1183,NCT05418179,Inflammatory parameters,Total Body lean mass Percentage (%),2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],
1184,NCT01221545,"Primary Objective to assess the safety and tolerability of AZD1656, following oral administration of single ascending supratherapeutic doses of AZD1656 to patients with type 2 diabetes mellitus in a fasted state.",Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1185,NCT02700048,Within Person Difference in Peak Epinephrine During Hypoglycemia,Naloxone Pharmacokinetics,2016-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1186,NCT01556880,incidence rate of DM,incidence of DM,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
1187,NCT03773185,Amyloid load,,2018-12-15,WITHDRAWN,OBSERVATIONAL,['NA'],
1188,NCT05404711,Feasibility of CGM use to determine Type 2 Diabetes Risk,Acceptability of CGM use for at-home T2D risk evaluation in youth,2022-10-11,COMPLETED,INTERVENTIONAL,['NA'],
1189,NCT03362983,Quality-of-care outcome measures (n=131),Interdisciplinary learning (n=20),2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1190,NCT06129448,Effect of Tumor necrosis factor- α (TNF-α) on cardiac functions,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1191,NCT01002053,Interval worsening of the severity of neuropathy,New functional neuropathy defined as any new sensory or motor deficit compared to preoperatively.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
1192,NCT05793645,Assessment of adherence,Description of Adverse events,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],
1193,NCT03161964,Ratio of Self-reported Hypoglycemic Episodes to Total Hypoglycemic Episodes Determined by Continuous Glucose Monitoring (CGM),Mean Blood Glucose,2017-10-19,TERMINATED,INTERVENTIONAL,['PHASE2'],
1194,NCT05519163,New-onset diabetic foot,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1195,NCT04722900,Body height,Magnetic resonance imaging,2021-01-15,RECRUITING,OBSERVATIONAL,['NA'],
1196,NCT02914886,Relative thickness as assessed by MRI,Side effects,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1197,NCT05491421,To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through incidence severity of serious adverse events in MAD Cohorts.,The anti-drug antibody (ADA) response through testing serum or plasma of the participant post dosing in SAD and MAD cohorts.,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE1'],
1198,NCT03002246,Comparison Between 5D Limb Vol and 2D Birth weight Prediction,Birth weight Predictions in Suspected Growth Abnormalities,2017-01-06,COMPLETED,OBSERVATIONAL,['NA'],
1199,NCT01059825,Change From Baseline in HbA1c at Week 12,Number of Participants Who Discontinued Study Medication Due to an AE,2010-02-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
1200,NCT05933356,The Positive and Negative Syndrome Scale (PANSS),,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
1201,NCT04093856,"Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia",Health-related quality of life,2020-01-14,COMPLETED,OBSERVATIONAL,['NA'],
1202,NCT02434315,Change from Baseline - time in glucose range - for penultimate sensor wear,,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
1203,NCT05528770,Difference in Daytime Time-in-range,Difference in Overall Time-below-range,2022-10-20,COMPLETED,INTERVENTIONAL,['NA'],
1204,NCT04608136,Change from baseline Insulin at 180 minutes,Changes in fat intake following dietary intervention,2020-09-21,COMPLETED,INTERVENTIONAL,['NA'],
1205,NCT00547872,Death and myocardial infarction,Symptomatic heart failure,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1206,NCT00995345,Change in HbA1c From Baseline (Week 0) to Week 24,Percentage of Patients Requiring Rescue Therapy for Elevated Glucose,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1207,NCT05902156,The Metabolic Parameter Monitoring Form,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1208,NCT05392452,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L,"Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)",2022-08-09,COMPLETED,INTERVENTIONAL,['NA'],Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L)
1209,NCT01795144,Incretin Effect,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1210,NCT02434744,"Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy",Changes in Serum Levels of Non-Esterified Free Fatty Acids,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1211,NCT03936049,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
1212,NCT05499702,Rate of leucine oxidation in response to rising glucagon concentrations,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
1213,NCT05336214,Change in practice-reported prescriptions of Continuous Glucose Monitors,Implementation and Maintenance,2022-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1214,NCT01879917,Beta-cell function,Postprandial glucagon,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hypoglycemia
1215,NCT01919476,Change in markers for glucose intolerance.,Change in metabolic markers,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Change in satiety markers
1216,NCT02584582,Glucagon concentration (postprandial),triacylglycerol (TAG),2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1217,NCT01475565,Change from Gestation Week 12-14 in Insulin Sensitivity at Gestation Week 32-34,Change from Gestation Week 12-14 in Physical Activity at Gestation Week 32-34,2013-05,TERMINATED,OBSERVATIONAL,['NA'],
1218,NCT04484259,P2Y12 reaction units (PRU),,2021-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1219,NCT00292890,"HbA1c levels, insulin doses and the number of experienced hypoglycaemic events",blood glucose measurements and the experiences of the patients,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
1220,NCT03925064,ultrasonographic myocardial performance index values,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA'],
1221,NCT00539435,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.",,2007-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
1222,NCT01408277,Mean Percent Change in Wound Area,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1223,NCT04335331,A1c order,Weight,2020-02-27,COMPLETED,OBSERVATIONAL,['NA'],
1224,NCT04582357,Physical activity program attendance,Security,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],
1225,NCT00231634,Percent change in body weight and change in Hemoglobin A1c (HbA1c) from baseline to Week 52.,"Change from baseline to Week 52 in BMI, FPG; safety evaluations (adverse events, hypoglycemic events) throughout study.",2001-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
1226,NCT03928132,"Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire",Acceptability Questionnaire,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1227,NCT01486238,Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.,Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1228,NCT01767831,Ability of Behavioral Intervention to Improve Glycemic Outcome,Relationships Between Physiology and Behavior Transferred to In Silico Environment,2013-03,TERMINATED,OBSERVATIONAL,['NA'],
1229,NCT02082756,Change in 2-hour postprandial blood glucose between baseline to week 12,Adverse effects,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1230,NCT01253304,Pharmacokinetics: Apparent Volume of Distribution (Vz/F),,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1231,NCT02689778,Effect of oral pirfenidone (1800 mg) in glomerular filtration rate,Number of patients with treatment related adverse events,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1232,NCT01926041,Number of Participants With New-onset Type 2 Diabetes Mellitus (DM),HbA1c Change Between Baseline and 6 Months,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],10-year Probability of Regression to Normoglycemia
1233,NCT04450407,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,2020-07-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1234,NCT01960205,oral glucose tolerance test,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1235,NCT03814395,Numbers of participants with adverse pregnancy outcomes,Fetal Humerus Length,2018-06-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1236,NCT06319287,Safety,Percent Area Reduction of Wound at 12 Weeks,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Wound-Q Scale
1237,NCT04721847,Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS),Diabetic peripheral neuropathic pain impact measure,2020-08-13,COMPLETED,INTERVENTIONAL,['NA'],
1238,NCT05138029,Review the patient's vision before surgery,Review the patient's vision for 6 months after surgery,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
1239,NCT05719181,Effect of Recombinant Human Bone Morphogenetic The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group.,,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE1'],
1240,NCT03698708,Center for Epidemiologic Studies - Depression Scale Revised (CESD-R),Hemoglobin A1c (HbA1c),2019-01-20,COMPLETED,INTERVENTIONAL,['NA'],Treatment Satisfaction Survey
1241,NCT03064841,"Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines.",Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],
1242,NCT01631643,Change in A1C from baseline to week 24,Change in 30 day mean glucose comparing first month to last month after 24 weeks,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
1243,NCT00904176,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1244,NCT02805361,The mean change in HbAlc from mean baseline and at Month 12.,Changes from baseline in Diastolic Blood Pressures,2016-08-21,COMPLETED,OBSERVATIONAL,['NA'],Capture influence of the combined effect of fasting and hot climate on the level of total ketone bodies levels in T2DM subjects treated with Dapagliflozin
1245,NCT02799121,Complete Wound Closure,Neuro-QoL,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1246,NCT02531776,Area under curve (AUC) of skin blood perfusion increase,"Skin reactions (bleeding, bruising, redness, swelling) on a scale from 0 to 4.",2014-12,COMPLETED,INTERVENTIONAL,['NA'],
1247,NCT00239707,"GIP, glucose, insulin measured frequently during infusions","GLP-1, ghrelin measured frequently during infusions",2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1248,NCT02776696,Percentage of glucose sensor readings within 70 to 180 mg/dl,Closed-loop acceptance questionnaire,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
1249,NCT04543630,Implant survival,Effect of implant placement and graft material on hematological and inflammatory parameters,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1250,NCT04240964,Composition of the DFO Metagenome,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
1251,NCT05605704,rate of fasting glycemia level reduction,,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",rate of H1B1C balance variation
1252,NCT01214356,Change in Urinary Albumin:Creatinine Ratio (ACR),Decrease in Estimated Glomerular Filtration Rate (eGFR),2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1253,NCT01856881,Subject incidence of anti-AMG 876 antibodies,Pharmacodynamic parameters,2013-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
1254,NCT00686816,weight loss,Weight maintained,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1255,NCT05995756,overall mean absolute relative difference (MARD),,2021-12-20,COMPLETED,OBSERVATIONAL,['NA'],
1256,NCT04558645,General Quality of life,Dyspnea,2020-09-18,COMPLETED,OBSERVATIONAL,['NA'],
1257,NCT05110365,sphygmomanometer,(EuroQoL five-dimensional instrument ),2021-06-26,COMPLETED,INTERVENTIONAL,['NA'],
1258,NCT05351476,Change from baseline whole-body lipolysis at 12 weeks,Change in adipogenesis,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],
1259,NCT03450200,"Change in signs of DPN after intervention, at follow-up",Change in walking speed,2017-06-17,COMPLETED,INTERVENTIONAL,['NA'],
1260,NCT01215435,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11,Number of Treatment Emergent Hypoglycaemic Episodes,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1261,NCT01343446,Coping style of Patients with Diabetes suffer from Sleep Disorder,,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
1262,NCT02418637,Feasibility (Likert scale),,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
1263,NCT04589351,Urinary albumin creatinine ratio (UACR),Magnetic resonans estimate of kidney parenchymal triglyceride fraction,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Urine extracellular vesicles
1264,NCT01091025,To identify if using the selective approach to screen for CFRD is as accurate as screening all patients with OGTT at annual review.,Which is the more cost effective way of screening all patients with OGTT?,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
1265,NCT02056366,Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Patients with Adverse events as a Measure of Safety
1266,NCT02588859,Medication usage in enrolled subjects,Reduction in HbA1C,2015-10-30,COMPLETED,OBSERVATIONAL,['NA'],
1267,NCT00709150,Reduction in symptoms of major depression,Quality of life,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1268,NCT00540709,Primary efficacy data was HbA1c.,Secondary efficacy data included HbA1c.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1269,NCT01400191,Endogenous glucose production,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1270,NCT00172536,Diastolic heart function,Blood test,2004-10,COMPLETED,INTERVENTIONAL,['NA'],
1271,NCT00184665,HbA1c,Hypoglycaemia,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1272,NCT01094769,Urine albumin/creatinine ratio (UACR),muscle sympathetic nerve activity (MSNA),2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1273,NCT04959552,Characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
1274,NCT05373004,estimated glomerular filtration rate,the change in Urine Albumin Creatinine Ratio (UACR),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","the rates of clinical events (myocardial infarction, ESRD, congestive heart failure, and stroke)"
1275,NCT01831102,total adiponectin concentration,Insulin sensitivity,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
1276,NCT04006028,Non-diabetic renal disease,Patient survival,2019-06-06,COMPLETED,OBSERVATIONAL,['NA'],
1277,NCT00542178,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy",Development or Progression of Macular Edema,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1278,NCT01601236,Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12,"Percent Change From Baseline of Serum Total Cholesterol, Triglycerides, LDL, HDL, Lp(a), Albumin, and Cortisol",2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Mean HbA1c
1279,NCT02577003,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Body Weight at Week 24,2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1280,NCT01650259,Percentage of Participants With Adverse Drug Reactions (ADRs),Change From Baseline in HbA1c at the Last Observation During the Observation Period.,2012-07-23,COMPLETED,OBSERVATIONAL,['NA'],
1281,NCT01973920,Adverse events and serious adverse events occurence,To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs routine use
1282,NCT02804750,Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events,Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1283,NCT02586545,"Change from baseline Hemoglobin A, Glycosylated (HbA1c) at 12, 24 and 36 months",The proportion of patients who meet national standard indicators reflecting quality of care,2015-08,COMPLETED,INTERVENTIONAL,['NA'],"Change from baseline diabetes symptoms at 12, 24 and 36 months"
1284,NCT00065663,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1285,NCT05888909,change in estimated glomerular filtration rate (eGFR) from baseline,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
1286,NCT03388229,association between frequency of food group/item consumption and HbA1c among T2D patients,"To measure the percentage of frequency of consumption of food groups among T2D patients ,",2017-08-08,COMPLETED,OBSERVATIONAL,['NA'],
1287,NCT04008745,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 8-weeks,Change from Baseline Functional balance at 8-weeks,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
1288,NCT05104593,Change in healthcare appointments,Change in number of participants with advanced directives,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1289,NCT03849339,AUClast of Metformin,Vd/F of Metformin,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1290,NCT02395315,Differences in alveolar bone vascularity among well-controlled and not well-controlled diabetic patients.,RANK-L to OPG ratio,2015-12,COMPLETED,OBSERVATIONAL,['NA'],Implant surgery-related complications
1291,NCT00350064,Change in Abdominal Visceral Fat,Endothelial Function,2004-04,UNKNOWN,INTERVENTIONAL,['NA'],
1292,NCT01991769,endothelial function,,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
1293,NCT01129960,Change From Baseline to Endpoint in Mean Pain,,2010-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
1294,NCT01817595,Time required to teach meter/internet platform,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
1295,NCT00511030,,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
1296,NCT02888769,Change in systolic blood pressure obtained in office during each interview,Change in proportion of non-smokers,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
1297,NCT01876992,% Cyclic Amine Mono Phosphate (cAMP) Response Element Binding Protein (CBP) White Blood Cell (WBC) Phosphorylation (Metformin Treated vs no Treatment),Fasting Blood Glucose.,2012-01,TERMINATED,INTERVENTIONAL,['NA'],Effect of Dose Escalation
1298,NCT05370612,Percentage of Time Where Blood Glucose is between 70-140 milligrams per deciliter (mg/dL),Qualitative Outcome: Interviews to understand Participant Sense of Control around Glucose Monitoring,2022-08-08,RECRUITING,INTERVENTIONAL,['NA'],
1299,NCT01352767,efficacy,Satisfaction,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1300,NCT05159089,Metabolic participants outcomes,Socioeconomic participant status,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Medication patients intake
1301,NCT02569684,Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
1302,NCT00351650,,,2006-07-09,COMPLETED,OBSERVATIONAL,['NA'],
1303,NCT04511468,Change the Risk of T2DM Progression,The assessment on the Safety of the ZCC Supplementation for the respondents,2021-06-23,UNKNOWN,INTERVENTIONAL,['NA'],Change in Vitamin C Level (optional)
1304,NCT05180591,Change in HbA1c values,Change in adjusted HbA1c,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory: Change in overall inflammation
1305,NCT00999050,Hemoglobin A1C changes,improvement in glycemic control,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],
1306,NCT04843592,the patient's compliance after using SOKARY mobile app,,2019-08-30,COMPLETED,OBSERVATIONAL,['NA'],
1307,NCT02026843,Aqueous secretory angiogenic and anti-angiogenic protein concentration,,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],
1308,NCT00566189,Improvement or reversal of type 2 diabetes mellitus,Retardation of progression or regression of albuminuria as detected by microalbuminuria assay in 24-h urine collection,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1309,NCT05537233,Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <4% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group,Change in NAFLD biomarkers,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in liver stiffness and hepatic steatosis
1310,NCT03934281,Epidermization rate at 6 months.,Epidermization rate at 2 months,2018-06-27,COMPLETED,INTERVENTIONAL,['NA'],
1311,NCT02065050,Hemoglobin A1c,BMI,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
1312,NCT00374595,Carotid Intima Media Thickness (CIMT),,2006-04,COMPLETED,OBSERVATIONAL,['NA'],
1313,NCT02909894,Blood glucose Area Under the Curve (AUC),Cognitive function - Part 4 - Rapid Visual Information Processing Test,2016-05-26,COMPLETED,INTERVENTIONAL,['NA'],
1314,NCT02611232,FPIR (first phase insulin response),Serum C-peptide AUC,2015-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
1315,NCT00317954,Changes in blood pressure,Changes in glomerular filtration rate,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1316,NCT01833559,The incidence of GDM at the second gestational trimester,Gestational outcomes,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],Child growth measures
1317,NCT04755946,Absolute change in Estimated glomerular filtration rate (eGFR),Change in serum irisin level,2021-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1318,NCT05999656,Rate of wound area change,Change in Wagner scale,2023-05-28,RECRUITING,INTERVENTIONAL,['NA'],
1319,NCT04192292,Difference in incretin effect between mixed meal tests,Variation in blood glucose during intervention blocks analysed by continuous glucose monitoring,2019-10-08,COMPLETED,INTERVENTIONAL,['NA'],
1320,NCT02455076,Change in HbA1c Concentration Inpatient,Change in Diastolic Blood Pressure,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1321,NCT04262661,Part 2: Number of treatment emergent adverse events,Maximum observed serum NNC0472-0147 concentration at steady state,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1322,NCT06187129,cross sectional area of peripheral nerves using nerve ultrasound,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1323,NCT01336322,Beta-cell function,Glucose control,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1324,NCT00976261,"Part B: Safety, tolerability parameters: adverse events, gastro-intestinal side effects, subject reported outcomes, clinical laboratory results, ECGs and vital signs",Part B: 3-O-Methyl-Glucose Kinetics,2009-10-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
1325,NCT02500706,Change From Baseline in HbA1c 26 Weeks After Randomisation,Change From Baseline in Body Mass Index 26 Weeks After Randomisation,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1326,NCT03655535,2 hr PPG,Change in oral hypoglycemic medication,2018-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
1327,NCT06098417,soluble biomarkers of liver fibrosis,Biobank,2015-09-22,RECRUITING,OBSERVATIONAL,['NA'],
1328,NCT01545791,"Number of serious adverse drug reactions (SADRs), including major hypoglycaemic events",Quality of Life as assessed by a treatment satisfaction questionnaire,2006-05,COMPLETED,OBSERVATIONAL,['NA'],
1329,NCT05145374,Measurement of Glucose Concentration,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
1330,NCT05411952,Change in mean of HbA1c from baseline to 6 months,Change in mean of Mediterranean Diet Quality Index Scale (KIDMED) from baseline to 6 Months,2020-08-13,COMPLETED,INTERVENTIONAL,['NA'],
1331,NCT05836350,fasting plasma glucose levels,cardiac function: tricuspid regurgitation systolic jet velocity,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1332,NCT00424437,Primary outcome is 24 week change in baseline in HbA1c,Patient satisfaction and preference.,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1333,NCT01211847,Triglyceride-lowering efficacy of DCCR,Improvement in other lipid profiles with DCCR,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1334,NCT02248454,"Predictors of fat ""sensitivity""",,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
1335,NCT02109835,Greater than 20% increase in plaque volume,Greater than 20% increase in coronary artery calcium score,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],"Incidence of major adverse cardiovascular events (MACE) during the 18-month follow-up period. MACE is defined as incidence of cardiac death, non-fatal myocardial infarction, STEMI and NSTEMI, unstable angina, late revascularization and onset of angina"
1336,NCT04083339,Peak VO2 during cardio-pulmonary exercise test (CPET);,Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score,2019-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in echocardiographic parameters
1337,NCT00351234,To see if the number of hypoglycemic events decreases with treatment of carnitine on type I diabetic patients. The measurements will be taken after the second 72-hour continuous glucose monitoring.,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],
1338,NCT01322321,Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months,Measure: anti-ACZ885 antibodies,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1339,NCT06080542,Interstitial glucose,Lactate,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],PHYSICAL ACTIVITY
1340,NCT03042936,Change From Baseline Hemoglobin A1c,Change From Baseline Shuttle Run Speed,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
1341,NCT04129268,Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
1342,NCT03502031,Combination Therapy - RAAS inhibition and Spironolactone to lower UP/Cr,Combination Therapy - RAAS inhibition and Spironolactone that develop hyperkalemia,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
1343,NCT02411682,Postprandial Glucose,Postprandial Free Fatty Acids,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],
1344,NCT01868646,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1345,NCT03926598,Participant Task Completion Rate for Usability Testing Session,,2019-06-05,COMPLETED,OBSERVATIONAL,['NA'],
1346,NCT05199077,percentage change,Changes of ECG examination results,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1347,NCT01158417,NF-Kb,GLP-1,2008-12,TERMINATED,INTERVENTIONAL,['NA'],
1348,NCT01456195,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1349,NCT04271631,Change from Baseline Hb1A1c at 3 months,Self-Monitoring Blood Glucose,2019-06-12,UNKNOWN,INTERVENTIONAL,['NA'],
1350,NCT05254496,Changes in HgbA1c,Changes in blood pressure,2022-04-04,RECRUITING,INTERVENTIONAL,['NA'],
1351,NCT01196728,Safety measurements,PK samples for CM3.1-AC100,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1352,NCT03091920,Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR),,2017-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
1353,NCT05797285,Wound Closure,Change in Quality of Life,2023-02-28,COMPLETED,INTERVENTIONAL,['NA'],Number of Adverse Events Observed
1354,NCT00660309,Change From Single Dose Peak to Steady State Peak in Renal Plasma Flow (RPF) After Aliskiren or Irbesartan,Change From Baseline in Retinal Blood Flow After Aliskiren or Irbesartan,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1355,NCT05603793,Stunting,Bone age,2022-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Household Dietary Diversity Scale (HDDS)
1356,NCT00418522,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population,"Change From Baseline in Diabetes Treatment Satisfaction Questionnaire-Status, Diabetes Treatment Satisfaction Questionnaire-Change, Diabetes-39, Mental Health Inventory-17, and SF-36 Vitality Domain Questionnaire",2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS
1357,NCT00231725,To collect complaint data on the Pre-filled Pen B when used by persons with type 2 diabetes to self-administer insulin in take-home situations for 2 months.,To assess overall patient perception of the device's performance through a patient questionnaire.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1358,NCT02467998,Healing,Side effects and adverse Events During Therapy,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
1359,NCT04101383,AUC(0-t),,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],
1360,NCT04410419,Mean difference of preoperative glucose between the two groups,Rate of peri-operative insulin use,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1361,NCT03845179,C-peptide,Lipids,2019-05-29,COMPLETED,INTERVENTIONAL,['NA'],heart rate
1362,NCT03188835,BAT triglyceride content,hormonal responses,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],
1363,NCT00911833,,,2009-05-19,COMPLETED,OBSERVATIONAL,['NA'],
1364,NCT02115412,Adherence determinants,Medication usage,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Adverse Events
1365,NCT05854251,Change in insulinogenic index (IGI) concentration following a standardized mixed-meal test,,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
1366,NCT01747083,Cmax,AUClast,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1367,NCT01499511,Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack),Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
1368,NCT01479075,Insulin sensitivity,Energy metabolism,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1369,NCT01043354,medication adherence,exercise adherence,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
1370,NCT01596504,Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours,Change From Baseline to Day 56 in the Cumulative Score Mean on the Appetite Perception Using a Visual Analogue Scale After Standardized Solid Breakfast,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1371,NCT02070835,healing rate,recurrent rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],complication rate
1372,NCT00385671,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine",Number of Patients With Treatment-Emergent Elevated Laboratory Analytes,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1373,NCT04817215,Mean change from baseline (Visit 1) in A1C at 26 weeks,Safety of repeat administration of ORMD-0801 in inadequately controlled T2DM subjects,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Means and mean changes from baseline over time for C-peptide
1374,NCT00417950,Postprandial hyperglycemia,Postprandial oxidative stress,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
1375,NCT03349944,HbA1c,Oral glucose tolerance test,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
1376,NCT00576667,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in hepatic transaminases (AST/ALT),2008-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
1377,NCT01339637,Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals,Compare SCOUT DS and FPG to HbA1c,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
1378,NCT00316667,,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],
1379,NCT03313856,Modification in HbA1c in patients with type 2 diabetes after of administration of combination with Guazuma ulmifolia and Tecoma stans,"Renal safety of administration of guazuma, tecoma through the determination of serum creatinine",2010-01-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1380,NCT01496820,Postprandial blood glucose(PPG),HDL-cholesterol,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1381,NCT06037486,Analysis of system accuracy based on DIN EN ISO 15197,,2022-10-17,COMPLETED,INTERVENTIONAL,['NA'],
1382,NCT05392231,Early prediction of gestational diabetes,,2022-02-10,COMPLETED,OBSERVATIONAL,['NA'],
1383,NCT05851820,overall length of hospital stay,,2020-09-25,COMPLETED,OBSERVATIONAL,['NA'],
1384,NCT05230615,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction From baseline (week 0) to",2021-11-21,COMPLETED,OBSERVATIONAL,['NA'],
1385,NCT04267770,Change in Basal Insulin Rate,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA'],
1386,NCT03123237,Renal Counts,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1387,NCT03145649,Infant head circumference at day 90,,2010-01-12,COMPLETED,OBSERVATIONAL,['NA'],
1388,NCT04114903,Change in Plasma Insulin,Stanford Leisure-Time Activity Categorical Item (L-Cat),2019-11-08,RECRUITING,OBSERVATIONAL,['NA'],"Daily online survey of cannabis use, alcohol use, exercise and diet"
1389,NCT04161170,Change of HbA1c (glycated hemoglobin) at 6months from baseline,time in range of >250 mg/dL by CGMS in interventional group C,2019-11-20,UNKNOWN,INTERVENTIONAL,['NA'],
1390,NCT03782155,Wound healing:Number of cells per clauster in tissue sample of wound.,,2021-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Incidence of treatment- adverse events
1391,NCT00783744,Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 %,"Frequency of subjects with FBG ≤ 100 mg/dl (5.5 mmol/l), 100 mg/dl < FBG ≤ 120 mg/dl (5.5 mmol/l < FBG ≤ 6.6 mmol/l), 120 mg/dl < FBG ≤ 150 mg/dl (6.6 mmol/l < FBG ≤ 8.3 mmol/l) and > 150 mg/dl (> 8.3 mmol/l)",2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1392,NCT06258148,Changes in glycosylated hemoglobin (HbA1c) from baseline at 24 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1393,NCT01967030,Incident Type 2 Diabetes,Maternal waist circumference,2008-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Metabolite profiles
1394,NCT02326259,Progression of diabetic retinopathy,,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
1395,NCT04170790,Heart Rate,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
1396,NCT05880654,Effect of SRP on GCF levels of IL-39 & IL35,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1397,NCT00005487,CVD,,1999-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1398,NCT01515930,Diabetes Management Scale,Blood Glucose Testing Frequency,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
1399,NCT03014479,Change From Baseline in Total Score for All Question Items in the Diabetes Therapy Related -QOL (DTR-QOL) Questionnaire at the End of Study,Number of Participants With Hospitalization for Type 2 Diabetes (Excluding Educational Hospitalization Without Worsening of Diabetes),2017-02-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
1400,NCT01401790,Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias),Family satisfaction with the software application,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
1401,NCT00926744,Objectively measured amount of physical activity,Incidence of musculoskeletal and joint pain,2006-04,UNKNOWN,INTERVENTIONAL,['NA'],
1402,NCT03468894,Change in Workplace sitting time,Change in perceived vigor,2018-03-22,WITHDRAWN,INTERVENTIONAL,['NA'],
1403,NCT01561508,change in stimulated c-peptide,change in total daily insulin dose per kilogram,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1404,NCT04257565,Wound Healing,Physical Function,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
1405,NCT05663931,Mean glucose levels,Infection,2023-01-10,RECRUITING,INTERVENTIONAL,['NA'],
1406,NCT04919954,Tebipenem Pivoxil Hydrobromide Tissue Penetration,Tebipenem Pivoxil Hydrobromide Area Under the Curve (AUC) in Tissue,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1407,NCT05120388,number of participants with insulin requirement,number of participants with diabetes at postpartum,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],
1408,NCT05163054,Incidence of hypoglycemia,Life quality.,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1409,NCT02295085,Incident cancer during the period of cohort follow-up,Incident renal disease during the period of cohort follow-up,1990-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Other incident conditions during the period of cohort followup
1410,NCT03867773,Change from baseline to week 8 in body weight,"Change from baseline to week 8 in sex steroid levels (estrogen, androgens, sex hormone binding globulin)",2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1411,NCT04424537,Change in fasting blood glucose level,Change in Muscle function as measured by relative power of jump,2024-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
1412,NCT04709887,Healing rate of wound surface,Recurrence rate of foot ulcer,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
1413,NCT03969719,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16,Change From Baseline in HbA1c at All Timepoints Other Than Week 16,2019-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
1414,NCT00128336,Weight,Change in mood state,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1415,NCT03622957,Glomerular Filtration Rate [ml/min/1.73m2],CV Events (Yes/No),2018-08-10,UNKNOWN,OBSERVATIONAL,['NA'],
1416,NCT02827266,Percentage of Participants With Hemoglobin Greater Than (>) 11 Grams per Deciliter (g/dL) After 8-Week Correction Phase,Number of Participants per Type of Diabetes,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1417,NCT00351884,Change from baseline in HbA1c at 24 weeks,Change from baseline in body weight at 24 weeks,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1418,NCT05354297,Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs,Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months,2022-07-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quantify the number of medical insurance claims made by subjects within each of the OneTouch Solutions programs using data harvested from a large medical insurance dataset
1419,NCT00913562,Flicker induced vasodilatation,,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
1420,NCT00854594,Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network,Attitudes Toward Healthcare Teams Scale and Subscales,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
1421,NCT04927871,Change of weight in kilograms,Percentage of Completion of the program.,2020-11-16,COMPLETED,INTERVENTIONAL,['NA'],
1422,NCT00309192,Macular edema reduction or stabilization 6 months after treatment.,Tolerance of the treatment.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1423,NCT01297738,Cerebral binding of [123I]FP-CIT to serotonin- and dopamine transporters and correlation with changes in in vivo and ex vivo insulin sensitivity,Insulin signalling pathways,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
1424,NCT00815399,Circulating Endothelial microparticles,"Glucose profile, lipid profile, hemoglobin A1c, carotid intima-media thickness",2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1425,NCT06042517,Glucose metabolic clearance rate,High blood glucose index (HBGI),2023-09-30,RECRUITING,INTERVENTIONAL,['NA'],
1426,NCT05717387,Change in percent of time in range (glucose between 3.9-7.8mmol/L) over 6 months measured with continuous glucose monitoring.,Change in quality of life,2023-04-11,RECRUITING,INTERVENTIONAL,['NA'],
1427,NCT05169034,System Performance,,2021-12-14,TERMINATED,OBSERVATIONAL,['NA'],
1428,NCT00282685,Improvement of neurological score: modified NIS(LL)+7,Heart rate variability,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1429,NCT03364387,"Composites of Myocardial Infarction, Hospitalization, Revascularization, Death",Heart failure,2018-03-05,COMPLETED,OBSERVATIONAL,['NA'],
1430,NCT03004664,Patients will improve their capacity for diabetes self-management: Measured through change in Patient Activation,Patients will successfully self-manage their diabetes as measured though change (reduction) in chronic stress levels,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],
1431,NCT00166673,Navigator Accuracy,Exploratory assessment of impact of Navigator on HbA1c,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1432,NCT03422263,Maximum oxygen uptake,Body constitution (Muscle mass predicted II),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Echocardiographic parameters (E/e' avg)
1433,NCT06164535,serum amyloid-β,HOMA-IR,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1434,NCT01200394,Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12,Plasma Concentration Versus Time Summary of PF-00489791,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
1435,NCT00062764,Number of Patients With Improvement in Liver Histology,Mean BMI Change,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1436,NCT05030844,The change in diabetes self managament of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Management Scale,Metabolic control variables,2021-07-14,COMPLETED,INTERVENTIONAL,['NA'],
1437,NCT01120119,C peptide,Glycometabolic control,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
1438,NCT02985099,Defect depth reduction (%),plaque index,2015-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1439,NCT06022601,HbA1c,Systolic and Diastolic Blood pressure,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
1440,NCT01370005,Mean 24-hour Systolic Blood Pressure Change From Baseline,Orthostatic Blood Pressure,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycaemic Adverse Events
1441,NCT01910051,anthropometric measures and metabolic biomarkers indicative of prediabetes,intra-subject and inter-subject variability of analyzed biomarkers,2013-09-25,COMPLETED,OBSERVATIONAL,['NA'],"the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk"
1442,NCT02071498,adherence,safety medication use,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
1443,NCT02024399,Improved body compositon (decrease in % fat; increase in % lean tissue) using DEXA,"Improved levels of fitness using ACSM guidelines / assessments to measure such constructs of fitness as flexibility, muscle strength, cardiovascular endurance and agility.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],Quality of life as perceived by the children and the parents.
1444,NCT00436176,Rate of HbA1c control (<7%),Rate of blood pressure control (< 140/90 mmHg),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1445,NCT00695526,the change of total to HDL cholesterol ratio,the change of UAE,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1446,NCT00437918,7 point SMBG (self monitoring of blood glucose),HOMA-beta for predicting the effectiveness of each agents,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1447,NCT00395746,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1448,NCT00894868,To evaluate the effect of vildagliptin on left ventricular function in patients with T2DM and CHF (NYHA class I-III) by showing that vildagliptin is at least not inferior to placebo with respect to change in left ventricular ejection fraction (LVEF).,To evaluate the efficacy of vildagliptin in patients with T2DM and CHF (NYHA class I-III) by assessing the HbA1c reduction with vildagliptin compared to placebo after 16 weeks of treatment.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1449,NCT00563004,Reduction in fasting plasma glucose of more than 20% in the treatment group compared to placebo,Reduction by half in the daily dose of oral hypoglycemic agents compared to baseline,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
1450,NCT05374343,Plasma concentrations of rongliflozin,Change from baseline in 24-hour urine glucose excretion in varying degrees of kidney function,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
1451,NCT01887964,Changes in metabolic syndrome risk components,Changes in blood glucose indices,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
1452,NCT02059187,Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24,Percentage of Participants With Hemoglobin A1C <6.5% at Week 24,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1453,NCT01899872,Circulating endothelial progenitor cells,Forearm vascular reactivity,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],
1454,NCT04298229,"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight",Hospital Readmission,2020-04-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1455,NCT01020123,HbA1c: Change From Baseline to 4 Month,EC50 to Characterise the PD Properties of AZD1656.,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1456,NCT01043965,"myocardial blood flow velocity, myocardial blood flow reserve",,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1457,NCT04854603,Insulin,Food pleasantness,2021-09-02,COMPLETED,INTERVENTIONAL,['NA'],
1458,NCT02581098,Wound macrophage isolation to determine miR-21,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1459,NCT00789737,Percent Change in Hemoglobin A1c,"Change in Postprandial Plasma Glucose, 2 Hours After a Meal Tolerance Test",2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1460,NCT00252837,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Audit of Diabetes Dependent Quality of Life (ADDQoL). ADDQoL will only be applied in Poland.,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
1461,NCT01113216,Identification of Genes or other factors that influence the development of CFRD,,2008-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
1462,NCT02028975,Plasma levels of biological markers of orosensorielle perception fatty acids,Measure the detection threshold for linoleic acid,na,UNKNOWN,INTERVENTIONAL,['NA'],
1463,NCT06108388,Hematopoietic colony formation in ALDHhiSSClow regenerative cell subsets,Frequency and absolute number of circulating ALDHhiSSClowCD133+ progenitor cells,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1464,NCT05431660,Plantar pressure senses,Vibration sense,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Individuals' information about diabetic foot
1465,NCT03028220,"% Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL)",Glucose Variability Measured by CONGA,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
1466,NCT01989754,Progression of Albuminuria,Cardiovascular (CV) Death,2014-01-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
1467,NCT02285231,2-h oral glucose tolerance tests (OGTTs,,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
1468,NCT02129231,Total antioxidant capacity,nerve conduction studies,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],alanine aminotransferase
1469,NCT05647824,Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device.,Subject Questionnaire on the Usability of TV4 BGMS,2020-02-05,COMPLETED,OBSERVATIONAL,['NA'],
1470,NCT04769037,Persistent confirmed multiple beta-cell autoantibodies,Measurement of Safety parameters,2021-04-22,RECRUITING,INTERVENTIONAL,['NA'],Stool calprotectin
1471,NCT01776528,Safety and tolerability,Pharmacodynamics,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1472,NCT05380544,Patient and clinician acceptability of the trial process and ESWT,"Validity, reliability and responsiveness of virtual follow-up for wound healing in research",2022-04-13,RECRUITING,INTERVENTIONAL,['NA'],
1473,NCT00231621,Percent change in body weight and the percent change in fasting serum triglycerides from baseline (Week 0) to Week 60.,"Absolute change in body weight, body mass index, triglycerides, and absolute and percentage changes in cholesterol measures from baseline to Week 60. Safety evaluations throughout study.",2001-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
1474,NCT01324921,Positive AUC for plasma glucose concentration,Positive AUC for serum insulin concentration,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1475,NCT04380064,Postoperative ERM Development,Visual Acuity,2020-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1476,NCT04417452,Maturation of the gonadal regulation,,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1477,NCT00836030,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",2009-01,COMPLETED,OBSERVATIONAL,['NA'],
1478,NCT05706155,Change in Glycated Hemoglobin,Adherence to a plant-based diet,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
1479,NCT00570687,EGP AOC0-480 - Meal Challenge,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1480,NCT05544643,Percentage of sets that failed due to unexplained hyperglycemia,,2022-08-04,COMPLETED,INTERVENTIONAL,['NA'],
1481,NCT04855292,Safety and tolerability assessed by incidence and severity of adverse events,The occurrence of TG103 anti-drug antibodies (ADA),2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1482,NCT05943626,Insulin sensitivity change from baseline,Average (per week) daytime alertness change from baseline,2023-06-13,RECRUITING,INTERVENTIONAL,['NA'],
1483,NCT01281228,Differences in neuronal activity in CNS reward and satiety circuits,Self-reported hunger,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
1484,NCT00896610,Blood glucose level,,2009-05-13,TERMINATED,OBSERVATIONAL,['NA'],
1485,NCT04741568,"Change in Diabetes Eating Problem Survey Revised (Markowitz et al., 2010)",Change in Children's Eating Behaviour Questionnaire (Wardle et al. 2001),2021-06-07,COMPLETED,INTERVENTIONAL,['NA'],Feasibility Outcomes: Usability of Online Content (Google Analytics)
1486,NCT05538819,Hospitalizations and emergency visits for heart failure,Hospitalizations for acute myocardial infarction or stroke,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
1487,NCT02555631,Change in Weight in Pounds,Number of Participants That Participated in Each Session,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
1488,NCT01096667,Change From Baseline on 24-hour Average SBP at Week 4,Number of Participants Who Discontinued Study Drug Due to an AE,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
1489,NCT01680133,Change from baseline in insulin sensitivity of adipose tissue and skeletal muscle lipolysis,Baseline skeletal muscle lipid accumulation,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
1490,NCT00789308,Level of stimulated c-peptide at 90-minute derived from the mixed-meal tolerance test (MMTT),Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation,2008-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1491,NCT04865770,"Change in kidney inflammation (medulla), T1 mapping (MRI)",Change in kidney function (creatinine clearance) (urinalysis,2021-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1492,NCT00627380,The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.,Safety: CD4 count and plasma HIV RNA,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1493,NCT00212914,The proportion of patients screened in each group,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],
1494,NCT02301806,"Change in endothelial function during the OGTT evaluated by flow-mediated vasodilatation (FMD). The change is defined as below, assuming the peak value and changes of FMD will be observed at t=60 min.",Change in endothelial function during OGTT* evaluated by endo-PAT. Change in endothelial function after 12-week treatment at the fasting state evaluated by endo-PAT and FMD.,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Change in the number of EPCs after 12-week treatment
1495,NCT01526941,"Steady state area under the glucose infusion rate profile, 6-12 hours",Adverse events,2001-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1496,NCT02738996,Postprandial glucose excursions measured with Area under curve,"Qualitative exploration of the knowledge, beliefs and experiences of those with type 2 diabetes on the use of technology to decrease sedentary behaviour and improve glycaemic control",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
1497,NCT05757258,"Association between incidence of MALE and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels","Association between incidence of cardiovascular death and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels",2019-10-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1498,NCT05037526,Composite adverse pregnancy and neonatal outcome,Respiratory distress syndrome,2021-09-24,RECRUITING,INTERVENTIONAL,['NA'],
1499,NCT02927951,Decrease in fall risk associated with walking assessed with the Physiological Profile Assesment,Patient Global Impression of Change (PGIC),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1500,NCT04877366,Post-prandial glycemic excursion (ARMs A and B),Matsuda Index (ARMs A and B),2021-07-21,COMPLETED,INTERVENTIONAL,['NA'],Plasma IL-6 iAUC (ARMs A and B)
1501,NCT02366416,Change of bloodglucose,Change of musculoskeletal pain,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
1502,NCT03618628,Peak Plantar Pressure,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA'],
1503,NCT05029804,Pedometer,,2021-09-30,UNKNOWN,INTERVENTIONAL,['NA'],
1504,NCT06206317,Static Two-Point Discrimination Test,,2024-02-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1505,NCT04013594,Glycemic variability,hand grip strength,2019-08-20,COMPLETED,INTERVENTIONAL,['NA'],
1506,NCT02955238,Change in Carotid Intimal Medial Thickness (CIMT) Measurement,Medication Adherence,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
1507,NCT03353818,Physical activity,Estimated VO2max,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
1508,NCT01546597,"Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1509,NCT02433262,To measure the prevalence of GDM diagnosed using WHO versus IADPSG criteria,To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG),2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
1510,NCT00694122,Blood Glucose,Growth Hormone,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1511,NCT04133493,Wound Healing,Pain reduction: visual analogue scale (VAS),2019-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Histology assessment from biopsies
1512,NCT00328848,Quality of medical management,Opportunity costs of caregiver time,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
1513,NCT05551858,Adverse events,Change in Pain Measurements numeric score from baseline to end of treatment with proglumide compared to Placebo,2022-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1514,NCT02569151,Death,"new, worsened, or improved microvascular and macrovascular events",2016-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1515,NCT00819741,Change in Glycosylated Haemoglobin A1c (HbA1c),Haematology: Haemoglobin,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1516,NCT03556033,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Inflammatory/atherogenic phenotype of circulating monocytes from the participating patients
1517,NCT04120259,Measurement of Fasting Blood Sugar,,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],
1518,NCT01824407,Complete closure,Rate of amputation and other adverse events,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1519,NCT04867707,Change in glycocalyx integrity,Change in Vascular function,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1520,NCT01749345,Quality of life,Low density lipoprotein (LDL) Cholesterol,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
1521,NCT03195855,Change in maximum ankle range of dorsiflexion in stance phase when both feet are in contact with the ground (double support phase).,Change in functional reach test,2018-05-11,COMPLETED,INTERVENTIONAL,['NA'],To investigate the compliance/adherence rates of the home exercise programme
1522,NCT03811587,Dosage of antidiabetic medication used,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],
1523,NCT00511732,Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1524,NCT00841867,To determine differences in glucose metabolism between subjects who have had partial pancreatectomy due to a benign lesion and those who have not had such a surgery.,,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
1525,NCT02851849,Change from baseline in HbA1c,Change from baseline in body weight,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1)"
1526,NCT02244879,C reactive protein (CRP),Metabolic and oxidative markers,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],body composition and bone mineral density
1527,NCT02313805,The total number of educational points addressed for the safe and effective use of insulin (of the possible 21 specified),"The number of educational points addressed under each of the four educational domains: insulin side effects, recognition and treatment of hypoglycemia, administration of insulin, and drawing up insulin using the syringe method.",2014-07,UNKNOWN,INTERVENTIONAL,['NA'],
1528,NCT03559621,weight-loss goal,Sence of Coherence,2019-04-14,COMPLETED,INTERVENTIONAL,['NA'],
1529,NCT00555854,HbA1c,"Lipids profile ,blood pressure, waist, BMI and medication Questionnaire: PAID PCD HCCQ TSRQ Health Care Behavioural a",2005-12,COMPLETED,INTERVENTIONAL,['NA'],
1530,NCT06050642,Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care],E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care],2023-09-04,RECRUITING,INTERVENTIONAL,['NA'],
1531,NCT00444483,The primary outcome measure regarding patients metabolic control was the improvement of quality of life six months after DTTP.,A secondary objective of the study was the comparison of QoL- subscale in patients already on insulin therapy with those newly on insulin therapy.,na,COMPLETED,INTERVENTIONAL,['NA'],
1532,NCT01010035,to identify the removal of the free and esterified cholesterol in type 2 diabetes patients,,2006-09,COMPLETED,OBSERVATIONAL,['NA'],
1533,NCT05625321,Dietary Intake,Perceived Quality of Life,2023-03-27,RECRUITING,INTERVENTIONAL,['NA'],
1534,NCT01948479,ulcer recurrence rates,peak pressure reduction with the addition of the intervention,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
1535,NCT04907721,Differences in the calculated GLUSENTIC index between individuals with or without MASLD without diabetes,"Simple linear regression between the variables, pancreatic steatosis and amino acid stimulated glucagon or insulin levels in individuals without diabetes.",2021-05-27,COMPLETED,INTERVENTIONAL,['NA'],Differences in fetuin-B
1536,NCT00859638,Physical Functioning Inventory (PFI),Eight Foot Walk Test,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
1537,NCT02339909,Number of Patients Attending Screening Appointment,Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
1538,NCT03257566,Screening the incidence of hypothyroidism in patients with type 1 diabetes,,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],
1539,NCT05479591,Change in Glycated Haemoglobin A1c (HbA1c),Change in body weight,2022-07-30,WITHDRAWN,OBSERVATIONAL,['NA'],
1540,NCT01113099,Statin prescription at hospital discharge,,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
1541,NCT01234155,Glycemic Control,Body Composition,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1542,NCT02389010,Number of closed skin ulcers within 4 weeks of treatment with cord blood platelet gel (CBPG) vs standard local medications,Cost of treatment,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1543,NCT04381429,Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.,Other CGM parameters: Time in range of blood glucose 70-140 mg/dl,2020-08-17,RECRUITING,INTERVENTIONAL,['PHASE4'],
1544,NCT03399825,Evaluation of the sensitivity and specificity of OCTA,,2018-01,WITHDRAWN,OBSERVATIONAL,['NA'],
1545,NCT00329225,HbA1c at each visit,FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1546,NCT05984979,VOC Patterns over time as boxplots,Correlation between VOCs and subgroups,2023-08-07,RECRUITING,OBSERVATIONAL,['NA'],
1547,NCT02277509,Percent Change in BMI,Sustained changes in HbA1c,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
1548,NCT03202875,Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR),Number of adverse events (AEs),2012-11-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
1549,NCT02012465,Incidence of hyperglycemia,Remission of primary oncologic diagnosis at one year,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1550,NCT04903756,Analysis of audio-recorded consultations between surgeons and patients.,Analysis of healthcare professional interviews,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1551,NCT00901043,Brachial artery flow mediated dilation (FMD),"Change in weight, waist circumference, blood pressure, fasting lipids, fasting insulin, HBA1c and glucose levels",2007-10,COMPLETED,INTERVENTIONAL,['NA'],
1552,NCT01898572,Carotid Intima Media Thickness (CIMT),CIMT,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Diet intake
1553,NCT04092140,Electromyogram,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
1554,NCT03829046,Number of Adverse Events,Alpha5/Beta3 Activation Levels,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1555,NCT00350701,Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo,Change in Inflammatory Mediator C-Reactive Protein (CRP) Following Treatment With Testosterone,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1556,NCT01864564,Number of Participants With a Composite Perinatal Outcome,Large for Gestational Age,2013-06-18,COMPLETED,INTERVENTIONAL,['NA'],
1557,NCT02479399,Incidence of malignant tumor,Safety developed by adverse events and laboratory tests,2014-07-17,COMPLETED,OBSERVATIONAL,['NA'],
1558,NCT00228605,Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients,Assess the patients' overall medication performance,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1559,NCT06232746,Safety of the DI Magnet System,,2024-02-13,RECRUITING,INTERVENTIONAL,['NA'],
1560,NCT01189461,Mean Total Number of Injections,Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 48 (End of Treatment),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1561,NCT00509262,Percentage of Participants With Hypoglycemic Events,Change From Baseline in Body Weight at Week 54,2007-10-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1562,NCT00748072,The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1563,NCT02129595,"insulin sensitivity: overall, muscle- and liver specific",brown adipose tissue activity,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Blood pressure
1564,NCT01183455,Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC),Pharmacokinetic Parameters of Aralast NP,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1565,NCT04171648,Change from Baseline Blood Glucose Response (Glycemic Response),waist to hip ratio,2020-03-02,TERMINATED,INTERVENTIONAL,['NA'],
1566,NCT00196989,Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control,Change from Baseline (Day 1) in QUICKI at Week 16,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1567,NCT01124617,Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12,Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1568,NCT00518115,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1569,NCT00529204,Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy,Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
1570,NCT05231031,Serum cortisol level,The perceived stress score (PSS),2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1571,NCT01498900,HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),2004-08,COMPLETED,OBSERVATIONAL,['NA'],
1572,NCT01885260,The effect of ISIS-GCGRRx on serum fructosamine,The tolerability of ISIS-GCGRRx,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1573,NCT00116831,Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,Number of Other Cardiovascular Events,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1574,NCT04512885,success rate,satisfaction measured by auto-questionnaire,2020-07-16,COMPLETED,OBSERVATIONAL,['NA'],
1575,NCT02373150,Safety and tolerability of imeglimin: laboratory assessments,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1576,NCT01113671,Reverse Cholesterol transport of the HDL,Serum inflammatory markers,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1577,NCT01374568,Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
1578,NCT03181737,Diabetes Self-Management Questionnaire (DSMQ-R),Subjective usefulness of the program,2017-08-03,TERMINATED,INTERVENTIONAL,['NA'],
1579,NCT00449891,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
1580,NCT02097277,Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12,Percentage of Participants With ANTI-BMS-986036 Antibody Response,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
1581,NCT03512236,AUCPram_0-8h,Safety and tolerability (Adverse Events recording),2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
1582,NCT02582840,24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set,Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1583,NCT00585936,,,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
1584,NCT02219269,Contraceptive method continuation and satisfaction,If Contraception is Accessed in post-partum or post-abortion setting,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
1585,NCT00118963,Glycemic control (HbA1c).,"Markers of endothelial dysfunction, inflammation and fibrinolysis including Small-dense-LDL, Lp(a) and Apo B100, von Willebrand-factor, ICAM, VCAM, selectin, endothelin, Amadori-protein, CRP, fibrinogen, IL-6, TNF-alfa, ADMA, PAI- and t-PA-activity",2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1586,NCT03388762,GlycoMark,Adverse events,2017-12-05,COMPLETED,INTERVENTIONAL,['NA'],
1587,NCT06156124,Clinical problems,Sociodemographic data,2023-06-13,RECRUITING,OBSERVATIONAL,['NA'],
1588,NCT02367690,Presence of Local Skin Reactions (LSR),Ulcer Closure,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1589,NCT05702931,Mean sensor glucose (mmol/L),Incidence of self-reported hypoglycaemic episodes,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1590,NCT00608348,Muscle sympathetic nerve activity,,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
1591,NCT03578094,Assessment of the anthropometric measurements of the infant according to the breastfeeding patterns,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA'],
1592,NCT04767880,Concentration differences in blood glucose following an OGTT,Continuous glucose measurements (CGM),2021-04-26,COMPLETED,INTERVENTIONAL,['NA'],
1593,NCT04559191,the normalized absolute change in total atheroma volume on serial intravascular ultrasound imaging.,the frequency of hypoglycemia,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1594,NCT00160017,HbA1c,"These intermediate outcomes will be measured as well, in both the intervention and the control group.",2005-01,COMPLETED,OBSERVATIONAL,['NA'],
1595,NCT02673554,Insulin secretory response after GIP bolus or infusion.,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1596,NCT05454059,HbA1c levels,Clinical attachment level (CAL),2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],
1597,NCT06319560,To compare the shearwave elastography of the placenta between the two groups,Hospital admission,2024-01-02,RECRUITING,INTERVENTIONAL,['NA'],
1598,NCT03497260,Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l),Carbon dioxide production during exercise,2019-01-04,COMPLETED,INTERVENTIONAL,['NA'],
1599,NCT00227383,Solid-phase gastric emptying time and score on Gastroparesis Cardinal Symptom Index(GCSI) at 2 weeks,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1600,NCT01755273,Resolution of diabetes,,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
1601,NCT03100084,Rate of acute cesarean section (due to suspected fetal distress),Abnormal intrapartum CTG patterns,2016-09-15,UNKNOWN,OBSERVATIONAL,['NA'],
1602,NCT04039763,Change in glycated haeomglobin (HbA1c),,2020-09-03,RECRUITING,INTERVENTIONAL,['NA'],
1603,NCT01415271,HbA1c,unplanned hospitalizations,2011-10,TERMINATED,INTERVENTIONAL,['NA'],
1604,NCT01829061,The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C,Obtain CLIA Waiver Status for the Quo-Test,2013-04,TERMINATED,OBSERVATIONAL,['NA'],
1605,NCT02378259,Body Mass Index (kg/m2),Attention,2014-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cancer or precancerous lesions
1606,NCT00455403,Change in Carotid Intima-media Thickness From Baseline to Year 1,,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
1607,NCT01162993,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"Effect SCS on health related quality of life, quality of sleep, mood, blood glucose control, large/small nerve fibre functions, predictive factors success of SCS treatment, small fibre loss/regeneration, cost-utility and cost-effectiveness",2010-04,UNKNOWN,INTERVENTIONAL,['NA'],
1608,NCT02592616,Ad-libitum meal energy intake,Satiety,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],
1609,NCT05009433,Childhood outcomes: changes in diastolic blood pressure,Covid-19 disease,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],The serotonin transporter (5-HTTLPR) polymorphism
1610,NCT00905073,insulin dose,renal function,1990-02,COMPLETED,INTERVENTIONAL,['NA'],
1611,NCT02975297,Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges,Post-quit Craving as Assessed by the Questionnaire of Smoking Urges,2016-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1612,NCT00032474,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1613,NCT01869621,Heritability,Single nucleotide polymorphisms (SNPs),2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1614,NCT06250192,Birthweight standard deviation score,Continuous glucose monitoring metrics 1 months post delivery,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
1615,NCT01728116,Primary Safety Endpoint: Early Device Removal Due to Device-Related SAE,Percentage of Subjects Who Achieve % Total Body Weight Loss Greater Than or Equal to 5% at 12 Months,2012-12,TERMINATED,INTERVENTIONAL,['NA'],
1616,NCT03215498,"Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 30 min",Number of hypoglycaemic episodes,2017-07-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1617,NCT05911659,Platelet Reactivity Index and maximum platelet aggregation,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],
1618,NCT02351323,Weight gain,Change in A1C,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1619,NCT04056208,Fasting plasma glucose concentration,Change in the composition of the gut microbiome,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1620,NCT01492062,Test the feasibility of using MMPPC controller for closed loop insulin delivery in a monitored inpatient clinical research environment.,Efficacy,2011-02,WITHDRAWN,INTERVENTIONAL,['NA'],
1621,NCT01017718,"How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease > 1 year, age 8 to 18a, insulin requirement > 0.5 IU/kg/d) show pathological nerve conduction velocity?",Is there a correlation between nerve conduction velocity in our study patients and the Young Score?,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
1622,NCT01666223,Change in GLP-1,Change in bile acid composition,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
1623,NCT05599633,Change of high density lipoprotein cholesterol (HDL-C) level,Change of heart rate from baseline,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],
1624,NCT00777712,Determine molecular mechanisms underlying impaired wound healing in diabetes,Characterize mechanisms responsible for dysregulated wound inflammatory cell function in patients with diabetes,2008-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1625,NCT04328363,Glucosa level,Reversion to normal glucose,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],
1626,NCT05329376,"Screening for depression, anxiety and common mental health disorders in elderly",Perception of stress:,2023-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1627,NCT02694575,EPC,Renal function,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],
1628,NCT05749874,Time to first occurrence of composite endpoint of new-onset diabetes and major cardiovascular events.,Time to newly diagnosed cancer,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Subgroup analysis 10 for primary outcome measure
1629,NCT04670094,Mortality up to 3 months from admission,Correlation between admission to ICU and in-hospital mortality,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],
1630,NCT04232774,Incidence of Serious Device- and Procedure-Related Complications,Procedure Success,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
1631,NCT01945645,Modelled cardiovascular disease risk,Smoking,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
1632,NCT05788731,The proportion of patients integrating the common law system,Proportion of patients resorting to one or more consultations with a general practitioner.,2023-01-18,COMPLETED,OBSERVATIONAL,['NA'],
1633,NCT01068951,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
1634,NCT05591235,Insulin resistance,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1635,NCT00983021,"Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes",The area under the NN1250 concentration-time curve after single-dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1636,NCT05968131,Change in Quality of Life,,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],
1637,NCT00266253,HbA1c mean change from baseline compared with placebo.,Pharmacokinetic and exposure-response relationship,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1638,NCT03662217,Evaluation of the total daily time of plasma glucose levels,Change in Fructosamin parameter,2018-10-28,UNKNOWN,INTERVENTIONAL,['NA'],Patients Diet compliance evaluation
1639,NCT00337142,,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],
1640,NCT02775253,The changes of UCP-1 expression in subcutaneous white adipose before and after cold acclimation program,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1641,NCT04841096,Mean difference change between groups in HbA1c concentration,Incidence of adverse events and reactions,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
1642,NCT06180109,Time of the maximum measured plasma concentration (Tmax),,2023-07-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
1643,NCT05284071,"Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months","Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.",2022-03-14,COMPLETED,INTERVENTIONAL,['NA'],
1644,NCT00974051,Blood Glucose Nadir,Percent of Nighttime Glucose Levels >250 mg/dl,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
1645,NCT01434407,Urine AGE,Urine isoprostanes,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
1646,NCT03140865,Change in performance on cognitive measures.,Change in brain volumes on magnetic resonance imaging (MRI).,2014-01,RECRUITING,OBSERVATIONAL,['NA'],
1647,NCT03241706,Glucose Infusion Rate,Peripheral Glucose Uptake,2018-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
1648,NCT06186843,Weekly one day food recall,Triglycerides,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Urine electrolytes (Na, K, Cl, Ca, Phosphorous)"
1649,NCT03089632,Changes in upper gastrointestinal symptoms assessed by the Gastroparesis Cardinal Symptoms Index (GCSI),Changes in glycemic control assessed by continuous glucose monitoring,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],
1650,NCT03176056,The reduction of medication effect score (MES),The improvement of carotid intima-media thickness (IMT),2016-02-02,COMPLETED,INTERVENTIONAL,['NA'],
1651,NCT04810260,Diabetes quality of life measured by the Diabetes Quality of Life instrument,Patient Health Questionnaire-9 for depression,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
1652,NCT04892680,Change in HbA1c at 6 months from baseline,Change in medication adherence at 6 months from baseline,2021-03-04,TERMINATED,INTERVENTIONAL,['NA'],Health care utilization at 6 and 12 months from baseline
1653,NCT02326129,"Compare 11β-HSD1 activity and 5α-reductase activity among obese adolescents with T2D, obese adolescents without T2D and normal weight controls",Metabolic signatures correlate with parameters of glucose tolerance,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
1654,NCT02205528,Change in HbA1c,Change in percent HbA1c,2014-08-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
1655,NCT01562678,Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1656,NCT01798225,Periodontal Pocket Probing Depth (PD),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1657,NCT01237314,4-hour glycemic response at 3 time points,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
1658,NCT05292495,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,ADA：anti-drug antibody,2022-03-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1659,NCT05574062,Continuation Phase Primary Endpoint: mean in HbA1c,Continuation Phase Secondary Endpoint 3- Time spent in target range (70 to 180 mg/dL [3.9-10.0 mmol/L]),2023-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1660,NCT02874313,Change from baseline in of retinal microaneurysm or hard exudates,Change from baseline of intraocular pressure,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1661,NCT00763802,CSME needing Photocoagulation,Vision Loss,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
1662,NCT06247514,Disordered Eating Behaviors (DEBs) - Change in Participant-Reported Outcomes (PROs),Change in participant's HbA1c,2024-01-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1663,NCT02261441,Cardiovascular risk factors,,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
1664,NCT00935220,"DPP-4 Inhibition: E_24,ss",DPP-4 Inhibition: E_24,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1665,NCT01102946,Fluorescein leakage area (mm2),Rod pathway integrity and oscillatory potential amplitudes,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1666,NCT03181165,Proportion of participants not on glucose-lowering medications,Diastolic Blood Pressure,2017-07-05,COMPLETED,INTERVENTIONAL,['NA'],Intervention Satisfaction
1667,NCT02628106,the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1668,NCT02790645,Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).,Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
1669,NCT02137720,HbA1c,Cholesterol,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
1670,NCT03489031,basal/total ratio,hypoglycemia,2016-04-11,COMPLETED,OBSERVATIONAL,['NA'],
1671,NCT03503552,Bone mineral density,Urine Markers,2015-02-13,COMPLETED,OBSERVATIONAL,['NA'],
1672,NCT05564039,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1673,NCT05369793,Change in HbA1c,Changes of Douleur Neuropathique-4 (DN4) questionnaire (DN4),2022-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Major adverse cardiovascular events (MACE)
1674,NCT00985101,endothelial damage,,2010-04,UNKNOWN,OBSERVATIONAL,['NA'],
1675,NCT06119035,Glucose levels will be analyzed,Serum samples,2023-11-06,COMPLETED,INTERVENTIONAL,['NA'],
1676,NCT02379299,Number of CHO interventions to treat hypoglycemia,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1677,NCT02961192,Change in mean daily steps,Change in LDL-C levels,2017-02-13,COMPLETED,INTERVENTIONAL,['NA'],
1678,NCT04696159,Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor,Change from Baseline on Gastroparesis Cardinal Symptom Index,2023-01-04,RECRUITING,INTERVENTIONAL,['NA'],
1679,NCT04649203,TSS (Total Symptom Score),,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
1680,NCT05562492,Time spent in the target glucose range between 3.9 and 10.0 mmol/L based on CGM glucose levels,Percentage of time of CGM availability,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],Human Factors Evaluation - Questionnaires
1681,NCT03088475,Self-efficacy: change is being assessed,Unplanned medical consultation,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
1682,NCT05622123,Correlation between residual beta cell mass and function,Correlation with other parameters,2023-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
1683,NCT03832907,Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading,"Percentage of Dexcom G6 CGM Sensor Values Within 15/15%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG",2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],
1684,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period,Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1685,NCT03483155,the incidence of Cardiovascular disease,,2018-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
1686,NCT00808535,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],
1687,NCT05037591,"Blood Glucose ""change"" is being assessed",waist-to-hip ratio (WHR),2021-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1688,NCT04812171,Influence of diabetes mellitus on apical periodontitis healing after non-surgical endodontic treatment,Association of glycated hemoglobin level (HbA1C) with apical periodontitis healing,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],
1689,NCT00812253,Hospital Length of Stay,Cardiac Output,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1690,NCT03531177,Waist circumference,Physical activity,2018-04-26,COMPLETED,INTERVENTIONAL,['NA'],
1691,NCT04761094,HbA1C,Hospital admission,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1692,NCT00108004,Understand management issues in subjects with type 1 and type 2 diabetes mellitus,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1693,NCT01681693,Plasma glucose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1694,NCT02409329,Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c),Change in Self-reported Medication Adherence,2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],Change in Glycemic Control - REACH Only vs. Control & REACH+FAMS vs. Control
1695,NCT00453934,,Number and type of adverse events.,2007-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
1696,NCT00351507,Effect on gastric emptying,"Effect on endogenous glucose appearance, glucose appearance and glucose disposal",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1697,NCT01934842,Non Inferiority of Analyte Levels,,2013-09,WITHDRAWN,INTERVENTIONAL,['NA'],
1698,NCT00508287,Safety: incidence of adverse events,"PD Measures: Fasting and postprandial serum glucose (AUC), serum insulin, and plasma glucagon concentrations. Acetaminophen plasma concentrations will be measured after a single dose of acetaminophen",2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1699,NCT01994811,Prevalence of non-communicable diseases,,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
1700,NCT00267839,"Bone parameters after 6, 12 and 18 months",Quality of live after 12 and 18 months,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
1701,NCT05641090,Trail Making Test-B and Stroop test,Nitric oxide,2021-12-16,RECRUITING,INTERVENTIONAL,['NA'],
1702,NCT01098461,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1703,NCT04897815,Changes of cerebral blood flow on fasting and 1 hour postprandial.,The relationship between the fluctuation of blood glucose and the change of cerebral blood flow.,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
1704,NCT05029297,"To demonstrate the efficacy and the non-inferiority of a new formulation of the capsaicin topical solution in ""roll-on"" compared to capsaicin in cream.",Grade of compliance/complacency of treatment.,2010-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1705,NCT04543032,Measurement of stride length,Assessment of Quality of life,2021-01-05,COMPLETED,INTERVENTIONAL,['NA'],
1706,NCT02999841,Change of the visceral fat area in square centimeter assessed by abdominal CT scans from baseline to 24 weeks.,Change of brain natriuretic peptide in nanograms per milliliter from baseline to 24 weeks.,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1707,NCT03246828,Change in plasma glucagon from baseline (0min),Continuous glucose monitor recordings,2017-07-03,COMPLETED,INTERVENTIONAL,['NA'],
1708,NCT05409131,Percent of time in range 70-180 mg/dL,Change in Diabetes Quality of Life (DQL)-brief total score,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1709,NCT00695565,Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation,Change in Blood Pressure From Baseline to Week 12,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1710,NCT04064203,p-glucagon,growth hormone,2017-07-05,COMPLETED,INTERVENTIONAL,['NA'],
1711,NCT01381900,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1712,NCT03073551,Glucose levels,Maternal weight gain,2010-07-27,UNKNOWN,INTERVENTIONAL,['NA'],
1713,NCT05925829,Safety of SVF and aaPRP in Type 2 Diabetes Patients,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1714,NCT02815787,The area under the plasma concentration-time curve (AUC) of Glyburide,The number of volunteers with adverse events as a measure of safety and tolerability,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1715,NCT00888628,Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.,Reduction of Insulin Requriements,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1716,NCT04247620,Glycemic Control (HbA1c),Social Vulnerability (CDC/ATSDR Social Vulnerability Index),2020-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1717,NCT00959725,Best-corrected visual acuity,Macular thickness,2009-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1718,NCT03220919,Doses,Hypoglycemia,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Adverse effects
1719,NCT03736083,Change in Diabetes Treatment Satisfaction Questionnaire- Parent version,Change in Glycemic control measured by A1c,2019-09,WITHDRAWN,INTERVENTIONAL,['NA'],Percentage of glucose sensor readings above 180 mg/dl
1720,NCT01624116,Change in body weight and fructosamine levels during Ramadan fasting.,Change in renal profile from baseline to end of Ramadan,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
1721,NCT01447992,estimation of the failure rates of system components,percent time of active CTR,2011-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1722,NCT01739829,To establish the safety and efficacy of xenotransplantation of DIABECELL,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1723,NCT04503408,Time of activities of daily living test,,2019-09-13,COMPLETED,OBSERVATIONAL,['NA'],
1724,NCT01082445,Tissue oxygenation improvement,Oxidation status reduction,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1725,NCT05230342,Evaluation of the total daily interstitial glucose over 140 mg/dl,16s ribosomal gene analysis,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1726,NCT03174340,Prescription of insulin during the follow-up,Compliance with the exercise (in the exercise group only),2008-02-21,COMPLETED,INTERVENTIONAL,['NA'],Dosage of short-acting insulin
1727,NCT00646724,Glucose and C-peptide levels,Complete Blood Count,2008-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1728,NCT00716170,Plasma glucagon responses,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
1729,NCT04656210,Atrophy difference based on two cerebral MRI volumetries,changes in amyloid biomarkers in blood at 4 years of inclusion,2021-10-14,RECRUITING,OBSERVATIONAL,['NA'],
1730,NCT02797314,Trabecular Bone Score,,2017-03-28,RECRUITING,INTERVENTIONAL,['NA'],
1731,NCT01208948,occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years,The time to CSME development,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1732,NCT00818935,Glycated Haemoglobin,"body weight, homocysteine, C-reactive protein, plasma lipids and lipoproteins, fasting body glucose, insulin, insulin resistance, serum urea, creatinine, C-peptide",2004-06,COMPLETED,INTERVENTIONAL,['NA'],
1733,NCT04940572,Preservation of auditory function.,Quality of sleep assessment on adult population - Qualitative questionnaire (no scale),2021-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
1734,NCT06025422,During the procedure difference in the mean in-shoe PPP by ROI associated with each toe gap standard,During the procedure PTSR associated with habitual footwear,2023-03-13,RECRUITING,OBSERVATIONAL,['NA'],
1735,NCT03393338,Number of emergency room visits and hospitalizations over 12 months,Physician Trust,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1736,NCT02739217,Description and number of abnormal laboratory values and adverse events that are related to treatment.,Change from baseline of antidiabetic treatment,2016-02-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements.
1737,NCT04259489,Glycemic achieving rate,The days of Hospitalization due to hypoglycemia,2020-01-31,UNKNOWN,INTERVENTIONAL,['NA'],
1738,NCT02449187,AUC(last),Vd/F,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1739,NCT03883230,GLYWD test result,Clinician's wound characterization,2017-07-27,COMPLETED,OBSERVATIONAL,['NA'],
1740,NCT00300976,"The occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death",All-cause mortality (deaths due to any cause),2006-05,UNKNOWN,INTERVENTIONAL,['NA'],Changes in QOL (EQ-5D)
1741,NCT01334645,Copeptin value,"Troponin, Myoglobin and Creatin Kinase values. Clinicals and paraclinicals events .",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
1742,NCT01537497,Modulation of carbohydrate and lipid metabolism,Area under the curve (AUC) of PF-05175157 after single oral doses,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1743,NCT00947427,C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1744,NCT03037099,Dietary glycemic index,Systolic blood pressure,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
1745,NCT01199692,,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
1746,NCT01966978,Mean Change From Randomization in A1c at Week 26,Change in Short Form-36 (SF-36) Questionnaire Score,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1747,NCT00272064,Changes of glycosilated haemoglobin (HbA1c),Hypoglycemic episodes,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1748,NCT01280682,Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide,HbA1c Levels,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1749,NCT00949442,HbA1c,Need of additional prandial insulin,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1750,NCT01333774,Change in HbA1c value between initial and final visit,Number of participants with adverse events in both study groups. The influence of different approaches to dietary advising on the appearance of adverse events.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
1751,NCT03312595,Percentage of Participants With Wound Closed,Time to Wound Closure,2017-09-14,COMPLETED,INTERVENTIONAL,['NA'],
1752,NCT02989649,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction,2016-12-22,TERMINATED,OBSERVATIONAL,['NA'],
1753,NCT01698008,Evidence for Improved Diabetic Care With Mobile Phone Application Use,,2012-01-28,COMPLETED,INTERVENTIONAL,['NA'],
1754,NCT01553266,Change from 12 months prior to intervention in HbA1c up to 12 months during the intervention,MDET educators' quarterly debriefing session group discussions regarding intervention issues,2012-03-01,COMPLETED,OBSERVATIONAL,['NA'],
1755,NCT01490879,Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment,Incidence of adverse events,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1756,NCT03889600,Feasibility - Implementation fidelity: percentage of indicated referrals that are made,Limited Efficacy - 30-Day readmission rate,2021-03-02,WITHDRAWN,INTERVENTIONAL,['NA'],Process Outcome- Referral Completion: percentage of patients who receive services post-referral
1757,NCT02577016,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in FPG at Week 24,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1758,NCT04066400,Effect of ATI-free Nutrition on hepatic inflammation,Quality of Life using the chronic liver disease questionnaire (CLDQ),2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
1759,NCT04885153,Changes from Baseline Vascular Cell Adhesion Molecule-1 (VCAM -1) at 3 Months,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],
1760,NCT05037058,Proportion of patients receiving guidance on individualized physical activity,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
1761,NCT01264796,quality of life,,2009-11,COMPLETED,INTERVENTIONAL,['NA'],
1762,NCT04583462,Change between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.,Change between below- knee arterial calcification score progression between T0 and T2years with initial below-knee arterial calcification score ≤ and >400 (subgroup analysis),2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
1763,NCT04655131,Number of positive events for each protein amount.,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA'],
1764,NCT03712046,Diagnostic accuracy of 18F-FDG PET-CT for the diagnosis of diabetic foot osteomyelitis,,2019-01-15,TERMINATED,INTERVENTIONAL,['NA'],
1765,NCT03985566,Change in insulin response,Change in glucose trajectories over 14 days of continous glucose monitoring,2018-07-03,COMPLETED,INTERVENTIONAL,['NA'],
1766,NCT03948347,Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic),Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2,2019-06-25,RECRUITING,INTERVENTIONAL,['NA'],
1767,NCT00159536,pre-eclampsia,Snoring and sleep quality,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1768,NCT04226378,Glycated hemoglobin (A1C),Annual incidence of severe hypoglycemia,2020-01-20,COMPLETED,OBSERVATIONAL,['NA'],A1C stratified by age cohort
1769,NCT01433380,Changes in carbohydrate and lipid metabolism,"Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)",2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1770,NCT04511715,Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging,Number of visits,2020-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1771,NCT00954343,Percentage decrease of ulcer size twelve weeks after treatment begin (i.e. first shock wave treatment) compared to the baseline (ulcer size at first treatment),Tissue oxygen concentration after shock wave treatment,2009-08,WITHDRAWN,INTERVENTIONAL,['NA'],
1772,NCT05505721,Body mass index (kg/m2),,2021-03-16,COMPLETED,OBSERVATIONAL,['NA'],
1773,NCT00018239,,,1999-10,COMPLETED,INTERVENTIONAL,['NA'],
1774,NCT00247455,Plasma GLP-1 concentration,C-peptide/insulin ratio as marker of hepatic insulin extraction,2002-03,COMPLETED,INTERVENTIONAL,['NA'],
1775,NCT02155361,Pain Scores on the Neuropathic Pain Scale (NPS),Motor amplitude (microvolt) of tibial nerve,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1776,NCT04473274,Adverse events attributable,A1c,2020-05-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
1777,NCT05887635,Tolerability Endpoint:,Change in ALT and AST from baseline to 24 weeks post procedure.,2023-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1778,NCT01003184,Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26),Hypoglycemia Rate Per Year,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1779,NCT03292185,Area under the plasma liraglutide concentration time curve,Local tolerability at the injection site,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
1780,NCT01313156,"Metabolic Syndrome, Type 2 Diabetes",,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
1781,NCT02140983,OGTT,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1782,NCT05794152,Adverse birth outcomes,Number of participants developing type 2 diabetes,2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],
1783,NCT02148250,Duration (in Hours) of 20 % Dextrose Infusion Requirement,Total Glucose Required to Maintain Euglycaemia,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1784,NCT01030926,Area under the NN1250 concentration-time curve after single dose,Time to maximum observed NN1250 concentration after single dose,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1785,NCT00426413,,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
1786,NCT01154374,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1787,NCT05086549,Rate of change in albuminuria (urine ACR),Rate of change in proteinuria (urine PCR),2021-09-29,COMPLETED,OBSERVATIONAL,['NA'],
1788,NCT05101135,Changes in HbA1c,,2021-11-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1789,NCT02674828,number of consecutive weeks step goal met,Habitual Total Weekday Activity Score,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1790,NCT04057339,Change in glycemic parameters,Change in hs-CRP,2019-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in mitochondrial structure and gene expression in skeletal muscle
1791,NCT04705506,Markers of vascular calcification,,2017-02-05,COMPLETED,INTERVENTIONAL,['NA'],
1792,NCT00752180,Mean AUCins.0-12h and Cins.max,"PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam",2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1793,NCT03855449,Task Analysis Wireframe Development part 2,,2019-06-05,RECRUITING,INTERVENTIONAL,['NA'],
1794,NCT02470039,Change in fasting plasma glucose (FPG),area under the serum insulin concentration-time curve,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1795,NCT02648204,Change in HbA1c,Change in Pulse Rate,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1796,NCT01529918,Patient's uptake and preferences,"The comparison of yield of actual diabetes detected from those who have high risk at self risk-assessment, compared to the usual diabetes detection rate in a random sample from the practice within a one year period.",2009-11,UNKNOWN,INTERVENTIONAL,['NA'],
1797,NCT05579119,Change of the mean daily blood glucose levels during hospital,Mean length of stay in days in the hospital among different groups,2022-07-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1798,NCT01177332,Intrahepatic lipid content (IHL) and hepatic ATP and PI concentrations,"Substrate oxidation and blood plasma levels of FFA, triglycerides, glucose and catecholamines",2010-04,COMPLETED,INTERVENTIONAL,['NA'],
1799,NCT04029480,Number of Participants Who Discontinue Study Treatment Due to an AE over 54 weeks,Change from Baseline in FPG at 54 Weeks,2019-10-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1800,NCT00150423,Safety Efficacy,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1801,NCT00194909,"Our primary outcome will be a reduction in the weekly average 11 point Likert pain scale (0 - no pain, 10 - worst possible pain) at 8 weeks.","Secondary outcomes will include the Rand-36 quality of life scale, McGill visual analogue scale (VAS) and a sleep interference scale.",2004-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1802,NCT04891315,Correlation of sVAP-1 levels with Fetal outcomes: Miscarriage,Correlation of sVAP-1 levels with patient characteristics: Medications at time of booking,2021-07-25,TERMINATED,OBSERVATIONAL,['NA'],
1803,NCT00455325,Insulin Sensitivity,Triglycerides,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1804,NCT00286624,• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.,• The impact of islet transplantation on the quality of life of transplant recipients.,2003-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1805,NCT06045598,Lumbal proprioception,Dynamic Balance,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],
1806,NCT02435199,"The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS).",The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events.,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1807,NCT05874635,App engagement,,2023-05-11,RECRUITING,INTERVENTIONAL,['NA'],
1808,NCT00173940,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
1809,NCT01441921,Changes from baseline in circulating levels of glucose and insulin according to the intervention arm,Changes from baseline in telomeric length of leukocytes (LTL),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
1810,NCT05870670,"AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period",Number of Treatment Emergent Adverse Events (TEAEs),2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
1811,NCT03544411,Change of malondialdehyde,Change of Glutahione,2018-07-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1812,NCT05266261,Bone mineral density,Bone turnover markers,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
1813,NCT00747968,steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1814,NCT00322257,HbA1c,Fasting plasma glucose,2006-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
1815,NCT03660189,Time to anion gap closure in hours,Total volume of intravenous fluids administered,2018-09-17,COMPLETED,INTERVENTIONAL,['NA'],
1816,NCT05726409,Satisfaction with the mobile application,Change in nutrition knowledge,2023-09,WITHDRAWN,INTERVENTIONAL,['NA'],
1817,NCT01002807,Blood samples to measure the pharmacokinetic parameters Cmax and AUC for the combination products versus each investigational product alone,"Safety and tolerability measures (adverse events, physical exams, vital signs, ECGs, and clinical laboratory assessments)",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1818,NCT04079660,fasting capillary blood glucose level,LOS,2021-02-01,COMPLETED,OBSERVATIONAL,['NA'],
1819,NCT05399134,Postprandial glycemic response of novel staple foods in Type 2 diabetics,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1820,NCT01108120,The recurrence rate of diabetic foot ulcers,cardiovascular events during the follow up period,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1821,NCT00131664,Mean Change From Baseline in A1C at Month 6,Mean Change From Baseline in Adiponectin at Month 12,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1822,NCT00604669,Mortality,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
1823,NCT05177172,Glucose tolerance,Subjective appetite variables,2021-12-01,COMPLETED,INTERVENTIONAL,['NA'],
1824,NCT05736263,Comparison of CGM-derived percentage time in range (TIR) when temporary target is enabled or disabled during exercise,CGM-derived percentage time below range (TBR < 54 mg/dl) during and after exercise trials,2023-03-31,RECRUITING,INTERVENTIONAL,['NA'],Associations between sleep quality and glycemic variations
1825,NCT01285245,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1826,NCT02768987,Change from baseline in daily physical activity energy expenditure over 24 weeks,Change from baseline in push-up test over 24 weeks,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
1827,NCT03940209,HbA1c,Health-related Quality of Life,2019-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1828,NCT04515849,To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks,To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on rate pressure product
1829,NCT00684658,Pediatric Quality of Life Inventory (PedsQL),Diabetes Conflict,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1830,NCT01052714,Beck Anxiety Inventory (BAI) Mean Total Score Change Per Week From Baseline to Termination,,2010-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1831,NCT00468039,glycosylated hemoglobin (HbA1c)at Baseline and week 24,"Safety assessed by monitoring and recording all adverse events, serious adverse events.",2007-03-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1832,NCT03968380,Glucose Tolerance,Waist circumference,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA'],
1833,NCT02859818,Self-efficacy evaluated with the 10 items-SEDM,"Outcome expectations, socio-structural factors and personal goals",2016-12,UNKNOWN,INTERVENTIONAL,['NA'],
1834,NCT00427154,Change in HbA1c,Change in body weight,2007-01-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
1835,NCT04267601,Change of HbA1C,,2017-07-06,UNKNOWN,OBSERVATIONAL,['NA'],
1836,NCT00728351,HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy,Changes in the fasting lipid profile,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1837,NCT06203067,HbA1c,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1838,NCT02814838,Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13,Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit in Patients With Screening C-peptide < Median Value,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1839,NCT00592241,Validate safety while using the ADI Insulin Pump by intended users. This objective will be assessed by independently and successfully carrying out a list of tasks.,Evaluate user's satisfaction.,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
1840,NCT05169359,Change from pre-visit diabetes distress score at 1 week post visit,Promis,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
1841,NCT04430660,Change in percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],
1842,NCT06279637,Glycemic Control (Hemoglobin A1C [HbA1C]),,2024-03-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1843,NCT02985853,Capillary Blood Glucose,,2008-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1844,NCT02757937,Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months,Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
1845,NCT04540016,"Area under the concentration-time curve (AUC0-t, AUC0-∞)",,2020-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
1846,NCT04450563,Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg),Rise in ketone level between interventions,2020-11-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1847,NCT01289990,Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment,Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1848,NCT02306122,Duration of Nonadherence Event,Probability of Pharmacist Action Triggered,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
1849,NCT03600116,Identification of Volatile Organic Chemical Indicators of Hypoglycemia,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA'],
1850,NCT05302050,Change in HbA1c,Significant change in HbA1c,2022-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1851,NCT02686281,Number of Participants with Serious and Non-Serious Adverse Events,Area Under the Concentration-Time Curve,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
1852,NCT03215069,Baseline-adjusted ISSI-2 at 48-weeks,Glucose tolerance status at 48-weeks,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life at 48 weeks
1853,NCT01339390,Change in Weight (From Baseline),,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
1854,NCT06037551,Analysis of system accuracy based on DIN EN ISO 15197,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1855,NCT02235584,The potentiating effects of GLP-1 on second phase insulin response when clamped at at bloodsugar of 7 mmol/l,Second phase insulin response to GIP infusion at 7mmol/l,2009-07,COMPLETED,INTERVENTIONAL,['NA'],Total insulin response to arginine infusion
1856,NCT04589533,Variation in fasting glycemia between the two groups of Centres during phase 3 of the study,Description of characteristics of patients with T2DM hospitalized in Internal Medicine,2019-09-19,UNKNOWN,OBSERVATIONAL,['NA'],
1857,NCT00875290,Reduce blood glucose variability among 0-3 year old children with type I diabetes.,Number of adverse events,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1858,NCT06199505,Change in HbA1c,Change from baseline in ADA and Nab,2023-11-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Change from Baseline in Body Weight
1859,NCT03141710,Change of oral glucose tolerance test (OGTT),Change of fermentation markers,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA'],
1860,NCT03130894,type 2 diabetes,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1861,NCT01142050,ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;,Serious adverse event frequency and severity,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1862,NCT03973827,Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",2019-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1863,NCT02711839,HbA1c After Intervention,Triglyceride After Intervention,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
1864,NCT01758380,Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority,"Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability",2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1865,NCT02229396,Change in HbA1c From Baseline to Week 28,Change in Systolic Blood Pressure From Baseline to Week 28,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1866,NCT02091336,fetal growth,insulin requirements to achieve glucose targets,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],need of c section
1867,NCT03755960,Visual analogue Scale (VAS) general complaints and pain,neurophysiological assessment of Nervus Suralis height of amplitude of action potential,2019-03-02,COMPLETED,INTERVENTIONAL,['NA'],
1868,NCT01511835,OGTT,Number of newborn infants requiring Neonatal Intensive Care (NIC),na,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1869,NCT04082884,Percentage of Time in Target Range of 70-180 mg/dL.,Average Sensor Glucose Level,2020-06-25,COMPLETED,INTERVENTIONAL,['NA'],
1870,NCT01439178,"intraocular VEGF levels (pg/ml) in both groups (measured in aqueous humor), using multiplex beads immunoassay",,2011-08,UNKNOWN,INTERVENTIONAL,['NA'],
1871,NCT01916265,AUCGlucose of different glucagon dosages given s.c.,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1872,NCT01855321,Percentage of improvement in Glycemic control after Vitamin D therapy.,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1873,NCT00748137,24 hours BGL > 8.3mmol/l (CGMS),HbA1c,2008-03,UNKNOWN,INTERVENTIONAL,['NA'],
1874,NCT00656864,Change in incretin-mediated insulin secretion and receptor regulation of glucose-dependent insulinotropic peptide (GIP) in patients with type 2 diabetes.,Change in adipocyte GIP receptor mRNA expression levels.,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1875,NCT04457531,Mean maximal nerve conduction velocity,low density lipid Protein cholesterol (LDL-C).,2020-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],"Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites"
1876,NCT00366132,Time to Complete Wound Healing,"o Durability of wound closure (i.e., status of wound at one week following determination of ""healed"")",2006-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1877,NCT00920582,Mean Change From Baseline in HbA1c Between Teplizumab and Placebo,Number of Participants With Serious Adverse Events,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
1878,NCT00751842,Meal Stimulated C-peptide (area under the curve),Insulin Dose,2008-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
1879,NCT05943899,Association between SGLT2i intake and hepatic fibrosis,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],
1880,NCT01046318,Clinical laboratory tests,Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF),2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1881,NCT00812578,Insulin secretion and insulin resistance,"Glycemic control, lipid status, inflammatory markers, BMD",2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1882,NCT05422807,Change in Body Mass Index (Weight Status) at 6 months and at 12 months,Waist circumference (weight status),2011-04,COMPLETED,INTERVENTIONAL,['NA'],Teen Quality of Life
1883,NCT04271709,Proportion of Subjects with Visual Acuity Worse than 20/40,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1884,NCT01304225,Incidence of severe visual loss after 1 year,Retinal sensitivity,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1885,NCT03121027,Anemia,,2011-05-11,COMPLETED,OBSERVATIONAL,['NA'],
1886,NCT00865345,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI-Yellow Springs Instruments),Device Related Moderate or Device Related Severe Adverse Events,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
1887,NCT04949152,MACE,,2016-06-01,RECRUITING,OBSERVATIONAL,['NA'],
1888,NCT00564395,Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
1889,NCT02203084,Albumin/creatinine ratio,,2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1890,NCT03411460,Satisfaction of patient-determined hospital care at discharge in the two groups,Number of hypoglycmic events with the corresponding glucose level,2017-04-19,TERMINATED,INTERVENTIONAL,['NA'],
1891,NCT00519727,safety and tolerability,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1892,NCT02648685,the proportion of basal/post-prandial blood glucose contributed to the overall glycaemia(HbA1c),,2015-11-30,COMPLETED,OBSERVATIONAL,['NA'],
1893,NCT00160485,Newborn birth weight,Incidence of neonatal metabolic derangement,2004-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
1894,NCT00699426,insulin secretion,blood pressure,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1895,NCT04608058,Change in Self-management behavior,Change in Glycated hemoglobin A1c,2019-07-30,COMPLETED,INTERVENTIONAL,['NA'],
1896,NCT02072551,Mean insulin secretion output,glucago secretion output,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
1897,NCT05764629,Hemoglobin A1c (HbA1c),Adverse events,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1898,NCT04477928,"Demonstrated feasibility of large-scale population screening, as evidenced by:",Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.,2020-07-17,RECRUITING,OBSERVATIONAL,['NA'],
1899,NCT00461136,To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.,To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1900,NCT04662879,Earlier detection of pancreatic ductal adenocarcinoma (PDAC),Depression and Anxiety as early indicators,2021-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1901,NCT01273558,RTG values using the MMTT and the stepwise hyperglycemic clamp methods,Rate of Urinary glucose excretion (UGE) during the MMTT and the hyperglycemic clamp procedure,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1902,NCT01093794,Cmax for Sitagliptin and Metformin,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1903,NCT03301792,Effect of Diabetes Group Care on postpartum weight retention,Psychosocial Stress and Depression,2017-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1904,NCT05368623,To determine the sensitivity and specificity of RETINA-AI Galaxy v2.0 for diabetic retinopathy screening in the primary care setting.,,2022-11-03,COMPLETED,OBSERVATIONAL,['NA'],
1905,NCT02579655,"Composite rate of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, hospitalizations for chronic disease-related ambulatory care sensitive conditions",Overall health care costs,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
1906,NCT03001583,Weight loss,Weight loss,2019-10-30,WITHDRAWN,INTERVENTIONAL,['NA'],
1907,NCT03552757,Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo,Change in Calcitonin - Semaglutide 2.4 mg Versus Placebo,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1908,NCT00339885,"T2D status, quantitative traits measurements",,1996-06-01,COMPLETED,OBSERVATIONAL,['NA'],
1909,NCT04864327,HbA1c,BP(systolic and diastolic blood pressure),2011-05-05,COMPLETED,INTERVENTIONAL,['NA'],
1910,NCT01065337,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred",Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1911,NCT01475461,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1912,NCT03309007,Change in Leucocyte LC3 Score,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1913,NCT03010683,"Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.",Endothelial Glycocalyx and Coronary Flow Reserve.,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
1914,NCT02868606,Transfer to intensive care unit (y/n),In-hospital death (y/n),2015-07,COMPLETED,OBSERVATIONAL,['NA'],
1915,NCT03688919,Change From Baseline in Youth Future Orientation (Objective Measure) at 8 Weeks (Z-score),Change From Baseline in Self-Care Inventory Revised at 8 Weeks (Z-score),2019-05-13,COMPLETED,INTERVENTIONAL,['NA'],
1916,NCT01819922,Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose,Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1917,NCT04930679,Fasting blood glucose,,2018-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
1918,NCT05508490,prevalence of acute kidney injury in diabetic ketoacidosis,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1919,NCT00155454,Recurrent vitreous hemorrhage rate,,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
1920,NCT06286566,Number of complication,Valuation of patient satisfaction,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1921,NCT00632008,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1922,NCT01387633,blood pressure,Self-monitoring of blood glucose,2011-06,UNKNOWN,INTERVENTIONAL,['NA'],
1923,NCT00491023,,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
1924,NCT04589325,Residual insulin secretion,HbA1c,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in International Physical Activity Questionnaire (IPAQ) scores from baseline and week 52.
1925,NCT01541956,Change from baseline in hemoglobin A1c(HbA1C) after 24 weeks of treatment with vildagliptin,"Number of patients with adverse events, serious adverse events and death",2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1926,NCT04536480,Change in total body fat mass (kg),Change in BMI in excess of the 95th percentile (%BMIp95),2023-04-15,RECRUITING,INTERVENTIONAL,['NA'],Adult eating behavior Questionnaire
1927,NCT03004612,Change from basal fasting and post2h OGTT glucose levels at 12 and 24 months,Incidence of type 2 diabetes,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1928,NCT00133952,Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48,Number of Participants Requiring Repeat Focal Photocoagulation at Any Time From Baseline Though Month 24,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1929,NCT01193179,"Adverse events, clinical laboratory tests",Secondary Outcome HbA1c,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1930,NCT05442840,Change in Baseline Hemoglobin A1C (HbA1C) at 10 months,Modifiable Risk Factor - Blood Pressure,2022-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1931,NCT00639600,"Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves","Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs",2008-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1932,NCT00069537,Accuracy of the GlucoWatch G2 Biographer and CGMS,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1933,NCT01991470,"Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System","Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST",2015-03,COMPLETED,INTERVENTIONAL,['NA'],
1934,NCT01195662,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants,"Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue",2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1935,NCT02518581,Activity-induced energy expenditure,,2015-08-12,COMPLETED,INTERVENTIONAL,['NA'],
1936,NCT00056290,Safety,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1937,NCT04451980,Adipose tissue T cell surface marker phenotype and antigen receptor sequence,Circulating T cell surface marker phenotype,2017-08-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1938,NCT01971125,Prevalence of Left Ventricular Dysfunction in patients with type II diabetes,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],
1939,NCT03930004,Left atrial dysfunction,,2018-07-06,COMPLETED,OBSERVATIONAL,['NA'],
1940,NCT03829514,Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1941,NCT04023734,Medication adherence,Patients' willingness to maintain the intervention,2019-08-16,COMPLETED,INTERVENTIONAL,['NA'],
1942,NCT00922402,Average time to glycemic target (90-130 mg/dL),Evaluation of organizational impact,2009-06,WITHDRAWN,INTERVENTIONAL,['NA'],
1943,NCT02707380,Paired T-test to compare test-retest Perceived dyspnea,,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
1944,NCT02803905,A1c </= 6.5% and no severe hypoglycemia,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1945,NCT05928572,Phase 1 CGM-derived time in range (TIR),Total healthy eating index (HEI) score,2023-07-25,RECRUITING,INTERVENTIONAL,['NA'],Phase 2 CGM-derived time in range (TIR)
1946,NCT03458286,Total wound healing,Diabetic foot ulcer reoccurrence rates,2018-04,UNKNOWN,INTERVENTIONAL,['NA'],
1947,NCT04061473,glucagon excursions measured as incremental area under the curve (iAUC),food intake,2019-04-02,COMPLETED,INTERVENTIONAL,['NA'],
1948,NCT06194240,12-Item Short Form Health Survey,Generic Adherence Profile for Chronic Diseases,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1949,NCT01729156,Whole Body Glucose Rd,VLDL-TG Oxidation,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1950,NCT02675257,Improvement of glycaemic control as measured by the HbA1c,Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36),2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],Inflammatory Marker: Adiponectin
1951,NCT03613857,Ischemic or hemorrhagic stroke,,2017-04-15,COMPLETED,OBSERVATIONAL,['NA'],
1952,NCT05319990,Insulin Sensitivity,Effective Renal Plasma Flow (ERPF),2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],
1953,NCT00791076,Total Amount of Insulin Administered While on Placebo/PP.,Frequency of Hypoglycemia Defined as < 60 mg/dl.,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
1954,NCT03299790,ECG (Electrocardiogram),Maximal oxygen uptake (ml/O2/kg/min),2017-10-06,COMPLETED,INTERVENTIONAL,['NA'],
1955,NCT03508323,HbA1c,,2018-04-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1956,NCT02361489,A1C,Hypoglycemia,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1957,NCT04207099,Rate of change in wound area of diabetic foot ulcers in ARM 2 vs ARM 1,Wound Healing Rate,2020-02-14,UNKNOWN,OBSERVATIONAL,['NA'],
1958,NCT05852639,To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes,To evaluate the incidence of adverse neonatal outcome in both groups,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],
1959,NCT03167866,HbA1c levels at 6 months from beginning of messages,Diabetes Quality of Life questionnaire,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
1960,NCT01504620,Accuracy of the blood glucose meter in comparison to a standard reference,Hematocrit Interference (Helios),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1961,NCT03182582,Bacterial Load Pre- and Post-Sharp Debridement,Percent Change in Wound Size - 1 Week Post-debridement,2017-01-05,COMPLETED,INTERVENTIONAL,['NA'],
1962,NCT00286572,Death and/or major adverse cardiac events,,2004-01,COMPLETED,OBSERVATIONAL,['NA'],
1963,NCT01309022,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
1964,NCT06138821,Change in Liver Fibrosis measurement at 12 months compared to baseline,Change in eating behaviors compared to baseline,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1965,NCT01704417,"BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise","BGminimum,30-180min,post-exe, minimum blood glucose concentration",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1966,NCT02136654,Change in A1C or blood pressure (systolic or diastolic blood pressure),change in health status,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Procedure related outcomes
1967,NCT02053714,Changes in knowledge of diabetes self-management from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Management Questionnaire.,Changes in diastolic and systolic blood pressure from baseline to six months.,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
1968,NCT00732862,HbA1c,Catecholamines,1998-02,COMPLETED,INTERVENTIONAL,['NA'],
1969,NCT00978835,Blood Pressure,Hemoglobin A1c,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
1970,NCT05247034,Rate-dependent depression on the frequency of stimulation of the H reflex,Diabetes 39 Instrument,2021-06-04,RECRUITING,INTERVENTIONAL,['NA'],
1971,NCT03903016,Assessment of PK parameter :INS-AUClast -,Adverse Events,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
1972,NCT05979246,marginal bone loss,Survival rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1973,NCT02502071,Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1974,NCT03285230,Health outcomes,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1975,NCT01710774,healing time for leg ulcer and/or diabetes related foot ulcer,"A new foot ulcer appears, the incidence of amputation and survival.",2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1976,NCT05475587,Body constitution of body constitution questionnaire (BCQ),,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1977,NCT00550329,,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
1978,NCT01773707,Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance,Change in C-peptide response to Oral Glucose Tolerance Test (OGTT),2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1979,NCT01225081,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
1980,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,2017-11-01,RECRUITING,OBSERVATIONAL,['NA'],
1981,NCT00585897,Hemoglobin A1c,Fasting glucose,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
1982,NCT00549874,Myocardial blood flow regulation,biomarkers of oxidative/nitrosative stress,2002-02,COMPLETED,INTERVENTIONAL,['NA'],
1983,NCT02972528,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of allogenic Platelet Lysate injection by clinical examination,2018-02-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1984,NCT03995498,Percentage of time of interstitial glucose concentrations spent between 4.0-10.0 mmol/L,Total number of confirmed hypoglycemia episodes requiring treatment,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
1985,NCT03314467,Presence of obstructive sleep apnea in diabetic patients is a predictive factor for diabetic retinopathy occurence,Correlation between severity of obstructive sleep apnea and presence of diabetic retinopathy,2017-10-06,COMPLETED,OBSERVATIONAL,['NA'],
1986,NCT06029517,Change in SSB intake for men affiliated with Native American athletic communities,Change in body weight,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],
1987,NCT02106039,Better diabetes control in diabetes patients with tuberculosis under treatment,Association between glycemic control and clinical-microbiological response to TB treatment,2014-04-28,COMPLETED,INTERVENTIONAL,['NA'],
1988,NCT00745914,Change in carotid plaque volume,"Change in inflammatory markers include C-reactive protein, interleukin-6, adiponectin, metalloproteinases",2008-09,COMPLETED,INTERVENTIONAL,['NA'],
1989,NCT01403025,The incidence of SADRs (Serious Adverse Drug Reactions),The incidence rate and type of ADRs (Adverse Drug Reactions),2011-07-19,COMPLETED,OBSERVATIONAL,['NA'],
1990,NCT00497666,,,2007-08,UNKNOWN,OBSERVATIONAL,['NA'],
1991,NCT02563457,Hemoglobin A1c blood level,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],Quality of life
1992,NCT02826044,Cumulative excretion of SP2086,The number of volunteers with adverse events as a measure of safety and tolerability,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1993,NCT06270836,Proportion of eyes improving ≥2 steps on the Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS),Proportion of eyes improving ≥3 steps on Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS),2024-03-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
1994,NCT03378908,Glycemic profile below pregnancy target capillary blood glucose concentration,Point-of-care glycated hemoglobin (HbA1c),2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1995,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)","Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)",2012-12-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1996,NCT02388113,glycosylated hemoglobin (HbA1c),,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1997,NCT05078658,Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period,Differences in urine metabolome between the LCD and RCD periods,2021-09-22,RECRUITING,INTERVENTIONAL,['NA'],
1998,NCT05112445,OCTA metrics and predict progression to PDR and/ or CI- DME,,2022-05-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1999,NCT04315519,Cardiorespiratory Fitness,The Strength of Hamstring Muscle,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
2000,NCT03249896,Percentage of patients who have excessive gestational weight gain (EGWG),Neonatal intensive care unit admission,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA'],
2001,NCT02305784,Blood concentration of YKL-40 (ng/ml),Change of Blood concentration of YKL-40 (ng/ml) during an exacerbation,2015-05,COMPLETED,OBSERVATIONAL,['NA'],
2002,NCT00395343,Change From Baseline in A1C at Week 24,Percent of Patients With A1C < 6.5% at Week 24,2006-12-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in A1C at Week 24
2003,NCT04928248,Change in hemoglobin A1c (HbA1c) levels,Change in body mass index (BMI) levels,2021-09-23,COMPLETED,INTERVENTIONAL,['NA'],Rate of use of the Disease Manager's diabetes module
2004,NCT05179954,Apolipoprotein C turnover rate,Apolipoprotein B-100 concentration,2022-05-09,RECRUITING,INTERVENTIONAL,['NA'],
2005,NCT01714232,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),2012-10,COMPLETED,INTERVENTIONAL,['NA'],
2006,NCT00596063,The primary objective is to test for bioequivalence based on AUC0-12h and Cmax between Wockhardt's Insulin Human Regular for injection and Novolin® R,"PK endpoints: AUC, tmax and t½ PD endpoints: AUC-GIR, GIRmax and tGIRmax Safety endpoints: AEs, haematology, biochemistry, urinalyses, physical examination, vital signs, ECGs, blood glucose and local tolerability.",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2007,NCT01441986,Area under the blood glucose (BG) concentration-time profile,Adverse events,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2008,NCT02137174,HBA1C,Hypoglycemia rate,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2009,NCT03056456,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Following Administration of Each Study Arm With a Standard Dual-wave Bolus,Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Glucose Relative to MMTT Following Administration of Each Study Arm With a Standard Dual-wave Bolus,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
2010,NCT02222350,change in 24-hour weighted mean blood glucose,change in postprandial plasma glucose level,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2011,NCT05391659,AUC,false positives and false negatives,2021-06-17,RECRUITING,INTERVENTIONAL,['NA'],
2012,NCT04476693,Total trial area under the curve (AUC) for insulin.,Total trial area under the curve (AUC) for triaclyglycerol,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2013,NCT05571800,Effect of mango consumption on glycemic control evaluated by HOMA-β,Effect of mango consumption on anthropometric measure WC/HC ratio,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
2014,NCT01067950,"The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment",Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2015,NCT02550548,Beta cell sensitivity,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
2016,NCT03702660,Glucagon,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2017,NCT02236481,Glycated Hemoglobin,Plasma levels of glucose,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
2018,NCT06287736,Change in PROMIS quality of life in relation to pain level,change in neuropathic symptoms using Michigan Neuropathy Screening instrument,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2019,NCT03241212,Change in knowledge about type 1 diabetes,Percent of text messages responded to in the study.,2017-09-12,COMPLETED,INTERVENTIONAL,['NA'],
2020,NCT05659537,Percentage of Participants with AEs and SAEs,Mean Change from Baseline in Hemoglobin A1c (HbA1c),2022-12-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
2021,NCT02474381,Infrapopliteal arterial patency of the affected extremity,Amputation rate of the affected extremity,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
2022,NCT00884819,Hepatic adiposity as assessed using MRI,"Reproductive parameters (androgens, hirsutism)",2008-12,TERMINATED,INTERVENTIONAL,['NA'],
2023,NCT01589029,Regression of retinal neovascularizations (NVE and NVD) in FA.,Change in HbA1c and inflammatory markers,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
2024,NCT02827383,Continuous Glucose Monitor,Heart Rate,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
2025,NCT00871416,"Location of the injected sterile, atmospheric air",Cutis/subcutis thickness on 14 recommended injection sites,1997-04-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2026,NCT05307237,Infection Rate,Electronic Medical Record (EMR) - Derived Outcome: fasting POC blood glucose,2022-04-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Process Indicators (Maintenance): Stakeholder and advisory board feedback
2027,NCT03068286,Anxiety (as measured by the 7 item Generalised Anxiety Disorder inventory),Patient Experience (As measured by the Patient Experience Questionnaire),2017-01-01,TERMINATED,INTERVENTIONAL,['NA'],
2028,NCT00915954,Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml,"Median Bioactive IGF-1 Area Under the Curve in Response to Placebo, OGTT, and rhIGF1 Testing",2008-12,COMPLETED,INTERVENTIONAL,['NA'],
2029,NCT01697150,Percent time of active CTR,Frequency analysis of lost data caused by system components,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
2030,NCT05464043,Retrospective study: characterization of hyperglycemia and diabetes after liver or kidney transplantation,Prospective: analysis of impaired glucose tolerance (prediabetes) and diabetes after liver or kidney transplantation,2019-06-20,COMPLETED,INTERVENTIONAL,['NA'],
2031,NCT05451914,Change in Blood Glucose Control,Satisfaction/Usability of My Diabetes Care (for Intervention Group),2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],
2032,NCT00367978,Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined.,change from baseline in estimated glomerular filtration rate (EGFR) at Week 24,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2033,NCT03824379,Change of Human Serum Osteocalcin level,Quality of Life (QoL) Assessment: D-39 Questionnaire,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2034,NCT00681850,"HbA1c, LDL-cholesterol, Systolic Blood Pressure","Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice",2008-03,COMPLETED,OBSERVATIONAL,['NA'],
2035,NCT01450943,Wound Closure by Week 15,Cost Effectiveness,2011-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2036,NCT04371978,Time to clinical change,"Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.",2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
2037,NCT04864860,postprandial blood insulin concentration,side effect of ecklonia cava,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2038,NCT00135915,,,2005-08,COMPLETED,OBSERVATIONAL,['NA'],
2039,NCT00251940,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"• Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
2040,NCT03421301,intestinal microbiota,inflammatory profile,2014-08-07,COMPLETED,INTERVENTIONAL,['NA'],
2041,NCT03407118,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm,Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm,2018-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
2042,NCT00168519,glucose metabolism,,2002-10,COMPLETED,INTERVENTIONAL,['NA'],
2043,NCT04159558,Satisfaction with the mobile application assessed by an ad hoc questionnaire,Treatment adherence assessed by Morisky Medication Adherence Scale (MMAS),2018-04-24,UNKNOWN,INTERVENTIONAL,['NA'],Health goals compliance assessed by an ad hoc questionnaire
2044,NCT01068860,"Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.","Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks",2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2045,NCT03751657,Change in HbA1c [Millimoles/Mole (mmol/Mol)],Change in Anti-insulin 287 Antibody Level,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
2046,NCT01986855,Percentage of Participants Who Discontinued Study Treatment Due to an AE,Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2047,NCT04176731,Percentage of Time in Range 70-180 mg/dL During Overall (Days 1-14) and Standard Therapy Period (14 Days),"Total Daily Bolus Insulin (Units, Units/kg)",2019-12-15,COMPLETED,INTERVENTIONAL,['NA'],
2048,NCT00980941,Appetite,Palatability of treatments,2007-12,COMPLETED,INTERVENTIONAL,['NA'],
2049,NCT03105011,Absolute change in laboratory-measured HgbA1C,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA'],
2050,NCT02356757,Ulcerative and non-ulcerative Foot lesions,Cost-effectiveness,2015-08-24,COMPLETED,INTERVENTIONAL,['NA'],
2051,NCT05734313,Depressive symptom severity,Hemoglobin A1c (HbA1c),2023-10-31,RECRUITING,INTERVENTIONAL,['NA'],Anxiety symptom severity
2052,NCT01328639,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in Satisfaction with care,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
2053,NCT02320110,Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children,"Irisin plasma levels and adiponectin, leptin, insulin and resistin.",2014-09,COMPLETED,OBSERVATIONAL,['NA'],
2054,NCT05268393,Interventionist adherence to session manuals,Glycemic control,2022-03-31,COMPLETED,INTERVENTIONAL,['NA'],
2055,NCT01005121,24 hr urine protein collection,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2056,NCT02352246,loss of abdominal fat mass (g),Change from baseline in food behavior after training (visual analog scale from Flint et al. 2000),2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
2057,NCT05275231,Acceptability: Changes in Satisfaction questionnaire,Changes in weight of participant's social contact,2022-04-04,COMPLETED,INTERVENTIONAL,['NA'],
2058,NCT04826159,Change in cardiac PCr/ATP ratio with dobutamine stress (Stage 1 only) measured by 31P-MRS at baseline and at EOT with 200 mg BID of IMB-1018972,"Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs",2021-04-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
2059,NCT01819129,Change From Baseline in HbA1c,Change From Baseline in Body Weight,2013-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2060,NCT04373967,glycated hemoglobin (HbA1c),Percentage of participants with clinically significant change from baseline in laboratory parameters.,2020-04-29,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2061,NCT05719740,"to test and evaluate the role of bone-derived factor (osteocrin) in glucose metabolism,in diabetic patients with risk of micro and macrovascular complications .","to identify bone-derived factor (osteocrin) may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus",2023-02,RECRUITING,OBSERVATIONAL,['NA'],
2062,NCT04048642,Change in total daily insulin requirements,Change in urinary catecholamines,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],
2063,NCT02371343,Birth size,Insulin like growth factor DNA methylation,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
2064,NCT00443755,Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR),Change From Baseline in the Inflammatory Biomarker Adiponectin,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Fat-Free Mass (FFM)
2065,NCT03976271,Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA,Oxidative stress responses using oxidative stress marker,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],
2066,NCT00390975,Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET),The safety and tolerability of tegaserod,2007-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
2067,NCT01450787,Conjunctival Staining Score,Tear Film Osmolarity,2012-01,TERMINATED,OBSERVATIONAL,['NA'],Corneal Staining
2068,NCT02263352,Change in Serum MDA,Change in Clinical attachment level (CAL),2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2069,NCT05743244,The area under the stimulated C-peptide curve (Y_AUC),,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
2070,NCT02231658,Change from baseline (week -1) in the number of reflux episodes,Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus,2015-07-16,TERMINATED,INTERVENTIONAL,['PHASE1'],
2071,NCT01359241,Percent of plasma glucose values within target range 3.9-8.0 mmol/l,Frequency of hyperglycaemia,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
2072,NCT03504605,Self-compassion items,,2018-08-15,COMPLETED,INTERVENTIONAL,['NA'],Pediatric Inventory for Parents
2073,NCT00973401,"Changes in amplitude/implicit times, retinal vessel diameter, dark adaptation and OCT",,2009-09,UNKNOWN,OBSERVATIONAL,['NA'],
2074,NCT01777282,Number of Participants With Any Hypoglycemic Event,Time to Study Withdrawal Due to Hyperglycemia,2013-02-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
2075,NCT00704197,To assess sex differences in adipose tissue gene expression in different fat depots,To assess sex differences in other characteristics of adipose tissue structure and function in different fat depots across sex including: preadipocyte kinetics; lipolysis and lipogenesis; macrophage content; and tissue oxygenation,2007-08,TERMINATED,OBSERVATIONAL,['NA'],
2076,NCT04498819,Feasibility: Adherence,Participant Attitudes: Diabetes Emotional Distress,2020-11-09,COMPLETED,INTERVENTIONAL,['NA'],
2077,NCT03428295,Percentage of time in severe hyperglycemic range,,2017-06-22,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2078,NCT00031226,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
2079,NCT00147719,To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2080,NCT01630369,Decrease of Hb A1c ≥ 1%,Assessment of efficacy of education courses in Diabetes Schools,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2081,NCT01881009,Target Sensor Glucose 70-150 mg/dl,Target Sensor Glucose 70-180 mg/dl,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
2082,NCT02266576,Change From Baseline in the Quality of Life Short Form Survey (SF-12),Change in From Baseline in Empowerment,2015-06,COMPLETED,INTERVENTIONAL,['NA'],Lipid Bioassays
2083,NCT03426345,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,2018-02-16,TERMINATED,INTERVENTIONAL,['PHASE3'],
2084,NCT00730561,Change in nerve conduction velocity,,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
2085,NCT02245399,change in HbA1c,urinary analyses,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Estradiol level
2086,NCT02704494,Serum creatinin,Number of patients with adverse events,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2087,NCT01422057,Major cardiovascular event,Total mortality,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
2088,NCT01940302,Metabolic Control,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2089,NCT06011356,Step count,Patient Activation Measure (PAM),2023-08-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2090,NCT00360061,HBA1c,Modified Health Care Climate Questionnaire (at baseline only).,2001-09,COMPLETED,INTERVENTIONAL,['NA'],
2091,NCT04931537,Urinary Albumin Creatinine Ratio，UACR,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],
2092,NCT00141401,Safety Efficacy,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2093,NCT02545738,Change in albuminuria,24h heart rate,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2094,NCT01165268,The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin,"Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin",2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2095,NCT00446277,central corneal thickness,intraocular pressure,2007-01,SUSPENDED,OBSERVATIONAL,['NA'],
2096,NCT01626469,Change in ophthalmic artery blood flow from baseline,Change in renal plasma flow (RPF) from baseline,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2097,NCT00536250,hepatic fat content and abdominal fat ratio,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
2098,NCT04492566,Time in Target Glucose Range,Mean CGM Glucose Level,2020-07-27,COMPLETED,INTERVENTIONAL,['NA'],Fetal Outcomes: Neonatal Intensive Care Unit Admission
2099,NCT03045250,Normative values for corneal confocal microscopy (CCM),Serum biomarkers - fibrinogen,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],
2100,NCT00272090,severe nocturnal hypoglycemias will be measured throughout the study period.,severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2101,NCT02606747,Foot sole tactile threshold,,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],
2102,NCT05565651,Outcome percentage Phyla,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2103,NCT02875821,changes in visceral fat area,Changes in liver fat,2016-04-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
2104,NCT06283394,Percentage of food purchasing expenditures spent on eligible healthy foods,Qualitative results,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2105,NCT01382303,Percentage Change in Proteinuia,Mean Change of TNF-a,2010-10-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
2106,NCT03827434,Change in mortality among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care),,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],
2107,NCT05025852,Body Mass Index (BMI) z-score,Neurocognitive development,2022-05-11,RECRUITING,OBSERVATIONAL,['NA'],
2108,NCT00209170,"Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2109,NCT00539175,pain intensity,"Semmes-Weinstein sensation, proprioception, quality of life",2004-10,COMPLETED,INTERVENTIONAL,['NA'],
2110,NCT00945165,Hyperglycemia,Mean Blood Glucose,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
2111,NCT02006836,AUCs With/Without Pomelo,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
2112,NCT00253240,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
2113,NCT01343056,"Hemoglobin A1C (HbA1C, %)",Systolic Blood Pressure,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
2114,NCT02635243,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product,Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2115,NCT02085681,Proportion of patients with confirmed Diabetic Retinopathy (DR) diagnosed at the eye hospital,Proportion of patients eligible for referral who had DR and who did not attend,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Drivers of acceptance
2116,NCT02266823,Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
2117,NCT05407467,HbA1c,Blood Pressure,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2118,NCT03729323,Blood pressure,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],
2119,NCT03693521,Change in physical activity level,Physical Activity on Prescription,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],
2120,NCT00302874,Mean blood glucose during hospitalization,"Disposition at discharge (home, nursing home)",2003-02,COMPLETED,INTERVENTIONAL,['NA'],
2121,NCT02292511,Global Cognitive Functioning,Antisaccade direction errors,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
2122,NCT00445913,The trial is designed to assure that the toxicity rate is acceptably low to warrant further study of the cell vaccine in efficacy trials.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2123,NCT00802022,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"The practical- and technical feasibility of the procedures, predicting successful pain relief by SCS by classifying patients according to the MDNS. Define possible other predictors for successful pain relief.",2009-01,COMPLETED,INTERVENTIONAL,['NA'],
2124,NCT01554566,serum lipids,C-peptide,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2125,NCT02730078,Diabetes-related distress,LDL-cholesterol,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Adverse event
2126,NCT04270578,Glucose tolerance during 75 g oral glucose tolerance test,blood sample,2012-05-23,RECRUITING,OBSERVATIONAL,['NA'],
2127,NCT04117269,Percentage of diabetic foot ulcers healed,Time to healing,2019-11-15,RECRUITING,INTERVENTIONAL,['NA'],
2128,NCT02060279,"β-carotene, FABP4 and C16:1n7 palmitolate levels",Macrophage expression of genes involved in lipid and lipoprotein metabolism and adipose deposition,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
2129,NCT00231608,The mean change from baseline to Month 6 in abdominal visceral fat as assessed by computed tomography; the safety of Topiramate for up to 12 months of continued treatment in male subjects with abdominal obesity.,"Mean change and percent change in body weight, and mean change in total abdominal fat, subcutaneous abdominal fat, body composition, and body mass index from baseline to Month 6.",1998-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2130,NCT02763423,Changes from baseline exogenous insulin dose at different time points post treatment,titres of islet antigen antibodies,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2131,NCT04076995,Area Under the Curve for Plasma osmolality,Mood assessment with a questionnaire,2019-09-18,COMPLETED,INTERVENTIONAL,['NA'],
2132,NCT02344602,The Change in Effective Renal Plasma Flow (ERPF) After an 8 week Treatment with Febuxostat,The Change in Skin Biopsy Measures of Neurohormonal Activation After an 8 week Treatment with Febuxostat,2012-12-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
2133,NCT02504762,Assessing conventional CABG vs HCR in diabetic patients with multivessel CAD,Number of patients we can enroll in 1 year,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
2134,NCT01005420,Insulin Sensitivity,Cognitive Performance,2007-02,WITHDRAWN,INTERVENTIONAL,['NA'],
2135,NCT02854748,"Cmax,ss of Lobeglitazone",AUCinf of Lobeglitazone,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2136,NCT04907006,Cmax,CLz/F,2021-08-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
2137,NCT05938712,Proximal tubular natriuresis with monotherapy,Safety: The number of allergic reaction events.,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
2138,NCT03939143,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2139,NCT05135676,Co-primary Outcome: CGM-measured percent time <54 mg/dL (non-inferiority),CGM Metrics by nighttime only (00:00 AM to 06:00 AM),2022-05-10,COMPLETED,INTERVENTIONAL,['NA'],Glucose Variability
2140,NCT04910321,Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L,Change of body mass index,2020-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2141,NCT02299479,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline.,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline in Subjects With Activity Effect.,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
2142,NCT00564551,Weight loss,Inflammatory Markers,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
2143,NCT05854797,Body Mass Index,,2022-10-28,COMPLETED,INTERVENTIONAL,['NA'],
2144,NCT03832933,Change in body weight by weight scale,Change in % FFM,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2145,NCT00797186,change in microvascular perfusion,,2008-11,UNKNOWN,INTERVENTIONAL,['NA'],
2146,NCT03174548,Area under curve (AUC) of sotagliflozin,Number (%) of subjects with treatment emergent adverse events,2017-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2147,NCT03403686,Assessing CD34+ cells function,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA'],
2148,NCT03866005,Required number of anti-VEGF injections,Need for adjunctive laser photocoagulation and/or use of intravitreal steroids,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
2149,NCT00312130,Change from baseline in acute insulin response to an iv glucose load at 6 weeks,Change from baseline in acute insulin response to an iv glucose load at 8 weeks,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2150,NCT05148390,"Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')",Incidence of device disintegration (removability in one piece),2022-04-24,COMPLETED,OBSERVATIONAL,['NA'],
2151,NCT02164266,Incidence of adverse events (AEs),Fasting serum insulin (Part 2 only),2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2152,NCT03811548,Change in HbA1c From Baseline to Week 24,Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),2019-05-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],Population pharmacokinetics assessment
2153,NCT01523405,Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire,Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP),2012-03,COMPLETED,OBSERVATIONAL,['NA'],
2154,NCT00789750,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),2009-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2155,NCT05278143,Severe hyperglycaemic events detection,Time in severe hyperglycaemia,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA'],
2156,NCT04040634,"Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure",Time to All-Cause Probable Dementia,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2157,NCT00741429,Change in FEV1 (L) from Baseline Visit in Parent Trial to Visit 2 of MKC-TI-126,Change in Hemoglobin Corrected DLco (mL/min/mmHg) from Final Assessment of Treatment Phase in Parent Trial to Visit 2 of MKC-TI-126,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
2158,NCT05717491,Fasting glucose value according to the level of precariousness,Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures,2021-12-14,RECRUITING,OBSERVATIONAL,['NA'],
2159,NCT03423355,Change in blood EPO levels,Change of diastolic function parameters,2021-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2160,NCT05979584,4-week wound healing rate,Infection evaluation,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],
2161,NCT00976326,Area under the NN1250 concentration-time curve after single-dose,Number of adverse events,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2162,NCT01743963,Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).,Feasibility/Reach/Adoption,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
2163,NCT01087242,glycosylated hemoglobin,"fasting blood glucose,2-hour postprandial blood glucose,true insulin,TG,TG、LCL-C、HDL-C、BMI,waistline, hipline,TCM syndrome and sign",2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2164,NCT05835037,Zinc-dependent effect on HbA1c at 1 year,Zinc-dependent effect on HbA1c at 6 months,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE4'],
2165,NCT01772914,Changes in copeptin levels after intake of a oral glucose tolerance test- and a mixed meal tolerance test liquid,,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
2166,NCT04998461,Comparison of gene expression in USC (Urinary Stem Cells),,2021-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2167,NCT01128621,Number of Participants With Relationship Between GSK1292263 Drug Exposures and Pharmacodynamic Parameters (Part B),,2009-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
2168,NCT05810311,Change in kidney oxygenation levels,Change in urinary reactive oxygen species (ROS),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2169,NCT00739323,,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
2170,NCT01464099,Maximum plasma concentration (Cmax) of insulin aspart,AUC (area under the curve) of insulin aspart,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2171,NCT01236846,serum 25-hydroxyvitamin D,Blood pressure,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
2172,NCT02324569,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) That Occurred Before Start of Treatment Period II,Change From Baseline in Self-Monitoring of Blood Glucose Before Breakfast,2014-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
2173,NCT01614327,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs with and without the assistance of the RiskAnalyzer.,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs and the RiskAnalyzer,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
2174,NCT00850824,glycosolated hemoglobin (HbA1c) levels,keeping specialty referral for medical exams,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
2175,NCT00316082,Change From Baseline in Hemoglobin A1 (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2176,NCT04756141,Mean Absolute Relative Difference (MARD),Continuous Glucose Monitor (CGM) Calibrations,2021-03-03,COMPLETED,INTERVENTIONAL,['NA'],
2177,NCT02915029,Patient Activation Measure (PAM) Level Greater Than 2,8-Item Morisky Score,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
2178,NCT04620590,Change in 24-hr sodium excretion,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2179,NCT00990444,Identification of the lowest dose of oral insulin in dextran matrix that produces a significant lowering of post-prandial blood glucose.,To establish the dose(s) when administered in a multi-dose fashion that lowers plasma glucose levels versus placebo in patients with Type 2 diabetes,2009-09,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2180,NCT05050500,The rate of heart failure occurrence,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
2181,NCT05089890,Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day).,Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline,2021-10,UNKNOWN,INTERVENTIONAL,['NA'],
2182,NCT06272695,Change in Time to glucagon treatment success at Week 6.,Change from baseline in hemoglobin A1c (HbA1c) at Week 6.,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],
2183,NCT00842894,Incidence of serious adverse drug reactions (SADRs),Change in body weight,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
2184,NCT03314246,Change in HbA1c,Change in diabetes treatment satisfaction,2017-04-03,COMPLETED,INTERVENTIONAL,['NA'],
2185,NCT01823341,"Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.",Percent of Mornings With Urine Ketones >/= 15 mg/dl,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2186,NCT01201109,Patient self-reported outcome questionnaire,Nerve conduction study and vibrotactile sense,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],
2187,NCT05583045,HbA1c,Creatinine,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2188,NCT05449821,Asprosin Levels,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2189,NCT02372149,Change in Overall Neuropathy Limitations Score (ONLS) after 3 months,Adverse Events,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2190,NCT00735501,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
2191,NCT00328172,Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12,Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2192,NCT04323189,Dipeptidyl peptidase 4 (DPP4),Mean heart rate,2020-08-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
2193,NCT02315274,Glucose variability,Changes is severe hypoglycemia,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
2194,NCT02104739,Monocyte NfkB Levels as Detected by Western Blotting,Peak Forearm Blood Flow,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2195,NCT05885906,Change in unstimulated Salivary flow rate,,2023-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2196,NCT06335771,Macrophage isolation in skeletal muscle tissue,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2197,NCT02999945,Fat Free Mass,macronutrients in breastmilk-protein,2019-03,WITHDRAWN,INTERVENTIONAL,['NA'],
2198,NCT02082704,HbA1c levels,Patient's perceptions of the optimal parameters for the SE game intervention.,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
2199,NCT05806554,Accuracy,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],
2200,NCT01386645,Disposition Index,Glycemic Variability,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
2201,NCT06318429,blood sugar,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2202,NCT04313920,Plasma Glucose Concentration,Gastric Emptying,2020-04-07,COMPLETED,INTERVENTIONAL,['NA'],
2203,NCT05092399,Effects of VLCD,Effects of VLCD and bariatric surgery,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
2204,NCT01745549,hematic fructosamine levels,patient's satisfaction,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
2205,NCT00988377,Blood glucose subjective appetite Food intake at 30 min,physical comfort palatability,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
2206,NCT04745702,Oral Glucose Tolerance Test,TNF (Tumor Necrosis Factor - alpha),2020-11-02,UNKNOWN,INTERVENTIONAL,['NA'],
2207,NCT00665093,HbA1c,"FPG, PG profile, weight, % of subjects on target",2007-05,COMPLETED,OBSERVATIONAL,['NA'],
2208,NCT02093221,Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC),Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
2209,NCT00068887,,,1999-09,WITHDRAWN,OBSERVATIONAL,['NA'],
2210,NCT03414723,Assessment of PK parameter: AUCtau,Adverse events,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
2211,NCT05417152,Scanning session completion status,,2022-06-29,COMPLETED,OBSERVATIONAL,['NA'],
2212,NCT04330911,Digital Spirometer,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
2213,NCT00212303,Blood pressure at 6 months,Systemic inflammation at 6 months,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2214,NCT00433628,,,2007-02-07,COMPLETED,OBSERVATIONAL,['NA'],
2215,NCT05697991,Prevalence of hepatic steatosis in T2DM,Pathogenesis of progressive disease,2015-03-23,RECRUITING,OBSERVATIONAL,['NA'],
2216,NCT02554877,Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo,"Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.",2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2217,NCT00711152,Change in glycated hemoglobin level,Hospitalizations with total length of stay,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2218,NCT03338829,Frequency of glucose monitoring,,2016-05-05,UNKNOWN,INTERVENTIONAL,['NA'],
2219,NCT02467920,the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.,The incidence and rate of hypoglycaemic events during the study,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
2220,NCT03380546,Composite endpoint: birth weight ≥ 90th percentile for gestational age (large for gestational age: LGA) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth injury.,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge.,2018-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2221,NCT03782259,Global Myocardial Strain,T2 Relaxation Time,2019-02-26,COMPLETED,INTERVENTIONAL,['PHASE4'],hsCRP
2222,NCT06009055,Heart rate variability（HRV）,,2023-09-17,RECRUITING,INTERVENTIONAL,['NA'],
2223,NCT04270656,"Variation of hepatic steatosis, between the insulin pump therapy (CSII) vs Multi injection treatement (MDI) groups.","Calculation negative predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.",2021-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
2224,NCT01295177,% of Wound healing closing measured each week,Complete wound healing,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2225,NCT03271879,"The primary endpoint is the burden of premature ventricular complexes, defined as the PVCs percentage of all beats in a pre-specified period captured on ICD or CRTD/P device",Left ventricular ejection fraction (EF),2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2226,NCT05144672,The relation between different stages of diabetic nephropathy and irisin level.,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2227,NCT01966380,Absorption of Wound Exudates.,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
2228,NCT04726319,Changes in risk-appropriate screening based on family history,Attitudes towards the FHAMe intervention,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2229,NCT02442921,Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.,,2016-02-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2230,NCT04509193,Any major or clinically-relevant nonmajor bleed resulting in hospitalization,New-onset vascular dementia,2020-08-21,COMPLETED,OBSERVATIONAL,['NA'],
2231,NCT02414958,Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) ),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
2232,NCT01211717,"Measuring Pain, using the short form McGill pain questionnaire",Measuring Muscle strength of the studied muscle,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
2233,NCT01542554,Change in blood HbA1c,Change in blood pressure,2012-03,UNKNOWN,INTERVENTIONAL,['NA'],
2234,NCT04876079,Time spent of glucose levels < 4.0 mmol/L,Percentage of participants experiencing a rebound hyperglycemia (≥ 10.0 mmol/L) within the first hour following the first carbobydrates consumption,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
2235,NCT04488887,coefficient of variation (CV),,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
2236,NCT06080451,Proportion of patient participants with subsequent follow-up visit within 3 months,Sustainability,2023-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2237,NCT00432029,Forearm Blood Flow,,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
2238,NCT02064881,Change in postprandial lipemia at 4 months,Number of Participants with Serious and Non-Serious Adverse Events,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2239,NCT02928666,Number of conflicting recommendations detected out of total number of conflicts,,2018-10,UNKNOWN,INTERVENTIONAL,['NA'],
2240,NCT02769377,HbA1c,Hypoglycemia,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2241,NCT05369871,Glycemic control evaluation for the 12-week main study,System satisfaction questionnaire evaluation,2022-08-29,COMPLETED,INTERVENTIONAL,['NA'],
2242,NCT00533494,"HbA1c, LDL, systolic blood pressure",,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2243,NCT02470455,Change in Glycosylated Hemoglobin (HbA1c) from baseline,Lipid profile,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
2244,NCT00571519,Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,2007-11-14,TERMINATED,INTERVENTIONAL,['PHASE3'],
2245,NCT04663295,Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L),"Time in Specific Range Stratified by Baseline HbA1c Ranges (< 7%, 7 - < 7.5%, 7.5 - 8%, > 8%)",2020-10-31,COMPLETED,INTERVENTIONAL,['NA'],
2246,NCT03337412,Chronological evolution of the physical activity score of patients benefiting from the education program with intervention of the adapted physical activity educator,musculoskeletal disorders,2017-11-13,COMPLETED,INTERVENTIONAL,['NA'],
2247,NCT05370339,Assessment of facilitators and barriers to good sleep quality and duration,Identification of common causes of sleep disruptors in adolescents with type 1 diabetes,2022-06-15,COMPLETED,OBSERVATIONAL,['NA'],
2248,NCT03818568,glomerular filtration,Mortality,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
2249,NCT03191331,gestational weight gain (GWG),Eating habits,2017-06-06,COMPLETED,INTERVENTIONAL,['NA'],
2250,NCT00424333,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2251,NCT02835989,Change in number of repeat EMS calls,Change in number of hospital admissions,2018-10-25,COMPLETED,INTERVENTIONAL,['NA'],
2252,NCT03069729,Pattern of thermal recovery,Correlation of DPN severity levels and DR severity levels,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],
2253,NCT06163248,Change in insulin resistance (M value),Change in lipid profile (mg/dl),2024-01-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Hunger and satiety (score)
2254,NCT00221156,Cardiovascular event free survival time,Change in lipid profile,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2255,NCT01874483,Occurrence of adverse events,"Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)",2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2256,NCT06083909,To explore the correlation of sarcopenia and obesity on insulin resistance,To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.,2022-04-06,COMPLETED,OBSERVATIONAL,['NA'],
2257,NCT05672433,Area under the curve for glucose during mixed meal test (mmol/L*min),Food consumption in kilocalories (kcal),2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Fasting Homeostatic Model Assessment for Insulin Resistance by C-peptide (arbitrary unit).
2258,NCT05223569,Changes in visual acuity,Changes in visual acuity after 48 weeks,2022-03-03,RECRUITING,INTERVENTIONAL,['NA'],
2259,NCT05071950,Postprandial glucose (mg/dl),side-effects of D-allulose,2021-03-10,COMPLETED,INTERVENTIONAL,['NA'],
2260,NCT00298844,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],
2261,NCT00072904,The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2262,NCT01068756,AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,Tmax (time of maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
2263,NCT04550468,Change from Baseline Hemoglobin A1c at 12 weeks,Continuous glucose monitoring,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2264,NCT01283425,frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.,Adverse events (AE's) count with InsuPatch and without.,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2265,NCT00222781,"Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM",Mathematical modeling of PET data.,2004-01,COMPLETED,OBSERVATIONAL,['NA'],
2266,NCT03715010,Measure of glucose AUC during 2H OGTT (Frame: 10 weeks),Measure of body composition (Time Frame: 10 weeks),2016-03-18,COMPLETED,INTERVENTIONAL,['NA'],
2267,NCT02677779,Bacterial Load,Bleeding: Proportion of Patients With Bleeding Necessitating Haemostasis,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
2268,NCT02831075,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2269,NCT00248352,Change in 10 year cardiac risk as estimated by the UKPDS risk engine at 6 months post discharge compared to baseline measures obtained at time of discharge,Quality of life as assessed by questionnaire,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
2270,NCT01859117,Adverse Events,Toe-brachial index (TBI),2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2271,NCT03590041,Diabetes Distress - Change in Patient Reported Outcomes (PROs),Change in Patient HbA1c,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2272,NCT01223196,Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp,Effect of Pioglitazone on TNF (Tumor Necrosis Factor) Alpha Converting Enzyme (TACE) Activity in Skeletal Muscle.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Percentage (%) of Haemoglobin A1C
2273,NCT01507311,Insulin secretory burst mass,Adverse events,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2274,NCT02154074,level of blood insulin,vital signs,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2275,NCT05823142,Sleep Health: Timing*,Diabetes distress symptoms,2023-12-20,RECRUITING,INTERVENTIONAL,['NA'],
2276,NCT00363844,tolerability,Plasma glucose,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2277,NCT04869917,Weight,Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,2022-03-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2278,NCT01918345,For the Effectiveness Phase: Change in baseline-adjusted weight,Feasibility,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Behaviour change
2279,NCT02403375,Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%,"Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)",2015-05-17,COMPLETED,INTERVENTIONAL,['NA'],
2280,NCT00351546,Effect on insulin sensitivity at 6 weeks,Gluconeogenesis rate after 6 weeks of treatment,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2281,NCT05058807,5 times sit to stand test,Single leg stance test,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2282,NCT02929654,A1c change from baseline after 12 weeks,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2283,NCT05007301,Frequency of device deficiencies,,2022-04-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2284,NCT05929079,Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE3'],
2285,NCT03642717,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,2018-08-21,COMPLETED,OBSERVATIONAL,['NA'],
2286,NCT00482443,The difference in HbA1c between the patient in the DID group and in the standard education group.,"The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
2287,NCT00376038,"Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine","Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2288,NCT02386579,RANKL,P1NP,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
2289,NCT00206297,Area under the curve for glucose,glucagon and gastric emptying,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2290,NCT06291155,Glomerular basement membrane (GBM) width and mesangial expansion,Kidney Transcript Changes,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
2291,NCT01030341,Hypoglycemic Episodes,Change in Gastroparesis Cardinal Symptom Index (GCSI) Total and Mean Score and Patient Assessed Gastro-Intestinal Quality of Life (PAGI-QOL) Score,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
2292,NCT04025775,Time in the target glucose range (5.6 to 10.0 mmol/l),AUC of glucose below 3.5 mmol/l,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],Average inter-dialytic weight gain
2293,NCT04660643,Percent Change from Randomization (Week 36) in Body Weight,Change from Baseline in IWQOL-Lite-CT Physical Function Composite Score,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
2294,NCT02215252,Daily Pain Numeric Rating Scale (NRS),Plasma Concentration of PF-05089771,2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2295,NCT00568035,Determine the safety of a three times daily application of QR-333 as compared to placebo.,Determine the efficacy of QR-333 on symptoms of diabetic neuropathy and the impact of QR-333 on the daily activities (including pain and sleep disturbance) of subjects with symptomatic diabetic neuropathy as compared to placebo.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2296,NCT01779375,M/I,Clamp Measure of Insulin Sensitivity,2013-06-16,COMPLETED,INTERVENTIONAL,['PHASE3'],OGTT Measures of ß-cell Function and Glucose Tolerance
2297,NCT02770079,Change in insulin sensitivity,Changes in the microbiota,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
2298,NCT00290394,Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2299,NCT00419835,effect of treatment on proteinuria after 8 months of follow-up,incidence of hyperkalemia,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2300,NCT03819790,Time in range within 12-hours (6 AM -6 PM) at week 13,HCP treatment satisfaction score,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2301,NCT00497172,in-stent LL,Target lesion or target vessel revascularization,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2302,NCT02199470,We aimed to evaluate the extent of β-cell function by determining fasting levels of C-peptide and those after meal stimulus.,,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
2303,NCT03387787,Random blood glucose <9.9 mmol/l in percent,"Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l",2018-01-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2304,NCT01715649,Hemoglobin A1c,Knowledge,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Participant engagement with telehealth technology
2305,NCT02713568,Area Under the Receiver Operating Curve (AUROC) for prediction of macrosomia (≥ P95),Comparative prediction rate for neonatal hyperbilirubinaemia,2016-03-08,COMPLETED,INTERVENTIONAL,['NA'],
2306,NCT02627690,Modification of Diet in Renal Disease (MDRD),number of deaths,2014-11-03,COMPLETED,OBSERVATIONAL,['NA'],
2307,NCT01185561,Center for Epidemiologic Studies Depression (CES-D) Score,State-Trait Anger Expression Inventory (STAXI) Anger Expression Sub-test Score,2007-03,COMPLETED,INTERVENTIONAL,['NA'],
2308,NCT00757276,Diagnosis of diabetes insipidus(DI) centralis versus psychogenic DI,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
2309,NCT00749047,Reduction in proteinuria,Reduction in non-fasting plasma glucose concentration,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2310,NCT00437489,Change in HbA1c From Baseline,Hypoglycemia Event Rate Per Month,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
2311,NCT01386671,Glycosylated hemoglobin (HbA1c),Dismutase superoxide,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2312,NCT00110500,To determine the maximum tolerated dose (MTD) of a single treatment by intramuscular injection by SB-509.,"To evaluate the lower extremity clinical effects of SB-509 treatment on lower limb diabetic neuropathy by symptoms, neurological examination, and lower extremity electrophysiological testing.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2313,NCT00354237,"improvement of peak VO2,",improvement of ventilatory threshold,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
2314,NCT00344370,NCEP LDL-C Target Attainment,Percent Change From Baseline in LDL-C,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2315,NCT00558883,effect of treatment of leucocyte count before and after test meal,"identification of gene arrays are registered of relevant pharmacodynamic structures and metabolism ways. Histological examinations of bioptats; Blood: hsCRP, PAI1; Lymphocyte subpopulations; blood lipids, plasma glucose fasting and postprandial",2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2316,NCT03259217,complete healing,rate of ulcer recurrence,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2317,NCT00760955,Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.,Change in Fasting C-peptide.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2318,NCT03126981,Insulin sensitivity index (SI),Interleukin-6 (IL-6),2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
2319,NCT05667220,Fasting blood glucose change,Fecal DPP4 activity change,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
2320,NCT05947916,The difference of Time in Range (TIR),"Number of newborns with neonatal birth injury, shoulder dystocia, neonatal jaundice, neonatal respiratory distress syndrome (RDS)",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse event record
2321,NCT00861809,Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters),Food intake,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2322,NCT05396443,"Change in diet quality of adolescent participants, as measured by the Healthy Eating Index Scores",Change in high blood pressure status,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],
2323,NCT02261168,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in liver volume and liver lipid concentration during the day,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
2324,NCT01152385,Change in Haemoglobin A1c (HbA1c),Change in High-sensitivity C-reactive Protein (Hs-CRP),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2325,NCT02083133,Hypoglycemia,,2013-10-01,COMPLETED,OBSERVATIONAL,['NA'],
2326,NCT00467688,Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarms,Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptoms,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
2327,NCT02627911,"Percentage of time spent in the tight glycemic control area 80-140 mg / dl during the night, continuously measured for 3 days with CGM","Measurement of AUC during physical activity , the two hours, then to lunch time , during dinner and throughout the night",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2328,NCT05844644,The change in glycemic control as measured by change in weight (percentage of total weight) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.,The change in quality of life from baseline at days 90 and 180 following the G4LP and supplementation with Release.,2023-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Clinically relevant changes in red cell distribution width (RDW) after 180 days.
2329,NCT03732209,Change in delay discounting,Change in waist and hip circumference,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Perceived treatment effectiveness and ease of use
2330,NCT06135935,The primary outcome will be area under curve for the plasma glucose response over 120 minutes after consumption of the ice creams.,CGM monitor readouts over 24 hours after consumption of the ice creams.,2023-11-12,RECRUITING,INTERVENTIONAL,['NA'],
2331,NCT06186063,Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP),Changes in plasma concentrations of osteocalcin,2024-02-12,RECRUITING,INTERVENTIONAL,['NA'],
2332,NCT01600664,Quality of life,Hyperglycemia events,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
2333,NCT02306343,assessment of skin irritation,area under the curve,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],
2334,NCT02032459,Maternal Vitamin D Status,Vitamin D Status in relations to pregnancy complications,2007-04,COMPLETED,OBSERVATIONAL,['NA'],"Relationship of Vitamin D to maternal diet, etc."
2335,NCT03792607,RNA sequencing analysis both in CD4+ and CD8+ cells,ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients,2019-02-14,UNKNOWN,OBSERVATIONAL,['NA'],
2336,NCT00947557,Hemoglobin A1c (HbA1c),Fasting Plasma Glucose (FPG),2009-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
2337,NCT00311870,change in glomerular filtration rate from study start to study end,change in urinary albumin excretion rate,1993-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2338,NCT01634997,Hemoglobin A1c,,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],
2339,NCT01040676,Hemoglobin A1c,Waist Circumference,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
2340,NCT00506194,Short-term intensive insulin therapy can decrease the insulin resistance and improve the Beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia.,Improve long term glycemic control,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
2341,NCT03956290,Percentage of patients who reduced eating duration by 4 hours,% of participants who achieve ≥ 5% weight loss,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2342,NCT05173675,Hemoglobin A1C (HbA1c),Diabetes distress measured by the 2-item Diabetes Distress Screening Scale,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2343,NCT00947635,Cholesterol and fatty acid synthesis,Blood lipid levels,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2344,NCT06308549,Diabetes Distress,Events of ketoacidosis/severe hypoglycaemia,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],MyDiaMate usage data
2345,NCT00499148,positive AUC for plasma glucose,positive AUC for serum insulin; adjusted peak values for plasma glucose and serum insulin; baseline plasma glucose and serum insulin concentrations; adjusted values for plasma glucose and serum insulin at individual postprandial time points.,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2346,NCT03487692,Hemoglobin A1C,CAHPS Provider Communication,2018-10-18,COMPLETED,INTERVENTIONAL,['NA'],Health center provider/staff satisfaction
2347,NCT00682916,"without any altering of dietary habits or exercise routine, individuals shall lose or maintain body weight during the active phase as compared to the placebo phase.",blood lipid levels during the active phase will be improved relative to the placebo phase.,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
2348,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
2349,NCT04706286,Cmax of CKD-393,,2021-02-18,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2350,NCT03352518,Generation and validation of predictive calibration models,Safety assessment of the intervention by the paucity of adverse events,2017-12-28,COMPLETED,INTERVENTIONAL,['NA'],
2351,NCT02493374,Mitigation of Type 2 Diabetes,,2016-05,WITHDRAWN,OBSERVATIONAL,['NA'],
2352,NCT03443986,Peripheral circulation,Plantar pressure distribution,2018-02-26,UNKNOWN,INTERVENTIONAL,['NA'],
2353,NCT05342740,Basic clinical and demographic information of participants in groups,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],
2354,NCT01947699,Glucose levels throughout the day,,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2355,NCT01822431,number of participants with abnormal results,,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],
2356,NCT00266643,Subscale of the UKU side effect rating scale to be measured during the switch period. The weeks during which the switch occurs are blinded.,"Weekly: Leeds Sleep Evaluation Questionnaire, Brief Profile of Mood States, Clinical Global Impression of Severity. Visits 2, 7, 11: Treatment Satisfaction Questionnaire for Medic",2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2357,NCT02166372,Evaluate the natural course of the diabetes of obese patients over a period of 10 years,,2014-03,RECRUITING,OBSERVATIONAL,['NA'],
2358,NCT02752113,Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion),"changes in albuminuria (urinary albumin to creatinine ratio [UACR]), assessed in the 24-hour urine",2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2359,NCT02898428,Hypoglycemia,,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
2360,NCT02012478,hemoglobin A1C,PAM scale,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Summary of Diabetes Self-Care Activities
2361,NCT00124553,All measures to be compared at end of study (6 months),All measures to be compared at end of study (6 months),2006-08,UNKNOWN,INTERVENTIONAL,['NA'],
2362,NCT04190849,Survival,Asymptomatic progression of liver disease,2017-11-14,RECRUITING,OBSERVATIONAL,['NA'],
2363,NCT00685698,Clinical Success (in ITT Population),"Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2364,NCT01498614,Prevalence of depression,Level of A1C,2009-03,TERMINATED,INTERVENTIONAL,['NA'],
2365,NCT05962983,change in hemoglobin A1c% (HbA1c%),change in waist circumference (inches),2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],eating motives
2366,NCT03076697,Disease diagnosis based on photography,Automated disease diagnosis,2015-04-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2367,NCT02674893,Modifications in wanting,Anthropometric modifications,2014-02-04,TERMINATED,INTERVENTIONAL,['PHASE4'],
2368,NCT05026528,HbA1c,,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],Patient-reported outcome and experience measures
2369,NCT01608776,Wound Reduction,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
2370,NCT05883267,Anxiety assessment - trait anxiety,VR Satisfaction and effectiveness assessment,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],
2371,NCT01930136,The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end,,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
2372,NCT04592263,Patient Reported Outcome,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2373,NCT03042520,Number of participants with hepatocellular carcinoma (HCC) development during 5-year follow-up period after sofosbuvir-based treatment,Renal disease,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
2374,NCT03056014,Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.,,2018-11-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
2375,NCT04152408,Incidence of (Serious) Adverse Events,User satisfaction assessed by the Likert scale,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
2376,NCT05106231,laboratory-analysed HbA1C improvement (HbA1c level below 42mmol/mol or 6.5%),Diabetes knowledge improvement (scores in percentage),2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
2377,NCT00069368,Urinary Outcomes,,2003-07,COMPLETED,OBSERVATIONAL,['NA'],
2378,NCT03543449,Operative mortality,Perioperative time-weighted average glucose,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA'],
2379,NCT00605111,HbA1c,FPG,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2380,NCT03324451,Change in Glycosylated Hemoglobin (HbA1c) Levels,Change in Body Mass Index,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2381,NCT02919059,Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure,Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index,2016-12-13,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2382,NCT04443842,Glycemic control,Change in physical activity level,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],Change in health service utilisation
2383,NCT05473806,Changes in Liver Stiffness Measurement at 24 weeks compared to baseline.,Analysis of predictors of HbA1c improvement after 24 weeks compared to baseline.,2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
2384,NCT05343767,To compare the hypoglycemic effect of two doses of a herbal medicinal product (NW Low-Glu) to that of Metformin as measured by the mean change in HbA1c levels in patients newly diagnosed with type II diabetes mellitus.,To compare the mean change in the 2h-post prandial glucose levels between each experimental arm and active-control arm (efficacy),2018-09-12,COMPLETED,INTERVENTIONAL,['NA'],To investigate the effect of NW Low-Glu on weight.
2385,NCT05981547,Glucose variability,A analysis of CGM glucose data for progression of glycaemia in a sub group,2023-11-22,RECRUITING,OBSERVATIONAL,['NA'],
2386,NCT01970462,Difference in Fasting Glucose,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4'],Hypoglycemia
2387,NCT02974491,Evaluating adequacy of the dialysis treatment,,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
2388,NCT01793974,Identify variations in the human genome associated with LADA by genotyping cases and comparing allele frequencies to an existing control database,Identify associations between genetic variants with certain measurable risk profiles that can be used to judge the health status or well being of a LADA case.,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
2389,NCT00594399,12 Month Fasting Glucose,"Physical Activity, Endurance",2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2390,NCT03234387,Maximal oxygen uptake (aerobic fitness),Insulin concentration,2017-11-17,TERMINATED,OBSERVATIONAL,['NA'],
2391,NCT03627039,"Cardiovascular composite (stroke, myocardial infarction, heart failure)",Costs,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Tracer outcomes
2392,NCT04161937,HbA1C,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
2393,NCT05979142,Composite standard,,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
2394,NCT05951946,"Cmax,ss",,2023-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
2395,NCT01513525,Area under the Curve (AUC) of liraglutide for each injection site,Adverse events,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2396,NCT01202526,Change in insulin sensitivity after RYGB,Change in insulin secretion in response to oral glucose after RYGB,2010-09,COMPLETED,OBSERVATIONAL,['NA'],Change in insulin secretion after iv glucose-glucagon after RYGB
2397,NCT00935922,Improved lipid profile,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
2398,NCT05976191,Blood Glucose Measurement Patient Satisfaction Form,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
2399,NCT04678284,Acceptability of Intervention,Diabetes Medication Adherence,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],
2400,NCT03550378,Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32,Number of Participants With Positive Anti-drug Antibodies (ADA) Titre to MEDI0382,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
2401,NCT01006603,Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.,Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β],2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2402,NCT01167881,The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.,The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2403,NCT01923181,Change in HbA1c (Glycosylated Haemoglobin),Number of Confirmed Hypoglycaemic Episodes Recorded,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2404,NCT01690169,Number of treatment emergent adverse events (TEAEs),"tmax, the time to maximum plasma concentration of NNC0113-0987",2012-09-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2405,NCT00479986,"Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)","Metabolic control (HbA1c, Glucose)",2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2406,NCT00304733,wound surface area reduction,time to wound healing (days),2001-08,UNKNOWN,INTERVENTIONAL,['NA'],
2407,NCT01522157,P-Triglycerides,P-HDL-Cholesterol,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
2408,NCT01448070,"Area under the curve (glucose infusion rate (GIR)), 0-8h",Physical examinations and vital signs,2002-10-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
2409,NCT06003530,Treatment related adverse events,Wound healing,2022-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2410,NCT01177813,Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks,Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycaemic Adverse Events
2411,NCT02759055,Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke,,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
2412,NCT01520818,HbA1c (glycosylated haemoglobin A1c),Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2),2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2413,NCT05512624,Pill Count Medication Adherence,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Incidence of seizure
2414,NCT01519674,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes.,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2415,NCT03734107,Diabetes-related hospitalizations,,2018-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2416,NCT00717977,Glucose Variability Measure: Amplitude of Glycemic Excursions by Time of Day,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2417,NCT02827630,Week 4 Change in Systolic Blood Pressure,Number of Treatment-Related Adverse Events,2015-05,COMPLETED,INTERVENTIONAL,['NA'],Provider Reported Outcomes: Results from a provider satisfaction [to DH] questionnaire administered at the end of using DH.
2418,NCT06296550,HbA1c,Diabetes Distress Scale,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2419,NCT00979225,Rates of aggregate adherence by study group to all applicable pharmacotherapy rules during the study period.,Inpatient hospitalization rates.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
2420,NCT00637338,"To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM.","To evaluate the effect of multiple, escalating, subcutaneously injected doses of PF-04603926 on additional exploratory efficacy biomarkers related to this drug's target in subjects with T2DM.",2008-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
2421,NCT05977218,HbA1c (mmol/mol),Self-reported quality of life,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],24-hour dietary recall
2422,NCT01410292,glycemic control,measures of satiety and appetite,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],
2423,NCT01508481,Incidence of diabetes,Insulin resistance,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
2424,NCT04307797,Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS),Part A/B - gastric inhibitory polypeptide,2022-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2425,NCT03880838,Diastolic Blood Pressure From One Year Before to One Year After Intervention,High-density Lipoprotein (HDL) Levels From One Year Before to One Year After Intervention,2019-06-20,COMPLETED,INTERVENTIONAL,['NA'],
2426,NCT00592397,"Changes in microarray gene expression profiles in blood and subcutaneous abdominal fat tissue from healthy obese men, as a consequence of changes in dietary macro nutrient composition.",Time to stabilization of gene expression changes due to dietary intervention.,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
2427,NCT03871660,Hyperglycaemia,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
2428,NCT03419195,Change in muscular mitochondrial function,,2018-02-07,COMPLETED,INTERVENTIONAL,['NA'],
2429,NCT01213212,"Glomerular Filtration Rate (GFR), absolute and percent change, at 6 months vs baseline.",Metabolic and inflammatory parameters.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2430,NCT01357304,Physical activity level,"Quality of life, measured using the EQ-5D questionnaire",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
2431,NCT04658693,Functional Gait Assessment (FGA),Neuropathic Pain Syndrome Inventory (NPSI),2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],
2432,NCT04109547,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Participants With Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2433,NCT01017523,Blood glucose control (hemoglobin AIc),Diabetes-related quality of life outcome (distress),2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2434,NCT00643851,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2435,NCT04416204,Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes,Rates of Gluconeogenesis in Healthy Subjects,2020-08-21,COMPLETED,INTERVENTIONAL,['NA'],
2436,NCT04347291,Change in Psychosocial Well-being (Patient Participants) Sustained Post-intervention Effect,Change in Support Burden (Support Person Participants) Sustained Post-intervention Effect,2020-04-28,COMPLETED,INTERVENTIONAL,['NA'],Change in Support Person Involvement Alignment (Support Person Participants - Outcome & Mediator)
2437,NCT05643521,The primary outcome is the 1H-Magnetic Resonance Spectroscopy (MRS) determined liver TG content.,"Secondary outcomes are fasting and postprandial plasma glucose, insulin, and plasma TG concentrations after 2 days VLCD or LC compared with 2 days of eucaloric conventional diet.",2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Explorative outcomes
2438,NCT02229240,Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26,"Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations",2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2439,NCT05676593,Rate of change in glycated hemoglobine at 3 months,Eating behavior questionnaire,2023-05-03,RECRUITING,INTERVENTIONAL,['NA'],
2440,NCT00505284,Mean Change in Average Pain Scores From Baseline at Each Study Week,Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2441,NCT00542113,Diabetes knowledge and prevention of parents of elementary school children,Self-reported parental physical activity,2001-09,COMPLETED,INTERVENTIONAL,['NA'],
2442,NCT00856908,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2443,NCT01957592,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,2014-10,WITHDRAWN,OBSERVATIONAL,['NA'],
2444,NCT02082132,Frequency of MODY,Comparison of clinical and biochemical characteristics of other subtypes of diabetes,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],
2445,NCT01055093,Change of insulin sensitivity (M-Value),Incidence of any diabetic complication,2005-09,RECRUITING,OBSERVATIONAL,['NA'],
2446,NCT03673111,Incidence of Treatment-Emergent Adverse Events (safety and tolerability),Body weight,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2447,NCT01718457,percent change in BMI,percent in Triglycerides levels,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],change in C-peptide levels
2448,NCT02219750,HbA1c,total insulin dose,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4'],C peptide
2449,NCT01373814,cardiac function,lipidomics,2010-09-03,COMPLETED,OBSERVATIONAL,['NA'],
2450,NCT02513277,Plasma glucose,Depression,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
2451,NCT05800509,Number and percentage of participants with interventional health education as accessed by the medical record of their infants' body weight in kilograms.,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2452,NCT01771614,Pancreatic endocrine function,Oxidative stress,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],
2453,NCT02155855,hemoglobin A1c,Frequency of contact with diabetes care team,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
2454,NCT02917031,Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks,Number of Participants With Adverse Events,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2455,NCT00287820,c-peptide,TD Scores,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2456,NCT02490553,airway obstruction,diabetes mellitus,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
2457,NCT00097279,HbA1c,8-point plasma glucose profiles,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2458,NCT02647736,Half life of Copeptin,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
2459,NCT05400694,Insulin,Food pleasantness,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2460,NCT04125160,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],
2461,NCT00308737,FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care,Change in Weight From Baseline at Month 24,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2462,NCT02120794,Overall Mean Change in A1C,"Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups",2014-06,COMPLETED,INTERVENTIONAL,['NA'],
2463,NCT00642616,Change in Post-bronchodilator FEV1 From Baseline to Week 52,Change in HbA1C From Baseline to Week 52,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
2464,NCT01233063,Change in added sugar,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
2465,NCT04256720,Clustering of common lifestyle behaviours,Examine associations socio-demographic factors and lifestyle behaviours,2018-12-10,RECRUITING,OBSERVATIONAL,['NA'],
2466,NCT04190693,Serious Adverse Events,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2467,NCT05804513,Growth hormone area under the curve.,Aldosterone peak,2023-04-17,RECRUITING,INTERVENTIONAL,['PHASE4'],Heart rate
2468,NCT02233140,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from baseline to 4 weeks.,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from 1 month to 3 months.,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
2469,NCT01469715,Absolute Relative Difference (ARD),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2470,NCT00572806,Blood glucose value,Hypoglycaemic episodes,2003-02-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2471,NCT00596687,Mean Blood Glucose Concentration,# Participants With Hypoglycemic Events,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2472,NCT04505566,Severity of Diabetic Retinopathy (DR),Progression of Diabetic Macular Edema,2020-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2473,NCT01278823,Test the effect of gastric bypass surgery on glycemic control in obese type 2 DM patients,Determine the effects of gastric bypass surgery on pancreatic beta cell function and incretin hormone secretion in obese type 2 dm patients,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
2474,NCT04125082,Hypoglycemia,Quality of Life Questionnaires,2019-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2475,NCT02834078,Change in Glycated hemoglobin,Change in Body Mass Index,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
2476,NCT03844646,Amount of Weight Lost (kg),Number of Participants Reporting at Least 5 Days of Moderate Physical Activity of 30 Minutes or More,2019-08-01,TERMINATED,INTERVENTIONAL,['NA'],
2477,NCT01087203,Change From Baseline in Average Diabetic Peripheral Neuropathy (DPN) Pain Score at Week 16,Serum Nerve Growth Factor (NGF),2010-03-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Subcutaneous Doses of Study Medication
2478,NCT04915716,blood glucose concentration,blood glucose concentration,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
2479,NCT01336673,Proportion of patients who experience at least one gastrointestinal side effect,Change of Hemoglobin A1c level from baseline after at least 12 weeks of Glucophage XR® therapy,2011-06,TERMINATED,OBSERVATIONAL,['NA'],
2480,NCT05923827,Change in HbA1c,Percentage of time <54 mg/dL,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
2481,NCT03777956,Pain intensity,Use of escape medicine (paracetamol) during treatment period.,2019-01-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
2482,NCT03405532,Renal O2 extraction,Renal blood flow,2018-01-11,SUSPENDED,OBSERVATIONAL,['NA'],
2483,NCT02087995,"The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement.",,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
2484,NCT04907110,Ex vivo muscle mitochondrial function,Exercise efficiency,2021-08-10,COMPLETED,INTERVENTIONAL,['NA'],
2485,NCT00387582,Prevention of vision loss at one year as evidenced by ETDRS visual acuity.,Reduction in retinal thickening based on Optical Coherence Tomography.,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2486,NCT04431687,"AUCtau,ss of CKD-501, D759, D150","Vd,ss/F of CKD-501, D759, D150",2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
2487,NCT04570111,Adherence to the study diet,Infant weight,2021-01-22,TERMINATED,INTERVENTIONAL,['NA'],
2488,NCT00638313,"To evaluate the safety and tolerability of escalating, single subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.",No secondary outcomes listed in the protocol.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2489,NCT00283842,Change in Mean Pain Severity Score From Baseline to 13 Weeks,Number of Patients With ≥50% Reduction in Mean Pain Severity Score.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
2490,NCT01771887,adhesion,Self-management behaviors,2013-02,COMPLETED,INTERVENTIONAL,['NA'],self-efficacy
2491,NCT01292798,Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline,Qualitative Assessment of Diabetic Macular Edema (DME),2011-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2492,NCT01598610,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
2493,NCT01224054,Food tolerance in patients submitted to bariatric surgery,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
2494,NCT04840446,Adhesiveness and survivability of the adhesives,Assess user preference or acceptance of the adhesives worn during the study,2021-02-08,COMPLETED,OBSERVATIONAL,['NA'],
2495,NCT05248841,Maximum GIR (GIRmax),Number of subjects with adverse events (AEs),2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2496,NCT06220773,The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2497,NCT01848379,Change from Baseline in Clinical Attachment Level (CAL) at 6 and 12 Months,Glycated Hemoglobin (HbA1c),2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Cellular Immune responses
2498,NCT04621890,Change in A1C (ΔA1C90-day) from baseline visit (visit 1) to 90-day visit (visit 2),Change in health-related empowerment from baseline visit (visit 1) to 90-day visit (visit 2) and to 180-day visit (visit 3).,2022-02-14,RECRUITING,INTERVENTIONAL,['NA'],
2499,NCT04802395,SGLT2/ GLP1,,2021-03-02,RECRUITING,OBSERVATIONAL,['NA'],
2500,NCT00893685,"Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period",Number of permanent transfers to elderly homes,2009-05,UNKNOWN,INTERVENTIONAL,['NA'],
2501,NCT02370927,Insulin concentrations,Lactate concentration,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
2502,NCT00715351,Body weight change,Changes in daily blood glucose values,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
2503,NCT00447213,Change in HbA1c from baseline,Preference for the study therapies,2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2504,NCT06176443,Metabolic improvements of type 2 diabetes,Change of body mass index,2020-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2505,NCT01947595,postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT)),distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager,2012-03,COMPLETED,INTERVENTIONAL,['NA'],"metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry"
2506,NCT01179048,"Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.,2010-08-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
2507,NCT03540758,Endogenous glucose production (EGP),,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2508,NCT01425424,"Prediabetes, Prehypertension and Vitamin D supplementation- A practice based clinical intervention",,2012-04,TERMINATED,INTERVENTIONAL,['NA'],
2509,NCT01394952,"Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina,2011-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
2510,NCT04623151,5-item Foot Care Detection Behaviour Scale,,2017-08-16,COMPLETED,INTERVENTIONAL,['NA'],
2511,NCT01181830,Blood pressure,Inflammation,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2512,NCT02285985,Change from baseline in the secretion of cytokines/adipokines by adipose tissue,change in reactive hyperemic index,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],change in percent arteriole dilation
2513,NCT05504096,Risk prediction model of diabetes using PPG features on the wearables,Validate that in-ear and wrist-worn wearables both provide relative accurate heart rate and heart rate interval measurements.,2021-10-08,COMPLETED,INTERVENTIONAL,['NA'],
2514,NCT06056687,Matrix metalloproteinase 2 (MMP-2),,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2515,NCT03236415,Percentage of uncovered struts at time of follow-up optical coherence tomography,Major adverse cardiac events,2017-08,WITHDRAWN,INTERVENTIONAL,['NA'],Subgroup analysis between 4 and 6 weeks
2516,NCT01184703,HbA1c,LDL-cholesterol,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2517,NCT05579743,Proportion of participants who successfully complete a weekly wound scan,,2023-01-06,RECRUITING,INTERVENTIONAL,['NA'],
2518,NCT01040468,The primary objective of this study is to compare the rates of diabetes remission over one year.,"To examine the attitudes that patients, health care professionals, and insurance providers have toward the use of bariatric surgery to treat type 2 diabetes.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2519,NCT02075567,Number of Participants with no Adverse Events as a Measure of Safety and Tolerability,Hormonal Response,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Blood Lactate Concentration
2520,NCT00548782,decreased insulin secretion,,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
2521,NCT04964921,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],
2522,NCT05854875,Change in glucagon levels,,2019-09-22,COMPLETED,INTERVENTIONAL,['NA'],
2523,NCT03408678,Insulin sensitivity and secretion,Body fat distribution,2017-01-23,COMPLETED,OBSERVATIONAL,['NA'],
2524,NCT05940376,time to epithelial healing,any adverse effect of topical insulin or need for amniotic membrane transplantation,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2525,NCT02019264,Time From Randomization to First Occurrence of MACE+,Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
2526,NCT00984841,Diabetes summary quality measure,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
2527,NCT01571609,insulin secretion,Indirect calorimetry,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
2528,NCT04303819,Plasma total bile acids in fasting state,Body mess index,2020-01-05,COMPLETED,OBSERVATIONAL,['NA'],
2529,NCT00371800,HbA1c,Compliance,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2530,NCT01140893,Change from baseline to 6 months of centrally measured HbA1c,Change from baseline in mean blood glucose value,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2531,NCT05666570,The reduction in wound size of the target wound between baseline and end of study,Rate of Device Related Adverse Events,2022-05-18,TERMINATED,OBSERVATIONAL,['NA'],
2532,NCT00108485,Change in Proteinuria,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
2533,NCT05424107,HbA1c levels,Decalogue of healthy eating,2018-09-04,COMPLETED,INTERVENTIONAL,['NA'],
2534,NCT00318422,HbA1c,"Glycemic control parameters (fasting plasma glucose, -glucose profiles)",2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2535,NCT00922376,Blood sugar levels (HbA1c),Self management,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
2536,NCT00436475,"Chang in Disposition Index, a Measure of Beta Cell Function",Change in Hemoglobin A1c,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2537,NCT03330054,Frequency Of Eye problems In Type 2 Diabetes with Chronic Kidney Disease,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
2538,NCT03246295,Urinary samples were analyzed,Urinary samples were analyzed,2015-10-20,UNKNOWN,OBSERVATIONAL,['NA'],
2539,NCT04120974,Change in Glycemic Control,Change in Blood Glucose Levels,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],Effect on Behaviour: Injection in Lipohypertrophy Areas
2540,NCT05528393,PRL,OGTT,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2541,NCT05628259,Diabetes Self-Management Scale,Triglyceride,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
2542,NCT00101673,Change from baseline in HbA1c at 12 weeks,Change from baseline in body weight at 12 weeks,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2543,NCT00884013,percent of patients eligible for quality measures (ABCS),use of EHR clinical reminders,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
2544,NCT01171976,Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12,EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2545,NCT04324684,rate of recovery,organ failure,2020-03-31,COMPLETED,OBSERVATIONAL,['NA'],
2546,NCT03713684,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
2547,NCT02137512,"Time Spent <70 mg/dL - Main Phase, Night Only","Time Spent >300 mg/dL - Main Phase, Day Only",2014-08,COMPLETED,INTERVENTIONAL,['NA'],Reported Serious Adverse Events - Extension Phase
2548,NCT06309082,H-CEUS score,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2549,NCT01383356,Area Under the Curve 0 to Last Measurable Value (AUC0-t),Area Under the Curve 0 to Inf (AUC0-inf),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2550,NCT06312553,Acceptability,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2551,NCT01990469,Change of HbAlc from baseline at Week 24,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2552,NCT00157339,"To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.",To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients.,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2553,NCT01286350,Hemoglobin A1c,Health-related quality of life,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Cost of intervention delivery
2554,NCT02793154,Part B: Assessment of Nausea by VAS Score,Part B: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD,2016-09-26,TERMINATED,INTERVENTIONAL,['PHASE4'],
2555,NCT04287179,Change in glycosylated haemoglobin (HbA1c),Number of treatment emergent adverse events (TEAEs),2020-03-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2556,NCT05457192,Glycosylated Hemoglobin (HbA1c) level,Spatiotemporal gait parameters,2022-07,RECRUITING,OBSERVATIONAL,['NA'],
2557,NCT05199714,Each participant's percentage of time glucose levels spent in the target range,Total bolus insulin delivery for each participant,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],Safety Endpoints
2558,NCT00005193,,,1986-09,COMPLETED,OBSERVATIONAL,['NA'],
2559,NCT03047278,Pharmacokinetic parameter (AUC),Pharmacokinetic parameter (Elimination half-life),2015-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2560,NCT02305862,To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI,To evaluate the change from baseline in creatine kinase at 26 weeks,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
2561,NCT05317845,Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope,Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD,2022-04-21,COMPLETED,OBSERVATIONAL,['NA'],
2562,NCT00005134,,,1988-09,COMPLETED,OBSERVATIONAL,['NA'],
2563,NCT01536613,Change in body weight,Occurrence of adverse events (non-serious and serious),2004-09,COMPLETED,OBSERVATIONAL,['NA'],
2564,NCT05713058,Glycemic control,Body weight loss,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],Beta cell function
2565,NCT05767372,Evaluation of oxygen saturation (SPO2) and heart rate (HR),Evaluation of forced expiratory volume at one second (FEV1) and maximum voluntary ventilation (MVV),2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2566,NCT00069056,,,2003-09-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2567,NCT00006159,,,1994-03,COMPLETED,INTERVENTIONAL,['NA'],
2568,NCT01364350,effects of TODAY treatment assignment on long-term glycemic control,microvascular complications,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
2569,NCT00006432,,,2000-01,COMPLETED,INTERVENTIONAL,['NA'],
2570,NCT02412774,Weight loss,HA1C,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
2571,NCT04217369,Time in Range,Laboratory HbA1c,2020-05-04,UNKNOWN,INTERVENTIONAL,['NA'],
2572,NCT06292468,Spatiotemporal gait parameters,,2023-07-07,COMPLETED,INTERVENTIONAL,['NA'],
2573,NCT03594240,Change in plasma homocysteine,Change in HbA1c level,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2574,NCT03698786,Plasma Acylated ghrelin concentration,Plasma Leptin concentration,2017-05-24,COMPLETED,OBSERVATIONAL,['NA'],
2575,NCT02183558,Gestational Diabetes Mellitus,Anthropometric measures in offspring,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
2576,NCT00044707,To determine the effect of pramlintide on the PK of an oral medication,safety and tolerability as measured by analysis of laboratory values and adverse events,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2577,NCT02144948,Decrease in HbA1c levels,change in gastrointestinal condition,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2578,NCT03106870,Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation,Number of Participants With Neonates Who Were Hypoglycemic,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
2579,NCT05626725,Change in blood glucose levels from start of exercise to nadir during or up to 30 min post exercise.,Total insulin delivery during (at least 15-min) of habitual PA and 30-min after,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
2580,NCT04904718,Change in glucose control with the use of DreaMed,,2021-12,WITHDRAWN,INTERVENTIONAL,['NA'],
2581,NCT01487421,HbA1c (glycosylated haemoglobin),Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs),2003-07,COMPLETED,OBSERVATIONAL,['NA'],
2582,NCT00446459,The Number of Subjects With a 10% Decrease in PRA Level at Month 8.,The Number of Transplants With a Negative Crossmatch at Transplant.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2583,NCT03951753,Change From Baseline in Total Clamp Disposition Index (cDI),Change From Baseline in Food Intake During Ad Libitum Meal,2019-06-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
2584,NCT02111967,Measurements of serum vitamin B12 and serum holotranscobalamin concentrations,Questionnaire results,2014-03,COMPLETED,OBSERVATIONAL,['NA'],
2585,NCT05184322,Number of treatment emergent adverse events (TEAEs),Incidence of anti-XW004 antibodies at end of study,2022-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2586,NCT01907854,Change in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Adverse Events (TEAEs),2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2587,NCT02667769,Plasma glucose day- and night profiles,,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],
2588,NCT01871207,Ocular concentration of Erythropoietin and VEGF.,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
2589,NCT01200849,Understanding of prescription medication,Change in HbA1c or blood pressure readings,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
2590,NCT00573950,The effect on pulse wave velocity (PWV),"the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP",2007-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2591,NCT01477034,Tumor Necrosis Factor alpha expression in adipose tissue,Fasting plasma lipopolysaccharide binding protein (LBP),2011-11,COMPLETED,INTERVENTIONAL,['NA'],
2592,NCT05303051,Assess the performance of the DNN score in different ethnicity and skin tones,Retrain the DNN algorithm,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2593,NCT00363519,tolerability,Plasma glucose,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2594,NCT01289119,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Percentage of Participants With a Decrease in HbA1c ≥2.0%,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
2595,NCT04007003,Change in Insulin Use,Change in Needle Re-Use,2018-06-26,TERMINATED,INTERVENTIONAL,['NA'],
2596,NCT02117622,Incidence of adverse events (AEs) by preferred term,Incidence of confirmed hypoglycaemia,2015-07-24,COMPLETED,OBSERVATIONAL,['NA'],
2597,NCT03716141,Wound Healing,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2598,NCT00807651,Exogenous insulin dose,HbA1c level,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2599,NCT00642915,Estimate the efficacy of combination therapy with Lantus plus Amarylin controlling blood glucose in Japanese patients with type 2 diabetes having failed oral antidiabetic drug therapy,Document the ability to preserve the endocrine pancreatic function with Lantus plus Amaryl combination therapy,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2600,NCT05596383,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR),fasting insulin,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2601,NCT01088711,Number of Participants Withdrawing From Study Therapy Due to an AE,Plasma Glucose Concentration,2010-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2602,NCT00327054,The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.,Changes in serum creatinine after six weeks intervention,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2603,NCT04326192,SUVmax,Ipsi- and contralateral BAT during SCS-activation,2021-02-19,RECRUITING,INTERVENTIONAL,['NA'],
2604,NCT05504005,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,2022-08-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2605,NCT05099198,Time until failure to maintain metabolic control,HbA1C change from baseline,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],
2606,NCT00953498,Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins,Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2607,NCT00292357,Healing velocity,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2608,NCT00252772,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Patient-reported outcomes: Well-Being Questionnaire (W BQ12),2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
2609,NCT06134934,Experiences with and acceptability of intervention design(s),Costs,2024-01-09,RECRUITING,INTERVENTIONAL,['NA'],
2610,NCT04271189,Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.,Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2611,NCT04508751,Fetal Liver PDFF,Maternal Hepatic Fat PDFF,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
2612,NCT01128153,"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)",2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2613,NCT01015937,,,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
2614,NCT05918523,Primary Endpoint: Long-term safety of REACT,Third Secondary Endpoint: Time from first injection to renal transplant.,2023-12-11,RECRUITING,OBSERVATIONAL,['NA'],
2615,NCT01964612,self-monitoring and self-control scale,health anxiety scale,2012-07,UNKNOWN,OBSERVATIONAL,['NA'],
2616,NCT00097084,HbA1c,Insulin Treatment Satisfaction,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2617,NCT01163006,fat oxidation,24h glucose pattern,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
2618,NCT00651014,Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.,"Safety/tolerability: adverse events, laboratory test results, vital signs.",2004-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
2619,NCT04007107,Intensity of Injection Site Pain,,2019-06-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
2620,NCT01804777,Blood Pressure,Hypertension,2013-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
2621,NCT05995262,HbA1c levels,,2023-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2622,NCT06213896,To determine the accuracy of diagnosis with artificial intelligence algorithm,To determine the sensitivity and specificity of EyeCheckup v2.0 to detect retinal and optic disc diseases,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
2623,NCT05803473,Time in range,Recurrent hypoglycemic events,2023-04-11,RECRUITING,INTERVENTIONAL,['NA'],Questionnaires
2624,NCT05766735,Change in Metformin at 13.5-months of follow-up,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],
2625,NCT03026426,Proportion of participants with a reduction of 50% or more in the Patient Health Questionnaire (PHQ-9) score at the 3-month assessment,Proportion of participants who improve level of activity at the 3- and 6-month assessments,2017-01-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
2626,NCT01049750,Evaluation of diabetic neuropathy in patients with erectile dysfunction,Glycemic control,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
2627,NCT03635437,Adverse events possibly or probably related to GABA treatment,Change in diabetes treatment satisfaction questionnaire,2018-09-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2628,NCT05107154,Pediatric Quality of Life (PedsQL),Glycemic Control,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2629,NCT06065930,Fasting Neuropilin-1 concentration in subcutaneous interstitial fluid,Metabolites in urine including acylcarnitines measured by Mass Spectrometry,2023-05-05,RECRUITING,OBSERVATIONAL,['NA'],
2630,NCT01159353,Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h),Hypoglycaemia and adverse events,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2631,NCT05093517,Muscle Insulin sensitivity,,2021-11-10,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1'],
2632,NCT00701935,Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months,Assessment of Event Rate of Treatment- Emergent Hypoglycemic Event,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
2633,NCT02073227,Plasma concentration of metformin following administration of a single dose of study drug,Percentage of participants with adverse events as a measure of safety and tolerability,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2634,NCT03725917,Change in the integrity of the skin (Ulceration),Changes in the integral pressure-time,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA'],
2635,NCT00147836,"glycemic control, the improvement of β-cell l function and the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients","the effects of different interventions (oral anti-hyperglycemic agents, multiple daily injections and continuous subcutaneous insulin infusion) on glycemic control, β-cell function and the remission rate in newly-diagnosed type 2 diabetic patients",2004-09,COMPLETED,INTERVENTIONAL,['NA'],
2636,NCT04381598,Bio-marker (Ghrelin) levels in Gingival crevicular fluid.,Probing depth,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2637,NCT02877680,Acceptability - Number of Participants That Felt The Intervention Was Well-Received,"Parent-Adolescent Relationship Intervention Process Measure, Adolescent Report",2017-07-31,COMPLETED,INTERVENTIONAL,['NA'],
2638,NCT05787067,Evaluation of Participants' Insulin Injection Administration Skill Levels,,2021-12-30,COMPLETED,INTERVENTIONAL,['NA'],
2639,NCT04126759,Validation of predictive algorithms for determining blood glucose levels,Number of encountered Device Deficiencies,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2640,NCT01859494,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (<75mg/dL) or Within +/-20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
2641,NCT02248779,insulin sensitivity,,2014-09-22,COMPLETED,OBSERVATIONAL,['NA'],
2642,NCT00111670,Absolute change from baseline in HbAlc\n\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2643,NCT04980027,Percentage of participants with Treatment Emergent Adverse Events (TEAEs),Change in DTSQs scores from Baseline to Week 12 and Week 24,2021-06-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2644,NCT02663544,Change in glucose tolerance,Change in pancreatic beta-cell function: glucose sensitivity,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Change in the homeostasis model assessment (HOMA) insulin resistance index
2645,NCT03422185,"What is the true burden of hypertension, diabetes, and hyperlipidaemia?","Is infection, notably HIV infection or its therapy, associated with increased risk of NCDs?",2013-05,COMPLETED,OBSERVATIONAL,['NA'],
2646,NCT03414320,Accepting mathematical model,,2018-01-11,COMPLETED,INTERVENTIONAL,['NA'],
2647,NCT06014437,"Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)",,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
2648,NCT00721552,Glucose tolerance as assessed by the area under the curve for glucose (AUCgluc) during a standardized meal test.,Beta-cell function as determined by hyperglycemic clamp tests and modeling analysis from mixed-meal tests.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
2649,NCT02933853,Area under the serum insulin aspart concentration-time curve,Maximum glucose infusion rate,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2650,NCT00722397,Blood draw to be processed and analyzed to yield genetic data.,Laboratory values.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
2651,NCT00394303,"Perioperative cerebrovascular event defined as any new, temporary or permanent, focal or global neurological deficit.",Re-hospitalizations,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
2652,NCT00120341,"changes in sensation using, vibration perception threshold testing, monofilament testing, and the Michigan Neuropathy Screening Instrument",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2653,NCT03299153,total cholesterol,Diastolic BP,2016-12-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
2654,NCT00837590,Vascular Function,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
2655,NCT04476108,Change From Baseline in Average Pain Intensity as Measured by the NRS,Change From Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L) (United States),2020-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
2656,NCT01399580,Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR),The change from baseline to each post-baseline assessment of thoracic bioimpedance,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2657,NCT01694940,There is no primary outcome measure for this study,,2010-12,RECRUITING,OBSERVATIONAL,['NA'],
2658,NCT01701570,Rating of perceived exercise effort (RPE) during exercise (Borg RPE scale),Serum lactate during exercise,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
2659,NCT00214214,to determine if Campath-1H can be used in patients recently diagnosed with type I DM,to determine if Campath-1H can eliminate or lower insulin requirements,2005-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2660,NCT01836523,Change From Baseline in Total Daily Insulin Dose,Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2661,NCT01874392,Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.,Test the Benefits of the AP Device Combined With the Technosphere® Insulin Powder System,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
2662,NCT01153243,Levels of inflammatory markers,"Levels of Vitamin D, PTH and Calcium",2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2663,NCT01952535,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2664,NCT02192424,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],insulin sensitivity
2665,NCT01694173,"• Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",• Any reduction in requirement of insulin dosage measured as a percentage decrease from baseline • Improvement of HbA1c levels as compared to baseline,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2666,NCT00274274,HbA1c,Duration of education,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2667,NCT03820050,System Performance,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],
2668,NCT01424891,NF-kappa B binding activity,Inflammatory markers,2004-04,COMPLETED,INTERVENTIONAL,['NA'],
2669,NCT00938275,Characterize and compare the pharmacokinetic profile of a single 500 mg dose of SRT2104 administered as an oral suspension and as a capsule formulation.,Assess the safety and tolerance of SRT2104.,2009-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
2670,NCT06127355,Maternal fasting glucose concentration at 36 weeks,Infant birth weight,2021-03-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2671,NCT04039503,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
2672,NCT00417716,Optical Coherence Tomography,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2673,NCT04206748,# of Neonates with hyperbilirubinemia-requiring therapy.,Effect of SMBG checks on pregnancy,2019-11-12,RECRUITING,INTERVENTIONAL,['NA'],
2674,NCT02221323,AUCINS.0-4h and AUCGIR.0-4h,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2675,NCT00543491,,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
2676,NCT03792321,Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT),Effects of testosterone replacement on hematocrit,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2677,NCT05139914,Insulin-mediated endothelial nitric oxide synthase (eNOS) phosphorylation measured in endothelial cells (ECs) at 14 weeks,Circulating C-reactive protein (CRP) biomarkers of vascular health at 14 weeks,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE4'],
2678,NCT00625859,Blood samples and urine samples,Hunger and craving will be assessed using two assessment tools: (1) a questionnaire to assess hunger and craving; and (2) a Visual Analogue Scale (VAS) to assess hunger.,2008-01-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
2679,NCT01623375,Area under the serum insulin degludec concentration-of i.v. administration,"Volume of distribution of insulin degludec, estimated during the terminal phase",2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2680,NCT03596203,Pain level,Changes in pain medication,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2681,NCT03504683,Peak glucose and mean amplitude of glycemic excursions (MAGE) glucose values,Inflammatory biomarkers,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Sleep Quality
2682,NCT01295788,Adherence to CGM (hours per week),Perception of Barriers/Facilitators to RT-CGM Use,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
2683,NCT02776397,Oxidative Stress,Non HDL-Cholesterol,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
2684,NCT00456885,Change in Body Mass Index,REE,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2685,NCT01675310,Gestational diabetes mellitus,insulin resistance,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2686,NCT00210275,Change in Behavioral intention related to referring patient for retinopathy screening,Change in Perceived Behavourial Control (Theory of Planned Behaviour),2005-07,UNKNOWN,INTERVENTIONAL,['NA'],
2687,NCT01044875,Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR),Patient pain score during laser procedure,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],
2688,NCT02886208,BMI,,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
2689,NCT04949022,Time in range (glucose between 3.9-10 mmol/l) before and during hybrid close loop insulin pump treatment,HbA1c before and during hybrid close loop insulin pump treatment,2021-08-23,UNKNOWN,INTERVENTIONAL,['NA'],Sensor glucose coefficient of variation before and during hybrid close loop insulin pump
2690,NCT04926740,Time to DKA resolution (efficacy outcome),Major adverse kidney events,2021-10-12,COMPLETED,INTERVENTIONAL,['NA'],
2691,NCT05478707,Microvascular blood volume (MBV),"Skeletal muscle oxygenation, deoxyhemoglobin (HHb)",2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
2692,NCT02092597,Exocrine pancreas function,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2693,NCT02209051,Proportion of patients with complete wound closure (i.e. complete skin re-epithelialization without drainage or dressing requirements) at 6 weeks after initiation of study treatment,Changes in Quality of Life assessment,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
2694,NCT00282971,Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in FEV1 at Week 24 LOCF,2006-03-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
2695,NCT01521962,Change in glycosylated hemoglobin (HbA1c; Japan Diabetes Society value),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2696,NCT05633628,HbA1c,The Patient Preferences for Patient Participation (4Ps),2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
2697,NCT02159846,Allergy or hypersensitivity to preparation,,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
2698,NCT04014569,Percentage of sensor glucose readings within range of 70-180 mg/dl,Number of Diabetic Ketoacidosis events,2018-05-02,TERMINATED,INTERVENTIONAL,['NA'],Number of physician override advisor recommendations
2699,NCT00469105,A1C,Patient satisfaction,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2700,NCT04203173,Resource Utilization and Cost,Self-Care Behavior Brooks Medication Adherence Scale (BMAS),2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2701,NCT02786134,Change in Global Myocardial Blood Flow in Response to Vasodilator,,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
2702,NCT00637546,Gait parameter: comfortable speed,Fear of falling (Falls efficacy scale),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2703,NCT02662569,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
2704,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
2705,NCT01074489,Blood glucose levels,,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
2706,NCT01910441,Mean Amplitude of Glycemic Excursions (MAGE),,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
2707,NCT02680873,resolution of diabetes,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
2708,NCT02342535,Change in Physical Activity (Minutes/Week),,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
2709,NCT03596177,Percent Change in Body Weight From Baseline to Day 59,Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
2710,NCT03523403,Gut microbiota profile,Plasma insulin levels,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],
2711,NCT02733185,"A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina",,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2712,NCT01311076,TGIRmax: Time to Reach the Maximum Glucose Infusion Rate (GIRmax) Pharmacodynamic Parameter.,Incidence of Hypoglycemia.,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2713,NCT05595681,Time to complete ulcer healing,Amount of index ulcers completely healed,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Other endpoints
2714,NCT02447601,Plasma concentrations of simvastatin and simvastatin acid.,Incidence of adverse events and serious adverse events,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
2715,NCT04791371,Change in insulin sensitivity,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA'],
2716,NCT01476995,Agreement of ClearView Scan versus Active Diagnosis,Sensitivity and Specificity of ClearView Scan versus Active Diagnosis,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
2717,NCT04698486,Fatty acid oxidation in Heart (µmol/min),VLDL-triglyceride uptake in adipose tissue (percent),2020-07-03,COMPLETED,INTERVENTIONAL,['NA'],
2718,NCT01557504,Number of Participants Who Discontinued Study Drug Due to an AE,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
2719,NCT00285896,"Area under curve (AUC)for plasma glucose, insulin, insulin secretion velocity and glucagon for the periods 0-48 hours(day 1-2) and 0-180 min (day 3). And also the lowest plasma glucose during the period 0-180 min day 3 and mean blood pressure",,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
2720,NCT00712842,Pattern ERG,Blood glucose,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
2721,NCT04419467,Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR),Percentage of Subjects Positive for Anti-drug Antibodies,2020-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
2722,NCT02091323,fasting plasma glucose(FPG),hemoglobin A1c (HbA1c),2014-03,UNKNOWN,INTERVENTIONAL,['NA'],weight loss
2723,NCT01293578,Patient Satisfaction and knowledge,Physician adoption and satisfaction with the decision aid.,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
2724,NCT00836329,Proportion of participants with new neuropsychological deficits (20% decline on two or more neuropsychological tests),"Neuropsychological deficits (i.e., predictive utility of neuropsychological performance on presence, number, and volume of lesions)",2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
2725,NCT05676619,Interrater reliability (Intraclass Correlation Coefficient) of 3D foot scans repeated at baseline (change),,2023-02-16,RECRUITING,INTERVENTIONAL,['NA'],
2726,NCT03047447,Hemoglobin A1c,Ketones (Blood),2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],
2727,NCT04527965,Between-group changes in liver fat content between baseline and month 12,Between-group changes in FIB-4 between baseline and month 12,2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],Between-group changes in plasma lipids (ceramides) using a targeted lipidomic approach between baseline and month 12
2728,NCT03507829,incidence of NODAT,"Mental component summary (MCS) and physical component summary (PCS) derived from the Kidney Disease Quality of Life Short Form (KDQoL-SFTM) at 6, 12 and 24 months after kidney transplantation",2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
2729,NCT00561704,"GFR, HbA1c and the adiponectin concentration.",,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
2730,NCT01120899,Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline,"Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline",2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2731,NCT00672451,Albumin Concentration in Urine,Rate of Decline of GFR,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2732,NCT01316068,Change from Baseline in urine albumin/creatinine ratio,Change from Baseline in urine albumin/creatinine ratio and serum creatinine,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2733,NCT05612269,Reducing the risk of cancer among Diabetics with SGLT2 inhibitors,measurement of inflammatory factors like interleukin-6,2022-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2734,NCT02808351,Contrast-induced nephropathy,Major adverse renal events,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2735,NCT00391196,Percent change in body weight from baseline.,Change from baseline HbA1c to 1 year;,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
2736,NCT04024306,Number of patients who developed Steroid-induced diabetes mellitus,Number of patients who didn't develop steroid-induced diabetes mellitus,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
2737,NCT02048189,Mixed measurement of insulin secretion and insulin resistance,Decrease in the time spent in baseline and prandial hyperglycemia,2012-03-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
2738,NCT00834496,The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.,,2009-01,WITHDRAWN,OBSERVATIONAL,['NA'],
2739,NCT00525330,The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.,To assess the safety and tolerability of KRP-104;,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2740,NCT02294370,glucose levels in tissue fluid,capillary glucose,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
2741,NCT01910805,Change in Diabetes Risk Awareness from baseline to 12 months postpartum,Change in physical activity levels from baseline to 12 months postpartum,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Change in physical activity levels from baseline to 6 months postpartum
2742,NCT04428658,Glycemic control,Patient-reported outcomes,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],
2743,NCT05506800,Incidence and mortality rate of cancer,Reproductive health,2016-03-03,SUSPENDED,OBSERVATIONAL,['NA'],
2744,NCT01767012,Amount of aqueous flare measured with a Laser flare meter,Anterior capsule opacification (measured as brightness of anterior capsular reflect on slitlamp photographs),2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],IOL tilt measured with a Purkinje-meter
2745,NCT04026750,Change From Baseline in Peak Glucagon Response to Hypoglycemia,Number of Patients Returning to Blood Glucose =>70 mg/dL,2019-09-15,TERMINATED,INTERVENTIONAL,['PHASE1'],
2746,NCT05243628,Change in HbA1c,Change in Coefficient of variation (CV),2022-03-31,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Percent Predicted Forced Expiratory Volume in 1 Second
2747,NCT02329366,"To identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with wounds",,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
2748,NCT04312802,Anaerobic threshold (AT) measurement correlation with cardiac perfusion,,2018-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2749,NCT03751839,failure load in kN,measurement of serum periostin in ng/ml,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2750,NCT04418869,Change in plasma glucose during exercise and recovery,Change in cardiac output.,2014-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2751,NCT01703234,Flow Mediated Dilatation,FGF-23,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2752,NCT03914924,Disease-related knowledge,Cardiometabolic Health Parameter: cardiac autonomic control,2020-01-20,RECRUITING,INTERVENTIONAL,['NA'],Morbidity associated with diabetes
2753,NCT02554643,Attenuation of expression of proinflammatory genes verified by qPCR-array technique ranging from at least 5% in pre and post-intervention measurements,Enhance physical performance verified by oxygen consumption measurement on treadmill,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2754,NCT02083991,Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT),Cumulative frequency of infections,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2755,NCT00754143,Safety and tolerability of FG-3019,Change from baseline in first morning urinary albumin creatinine ratio (ACR),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2756,NCT00175734,To determine what hemoglobin level is best for diabetic dialysis patients. Specific parameters: endothelial cell function and related expansile capacity of blood vessels. *Assessed through labs and pulse wave velocity test,"Pulse rate, BP, respiratory rate, peripheral oxygen saturation, ECG during 6-min walk-test and Health Related Quality of Life Assessment as measured by questionnaires",2005-08,UNKNOWN,INTERVENTIONAL,['NA'],
2757,NCT02620072,Dysglycemia or diabetes,Progression to diabetes,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events
2758,NCT00601250,HbA1c Change From Baseline at Week 24,2 Hour Post-Prandial Glucose (PPG) Increment Over Fasting Plasma Glucose (FPG) at Week 24,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2759,NCT01180283,Evidence that lodenafil carbonate improves erectile function in patients with diabetes type 2.,Adverse events in type 2 diabetes patients taking lodenafil carbonate and laboratory tests changes after this treatment.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2760,NCT02620644,Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
2761,NCT05359341,Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group,The change in lipid profile in patients in sitagliptin group versus empagliflozin group,2020-09-20,COMPLETED,INTERVENTIONAL,['NA'],Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group.
2762,NCT05287906,Gastric inhibitory polypeptide,,2022-04-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2763,NCT02010827,Differences in Endogenous glucose production during the three days measured as total Area under the curve (tAUC),"differences in appetite, hunger, satiety between the three days",2013-11,COMPLETED,OBSERVATIONAL,['NA'],
2764,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),2006-08,COMPLETED,OBSERVATIONAL,['NA'],
2765,NCT00317707,cardiovascular deaths and hospitalization for cardiovascular causes,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2766,NCT02389127,Level of HbA1c in T2DM and cirrhosis,,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
2767,NCT03407508,HbA1c,Gingivitis,2018-10-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2768,NCT01738802,Change in the markers of oxidative stress and inflammation,Hemoglobin A1c,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
2769,NCT04905823,Adverse events,Values of continuous glucose monitoring,2021-03-31,COMPLETED,OBSERVATIONAL,['NA'],
2770,NCT02783612,Assessing the compliance of the research group compared to the control group.,,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
2771,NCT05729282,Fasting plasma/serum insulin (relative change),Continuous glucose monitoring (CGM) profile,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Deuterium tracer enrichment in body water (measured in saliva)
2772,NCT02004678,time to reach maximum plasma concentration (Tmax),number of patients experiencing laboratory adverse events,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2773,NCT01714674,Cardiac troponin T,Blood pressure,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],
2774,NCT02194790,The difference of rate of estimated glomerular filtration(eGFR) decline,Change from baseline in Hemoglobin A1C,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
2775,NCT00870194,Change in HbA1c (Percent),Incidence of Confirmed Hypoglycemia(Overall),2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2776,NCT02739971,"Change from baseline in AGEs markers in serum (carboxymethyl lysine, CML and Methylglyoxal ,MG ) at 6 months",retention rate to the diet,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Change in microbial diversity and composition of fecal microbiome following AGE reduction in diet
2777,NCT05098600,Measurement of Vitamin D levels,Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],
2778,NCT03775057,Percentage of patients reaching fasting SMPG target without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of emotional well-being using WHO-5 well-being index,2018-08-22,UNKNOWN,INTERVENTIONAL,['NA'],
2779,NCT05642143,"Evaluation of differences in bone turnover markers between T2D patients with and without previous fractures by biochemical analysis of different bone markers (CTX, P1NP, osteocalcin (OC), ucOC, sclerostin, osteoglycin and osteopontin).",Compare muscle mass and strength in T2D patients with and without neuropathy,2023-02-24,RECRUITING,OBSERVATIONAL,['NA'],The correlation between levels of Advanced Glycation End Products (AGEs) (assessed by skin autofluorescence) and bone material strength (assessed by microindentation).
2780,NCT03288233,Average end expiratory alveolar concentration of CO (ppm) 5 hours after lunch,,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
2781,NCT01663298,FGF2 methylation level,Wound healing indices (WHI),2010-08,COMPLETED,OBSERVATIONAL,['NA'],
2782,NCT04965506,The change in HbA1c from baseline to 20 weeks,Number of participants with treatment-related adverse events,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2783,NCT02966626,Change in HbA1c,Change in body mass index,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
2784,NCT00236626,Mean change in insulin sensitivity from baseline to Month 9.,"Mean change, baseline to Month 9, in body weight and composition, Body Mass Index (BMI), lipid profile, fasting glucose; blood pressure; safety evaluations (adverse events) during study.",2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2785,NCT02740829,Endogenous glucose production following intranasal glucagon compared to placebo,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2786,NCT04200586,Change in myocardial perfusion reserve index,,2020-04-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2787,NCT01434186,Mean Change in HbA1c From Baseline to Week 16,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2788,NCT03631121,Change of glycemic variation,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2789,NCT03230786,Change from baseline in blood HbA1c at 12 weeks versus placebo.,Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
2790,NCT01874366,Food Effect,Time to peak plasma concentration (t-max),2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2791,NCT02189135,Number of patients with hypoglycaemia in usual care versus telemedicine during Ramadan,Glycaemic control of patients measured with HbA1c in patients under usual care versus telemedicine from baseline to end of treatment,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2792,NCT03443635,High or Medium (Versus Low) Mediterranean Diet Adherence,Food Costs,2018-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2793,NCT04465877,"Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
2794,NCT01317576,Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise,"Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
2795,NCT04074317,Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL,Insulin Area Under the Concentration (AUC) Curve,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
2796,NCT05747872,Change in ulcer surface area,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA'],
2797,NCT02632747,Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.,"Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril",2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2798,NCT01492153,Change in body weight,Adverse events (AEs) including hypoglycaemic episodes,2003-02-11,COMPLETED,OBSERVATIONAL,['NA'],
2799,NCT04175496,Postprandial insulin response,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA'],
2800,NCT01108978,Evaluation absolute and percentage reductions in low-density lipoprotein cholesterol (LDL-C) by fasting biochemistry examination,"Evaluation of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides by fasting biochemistry examination",2010-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
2801,NCT03785379,Change from baseline Glycated Hemoglobin (HbA1c) at 6 months,Change from baseline Glycated Hemoglobin (HbA1c) at 12 months,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
2802,NCT05701254,"Compare cortical bone tissue levels of pentosidine (AGE), pyridinoline (normal enzymatic collagen crosslinks), and matrix-bound water between T1DM and controls.",Compare cortical bone tissue heterogeneity in nanoindentation measures of modulus and hardness between T1DM and controls.,2019-06-18,RECRUITING,OBSERVATIONAL,['NA'],
2803,NCT06021119,peak postprandial plasma glucose (PPG) level in mg/dl,Time in range %,2023-03-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
2804,NCT05314036,Establishment of proposed Wellness Transformation Network clinical trial procedures.,Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration.,2022-01-17,COMPLETED,INTERVENTIONAL,['NA'],
2805,NCT00412347,,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
2806,NCT04085705,Presence of contact allergy for wound dressings,Presence of eczema,2019-09-17,UNKNOWN,OBSERVATIONAL,['NA'],Past ulcers
2807,NCT00650806,Percent Change in Body Weight From Baseline to Week 12,Change in Waist/Hip Ratio From Baseline to Week 12,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2808,NCT01814787,Number of Children With Documented Risk Factors for Type 2 Diabetes,,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
2809,NCT03053518,Observed Incremental Area Under the Curve (iAUCobs),,2017-06-30,TERMINATED,INTERVENTIONAL,['NA'],
2810,NCT01313949,To assess the effectiveness of the training program in improving glycemic parameters in diabetic patients before and after the training.,"To assess the efficacy of the training in improving the participants' knowledge of diabetes, as compared to the control patients.",2009-02,COMPLETED,INTERVENTIONAL,['NA'],
2811,NCT00466518,Changes in pharmacokinetics,Determine tolerability of sitagliptin therapy in post-kidney transplant patients.,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
2812,NCT00263861,Glycemic control as measured by Glycosylated Hemoglobin Assay,,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
2813,NCT00117780,Mean HbA1c,Hypoglycaemia,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2814,NCT00368394,"Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2815,NCT00130312,Safety and tolerance of sulodexide therapy long-term,Change in urinary protein/albumin excretion,2005-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
2816,NCT03909841,Cognition,Quality of Life: The Chinese (Hong Kong) 12-item Short-Form Health Survey version 2,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2817,NCT05692778,Experiences of using an eHealth tool supporting the foot assessment,Long term effect,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2818,NCT04856683,Prediction of frailty,Inappropriate therapeutic regimen,2020-08-10,RECRUITING,OBSERVATIONAL,['NA'],
2819,NCT00221715,"Bypass permeability 5 years after surgery, assessed trough Doppler ultrasonography",leg salvage,2002-07,COMPLETED,INTERVENTIONAL,['NA'],
2820,NCT04614168,The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia,Four Choice Reaction Time Test,2021-07-26,UNKNOWN,INTERVENTIONAL,['NA'],
2821,NCT00626080,"Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET",Weight change,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
2822,NCT01713348,Time in Range,HbA1c,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2823,NCT00311818,"Frequency of subjects with HbA1c: ≤ 6.5 %, 6.5 %< HbA1c ≤ 7.0 %, 7.0 %<HbA1c ≤ 8.0 % and HbA1c > 8.0 %","Frequency of subjects with hypoglycemic events (overall, severe, nocturnal, symptomatic)",2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2824,NCT00442156,OCT-measured retinal thickness and visual acuity,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
2825,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],
2826,NCT01805830,HbA1c,HOMA-IR,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2827,NCT04011020,Incidence of Treatment Adverse Events in T1D Subjects,Efficacy of SCE therapy in immune modulation,2022-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2828,NCT06275412,Glycemic Control,Diabetes-Specific Family Support,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Intervention Satisfaction
2829,NCT05781334,Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors),,2023-06-09,RECRUITING,INTERVENTIONAL,['NA'],Number of participants with heart failure readmission
2830,NCT02024516,adiponectin change,Body Mass Index change,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
2831,NCT03538106,Risk factors associated with a cesarean delivery in patients with diabetes type 1,Risk factors associated with an emergency cesarean delivery in patients with diabetes type 1,2016-11,COMPLETED,OBSERVATIONAL,['NA'],
2832,NCT03834207,Acceptability & usefulness of the C3-Cloud system,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
2833,NCT02540733,Barthel index,,2012-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2834,NCT05343494,Fidelity - sessions attended,Intervention acceptability,2022-04-04,COMPLETED,INTERVENTIONAL,['NA'],Qualitative interviews
2835,NCT01703611,HbAIc decrease,Weight change,2012-12,COMPLETED,INTERVENTIONAL,['NA'],Blood pressure
2836,NCT02460718,patient activation,composite measure of healthcare utilization,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
2837,NCT00256633,The primary outcome measure will be to determine if DNA characteristics are associated with CV risk in type 2 diabetes mellitus.,,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
2838,NCT01881828,"Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.",Change in Blood Pressure,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Vascular Dysfunction
2839,NCT05046873,"AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose","Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose",2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2840,NCT00762957,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
2841,NCT05569876,Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC),Physiological parameters indicative of hypoglycemia,2022-11-11,COMPLETED,INTERVENTIONAL,['NA'],Change in cognitive performance across the glycemic trajectory.
2842,NCT05018585,Change in hemoglobin A1c (HbA1c).,Number of episodes per patient of diabetic ketoacidosis between baseline and Month 24.,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE3'],
2843,NCT02644759,Exogenous insulin dose,HbA1c level,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2844,NCT00372463,Self-efficacy,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2845,NCT04807218,Change in hemoglobin A1c (Percent),Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications,2021-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Acceptability of referral over time
2846,NCT02078635,Change from baseline of the maximum vessel wall volume of the carotid arteries,initiation of statin therapy,na,WITHDRAWN,INTERVENTIONAL,['NA'],Palatability of the test / control diets
2847,NCT00772265,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam.",2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2848,NCT01848990,Change From Baseline to 12 Months in HbA1c,Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2849,NCT04668703,change in diabetic retinopathy severity score (DRSS),"change in the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5, IL-6, and IL-8",2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
2850,NCT00359762,Time to Treatment Failure,Hypoglycemia Rate Per Year in Period III,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2851,NCT03868683,Glucose [,Insulin,2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],
2852,NCT01743599,Retrograde ejaculation (a minimum of a total of 1 million sperm in postejaculatory urine),Erectile dysfunction,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
2853,NCT02610088,Vascular function assessed by Flow-mediated vasodilation (FMD),Carotid intima-media thickness (cIMT) assessed by ultrasound,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
2854,NCT02910141,HbA1c,Weight or BMI,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
2855,NCT01527552,"Cmax, maximum insulin aspart concentration",Adverse events,2002-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2856,NCT02251834,Blood Pressure,A1C,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
2857,NCT03253237,Glycemic variability in individuals with type 2 diabetes mellitus in primary care measured by continuous glucose monitor device,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
2858,NCT03165786,Hypoglycemia Fear Scale Score (HFS_2),Glycemic variability,2016-10-26,COMPLETED,INTERVENTIONAL,['NA'],
2859,NCT01988987,Result of an early postpartum 75-gram oral glucose tolerance test (GTT) result,Result of a postpartum 75-gram oral glucose tolerance test (GTT),2013-02-22,COMPLETED,OBSERVATIONAL,['NA'],
2860,NCT01801254,postprandial blood glucose and triglycerides,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2861,NCT02589210,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
2862,NCT05628532,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Distress Scale (DDS),2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],
2863,NCT00482183,"The primary angiographic end point is in-stent luminal late loss, as determined by quantitative angiography.","Secondary end points include the percentage of in-stent stenosis of luminal diameter, the rate of restenosis.",2003-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2864,NCT01978405,The changes of endothelium-dependent arterial dilation before and after contrast administrated,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2865,NCT01130727,flow-mediated dilation (FMD),plasma levels of flavonols,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
2866,NCT03262363,Change from Renal Function at 6 months,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2867,NCT05593081,Change in serum hemoglobin A1c level,The incidence of chronic complications of diabetes mellitus,2022-05-20,RECRUITING,OBSERVATIONAL,['NA'],
2868,NCT01554618,Percentage of Patients Positive for Anti-Drug Antibodies (ADAs) to Exenatide up to Week 24,Plasma Exenatide Concentrations to Week 52 Among Patients Who Received Open-Label Exenatide (Treatment Period),2011-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2869,NCT05548699,Daily stress levels over time,Alcohol misuse over time,2023-05-02,RECRUITING,OBSERVATIONAL,['NA'],Stressful life events
2870,NCT03837405,diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous,Weight change,2018-12-12,COMPLETED,INTERVENTIONAL,['NA'],Mindfulness
2871,NCT03428308,Number of follow-up visits,Change in blood cholesterol (blood test),2018-04,UNKNOWN,INTERVENTIONAL,['NA'],Success of intersectoral cooperation
2872,NCT03368807,Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM,Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM,2017-12-11,COMPLETED,OBSERVATIONAL,['NA'],
2873,NCT02459353,Glycemic Variability (Standard Deviation),blood pressure DBP,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
2874,NCT04305431,Facilitators and Barriers,Second Phase Secondary Outcome,2021-02-25,RECRUITING,INTERVENTIONAL,['NA'],
2875,NCT05847413,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL at 12 weeks.,,2020-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2876,NCT05125445,change in margianl bone level,,2021-02-11,COMPLETED,INTERVENTIONAL,['NA'],
2877,NCT01365416,,,2011-12-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2878,NCT02137863,"Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin",complete blood count,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2879,NCT00943917,Mean Change in HbA1c (ITT),,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2880,NCT03303196,Mean Plasma Glucose Level.,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA'],
2881,NCT01116531,Concentration of O-desmethyltramadol,Concentration of O-desmethyltramadol,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2882,NCT03542682,Time to Maximum Glucose Infusion Rate,Area Under the Curve for the Glucose Infusion Rate,2018-05-30,COMPLETED,INTERVENTIONAL,['NA'],
2883,NCT02251431,ACR,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2884,NCT03898076,The difference of Predictive A1c level from CGM data with Real A1c level from EMR,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2885,NCT04345016,rate of diabetic foot ulcer recurrence in after phase of trial,rate of lower extremity amputations in after phase of trial,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],
2886,NCT05798442,Reduced BMI and visceral obesity,Reduced alcohol consumption and tobacco smoking,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2887,NCT01627340,Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies,Number of Subjects Reporting Any Serious Adverse Events (SAEs),2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
2888,NCT01630850,HbAlc <7.0% and an absence of severe hypoglycemic events,,2012-05,RECRUITING,INTERVENTIONAL,['NA'],
2889,NCT00476437,Incidence of hypoglycaemic episodes,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2890,NCT02217943,Composite Measure of Glycemic Control - Recurrence,Assess the changes in SF-36 Health Survey,2014-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2891,NCT05549583,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",2018-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
2892,NCT00568620,Insulin sensitivity,Incretin effect,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
2893,NCT04221399,Concentration of serum glucose,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2894,NCT01862237,Left Ventricular Mass measured by echocardiography,Magnetic Resonance Imaging (MRI) parameters.,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
2895,NCT03105219,Urinary albumin excretion,Retinol binding protein,2017-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2896,NCT01515592,Antibody against liraglutide,24-hour profiles of serum insulin,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2897,NCT06184373,Comparative experience of OGTT and CGM,Medical care,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Infant outcomes
2898,NCT05719155,AUClast,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
2899,NCT01305551,"Evidence of BE on single-dose pharmacokinetic parameters half-life (T-HALF) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.","Active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin, from 5 mg Saxagliptin/500 mg Metformin XR FDC tablet & from 5 mg Onglyza administered together with 500 mg Glifage® XR in single-dose fed & fasted state pharmacokinetics in healthy subjects",2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2900,NCT04073576,Performance of the AHCL system,Safety of the AHCL system,2019-05-20,UNKNOWN,INTERVENTIONAL,['NA'],
2901,NCT01497574,Area under the insulin concentration curve (AUC),Adverse events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2902,NCT02175732,HbA1c,Depression,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
2903,NCT02135068,Nadir blood glucose levels during exercise,Mean daytime and nighttime glucose values,2015-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2904,NCT00790660,Evaluation of safety through clinical safety labs and adverse events,Evaluation of routine PK and PD parameters,2008-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
2905,NCT03588234,Food literacy level,Fast food consumption,2018-06-28,COMPLETED,OBSERVATIONAL,['NA'],
2906,NCT06329882,Change in glycemic profile,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2907,NCT01892124,Change in Body Mass Index,Changes in Blood Pressure,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Changes in Food Habits
2908,NCT00862849,Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]),Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2909,NCT02622113,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Percentage Change in Body Weight,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2910,NCT00213213,"- Infant pain score during the newborn screening test, assessed by the Premature Infant Pain Profile (PIPP), or individual parameters of PIPP (facial grimace, heart rate, oxygen saturation)",- Serum Glucose concentrations in infants of diabetic mothers,2003-07,UNKNOWN,INTERVENTIONAL,['NA'],
2911,NCT05264727,Change in Glucagon Suppression (G50) caused by amino acids vs. saline,glucagon suppression (G50) is greater in obese compared to lean people without T2DM,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE4'],
2912,NCT02419859,Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood),Hypoglycemic events,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
2913,NCT03697109,"In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.",In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET,2018-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2914,NCT03077997,Diabetes Distress (As measured by the Diabetes Distress Scale),EuroQol 5D5L,2017-03-15,TERMINATED,INTERVENTIONAL,['NA'],
2915,NCT04871958,Blood glucose Time-In-Range (TIR) during hospital stay,Accesses to the isolation room,2021-03-19,TERMINATED,INTERVENTIONAL,['NA'],
2916,NCT00981448,Change in acute insulin response from IVGTT.,change in urinary zinc,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
2917,NCT02914821,Sugar-Sweetened Beverages Sold by Universal Product Code (UPC),Changes in types of beverages purchased,2016-09-01,TERMINATED,INTERVENTIONAL,['NA'],
2918,NCT01121289,Area under the serum NN1218 concentration-time curve,Area under the serum NN1218 concentration-time curve,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2919,NCT04226846,Comparison between Bios device readings and glucose values,,2019-12-09,UNKNOWN,OBSERVATIONAL,['NA'],
2920,NCT00299871,HbA1c levels at baseline and endpoint (at 13 weeks).,"Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.",2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2921,NCT03257228,Insulin like growth factors in patients with OLP and diabetes mellitus,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA'],
2922,NCT02220907,Number of Participants With Adverse Events,Percentage Change in Body Weight From Baseline,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2923,NCT04515745,Ever applied for public disability program benefits (Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI)),Application for Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI) benefits.,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],Ever participated in labor force conditional on enrollment in disability programs.
2924,NCT04068285,walking speed,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
2925,NCT00361023,,,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
2926,NCT02938806,Analysis of gut microbial composition and diversity by 16S rRNA sequencing,Analysis of urine metabolite concentrations measured by mass spectrometry,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
2927,NCT01973231,Change in Glycosylated Haemoglobin (HbA1c) From Baseline,Number of Treatment Emergent Adverse Events (TEAEs),2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2928,NCT00742976,change in weight; change in extracellular volume,"sodium excretion in urine, 24 hour blood pressure, body composition change,urine osmolality, urine albumin excretion, GFR, HbA1c, Blood lipid profile, NT-proBNP, plasma Albumin, Plasma metanephrines, aldosterone, active renin, angiotensin II",2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2929,NCT02915263,Change in Neuropathic Pain Severity as Measured by the Pain Visual Analogue Scores (VAS).,Change in Autonomic Neuropathy as Measured by Standardized Autonomic Nervous System Testing.,2017-09-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
2930,NCT04962048,Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale,Change of microcirculation with thermal imaging (TH),2021-05-28,TERMINATED,INTERVENTIONAL,['NA'],
2931,NCT06227247,Receipt of intervention (Exercise Session Completion),,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
2932,NCT01682954,Body Weight,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2933,NCT03616275,Changes from Baseline Autonomic function (Heart rate variability) at 3 and 6 months,Changes from Baseline salivary cortisol at 3 and 6 months,2017-10-17,COMPLETED,INTERVENTIONAL,['NA'],
2934,NCT01464073,body fat mass reduction,biological parameter,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
2935,NCT03111433,change in soluble interacellular adhesion molecule level,,2017-03-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
2936,NCT02343146,Glycemic Control/HbA1c,Child eating as measured by Remote Food Photography by the parent,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
2937,NCT01231178,Body weight,Body composition,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
2938,NCT03909802,Wound size,,2019-07-06,COMPLETED,INTERVENTIONAL,['NA'],
2939,NCT03746093,Changes in HbA1c levels from baseline to visit 2 and 3,Changes in fasting serum triglycerides from baseline to visit 2 and 3,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],
2940,NCT03182842,Time within 3.9 and 10 mmol/l,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA'],
2941,NCT02626936,Percentage of time below 4.0 mmol/L,Total glucagon delivery,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2942,NCT00219089,Change from baseline in mean sitting diastolic blood pressure after 8 weeks,Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2943,NCT05197829,Change in the Problem Areas in Diabetes Score,Number of Sensor Checks Per Day,2022-01-05,COMPLETED,INTERVENTIONAL,['NA'],
2944,NCT00762242,change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements,,2007-05,TERMINATED,OBSERVATIONAL,['NA'],
2945,NCT04150107,Average Exogenous Total Insulin Compared to Baseline,Daytime Low Blood Glucose Index (LBGI) Compared to Baseline,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
2946,NCT02028078,Tracer to Tracee Ratio (the absolute relative difference ARDi ),Tracer to tracee Ratio,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to reach each hypoglycaemic level
2947,NCT02888951,Volume of Gastric Contents,"Episodes of intra-operative regurgitation, vomiting or aspiration",2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
2948,NCT02210871,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs),2014-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2949,NCT01369277,Renal clearance (CLr),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2950,NCT05773183,To compare differences in steroid metabolomics in men with prostate cancer pre- and post-androgen deprivation therapy (ADT),To compare differences in metabolic phenotype in (i) hypogonadal men compared to healthy men (ii) hypogonadal men pre and post testosterone replacement therapy (iii) men with prostate cancer post initiation of Androgen Deprivation Therapy,2023-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2951,NCT00654056,Insulin sensitivity,Changes in insulin signaling proteins?,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
2952,NCT00488033,"Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina",Number of Participants With Limb Amputation or Peripheral Vascular Revascularization Procedure,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
2953,NCT01338922,Diabetes burden (main carer),Diabetes treatment satisfaction,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
2954,NCT05857319,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,Dropout rate,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2955,NCT02508779,"Reduced consequences of extreme BG (e.g., diabetic ketoacidosis, SH)",Improved internal locus of control (as confirmed by the Perceived Competence for Diabetes Scale and the Treatment Self-Regulation Questionnaire),2015-07,COMPLETED,INTERVENTIONAL,['NA'],
2956,NCT01105884,complete healing of the wound,,2009-10,WITHDRAWN,INTERVENTIONAL,['NA'],
2957,NCT01474161,"Safety parameters (Study Parts II, III and IV)","Pharmacokinetics parameters (Study Parts II, III and IV)",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2958,NCT01001962,New onset of hypertension,Mortality cardiovascular,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2959,NCT01506310,Serum fasting glucose values.,The mean birth-weight of newborns,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2960,NCT05917808,Change in 2 hour glucose in OGTT,Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT,2023-05-29,RECRUITING,INTERVENTIONAL,['NA'],
2961,NCT02667652,body mass idex,blood fat,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
2962,NCT03997032,Plasma homocysteine level,Retinal vessel diameters,2017-07-31,COMPLETED,INTERVENTIONAL,['NA'],Intraocular pressure
2963,NCT01221207,Number of Participants Who Achieve Full Wound Healing.,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
2964,NCT00801450,central subfield macular thickness,Intraocular pressure,2007-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2965,NCT03078101,The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone,Mean changes in salt sensitivity after 3 months of empagliflozin treatment,2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of hospitalizations during the study.
2966,NCT02548585,Change From Baseline in Body Weight to the EOT (Cohort 4),"Percent Change From Baseline in Incretin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)",2015-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2967,NCT02080741,Telomere length,Level of expression of candidate genes,2014-09-23,TERMINATED,INTERVENTIONAL,['NA'],Analysis of the specific psychological interview EMIC
2968,NCT00856882,,,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
2969,NCT05649553,Change in HbA1c,Changes in quality of life,2022-09-15,COMPLETED,INTERVENTIONAL,['NA'],
2970,NCT02076555,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
2971,NCT05485961,Time to first occurrence of CV death or MI (Phase 3),Total number of hospitalizations (Phase 3),2022-10-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2972,NCT01535612,"Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device",Dermal Irritation,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
2973,NCT06203275,Change in HOMA-IR .,The secondary outcome is the change in expression of GRK2,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2974,NCT00630825,Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC),2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2975,NCT00968812,Change in HbA1c From Baseline to Week 52,Change in HbA1c From Baseline to Week 104,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2976,NCT03478202,Change from baseline in weight,Change from baseline in fasting Insulin level,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2977,NCT02846571,HbA1C ≤ 7% or a ≥ 2.5 decrease from baseline (before transplant),,2019-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2978,NCT02095418,To evaluate incidence of NODAT in patients of two arms,"To evaluate patient overall survial, OS",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
2979,NCT02417012,Change in Hba1c,Change in glucose lowering medication,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Change in low grade inflammation
2980,NCT02375737,Adherence to the program's intervention,Clinical effectiveness/impact on cholesterol,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
2981,NCT02294526,Change from baseline in fasting insulin at 6 months,Change from baseline in blood pressure at 6 months,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2982,NCT04295005,Indirect healthcare cost,,2020-11-16,COMPLETED,OBSERVATIONAL,['NA'],
2983,NCT00005462,,,1991-09,COMPLETED,OBSERVATIONAL,['NA'],
2984,NCT01972893,To evaluate Safety and tolerability of ZYD1,Pharmacokinetics (PK) and Pharmacodynamic (PD) effect after single and multiple subcutaneous dose administrations in healthy adult male volunteers Gender effect study.,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2985,NCT03329118,The number of volunteers with adverse events as a measure of safety and tolerability.,,2017-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2986,NCT01824277,Change in A1C over the study period.,Changes in the patient perioperative outcomes,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
2987,NCT01473654,Physical Activity,hemoglobin a1c,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
2988,NCT04162067,HbA1c,Clinical outcomes stratified by age group,2020-01-06,COMPLETED,OBSERVATIONAL,['NA'],"HbA1c in the subgroup of patients using CSII therapy, stratified by patients considered ""atypical"" for pumping by Canadian regulatory authorities"
2989,NCT05215730,Change in wound size,Physiological parameter - Average time to wound closure,2021-07-07,COMPLETED,INTERVENTIONAL,['NA'],
2990,NCT03330301,Bone facture,Mental diseases,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],Congenital disorders
2991,NCT05741489,Number of Participants With Nocturnal Hypoglycemic Episodes,Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE),2022-08-10,COMPLETED,INTERVENTIONAL,['NA'],
2992,NCT03215173,Change in postpartum weight retention,Change in Readiness to Change,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2993,NCT00275223,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
2994,NCT04115657,Postprandial insulin,Appetite control,2019-05-02,COMPLETED,INTERVENTIONAL,['NA'],
2995,NCT00965315,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
2996,NCT03146975,"Changes in beta defensins 1, 2 and 3",Changes in percentage of diseased sites,2014-03-02,COMPLETED,INTERVENTIONAL,['NA'],
2997,NCT00840164,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],
2998,NCT06181721,Percentage of time in hyperglycemic range (defined as > 13.9 mmol/L (>250 mg/dL)),Average number of hypoglycemic treatments when CGM is less than 3.9mmol/L,2023-09-05,COMPLETED,INTERVENTIONAL,['NA'],
2999,NCT04164641,Number of re-ulceration occurrences,Percentage of patients who do not experience re-ulceration after custom orthosis,2019-12-09,RECRUITING,INTERVENTIONAL,['NA'],
3000,NCT01681290,Bilateral change in sensory nerve conduction velocity,Quality of life questionnaire,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3001,NCT01773668,Performance data,Physical duration,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
3002,NCT00647595,Central adiposity,neonatal adiposity,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3003,NCT02006342,Time to Anion Gap Closure,Number of Participants Who Developed Hypoglycemia,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
3004,NCT00325910,Combined endpoint of all cause mortality and all cause hospitalization at 6 months,Development of Lactic Acidosis,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
3005,NCT03546972,Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates,Changes in proposed behavioral mediators through survey,2017-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3006,NCT01881724,Change in HbA1c from baseline,sleep duration,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],
3007,NCT06273059,The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.,To describe genetic variation in young-onset DM with diabetic complications in various systems:,2022-09-12,RECRUITING,OBSERVATIONAL,['NA'],
3008,NCT02931292,Percent excess body mass index loss (%EBMIL),percent of complications,2005-06,COMPLETED,OBSERVATIONAL,['NA'],
3009,NCT04431141,"AUCτ,ss of teneligliptin and empagliflozin",t1/2β of teneligliptin and empagliflozin,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
3010,NCT00971048,Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.,Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT),2009-09,COMPLETED,INTERVENTIONAL,['NA'],
3011,NCT05314140,Proportions of diabetic patients with high coronary artery calcium score,Description of adverse events regarding to the coronary artery calcium score,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3012,NCT02064335,Physical fitness,,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
3013,NCT01465620,Change from Baseline in NTSS6 score at 3 months,change from baseline of thermal and vibration thresholds,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3014,NCT01238406,Sleep efficacy,Total wake up time per night,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
3015,NCT01680653,Duration of Nocturnal Hypoglycemia,Duration of Glucose Readings <70 mg/dl,2012-05,COMPLETED,INTERVENTIONAL,['NA'],Prolonged Episodes of Hypoglycemic Events
3016,NCT01251497,,,2009-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3017,NCT03628963,Patient Activation,Acceptability,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],
3018,NCT01278485,Number of Participants With Hemoglobin A1c <7.0% at the Time of Enrollment,Number of Participants Reporting Body Weight Fears in the 12 Months Prior to Enrollment,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
3019,NCT01480934,Development of Posterior capsule opacification.,"duration of diabetes, stage of diabetic retinopathy",2005-06,COMPLETED,OBSERVATIONAL,['NA'],
3020,NCT06173765,Change in primary clinical marker of inflammation IL-6,Change in fasting Lipids,2022-08-31,RECRUITING,INTERVENTIONAL,['NA'],
3021,NCT02862860,Amplitude of glycemic variations,,2012-05-29,COMPLETED,INTERVENTIONAL,['NA'],
3022,NCT00110370,(A1C less than 7%) with once-daily insulin glargine in combination with OADs.,"body weight, SAE's and study drug related AEs.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3023,NCT05851651,Infant Feeding pattern,Women's prevalence of Impaired Glucose Tolerance,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],"Women's experience, perception, and attitude for AME practices"
3024,NCT01275131,"Early Exposure to Insulin (%AUC[0-60]), Stage 3","Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3025,NCT01990300,Changes From Baseline in Glycosylated Hemoglobin (HbA1c),Changes From Baseline in Fasting Blood Glucose (FBG),2011-11-28,COMPLETED,OBSERVATIONAL,['NA'],
3026,NCT01226537,Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test,,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3027,NCT05227677,The achievement rate of HbA1c (≤7%),The extent of change of HbA1c,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],
3028,NCT02526524,Change in HbA1c (%) at 16 Weeks,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3029,NCT00954694,"The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise.","Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.",2009-08,UNKNOWN,INTERVENTIONAL,['NA'],
3030,NCT06225154,Serum and saliva IL-1β levels (pg/ml),HbA1c ( %),2015-02,COMPLETED,INTERVENTIONAL,['NA'],Clinical Attachment Level (mm)
3031,NCT03210896,"Chemical components in breath will be captured into absorbent tubes followed by GCMS analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration.",Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition.,2017-07-10,COMPLETED,INTERVENTIONAL,['NA'],
3032,NCT02622295,Post-training Bone Turnover: Osteocalcin,Post-training Subject-report Measures: EQ-5D,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
3033,NCT00447629,Safety,Pharmacokinetics,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3034,NCT02924311,Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients,Number of participants with ocular and non-ocular safety events,2016-09-21,COMPLETED,OBSERVATIONAL,['NA'],Number of patients with prior intraocular steroids (DME Monitoring)
3035,NCT03670043,Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire,,2019-03-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
3036,NCT00674050,PK parameters of serum insulin,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3037,NCT02386930,HbA1c%,physical exercise in minutes per day,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
3038,NCT02230631,The percentage of patients experiencing at least 1 hypoglycaemic event,Difference in the reported incidence rates of hypoglycaemia,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
3039,NCT02999386,All cause Mortality,Hospital length of stay,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
3040,NCT00270439,Insulin sensitivity as measured by the minimal model and HOMA score,Decreased use of oral hypoglycemics,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3041,NCT02934425,Net incremental area under the curve (AUC) appetite VAS ratings,Composite daily hunger and fullness VAS ratings,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
3042,NCT01161862,Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl),Nadir Blood Glucose in Each Arm,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
3043,NCT04550403,prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients,number of days of hospitalization in patients with and without diabetes,2020-07-30,COMPLETED,OBSERVATIONAL,['NA'],
3044,NCT00021879,,,2001-03,COMPLETED,OBSERVATIONAL,['NA'],
3045,NCT00004647,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3046,NCT02737891,Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate,Change From Baseline to End of Treatment in Body Weight,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3047,NCT00407680,HbA1c,Serum angiotensinogen,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3048,NCT02123251,Changes in HDL From Baseline to the End of Intervention (December 2015),Change From Baseline to End of Intervention (December 2015) in Physical Component Summary Measure of the Short Form (SF-36v2) Health Survey,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
3049,NCT02806349,HbA1c,fasting insulin,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],ALT
3050,NCT01272193,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3051,NCT05013346,Islet auto-antibody titre and positivity proportions,Type 1 diabetes genetic risk score,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
3052,NCT06227520,Wound Healing,Ulcer Reoccurrence,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3053,NCT02726425,Change in disease control (HbA1c),Health Service Utilization,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
3054,NCT02313090,HbA1c,low density lipoprotein cholesterol,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
3055,NCT03664414,Change in the glomerular filtration rate,Change in health-related quality of life,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3056,NCT04547348,Time until remission,Incidence of Adverse Events and Serious Adverse Events,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
3057,NCT00552942,diabetic indices,"interleukin and cytokine levels, weight loss",2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3058,NCT01307514,,,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],
3059,NCT01492205,Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors),Incidence of adverse drug reactions,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
3060,NCT01370681,Geometric mean AUCt,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3061,NCT01499082,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in HbA1c From Month 6 to Month 9
3062,NCT05967923,Range of motion of the shoulder,Shoulder and hand disability,2023-07-05,RECRUITING,INTERVENTIONAL,['NA'],
3063,NCT00174668,Total daily insulin dose,Physical examination,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3064,NCT01891955,Fasting glucagon,Fasting HbA1c,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
3065,NCT00138554,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3066,NCT05145140,Diabetic Foot Ulcer relapse rate,C-reactive protein(CRP),2022-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3067,NCT03624803,"To describe baseline characteristics of patients starting Dapagliflozin together with other anti-diabetic medications , alone or in combination. And to describe if Dapagliflozin was given as 2nd line , 3rd line or later in combination therapy.",To record the change in blood pressure (mmHg) from baseline.,2019-03-09,COMPLETED,OBSERVATIONAL,['NA'],
3068,NCT05320276,Frequency of patients with chronic diseases seen in the emergency department who have not been offered an educational program,Identification of reasons for refusal to participate,2022-02-28,COMPLETED,OBSERVATIONAL,['NA'],
3069,NCT03061981,"[Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments",Renal clearance (CLR),2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Key metabolites of DA-1241 in Cohort 6
3070,NCT03877068,Number of Clinically Significant Hypoglycemia Events While Hospitalized,Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) After Discharge,2019-06-26,COMPLETED,INTERVENTIONAL,['NA'],
3071,NCT02822534,The steady-state urine concentration (Css) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3072,NCT03153007,"Assessment of signs and symptoms, impacts on functioning and HRQoL among subjects with DFU",,2017-08-11,COMPLETED,OBSERVATIONAL,['NA'],
3073,NCT06234787,To determine the cumulative incidence or risk of potential hypoglycemia during ICU admission,"To describe the theoretical cumulative incidence of potential hypoglycemia with alternative thresholds of 70, 75, 85, or 90 mg/dL",2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],
3074,NCT06321302,Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52,Occurrence of ocular AEs of special interest in the study eye between baseline and EOS,2024-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3075,NCT03452605,BOLD fmri response,,2015-11-20,COMPLETED,INTERVENTIONAL,['NA'],
3076,NCT02235298,Epicardial Fat Thickness,Left Ventricular Mass (LVM),2015-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
3077,NCT02372955,arterial stiffness,composite intravascular volume status,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3078,NCT02545842,Percentage of patients with HbA1c <7% achievement,Percentage of patients experienced hypoglycemic events,2015-09-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3079,NCT06202742,Subjective Sleep Quality,Objective sleep parameters,2024-03-08,RECRUITING,INTERVENTIONAL,['NA'],
3080,NCT05717933,thyroid abnormalities among children and adolescents with type 1 diabetes mellitus when its first detected and its relationship with disease-related variables.,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3081,NCT06185192,Fasting Insulin levels,"Species prevalence in stool, blood, and saliva",2023-12-13,RECRUITING,INTERVENTIONAL,['NA'],
3082,NCT04880850,Change in Glycated haemoglobin (HbA1c),Change in body weight,2021-05-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3083,NCT01347814,Gastric emptying half time,Appetite sensations,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
3084,NCT03554486,Percentage of Time in Range: Sensor Glucose Readings <70 mg/dl,Mean Sensor Glucose in mg/dl,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
3085,NCT00822471,"Improvement in the percent of subjects correctly identifying guideline-recommended treatment targets for the ""ABC's of Diabetes"", where A = A1C < 7%; B = BP <130/80mmHg and; and C = LDL-C < 100mg/dl.",Decrease the percentage of participants with self-reported ED visits and hospitalizations for severe hypoglycemia and hyperglycemia.,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
3086,NCT00437970,Medication side effects,Endothelial dysfunction.,2008-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
3087,NCT05521893,Average postprandial glucose concentration,Incidence of caesarean section,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],
3088,NCT04442451,Capillary density,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3089,NCT04219085,Composite Primary Outcome,hypertensive disorders of pregnancy.,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],
3090,NCT00543595,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3091,NCT02231736,The quality of HbA1c influences micronuclei formation in binucleated cells,Type 2 diabetes duration of the subjects influences chromosomal damage,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],
3092,NCT02655757,Changes in late lumen loss of target lesion,Incidence rate of MACE,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3093,NCT06296836,Mean glucose levels,Mortality,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Mean glucose levels while receiving metformin in the continuation arm and while not receiving metformin in the discontinuation arm
3094,NCT05326204,Fetal weight,perinatal complications,2021-12-30,RECRUITING,OBSERVATIONAL,['NA'],
3095,NCT01384058,"Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs",Change of the concentrations of triglycerides,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3096,NCT01868191,Change from baseline in intraepidermal nerve fiber density,Change in neuropathic deficits,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3097,NCT03529123,Change in HbA1c,Change in SMPG profiles,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
3098,NCT00246987,Change in HbA1c from baseline to Week 24,Changes achieved from baseline in FPG after 24 weeks. Changes achieved from baseline in 3 hour post-prandial AUC for glucose and insulin levels after 24 weeks vs. placebo.,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3099,NCT05743907,HbA1c(%),,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE4'],
3100,NCT04599738,Change in insulin response from baseline for 180 minutes,Satiety by visual analogue scale for 4 hours,2017-03-06,COMPLETED,INTERVENTIONAL,['NA'],
3101,NCT06278181,asymptomatic malaria,symptomatic malaria,2023-09-21,RECRUITING,OBSERVATIONAL,['NA'],strongyloides infection
3102,NCT04392557,side effects,lipid metabolism/atheroscelorisis,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3103,NCT00191464,HbA1C,Apolipoproteins [substudy],2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3104,NCT03504059,Changes in the composite ICH score of adolescents from baseline to year 2 and 4,Changes in the composite ICH score of adolescents from baseline to adulthood,2017-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3105,NCT04069611,Probing Pocket Depth (PPD),Patient Satisfaction,2020-01-30,RECRUITING,INTERVENTIONAL,['NA'],
3106,NCT04726163,Percentage of time spent in the range 70-180 mg / dl (TIR),Time spent bellow glycaemia < 70mg/dl,2021-01-29,TERMINATED,INTERVENTIONAL,['NA'],
3107,NCT05097534,Change from baseline HbA1c,Change from baseline medication Adherence,2021-12-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
3108,NCT02053077,"Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week",Usability: Coverage of the GlucoTab,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
3109,NCT05470842,"Proportion of participants with captured hypoglycaemia; within that group, the time spent in the hypoglycaemic range","Emergency department re-attendances and/or hospital re-admissions for falls, fractures, heart attacks, ischaemic strokes and death within 30 days",2023-06-06,COMPLETED,INTERVENTIONAL,['NA'],
3110,NCT04632862,HbA1c level at Week 24 after administration of the IP,"HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",2020-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3111,NCT04864483,Incidence of early day hypoglycemia,Patient satisfaction and preference,2021-03-21,COMPLETED,INTERVENTIONAL,['NA'],
3112,NCT01618162,Change in Glycosylated Haemoglobin (HbA1c),Number of Adverse Events (AEs),2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
3113,NCT03701087,incidence of gestational diabetes recurrence,,2018-08-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
3114,NCT02782195,To measure the rate of glucose absorption after a standard evening meal,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
3115,NCT05816759,AUCt of CKD-383,,2023-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
3116,NCT03666546,Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)],"Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min))",2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes
3117,NCT00813020,"AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration",Cmax of the plasma NN9535 curve,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3118,NCT05626842,Primary study objective- HbA1c,Secondary study objective- participant experience,2021-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3119,NCT04022499,Weight loss,Attendance,2019-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3120,NCT02299960,Test-retest-reliability EndoPAT,Clinical feasibility of circulating endothelial cells and EndoPAT,2014-08,COMPLETED,OBSERVATIONAL,['NA'],
3121,NCT05421390,Change in whole-body insulin sensitivity,Change in C-reactive protein,2022-06-10,RECRUITING,INTERVENTIONAL,['NA'],Change in subcutaneous adipose tissue gene expression signature
3122,NCT03708887,Change in blood lipids from baseline,Change in gut microbiota from baseline,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3123,NCT04127383,Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care,Productivity losses,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3124,NCT01798706,Absolute Change in HbA1c From Baseline to Week 24,Percentage of Participants With Gastrointestinal Disorders,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3125,NCT00130845,time to progression of diabetic retinopathy,time to moderate vision loss,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3126,NCT00297401,Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.,Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3127,NCT04769687,inflammation,fragility,2020-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
3128,NCT00924599,Gestational diabetes not present in pregnancy,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
3129,NCT00751114,HbA1c: Change From Baseline to Study Endpoint,Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3130,NCT05029271,Endpoints are exploratory and descriptive related to time in glycemic range.,,2023-04-17,COMPLETED,INTERVENTIONAL,['NA'],
3131,NCT00935064,Expiration/Inspiration Ratio Before and After Treatment,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
3132,NCT02713321,Diabetes-related preventable hospitalizations,Number of months of Medicaid coverage,2017-01-24,COMPLETED,OBSERVATIONAL,['NA'],
3133,NCT05893784,Fatigue Severity Scale,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],
3134,NCT06062576,2-week reduction rate of wound area,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
3135,NCT04336176,Pressure Time Integral,Modified Monitoring Orthopaedic Shoes questionnaire,2018-03-22,COMPLETED,INTERVENTIONAL,['NA'],
3136,NCT06296992,Retention for follow-up measurements,Quality of Life (PedsQL 4.0),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Motivation for Physical Activity (EMI-2)
3137,NCT00403026,"Electrophysiological changes (ERG, VEP)","Ocular side effects (infection, RD, IOP rise, cataract)",2006-08,UNKNOWN,INTERVENTIONAL,['NA'],
3138,NCT02330549,Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR ) Index,Number of Participants With Abnormal Physical Examination Findings,2015-07-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
3139,NCT06315361,Prevalence of significant fibrosis by non invasive tests,Identification of MACE,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3140,NCT01481623,"Identification and genetic, clinical and metabolic characterization of monogenic diabetes forms",Clinical and biological characterization of total or partial deficiency of the genes responsible for monogenic diabetes,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],
3141,NCT01647308,Total apoC-III,Insulin Sensitivity,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
3142,NCT02668601,hypothalamic CBF,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
3143,NCT02175784,Change in HbA1C from baseline,"Safety assessed by the adverse events, vital signs. and laboratory tests",2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE4'],
3144,NCT02284269,Incidence of adverse events,The change from baseline in Fasting Plasma Glucose,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],
3145,NCT01988246,Number of Participants With Ocular and Non-Ocular Adverse Events,Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score,2013-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change From Baseline in Retinal Thickness
3146,NCT00605592,A decrease in the average daily insulin requirement post-islet cell transplantation.,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3147,NCT02960295,Compliance With Requirements for Frequency of Glucose Measures,Glucose Concentrations,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
3148,NCT04121572,To utilize capnography as a noninvasive tool for the detection and monitoring of DKA,To find the ability of EtCO2 in ruling in or out DKA,2019-10-10,RECRUITING,OBSERVATIONAL,['NA'],To evaluate the different severity grades of DKA using EtCO2 Monitoring
3149,NCT02172313,Area under the semaglutide plasma concentration time curve,Area under the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) plasma concentration time curve,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3150,NCT00012662,,,na,COMPLETED,INTERVENTIONAL,['NA'],
3151,NCT04146740,Blood glucose level,Edinburgh Post Natal Depression scale (Punjabi version),2019-03-12,COMPLETED,INTERVENTIONAL,['NA'],
3152,NCT03789526,changes in ultrasound images of the Tenoasynovitis.,,2018-12-11,COMPLETED,INTERVENTIONAL,['NA'],
3153,NCT02138331,Total daily insulin dose,Pancreatic β-cell Mass,2014-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hemoglobin A1c
3154,NCT00706017,Incidence of SADR (serious adverse drug reactions ) incl major hypo (hypoglycaemic events),Weight,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
3155,NCT02897349,Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Percentage of Participants With Any Severe Hypoglycaemic AE,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
3156,NCT00086450,"5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke",Rates of Individual MACCE Endpoints,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3157,NCT00962026,Incidence and severity of infection in study participants,"Changes in participants' HbA1c levels, insulin doses, and beta cell preservation",2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3158,NCT03462940,Change in vascular function,Change in lipid levels,2018-04-02,TERMINATED,INTERVENTIONAL,['NA'],
3159,NCT01415726,Inflammation control,Metabolic control,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3160,NCT00820313,Biomarkers of Cardiovascular Disease,Dietary Intake,2006-10,UNKNOWN,INTERVENTIONAL,['NA'],
3161,NCT02061579,Changes in Self-Reported Physical Activity Level Across Study Visits,Changes in Patient Satisfaction During Intervention Period,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
3162,NCT00836940,Change from baseline in HbA1c compared with placebo at the end of 12 week treatment period,Waist circumference,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3163,NCT04994288,HbA1c,salvage treatment,2021-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3164,NCT00866658,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
3165,NCT02870816,The number of participants out of 60 with complete healing of their diabetic foot ulcers as measured by complete epithialization of the foot wound comparing the two active treatment groups,Cost effectiveness of each treatment modality.,2016-08-31,COMPLETED,INTERVENTIONAL,['NA'],
3166,NCT02231021,Change in glycohemoglobin(HbA1c) from baseline,The number of subject with any change of findings in electrocardiogram from baseline,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
3167,NCT04970108,Systolic blood pressure (SBP),Adverse events,2023-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
3168,NCT00005485,Cardiovascular Disease,Mortality,2000-09-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
3169,NCT04488848,Interleukin-6,,2019-04-11,UNKNOWN,INTERVENTIONAL,['NA'],
3170,NCT02680054,Time of Peak Glucose Level Following Test Meal,Number of Participants With Hypoglycaemia Events Following the Insulin Dosing,2016-02,TERMINATED,INTERVENTIONAL,['PHASE4'],Acceptability of Giving Insulin at Different Times Related to Test Meal
3171,NCT03323788,Response of muscle mRNA to acute exercise,,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],
3172,NCT00358124,"Other efficacy variables were the change from baseline in FPG, serum lipids and weight.",Health-related quality of life was compared between the baseline visit and the follow-up assessments,2001-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3173,NCT01204775,Mean Change in HbA1c From Baseline to Week 16,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3174,NCT00989924,The smooth index of corrected QT interval (SIQTC) measured by MCG,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],
3175,NCT06278571,Number of participants with body mass index profile in control target,The proportion of patients with adequate knowledge of diabetes,2023-01-30,RECRUITING,INTERVENTIONAL,['NA'],
3176,NCT01299012,Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
3177,NCT02291666,Metabolic ratio,Renal clearance,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3178,NCT00982254,Glucose Infusion Rate (GIR),Adverse Events,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3179,NCT05333835,Mean Change From Baseline in HbA1c at Week 26,Number of Hypoglycaemic Episodes at Week 26,2022-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3180,NCT03503370,Time to new foot complication among all randomized participants,Susceptibility to chlorhexidine among bacterial pathogens on the feet,2019-01-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to new foot complication among participants with a healed foot complication at randomization.
3181,NCT04096794,changes in serum hemoglobin A1c level,Adverse effects,2016-09,RECRUITING,OBSERVATIONAL,['NA'],
3182,NCT02426541,Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake,Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8,2015-03-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
3183,NCT04217902,Description of individual experiences of patients and health care professionals in diabetes care.,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3184,NCT05670769,Diabetes Self-Care Activities Questionnaire,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3185,NCT00482768,glycosylated hemoglobin,Change in risk of coronary heart disease,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
3186,NCT05147259,Onset of appearance,Assessment of development of Anti-drug Antibodies (ADAs),2021-11-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3187,NCT01477567,Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs,Number of Participants Forming Antibody to LY3009385,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3188,NCT05624034,EGG findings,Factors affecting the condition,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],
3189,NCT04981847,Hemoglobin A1c,Blood pressure,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3190,NCT05219994,Insulin change in response to OGTT,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],
3191,NCT06124443,Assesment of prevalence of congenital heart defects among infants of diabetic mother compared to that in infants of non-diabetic mothers.,,2024-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3192,NCT05435157,Residual gastric volume,Antral cross-sectional area,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],
3193,NCT01565824,Well-Being Questionnaire (W-BQ12),,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
3194,NCT02547935,Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24,Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24,2015-09-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3195,NCT03849755,Change in the percentage of time in glucose target range (glucose levels 3.9-10 mmol/l or 70 - 180 mg/dl),Evaluation of usability of PEPPER system by conducting the usability test,2018-11-15,COMPLETED,INTERVENTIONAL,['NA'],
3196,NCT03389490,Glycemic variability,Heart rate variability,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3197,NCT04499846,Compliance rate to the statin treatment,Compliance rate to the statin treatment according to treatment duration.,2020-06-11,COMPLETED,OBSERVATIONAL,['NA'],
3198,NCT00841048,"Safety and Tolerability (Adverse events, vital signs, ECGs, physical examination, laboratory variables",Pharmacodynamic measurements allowing to assess AZD4017 effect in different tissues,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3199,NCT02636192,Number of Participants with a recorded diagnosis of Diabetic Ketoacidosis (DKA),,2015-07-31,COMPLETED,OBSERVATIONAL,['NA'],
3200,NCT05294458,"Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted state",Evaluate immunogenicity for cotadutide administered as low and high concentration SC formulations and an IV formulation,2022-03-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Temperature needed at the injection site to homogenize at the point of injection
3201,NCT03786718,User Experience - Qualitative,Change in Patient Activation,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],
3202,NCT02622282,Change in Physical Activity,Change in Quality of Life,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
3203,NCT02151461,Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr,Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3204,NCT00711503,Δ 2-h AUC C-peptide response,"Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3205,NCT00614120,Change in Glycosylated Haemoglobin A1c (HbA1c),Hypoglycaemic Episodes,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3206,NCT00286442,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3207,NCT00106561,percent reduction in 24 hour urine protein excretion,,2002-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3208,NCT03912766,change of serum sodium after surgery,,2016-02-01,COMPLETED,OBSERVATIONAL,['NA'],
3209,NCT05579314,"Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities",,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],
3210,NCT00813228,Changes in plasma TGF-Beta 1 levels.,"Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.",2009-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3211,NCT03124043,Change in HbA1c,Change in Treatment Satisfaction,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
3212,NCT01400971,Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy,Number of Participants Who Achieved Their Personalized HbA1c Target by the End of the Study,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
3213,NCT04656106,Change in HbA1c (Glycosylated Hemoglobin),Change in body weight,2021-04-27,COMPLETED,OBSERVATIONAL,['NA'],
3214,NCT04789798,BMI,The number of patients who added insulin to their oral antidiabetic medication or switched to oral antidiabetic medication by discontinuing insulin,2013-10-21,COMPLETED,INTERVENTIONAL,['NA'],Urine microalbuminurea
3215,NCT06325917,glycemic control,diabetes self management behaviors,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3216,NCT05208164,Sleep Impairment,Inflammatory Markers,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],
3217,NCT04943614,Functional reach test,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],
3218,NCT00848822,This study could help find if there are particular times of day or times during sleep that change glucose the most.,This study may help make recommendations about the best time to test glucose values and better help children with Type 1 Diabetes Mellitus control their glucose levels.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
3219,NCT02789319,Analytical accuracy and clinical performance criteria,Device issues,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Results
3220,NCT03973515,Area under the plasma concentration versus time curve (AUC),The change for plasma insulin,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
3221,NCT01303302,Comparison of the differences in HbA1c levels,Improvement in weigth and metabolic parameters,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
3222,NCT05703880,Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in the US.,Incidence rate of proliferative diabetic retinopathy in patients who initiate finerenone with prior non-proliferative diabetic retinopathy,2023-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3223,NCT04092738,Change in Waist circumference,Change in subjective occupational physical activity,2019-03-04,UNKNOWN,INTERVENTIONAL,['NA'],"Sociodemographic variables (age, gender, socio economic status)"
3224,NCT02372630,JNK-1 Protein in MNC,Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
3225,NCT05301855,The fifth part of the questionnaire is the Beliefs about medicine which is assessed using the Arabic version of the Beliefs about Medicines Questionnaire Specific (BMQ-Specific).,,2022-03,RECRUITING,OBSERVATIONAL,['NA'],
3226,NCT02284230,Plasma glucose during oral glucose tolerance test at week 26,Plasma liraglutide,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3227,NCT03516474,Lower rates of DFU recurrence in patients monitored using mHealth,,2018-05-15,UNKNOWN,OBSERVATIONAL,['NA'],
3228,NCT03889522,Examine the relationship between artificial sweeteners and hemoglobin A1c,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
3229,NCT04416737,Glucagon response to induced hypoglycemia,Glucose Values,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3230,NCT00138619,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 24 weeks and 104 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3231,NCT03345667,Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema,Frame between the injections,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3232,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],
3233,NCT01743781,The acceptance rate of comprehensive eye examination in both groups,knowledges of eye disease and attitude of eye examination,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
3234,NCT02872974,Carotid intima-media thickness,Cardiovascular risk factors,2016-08,COMPLETED,OBSERVATIONAL,['NA'],
3235,NCT02173834,Difference in sympathetic stimulation to BAT between lean and obese individuals,Difference in correlation between sympathetic stimulation of BAT as assessed with 123I-MIBG SPECT scans and metabolic BAT activity as assessed with 18F-Fluorodeoxyglucose(FDG)- positron emission tomography(PET)-CT scan in lean and obese individuals,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
3236,NCT01557907,Insulin levels,Number of participants with adverse events,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3237,NCT02024542,Tensile Strength of White Adipose Tissue,,2011-02,RECRUITING,OBSERVATIONAL,['NA'],
3238,NCT02011529,Hemoglobin A1c,LDL cholesterol,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Brief Psychiatric Rating Scale (BPRS)
3239,NCT02004561,Change in Glucose Tolerance,Changes in nutritional health,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Fat distribution
3240,NCT02290860,abnormal glucose tolerance,,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
3241,NCT00516620,Body Weight,"Biomarkers of diet and obesity-related chronic diseases (serum lipids, homocysteine and C-reactive protein) and genotypes",2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3242,NCT03503942,Diabetes incidence,Metformin adherence,2017-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3243,NCT04283994,EHR documentation of Goals of Care discussions,Goal concordance,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Factors
3244,NCT01722682,Insulin secretion under stimulation,Islet function,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3245,NCT00638131,change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF,change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;,2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
3246,NCT00065676,Does quercetin effect glucose absorption,,2010-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
3247,NCT05168488,Capillary glucose (change during exercise),percent time in hypoglycemia,2021-11-16,COMPLETED,INTERVENTIONAL,['NA'],
3248,NCT02244385,Blood Pressure,Uteroplacental assessment,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Urinary podocyte markers
3249,NCT03397225,Hemoglobin A1c,,2013-11-15,COMPLETED,INTERVENTIONAL,['NA'],
3250,NCT05007990,Natural History,,2022-09-08,RECRUITING,OBSERVATIONAL,['NA'],
3251,NCT00971139,Impacts of the OPPC service on organizational processes/organizational change such as care processes,"Characteristics of high/low volume users, patient-caregiver communication and use patterns",2009-11,COMPLETED,INTERVENTIONAL,['NA'],
3252,NCT02302716,Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c),Percentage of Participants With Hypoglycemic Events,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3253,NCT04216485,Gestational weight gain,Incidence of Gestational Diabetes Mellitus,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
3254,NCT02130401,Measurement of glycosylated hemoglobin (A1c),Feasibility and acceptability of the device as an intervention for the diabetes population,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
3255,NCT05570357,HbA1C,Lipid profile,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3256,NCT05663736,HbA1c,CK-MB,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
3257,NCT01106573,,,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],
3258,NCT00861445,The primary objective of this trial is to evaluate the efficacy of SPM 927 in reducing pain in subjects with diabetic distal sensory polyneuropathy,Examine the pharmacokinetics of SPM927 (assessment at all site visits during entire trial participation),2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3259,NCT03152994,fasting blood glucose(FBG),Exercise capacity (composite outcome measure),2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],Symptom Evaluation(composite outcome measure)
3260,NCT01843114,Total retinal blood flow,Retinal blood velocities,2015-01-12,COMPLETED,INTERVENTIONAL,['NA'],
3261,NCT00816218,Vascular Endothelial Function,Insulin Resistance,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3262,NCT03050229,Reduction of nocturnal blood pressure measured by ABPM,The correlation between blood pressure and body weight,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3263,NCT03057470,Reduction In Plasma Glucose (YSI),"Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction",2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3264,NCT01476501,Change in serum vitamin D from baseline to 3 and 6 months,Change in bone health from baseline to 3 and 6 months,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3265,NCT00668239,diffuse macular oedema,morphofunctional assessment of retina,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
3266,NCT02606838,Number of Subjects With Numeric Meter Results When Users Obtain Fingerstick Capillary Blood Using the Styx Lancing Device ( 28 Gauge Lancets),Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding the Styx Lancing Device,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
3267,NCT02384356,"Health Status using general health-related quality of life, perceived health, and PHQ8","Demographics, use of formal care and access, substance use, NCD diagnoses, self-care behavior, knowledge/perceptions, and anthropometric measures",2014-06,COMPLETED,OBSERVATIONAL,['NA'],
3268,NCT05003154,Concentration of glycosylated hemoglobin A1c,Proportion of patients with abnormal resulets of postnatal oral glucose tolerance test,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3269,NCT04515576,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD):Change from baseline to Day 29 in Fasting Glucose (FG),2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
3270,NCT03277742,Blood glucose control,,2017-09-20,WITHDRAWN,INTERVENTIONAL,['NA'],
3271,NCT05553912,HbA1c at Month 6,Quality of communication assessed using 3 questions from the CAHPS Clinician and Group survey,2022-11-02,RECRUITING,INTERVENTIONAL,['NA'],Clinician satisfaction survey
3272,NCT01659697,occurence of diabetes,change in Body Mass index and Physical activity,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
3273,NCT01123980,Change in Glycosylated Haemoglobin (HbA1c),Number of Hypoglycaemic Episodes,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3274,NCT04723160,consistent rate of diagnoses,full coincidence rate of software's diagnoses,2020-08-10,COMPLETED,OBSERVATIONAL,['NA'],
3275,NCT04496401,To characterise the bioavailability of Envarsus® and compare it to the bioavailability of tacrolimus,Assessment of biological and clinical tolerance/ safety: Incidence of serious adverse events,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
3276,NCT05917093,Change in Blood Glucose,Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,2024-03,RECRUITING,INTERVENTIONAL,['NA'],Patient's Perceived Involvement in Care Scale (PICS)
3277,NCT01553526,Target Lesion Failure (TLF),Clinical Procedural Success,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],
3278,NCT03170518,Percentage of Participants with Adverse Events as a Measure of Safety and Tolerability,Percent Change in Body Weight From Baseline at Week 26 and Week 52,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Urinary Albumin/Creatinine Ratio (ACR) From Baseline at Week 26 and Week 52
3279,NCT00390728,"Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.",Proportion of patients reaching HbA1c target as per participation with the Prescription Plan,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3280,NCT02904512,Number of Participants With Hypoglycemic Events (< 70mg/dL),,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
3281,NCT02984605,glycated hemoglobin,,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],
3282,NCT04569214,Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3283,NCT00057499,"Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests",T cells' secretion of IL-4 and Interferon (IFN)-gamma,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3284,NCT04443153,Glycemic Outcomes,High Blood Glucose Index,2020-09-04,RECRUITING,INTERVENTIONAL,['NA'],
3285,NCT00362193,Glycemic relapse: increase in HbA1c by 1% over baseline and >8%,Fasting Lipid Panel,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3286,NCT01130207,Changes in microflora after bariatric surgery,,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
3287,NCT00805506,To collect sufficient glucose data by means of continuous glucose monitoring for the purpose of detecting clinically relevant alterations in blood glucose throughout a typical or modal day.,,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
3288,NCT02330042,Number of participants with measureable macular edema by OCT imaging,,2014-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3289,NCT01053234,Prothrombin fragment 1+2,C-reactive protein,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
3290,NCT00836225,To evaluate the safety and tolerability of single and multiple doses of ISIS-SGLT2Rx administered subcutaneously,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3291,NCT01610674,Barrier analysis,feasibility study,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
3292,NCT04599075,Neonatal Hypoglycemia,Umbilical Cord Blood Level of Insulin,2021-03-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
3293,NCT01021930,Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT.,MACE,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3294,NCT03631134,Changes of glycemic variation,Change of insulin dose,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3295,NCT05526430,Dose Limiting Toxicity (DLT),Visual Analog Scale (VAS),2022-09-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
3296,NCT02258373,"Percentage of Time in Range of 70 to 180 mg/dl, Measured With CGM",Number of Participants With >=1 Serious Adverse Event Other Than SH,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
3297,NCT01301092,Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV),)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3298,NCT02533648,muscle oxidative stress in diabetic patients,Tolerance of the treatment measured by any adverse events during treatment and between each visit.,2011-09-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
3299,NCT01393275,alteration of HbA1c-level (haemoglobin A1c),follow up of all parameters mentioned above,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
3300,NCT02857491,perioperative hemorrhage of the surgical eye,best-corrected visual acuity,2014-07,COMPLETED,INTERVENTIONAL,['NA'],grade of surgical difficulty
3301,NCT00924534,Change from baseline in Creatinine kinase level to Day 35,Change from baseline in High density lipoprotein cholesterol level to Day 28,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
3302,NCT04814849,number of participants reporting financial burden,number of participants reporting emotional and/or psychosocial burden,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],
3303,NCT03451630,Change in Hospital Readmission Rate,Gaps in care,2018-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3304,NCT01069393,Improvement in HbA1c (glycosylated haemoglobin),Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
3305,NCT03258268,HbA1c,Hypoglycemia,2017-08-07,COMPLETED,INTERVENTIONAL,['NA'],
3306,NCT05108987,Body Weight,Flow-mediated dilation,2021-09-25,RECRUITING,INTERVENTIONAL,['NA'],
3307,NCT03233178,"Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control",Change in triglycerides from baseline to follow-up,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
3308,NCT00753181,Average daily blood glucose level,"Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables",2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3309,NCT03113916,Waist Circumference in Centimeters,Number of Vegetable Servings Per Day (Transformed Using the Natural Log),2014-06-23,COMPLETED,INTERVENTIONAL,['NA'],Recruit Participants for Sustainability Phase
3310,NCT02314637,Number of Participants With Adverse Events,Change From Baseline in Fasting Plasma Glucose at Week 52,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3311,NCT03680794,sCD160 concentration in the aqueous humor,Stromal cell-derived factor 1 (SDF-1),2018-06-27,RECRUITING,INTERVENTIONAL,['NA'],
3312,NCT00690287,Pharmacodynamic variables,Pharmacokinetic variables,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3313,NCT01162772,catecholamine,Homeostasis model assessment-estimated insulin resistance,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
3314,NCT04656093,Beliefs about Medicines Questionnaire (BMQ scores),Illness Perceptions Questionnaire (IPQ scores),2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
3315,NCT02092870,Percent change in wound size from baseline at 12 weeks,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3316,NCT02826655,Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy.,,2016-06,TERMINATED,INTERVENTIONAL,['NA'],
3317,NCT02405949,"Predictive value of the genetic test in identifying individuals who will have a good response to bariatric surgery, in terms of type 2 diabetes remission after the surgery.",,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
3318,NCT05314855,Amplitude of SCN activity rhythm (peak-trough change in SCN activity),,2023-01-04,RECRUITING,OBSERVATIONAL,['NA'],
3319,NCT00704132,Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
3320,NCT02695095,incidence of acute liver injury,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3321,NCT00174681,Percentage of subjects achieving HbA1c < 7% at the end of the study.,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3322,NCT03252132,Muscle strength (isokinetic strength),,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],
3323,NCT01432275,Overall User Preference for the FreeStyle InsuLinx System Compared to Current Method.,Preference Questionnaire (Insulin Calculator Not Activated),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
3324,NCT03111238,Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.,,2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
3325,NCT02854696,Incremental cost- utility ratio at 1 year,Assessment of total cost of islet cell transplantation,2016-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3326,NCT05165615,Percentage of time in target ranges,The 5-item World Health Organization well-being index (WHO-5 index),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
3327,NCT02204657,Glycemic Control by Measurement of HbA1c,Hypoglycemia,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
3328,NCT02365363,Exercise intensity,Substrate Oxidation,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
3329,NCT00435240,"waist circumference at baseline, 3 months and 6 months","C-reactive protein at baseline, 3 months and 6 months",2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3330,NCT00642278,Change in HbA1c From Baseline to Week 12,Percent Change in Body Weight From Baseline to Week 12,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3331,NCT00947024,Bioequivalence based on AUC and Cmax,,1993-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3332,NCT02114008,Residual gastric volume (RGV) in morbidly obese diabetics. A comparison of 3 hour versus 8 hour fasting,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
3333,NCT02834858,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3334,NCT02354027,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability.,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3335,NCT00286962,incidence of hypoglycemia; data taken from patient diaries during either study arm.,"daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms",2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3336,NCT04317404,Post-injection glucose levels,KOOS Knee survey,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],
3337,NCT06143449,Provide data on disease management.,,2015-10-01,RECRUITING,OBSERVATIONAL,['NA'],
3338,NCT02813759,Satiety,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
3339,NCT00767260,area under the curve of c-peptide,area under the curve of serum insulin,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3340,NCT05027334,Fasting blood glucose (FBG),Weight,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
3341,NCT01529216,HbA1c,HbA1c,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3342,NCT02449330,Change of the ratio of peak velocity of early transmitral diastolic filling by echocardiography (E) to early diastolic mitral annular velocity by tissue Doppler echocardiography (E/e'),Change of plasma levels of NT-proBNP,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3343,NCT01762046,Metformin response,Vitamin D,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3344,NCT00705952,"Whether weight loss achieved through a programme of intensive lifestyle management can result in enhanced production of Glucagon-Like Peptide-1 together with improvements in glycaemic control, in patients with new onset type 2 diabetes.","To examine the changes in hormonal regulators of energy homeostasis (leptin, adiponectin, ghrelin) and cardiovascular risk factors occurring with this intervention.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],
3345,NCT04439474,HBA1C,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA'],
3346,NCT03685773,Endogenous glucose production (EGP),Change in Arterial Spin Labeling (ASL) signal,2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3347,NCT05188586,Specificity,Stage Shift,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],
3348,NCT03962010,Change in HbA1c,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3349,NCT05039307,Change from baseline in the adherence to a healthy lifestyle score at 12 months,Change from baseline in systolic and diastolic blood pressure at 12 months,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3350,NCT04547439,Melatonin and Cortisol Rhythm,,2021-02-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
3351,NCT04182451,Efficacy of Meso Wound Matrix,Health Economics,2019-12-05,COMPLETED,INTERVENTIONAL,['NA'],
3352,NCT01890226,Change in Composite Quality Score,Change in Health-related Quality of Life,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
3353,NCT01221194,Number of Participants Who Developed Foot Ulcer During Study Time Frame,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
3354,NCT03797885,"Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis",Type of pharmacological treatment,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],
3355,NCT03634098,"To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH",Constitution of a bio-collection,2018-10-25,COMPLETED,INTERVENTIONAL,['NA'],
3356,NCT00237094,,,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
3357,NCT00633763,Difference in fallypride binding in the pancreas of long-standing T1DM patients versus healthy controls,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
3358,NCT03536364,Effect of food order on postprandial glucose excursions as measured by incremental area under the curve (iAUC) for glucose ((mg/dl)*180) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,Effect of food order on satiety as measured by a visual analog scale (cm) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3359,NCT03815955,Positive and Negative Affect,,2019-03-14,COMPLETED,INTERVENTIONAL,['NA'],
3360,NCT05536804,Change from Baseline in Kidney Oxygenation in Participants With or Without T2D,Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR),2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
3361,NCT01845831,Change in HbA1C,Hospital Mortality Rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3362,NCT05498688,Plasma fatty acid composition,Subjective appetite,2022-08-25,RECRUITING,INTERVENTIONAL,['NA'],
3363,NCT02118714,Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26,Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B,2015-04-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3364,NCT03101865,Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl),AUC of glucose below 3.5mmol/l (63mg/dl),2017-08-08,COMPLETED,INTERVENTIONAL,['NA'],Percentage of time of CGM availability
3365,NCT06111508,Change in Time in Range,Frequency of Dose Changes,2023-11-29,RECRUITING,INTERVENTIONAL,['NA'],
3366,NCT02377362,Number of Participants With One or More Treatment Emergent Adverse Events (Parts B),Change From Baseline in Hip Circumference (Part B),2015-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
3367,NCT03235908,Copeptin level,operational function (functioning) after 12 months compared to baseline assessed by questionnaire,2017-05-01,COMPLETED,OBSERVATIONAL,['NA'],
3368,NCT05411965,Pharmacokinetic variables - Cmax,Pharmacokinetic variables - t1/2 of Pioglitazone M-IV,2022-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
3369,NCT04501107,AUCLIS.0-1h,AUCGIR.4-8h,2020-08-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3370,NCT05319275,mTCNS total score change from baseline at week 24,Changes in Nerve Conduction Amplitude from baseline at week 24,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
3371,NCT01792635,Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B,Ra in Part B in PF-05175157 200 mg BID Group,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
3372,NCT03036774,Number of patients with full stomach,Intraoperative hypoxemia,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],
3373,NCT03476876,Wound Saturation of Oxygen at 16 Weeks,Number of Participants With Wound Complications at 16 Weeks,2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3374,NCT03360604,Change in cognitive performance on a Letter Memory Task,Fullness,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],
3375,NCT00547027,weekly physical activity,physical activity stage of change,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3376,NCT02353273,"Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below. (AUC0-∞, AUC0-t, Cmax)(Cmax,ss, AUC0-τ)","Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below, if appropriate. (Tmax,ss)",2015-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
3377,NCT00954577,"Reduction in diabetes risk factors including insulin secretory capacity, insulin sensitivity, body fat content, dyslipidemia, and circulating concentrations of pro-inflammatory cytokines.",Improvement in self-esteem and in health-related behaviors.,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],
3378,NCT02935868,"Salivary peroxidase - collection of stimulated saliva in 10 minutes, measurement by a spectrophotometer.","Plaque index - measured by visual observation and classification in scores (1 for presence, 0 for absence)",2013-11,COMPLETED,OBSERVATIONAL,['NA'],
3379,NCT03076424,Intestinal Microbiome Composition,Hemoglobin A1-c,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],
3380,NCT02382536,In-line fluid pressure,Leakage,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Number of subjects with adverse events
3381,NCT02917057,Changes from baseline in weight (kg),Frequency of Vomiting,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3382,NCT03058029,Percent change in body weight,Change in HbA1c,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Proportion of subjects with weight loss ≥7.5%
3383,NCT01171456,Effect of metformin versus placebo on the development of GDM,Effects on maternal and fetal pregnancy outcomes of pre-conception metabolic intervention with metformin.,2010-04,WITHDRAWN,INTERVENTIONAL,['NA'],
3384,NCT00935532,Change in HbA1c From Baseline to Endpoint (Week 26),Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3385,NCT00398060,Weight,"Blood pressure (diastolic, systolic)",2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3386,NCT04984044,Change from baseline Michigan Neuropathy Screening Instrument (MNSI) scores at 8 weeks.,Change from baseline Serum 25(OH) D level at 8 weeks.,2020-11-07,COMPLETED,INTERVENTIONAL,['NA'],
3387,NCT01618045,Monocyte Function,Lipid Profile,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
3388,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
3389,NCT03164187,Percentage of patients achieving HbA1c level ≤ 7 %,Mean daily dosage of Diabeton MR,2016-09-01,COMPLETED,OBSERVATIONAL,['NA'],
3390,NCT01912092,"Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)",Wound surface area,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
3391,NCT01107717,Difference in HbA1c level,hypoglycemic events,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3392,NCT02762578,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Device Specific Questionnaires II (Would You Recommend the Pen?),2016-05-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3393,NCT04627636,- Visual analogue scale for pain (VAS-P) for pain assessment,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3394,NCT01301339,Do Air Force personnel who fail the Air Force physical fitness test have a higher incidence of pre-diabetes than those who pass the test?,"And for those who fail, do they have higher cardiovascular risks as correlated with fasting lipid panel.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],
3395,NCT00144937,Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months),All the above-mentioned primary and secondary outcomes will be evaluated at 12 months,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3396,NCT03528174,Mean Absolute Relative Difference of Sensed Glucose Values,Mean Draize Scale for Erythema for the Right Sensing Cannula at End of Study for All Subjects,2018-04-16,COMPLETED,INTERVENTIONAL,['NA'],
3397,NCT00501397,"urine collections for volume, glucose, & creatinine at Day 1 Session 1, Days 5 & 6 Session 3.","Vitals: Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup",2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3398,NCT03240874,Number of Participants Who Used the SweetMama Application,Difference in Hemoglobin A1c From Enrollment to Delivery,2017-08-02,COMPLETED,INTERVENTIONAL,['NA'],Clinical Outcomes of Pregnancy - Number of Babies With Neonatal Intensive Care Unit Admission
3399,NCT01234727,,,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
3400,NCT01845324,width of fetal interventricula heart septum,glucose control in patients with normal and abnormal interventricular septal width,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],
3401,NCT04653207,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3402,NCT00674466,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3403,NCT01030471,Diabetes-Related Family Conflict Scale (DFCS)-Measure of family conflict around diabetes-specific tasks,Hemoglobin A1c value,2009-09,WITHDRAWN,INTERVENTIONAL,['NA'],
3404,NCT01529385,Microcirculation for Dorsum of Foot,Physical Activity Level,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
3405,NCT01758471,euglycemia,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3406,NCT06066801,the remission of DFO,Incremental cost effectiveness ratio,2024-03-14,RECRUITING,INTERVENTIONAL,['NA'],
3407,NCT02473809,Change in collagen I cross-linked C-terminal telopeptide measured in serum,Change in procollagen type I N-terminal propeptide measured in serum,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3408,NCT00985257,Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method,,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
3409,NCT05168306,Difference in bodyweight from the control arm at 6 months,,2021-12-05,TERMINATED,INTERVENTIONAL,['NA'],
3410,NCT01090752,Effects of Pioglitazone on 24h Blood Pressure Control,Effects of Pioglitazone on Salt Sensitivity,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3411,NCT05712720,Change in Central Subfield Thickness,Repeat-dose AUC of RZ402,2023-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3412,NCT01396772,Average number of vegetable and fruit servings consumed per day,average number of physical activity minutes per day,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],
3413,NCT01322256,The difference between AUCs for PET/CT scan and scintigraphy,,2012-10,TERMINATED,INTERVENTIONAL,['NA'],
3414,NCT00194805,glycosylated hemoglobin (A1C) levels.,"Study participants who receive the web-based telehealth intervention will have fewer depression symptoms and higher quality of life, social support, at the 12 month (long-term) follow-up than participants in the control group.",2003-09,COMPLETED,INTERVENTIONAL,['NA'],
3415,NCT05949320,Eating Behaviour Questionnaire from the EatSmart Restaurant Star+ Campaign,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
3416,NCT02407899,Absolute changes from baseline in Fasting C-peptide levels at week 104.,"Absolute changes of body weight and BMI level from baseline and at week 26, 52, 78 and 104.",2015-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3417,NCT01788033,C-peptide level,Number of Adverse Events,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3418,NCT03553524,Compare the efficacy of the morning and afternoon HIIT in lowering blood glucose values in participants with type 2 diabetes.,Respiratory exchange ratio (RER),2021-10-30,WITHDRAWN,INTERVENTIONAL,['NA'],
3419,NCT01693510,Gestational weight gain within IOM guidelines,Bone outcomes,2012-11-12,COMPLETED,INTERVENTIONAL,['NA'],
3420,NCT00426920,AUC,AUC,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3421,NCT01521624,Serum concentrations of various markers of oxidative stress,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
3422,NCT01143714,Change in Wound Area,Number of Sharp Debridements Performed During the 4-week Treatment Phase and the 8-week Follow-up Period (12 Weeks Total),2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3423,NCT02131961,Proportion of contact cast systems intact by day 14,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3424,NCT02036528,Complete wound clearing of infection,DFU Area % Change,2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3425,NCT01914146,1. Presence or absence of orthostatic hypotension,3. The nadir of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during tilt table test.,2015-04,WITHDRAWN,INTERVENTIONAL,['NA'],
3426,NCT00497198,Change From Baseline in Hemoglobin A1c(HbA1c) at Week 12,Change From Baseline in Low Density Lipoprotein Cholesterol(LDL-c) at Week 12,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3427,NCT03154398,the percentage of patients progress to advanced diabetic nephropathy,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA'],
3428,NCT05086445,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,2021-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
3429,NCT04624672,RATE OF PARTIAL REMISSION OF DIABETES,RATE OF COMPLETE REMISSION OF DIABETES,2021-08-25,TERMINATED,INTERVENTIONAL,['PHASE4'],
3430,NCT00627146,"The difference in change in daily insulin need between baseline and month 48, between placebo and ChAgly CD3 treated patients",,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3431,NCT03936010,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
3432,NCT03424044,Percent of Time With Sensed Glucose < 70 mg/dl,Mean Amount of Glucagon Delivered in One Day,2018-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3433,NCT03665870,Fear of Hypoglycemia,Knowledge of Diabetes,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3434,NCT00787475,HgA1C level,Measurement of systolic blood pressure,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
3435,NCT03182712,Changes on hs-CRP (High-sensitivity C reactive protein),Changes on Total Antioxidant activity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
3436,NCT03403283,Increase in acid sphingomyelinase (ASM) expression and activity in bone marrow-derived endothelial progenitor cells (EPCs),,2014-01,RECRUITING,OBSERVATIONAL,['NA'],
3437,NCT00792662,Hemoglobin A1C as a Marker for Glycemic Control,Instrumental Activities of Daily Living (IADL) Scale,2008-11-18,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
3438,NCT05095038,Fasting blood glucose,Change in subjective assessment of investigational product,2022-02-10,TERMINATED,INTERVENTIONAL,['NA'],
3439,NCT04550806,Area under the curve of GA combined with body composition for GDM diagnosis,GDM prediction model establishment,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
3440,NCT02322554,Healing,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
3441,NCT00099957,Postprandial serum total triglycerides at 4 weeks,Postprandial apo B-48 and apo B-100 in the two lipoprotein fractions - chylomicrons and VLDL1+VLDL2+IDL (VLDL/IDL) at 4 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3442,NCT05539066,Compliance rate of BMI (Body Mass Index),Incidence of hypoglycemia,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3443,NCT05132725,TTG-IgA,BMI,2021-11-15,UNKNOWN,INTERVENTIONAL,['NA'],
3444,NCT04192422,Neonatal sensor glucose time in target,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
3445,NCT01768208,The primary objective of the study is to evaluate the changes in the metabolomic parameters before and after Saxagliptin treatment in type 2 diabetic patients.,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3446,NCT00965510,"Scores on PHQ9, PAM and health indicators",Satisfaction with care coordination model.,2009-09,TERMINATED,INTERVENTIONAL,['NA'],
3447,NCT01889355,Enhanced Meter Feature Usability,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
3448,NCT04074668,Mitochondrial Function,Kidney Injury Biomarkers,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],Epigenetic profiling
3449,NCT03784027,Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl),Percentage of time of CGM availability,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
3450,NCT02463084,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42),Change in brain perfusion,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
3451,NCT01432509,Type 2 Diabetes occurrence,Others cardiovascular risk factors,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
3452,NCT02919345,Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion),Change in body composition (% of fat mass and % free fat mass),2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Waist Circumference
3453,NCT04503174,Percent of Boluses Using the Auto Population Feature Resulting in Fewer Readings Less Than 70 mg/dL Than Those Not Using the Feature,"Diabetes Impact and Satisfaction Scale (DIDS), Impact Score",2020-08-04,COMPLETED,OBSERVATIONAL,['NA'],
3454,NCT04352738,Intrahepatic free glucose concentration,First-pass hepatic extraction of glucose,2021-04-15,COMPLETED,OBSERVATIONAL,['NA'],Changes in intrahepatocellular lipid (IHCL)
3455,NCT02909829,AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.,1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal,2017-10-31,COMPLETED,INTERVENTIONAL,['NA'],
3456,NCT00402727,Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population,Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3457,NCT02577120,Ceramiseal and EpiCeram restore barrier function to wounds in patients,,2019-01-09,RECRUITING,INTERVENTIONAL,['PHASE4'],
3458,NCT01478763,,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
3459,NCT03091673,Change in Plasma Glucose,Plasma Glucagon Tmax,2017-03-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
3460,NCT05348863,HbA1c,Physical activity using accelerometry,2022-10-28,RECRUITING,INTERVENTIONAL,['NA'],
3461,NCT05613985,To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint:,The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint:,2021-09-14,RECRUITING,INTERVENTIONAL,['NA'],
3462,NCT01013766,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F",Relationship between pharmacokinetic and pharmacodynamic parameters,2009-08-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
3463,NCT05698875,Mean glucose (mmol/l),"Range times (Time in range, time above range, time below range)",2023-02-14,COMPLETED,INTERVENTIONAL,['NA'],
3464,NCT05329610,Adherence to the intervention,Blinding to the intervention,2022-04-05,COMPLETED,INTERVENTIONAL,['NA'],Fractional shortening (%)
3465,NCT01242202,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
3466,NCT02153190,Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period,Low Blood Glucose Index (LBGI),2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3467,NCT01876914,Total retinal blood flow & visual acuity,The degree of parafoveal ischemia as identified by OCT and visual acuity,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
3468,NCT01979081,Physical Functioning Inventory,Patient Specific Functional Scale (PSFS),2013-01,COMPLETED,OBSERVATIONAL,['NA'],Brief Pain Inventory
3469,NCT04495231,Presence of metabolic syndrome,"Cardiovascular risk as estimated by Progetto Cuore Score (english translation: ""Heart Project Score"")",2007-09-01,COMPLETED,OBSERVATIONAL,['NA'],
3470,NCT06323161,Change in Glycated Haemoglobin (HbA1c),Number of Clinically Significant Hypoglycaemic Episodes (level 3),2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
3471,NCT05843175,Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition,Placenta efficiency,2023-06-22,RECRUITING,INTERVENTIONAL,['NA'],Sleep quality (questionnaire)
3472,NCT01371955,comparison of prevalence of homozygous polymorphism between the DN-group and the non-DN group,delay between diabetes diagnosis and ND onset by genetic polymorphism,2011-01,COMPLETED,OBSERVATIONAL,['NA'],HbA1c
3473,NCT00732407,arterial stiffness and platelet function,"oxidative stress parameters (oxidized LDL and Isoprostanes), markers of inflammatory status (highly sensitive CRP test) and 24 hours blood pressure monitoring",2008-09,UNKNOWN,INTERVENTIONAL,['NA'],
3474,NCT02118376,Dual energy X-ray absorptiometry,lab testing,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],lab testing
3475,NCT04682977,Executive functioning using the Executive Function Performance Test,Participation in life activities and roles using the Late Life Functioning and Disability Index,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA'],
3476,NCT00282360,silent ischemia,symptomatic myocardial ischemia,1999-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
3477,NCT03362112,Lipoprotein-associated Phospholipase A2,C Peptide,2015-01-30,COMPLETED,OBSERVATIONAL,['NA'],
3478,NCT03936660,Implementing a clinic-level multifaceted intervention,Measurement of average time from baseline to patient event.,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3479,NCT03910361,Changes from baseline intrahepatic fat (%),,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3480,NCT03738852,Brain glucose levels,,2018-11-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3481,NCT01527981,Changes in depression severity,Changes in glucose levels,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3482,NCT00675857,Change from baseline to Week 26 in HbA1c levels,Change in fasting serum glucose levels,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3483,NCT04349696,Blood glucose concentration change from baseline at 2 hours after drug administration,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3484,NCT03787563,Number of Subject with adverse events,Flash Glucose Measurements,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
3485,NCT00299169,mean LDL levels,the proportions of participants taking statins at the end of the trial,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
3486,NCT04634838,Percent reduction of wound size,Number of infectious episodes,2021-02-02,TERMINATED,INTERVENTIONAL,['NA'],
3487,NCT01597882,Grip strength,Sickness behaviour scale,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
3488,NCT03457012,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),2018-03-29,COMPLETED,OBSERVATIONAL,['NA'],
3489,NCT00235443,Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.,Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS),2004-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3490,NCT01796366,Number of treatment emergent adverse events,Area under the glucose infusion rate-time curve,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
3491,NCT01708083,Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
3492,NCT00970294,"Recruitment, Retention, Adherence",Glycemic Control,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
3493,NCT00824330,Arterial baroreflex sensitivity,Increase in Gosling's pulsatility index,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
3494,NCT01668485,Whole body glucose counterregulation,Gluconeogenesis from lactate,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3495,NCT02486237,Number of patients with microvascular and cardiovascular complications,Number of patients with microvascular and cardiovascular complications stratified by diabetes pharmacologic treatment,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
3496,NCT01976858,To determine serum concentrations of PEX168,To determin HbA1c levels of PEX168,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability
3497,NCT00147745,Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose,Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3498,NCT05540197,Early islet graft function,Insulin concentration,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3499,NCT05759884,central macular thickness (CMT),nonperfusion (NP),2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],
3500,NCT06005987,Compliance,Percentage of in-range blood glucose levels,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3501,NCT01211197,Metformin: Maximum Measured Concentration (Cmax),"Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3502,NCT01540396,Diagnosis of gestational diabetes,Maternal birth trauma,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
3503,NCT03917238,Pancreatic uptake of gallium-68-NODAGA-exendin-4,,2019-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3504,NCT04082091,Early Impact Measure of Intervention for Detection,Change in Physiological Characteristics of Intervention Participants - Physical Activity,2019-09,UNKNOWN,OBSERVATIONAL,['NA'],
3505,NCT00900146,Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III),Percentage Change From Baseline in Fasting Lipids Profile at Month 4 (Period II),2009-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3506,NCT05189015,angiotensin(1-7),LDL,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3507,NCT06115213,Emergency room visits,New diagnosis of peripheral artery disease,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3508,NCT00476281,nutritional and respiratory parameters,abnormal glucose tolerance,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
3509,NCT03830281,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16,Percentage of Participants With at Least 1 Event of Unexplained Hyperglycemia >300 mg/dL Confirmed by SMBG That Leads to an Unplanned Infusion Set Change,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3510,NCT01182935,Number of subjects with type 2 diabetes diagnosed with oral glucose tolerance test (OGTT),The relation between serum 25(OH)D levels and blood glucose levels at OGTT,2010-04,COMPLETED,OBSERVATIONAL,['NA'],
3511,NCT00591903,,,2007-12-14,COMPLETED,OBSERVATIONAL,['NA'],
3512,NCT02152384,"Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro",Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3513,NCT03273738,metabolic changes in type 2 diabetes,,2018-10-02,UNKNOWN,OBSERVATIONAL,['NA'],
3514,NCT00937222,The primary outcome measure is HDL-C,"Serum lipids, glucose, HbA1c, anthropometrics and blood pressure",2009-06,COMPLETED,INTERVENTIONAL,['NA'],
3515,NCT06147752,Change of homeostasis model assessment-insulin resistance（HOMA-IR）,Change of hepatic steatosis value,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],
3516,NCT00797771,"User satisfaction regarding the ""Adi"" pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit",Number of severe hypoglycemic events,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
3517,NCT00410722,Fasting insulin,Cancer cell proliferation,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3518,NCT02154126,Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
3519,NCT00501020,The primary efficacy variable was HbA1c change from baseline (visit 3) after 24 weeks of treatment with either RSG+MET combination therapy or Metformin monotherapy.,"Secondary efficacy variables included: the change from baseline (visit 3) at week 24 (visit) in FPG, immunoreactive insulin, HbA1c and FPG responders, Questionnaire-Tolerability of GI side-effects, and Questionnaire - Quality of Life.",2001-06-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3520,NCT01942694,Time to Development of Diabetes,Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).
3521,NCT06248190,Improved control of at least one condition that was not optimally controlled at baseline,Heathcare utilisation and cost,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
3522,NCT02064023,Composite obstetrical/perinatal endpoint consisting of specific elements (see description),Mean maternal HbA1c during pregnancy,2014-04,TERMINATED,INTERVENTIONAL,['NA'],Number of episodes of severe hypoglycemia
3523,NCT02348190,protein kinase C enzyme activity in tissue samples,protein kinase C enzyme activity in T cells,2003-06,COMPLETED,INTERVENTIONAL,['NA'],
3524,NCT05974566,Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),Change in renal function level,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3525,NCT02088268,effect of PRP on diabete wound closure,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
3526,NCT02596932,Mean neonatal blood glucose levels,Maternal hypoglycemia,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
3527,NCT02201004,Change in HbA1c from baseline,Number of subjects with adverse events,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3528,NCT02131766,USS Virginia Time Within Target,Morning Glucose Levels,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
3529,NCT04201496,CGM-measured time in the target range 70-180mg/dl (TIR) during the day,Number of hyperglycemic episodes as defined by contiguous CGM above 300 mg/dL,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
3530,NCT02726256,"HOMA-IR, HOMA-β",,2007-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3531,NCT00961324,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the NN1250 concentration-time curve during one dosing interval at steady state,2009-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
3532,NCT02225691,Baseline change in HbA1c at month 3 and 6 between paired testing and control arms for each of the 3 patient segments.,Proportion of patients who achieve good glycemic control (HbA1c≤7%),2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Baseline change in self-care scores (based on Diabetes Self-Efficacy Scale Questionnaire)
3533,NCT04905589,Diurnal glucose Incremental area under curve (iAUC) concentrations,Peptide tyrosine tyrosine (PYY) Incremental area under curve (iAUC),2021-04-30,COMPLETED,INTERVENTIONAL,['NA'],
3534,NCT01031680,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3535,NCT01655810,Change from baseline in carotid intima-medial thickness,Urinary Calcium,2012-08-13,COMPLETED,INTERVENTIONAL,['NA'],
3536,NCT02009488,"Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT","Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method",2014-09-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3537,NCT00044447,Change in HbA1C from baseline to Week 26.,Incidence of hypoglycemia.,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3538,NCT05343962,PROMIS Scale v1.2 - Global Health9. Spanish version,PROMIS-10_Q01. Spanish version.,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
3539,NCT05298111,Changes in fasting and postprandial blood glucose,Changes in food intake,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],Habitual physical activity
3540,NCT01791114,Insulin Sensitivity,Metabolic profile,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Thermoregulation
3541,NCT03434119,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,"Percentage of Participants With Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Hypoglycemia) During the On-Treatment Period",2018-02-20,TERMINATED,INTERVENTIONAL,['PHASE3'],
3542,NCT04424706,total MMP-9 levels,,2020-06-30,UNKNOWN,OBSERVATIONAL,['NA'],
3543,NCT01363141,Change in Blood Glucose and Insulin levels in 1 year as compared to baseline,Change in markers of cardiovascular disease in 1 year as compared to baseline,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
3544,NCT05685810,Kidney disease,Insulin resistance,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3545,NCT06264258,Change in glucose average and variability,Change in game play patterns over time,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],
3546,NCT01341899,Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation,mortality and dysfunction of other endocrine glands,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3547,NCT02964104,Number of treatment emergent adverse events (TEAE),"AUCGIR,0-24h,SS, area under the glucose infusion rate-time curve at steady state",2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
3548,NCT04507867,Overall Mortality at Day 40,Number of Participants With Distension on Day 3,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],Number of Deceased Participants Stratified by Urea Level
3549,NCT04645641,System Performance,System Related Adverse Device Effects,2020-10-12,UNKNOWN,INTERVENTIONAL,['NA'],
3550,NCT02490969,All-cause mortality,,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
3551,NCT02432859,"The wound fluid level of VEGF, VEGFR-2, HIF-1α and NO (pg/ml)",Wound surface area(cm2),2013-11,COMPLETED,INTERVENTIONAL,['NA'],
3552,NCT05188027,Blood glucose,carbohydrate supplementation,2021-11-16,RECRUITING,INTERVENTIONAL,['NA'],
3553,NCT00989339,endothelial function,carbohydrate metabolism,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3554,NCT02578563,Change from baseline in the HbA1c level after 1 year,Change from baseline in Waist circumference at 12 months,2016-02-12,COMPLETED,OBSERVATIONAL,['NA'],
3555,NCT02324036,Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient),"Improvement in ""red flag"" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)",2014-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3556,NCT00005248,,,1989-08,COMPLETED,OBSERVATIONAL,['NA'],
3557,NCT02539160,Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %),Platelet Reactivity Measured by VerifyNow P2Y12,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
3558,NCT01124656,Incidence of Adverse Events.,Change from Baseline for Glycosylated Hemoglobin.,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
3559,NCT01345227,Adverse events related to the procedure of intra bone marrow islet infusion,Beta-cell function,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
3560,NCT03018444,Postprandial GLP-1 secretion,Resting Energy Expenditure,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
3561,NCT04181853,genetic molecules,,2020-02-05,COMPLETED,INTERVENTIONAL,['NA'],
3562,NCT04349670,Complications,Correlation of symptoms,2020-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3563,NCT04426422,gut micribiota,glycemic control,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3564,NCT04813133,Serum High Density Lipoproteins (HDL),,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
3565,NCT00952991,Gastrointestinal Symptoms,Glucagon Secretion,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3566,NCT01079325,To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months,To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3567,NCT00924053,Vz/F,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3568,NCT00879125,glycemic control,Correction of lipid profiles,1999-11,COMPLETED,OBSERVATIONAL,['NA'],
3569,NCT06251635,Resting State Functional Connectivity (assessed through Functional MRI),Processing Speed,2024-02-28,RECRUITING,INTERVENTIONAL,['NA'],
3570,NCT00138515,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3571,NCT01715428,carotid intima-media thickness,changes in atherogenic lipoproteins,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
3572,NCT02715193,"Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Days 3 and 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.",Changes from baseline over time of lipase,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3573,NCT04742751,Drug adherence/Pill Counts,Glycemic Control,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],
3574,NCT01212198,Incidence of diabetes in patients with high risk for diabetes and gestational diabetes in Koreans,,2005-05,UNKNOWN,OBSERVATIONAL,['NA'],
3575,NCT02404870,AUC of FGF23,"1, 25 vitamin D",2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
3576,NCT02526810,mean amplitude of glycemic excursions( MAGE),the level of blood 8-hydroxy-2-deoxyguanosine(8-OHdG),2015-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],the incidence of severe hypoglycemia
3577,NCT03324737,Weight at 4 months post-delivery,Breastfeeding Status,2017-11-16,COMPLETED,INTERVENTIONAL,['NA'],
3578,NCT02003274,1. Composite plasma glucose and hormone responses to a mixed meal; 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],
3579,NCT01774474,Change in central subfield mean macular thickness as a measurement of efficacy,No. of subjects developing clinically significant macular edema as a measurement of efficacy,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in central subfield mean macular thickness as a measurement of efficacy
3580,NCT03605810,Performance of classification to predict eGFR,,2018-07-15,COMPLETED,OBSERVATIONAL,['NA'],
3581,NCT01177384,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2011-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
3582,NCT03725709,Exam metabolic profiles of CSF and plasma in diabetes. (Metabolites analysis of CSF and plasma),,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3583,NCT01720290,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of hypoglycemic episodes,2002-07-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
3584,NCT04481997,Reasons for prolonging DAPT over 1 year,Diabetes control (HbA1c values),2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],
3585,NCT05128097,Retrospective study of the management of the main geriatric risks in the University HÔptaux de Strasbourg,,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
3586,NCT02317484,HbA1c change level,Body composition and visceral fat change levels,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
3587,NCT00607906,vital signs assessments:,Correlation between drug concentrations & blood sugar levels:,2007-11-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
3588,NCT02025296,proportion of patients achieving the target of HbA1c <7% without hypoglycemia,Lifestyle,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
3589,NCT02540486,Percentage of subjects reaching fasting plasma glucose (FPG) target,Serious adverse events,2013-12,COMPLETED,INTERVENTIONAL,['NA'],List of concomitant medications initiated after randomization
3590,NCT01354990,Number of Participants With Concomitant Conditions,,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
3591,NCT06195488,determine stomach fullness,Incidence of risk factors,2022-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3592,NCT06263348,Incidences of ADRs and SAEs,Response rate,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE4'],
3593,NCT00817271,P-Glucose levels,"Pharmacodynamics (P-Glucose, S-Insulin and S-C-peptide)",2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3594,NCT01241864,HbAlc <6.5% and an absence of severe hypoglycemic events,HbAlc < 6.5% and an absence of severe hypoglycemic events measured after last transplant,2010-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
3595,NCT05107388,Incidence rate of hyperglycemia,,2021-12,UNKNOWN,INTERVENTIONAL,['NA'],
3596,NCT05202067,Medication adherence,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3597,NCT02001337,To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.,,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
3598,NCT05944640,TIR,Mean sensor glucose concentration,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],
3599,NCT02785198,Wound healing change quantified by digital photo planimetry,"The biochemical changes during wound healing, is assessed by biochemical markers in peripheral venous blood samples.",2016-04,TERMINATED,INTERVENTIONAL,['NA'],
3600,NCT05887817,Change in CAVI,Change in urinary L-FABP,2023-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
3601,NCT01061216,Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.,Feasibility of RCS for longer-term ID infusion,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3602,NCT02138188,"Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII.",Measures of Coping Strategies at Baseline,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],
3603,NCT06014684,Peripheral Insulin sensitivity,24h substrate metabolism,2023-07-13,RECRUITING,INTERVENTIONAL,['NA'],Blood glucose levels measured continuously over 7 days.
3604,NCT00832624,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18,,2008-11-26,TERMINATED,INTERVENTIONAL,['PHASE4'],
3605,NCT00663949,decreasing urinary protein,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3606,NCT01702311,Mean Fasting Blood Glucose,Number of Subjects With BG > 300 mg/dL,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3607,NCT00123227,Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR),Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3608,NCT00819884,"24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)",Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24),2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3609,NCT00295659,,,2001-01,COMPLETED,OBSERVATIONAL,['NA'],
3610,NCT00461006,Relative change from baseline in glomerular filtration rate,"Adverse events (AEs), laboratory parameters.",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3611,NCT01153100,Reduction in rebound hyperglycemia (blood glucose levels over 180 mg/dl),Reduction in time to get back to control of glycemia (140-180 mg/dl) if rebound hyperglycemia occurs,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3612,NCT02409511,Complementary markers for improving the performance of MA,To test whether the enhancement of this specific marker of kidney injury is able to identify those patients in which MA really means diabetic nephropathy.,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
3613,NCT03195257,C-terminal telopeptide of type I collagen (CTX).,N-terminal propeptide of type 1 procollagen (P1NP).,2012-11-17,COMPLETED,INTERVENTIONAL,['NA'],
3614,NCT02312050,The change in eGFR from Screening to measurements taken at Week 26,Incidence of major cardiac events,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3615,NCT02867436,Change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard gluten-containing diet.,Differences in fecal microbiome between children on normal diet and children on gluten-free diet over the first year of diabetes duration;,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
3616,NCT04595474,Proportion of subjects with advanced fibrosis,Lipid profile,2021-01-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3617,NCT02859779,Needs and expectations of adolescents with type 1 diabetes for skills to be developed during the educational sessions,Needs and expectations of parents of adolescents with type 1 diabetes for skills to be developed during the educational sessions,2017-02-04,COMPLETED,INTERVENTIONAL,['NA'],
3618,NCT00118950,HaemoglobinA1c,"Adverse events and safety variables (e.g. hypoglycaemia, haemoglobin, white blood cell count, cobalamine and folate).",2001-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3619,NCT05769439,evidence-based DhMRs concerning incident obesity,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3620,NCT01438814,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment,Change From Baseline in HbA1c Over Time,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3621,NCT04662866,Endogenous glucose production during fasting,,2021-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Intraabdominal fat
3622,NCT01040104,Time to wound healing / Scar maturation,,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
3623,NCT00399711,HbA1c,Percentage of subjects achieving sudden levels of HbA1c,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3624,NCT02863887,Percent weight loss,Change in Pulse,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
3625,NCT04551625,"High amplitude, antegrade contractions assessed with HRCM",Distance of capsule movement.,2020-10-15,UNKNOWN,OBSERVATIONAL,['NA'],
3626,NCT00590876,fMRI,,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
3627,NCT01377688,Blood pressure and /or Estimated Glomerular Filtration Rate (eGFR),,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
3628,NCT00665106,Ocular safety,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3629,NCT01964976,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
3630,NCT00302224,"To evaluate the safety and tolerability of 14 daily doses; To determine the pharmacokinetic (PK) profile in plasma of DIO-902 after a single dose, and after fourteen daily doses; To evaluate the pharmacodynamic effects of fourteen daily doses","To explore the impact of treatment with the enantiomer of ketoconazole on markers of inflammation and coagulation as well as on lipomic profiles, pre- and post-treatment",2005-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3631,NCT01136512,Vitamin B12 level,methylmalonic acid,2007-08,COMPLETED,OBSERVATIONAL,['NA'],
3632,NCT00744965,Mean Fetal Weight at Birth,Need for Insulin Therapy,2008-09-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
3633,NCT02750410,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Total Insulin Dose,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3634,NCT00605020,HbA1c,Change in weight,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3635,NCT01425645,Proportion of study subjects achieving a 7% weight loss,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
3636,NCT03073070,Measurement of RBC survival in diabetic children using biotin-labeled RBCs,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
3637,NCT03653533,Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function,,2019-01-07,TERMINATED,INTERVENTIONAL,['NA'],
3638,NCT01353495,Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth,,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
3639,NCT01579292,Body mass index,Fasting plasma glucose,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3640,NCT03208010,Change from baseline in body mass index (BMI) at 36 months,Text Messages Intervention - Follow-up Phone Call Interview,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
3641,NCT00208637,Dietary intake as measured by 3-day weight diet records,All measures to be compared at end of study (6 months),2002-08,COMPLETED,INTERVENTIONAL,['NA'],
3642,NCT04226820,exercise test wilt hand held dynamometer,Blood pressure analysis,2020-02-01,RECRUITING,INTERVENTIONAL,['NA'],
3643,NCT01023919,To investigate the difference of surface coverage pattern between diabetic patients and non-diabetic patients after DES (Cypher stent or YINYI stent)implantation,To investigate the differences of surface coverage pattern，malapposition and the incidence of thrombosis between Cypher stent and YINYI in non-diabetic patients,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3644,NCT05069545,Change in time in range (3.9-10 mmol/L),DHSS-HCP(Health Care Professional),2021-10-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
3645,NCT03972904,Insulin resistance index changes,Glycated albumin changes,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],BMI changes
3646,NCT05439928,Time to Resolution of Metabolic Acidosis,Cost savings,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3647,NCT01570660,whole body insulin sensitivity,intrahepatocellular lipid content,2002-02,COMPLETED,INTERVENTIONAL,['NA'],
3648,NCT04017832,Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%),Number of Participants With Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes During Exposure to Trial Product,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
3649,NCT04467255,Six-minute walk test,Surface multichannel electromyographic variables.,2018-05-03,RECRUITING,INTERVENTIONAL,['NA'],
3650,NCT00194506,Hemoglobin A1c,Utilization,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
3651,NCT03041571,Patient provider orientation scale score (PPOS),Medical honors students focus group,2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],
3652,NCT04523363,Birth Weight,Placental Pathology,2025-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
3653,NCT02050191,attitudes and perceptions re: feasibility of web portal,,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
3654,NCT01468987,Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA) at 26 Weeks,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3655,NCT04242758,Urinary Phthalates concentration,Albumin excretion,2019-06-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3656,NCT02051842,Oxidative stress,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Oxidative stress
3657,NCT04616027,Fraction of unbound drug in plasma [fu],Incidence of treatment emergent Electrocardiogram [ECG] abnormalities,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
3658,NCT01087541,Glycosylated Haemoglobin A1c at 6 Months,Systolic and Diastolic Blood Pressure,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
3659,NCT05037695,NGAL values in pre-specified periods,Death,2021-07-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3660,NCT01512940,Percent excess weight loss,Resolution of comorbidities,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],
3661,NCT01326299,Positive AUC from 0 to 240 minutes for plasma glucose.,Plasma glucose concentrations,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3662,NCT00143013,,,2004-10,UNKNOWN,OBSERVATIONAL,['NA'],
3663,NCT03832725,Remission of Type 2 Diabetes,Metabolom Markers,2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],
3664,NCT02229175,Retinal thickness,Number of injections of bevacizumab needed,2021-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3665,NCT02862067,SGLT2 inhibition effects on cardiorespiratory fitness (CRF).,,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
3666,NCT03772067,Clock genes mRNA expression,Body Weight,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA'],
3667,NCT02365233,Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit,,2013-05-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
3668,NCT03883503,Difference in copeptin levels between the interventions,Difference in Response to lottery Experiment before and after the intervention,2019-02-25,COMPLETED,INTERVENTIONAL,['NA'],
3669,NCT05221580,Change in Glycosylated Haemoglobin (HbA1c),Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ)),2022-03-18,COMPLETED,OBSERVATIONAL,['NA'],
3670,NCT00698269,Change in HbA1c,Number of adverse drug reactions (ADR),2008-02,COMPLETED,OBSERVATIONAL,['NA'],
3671,NCT01611363,"Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM","Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia",2011-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
3672,NCT05387434,Change in Body Weight From 0-6 Months,Average Program Attendance,2021-03-03,COMPLETED,INTERVENTIONAL,['NA'],
3673,NCT03840161,CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.,Treatment satisfaction questionnaire,2018-07-16,COMPLETED,OBSERVATIONAL,['NA'],
3674,NCT04339283,Change form Baseline Pulse on the 28th day,Change from Baseline Body Mass Index on the 28th day,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
3675,NCT02887625,HbA1c,change in body weight,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
3676,NCT04750837,size of the ulcer reduce to zero cm,,2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
3677,NCT01571297,Effect of RM-131 on gastric emptying time,Safety and tolerability of RM-131,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3678,NCT00553787,Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3679,NCT03722199,FMD -Flow mediated dilatation test,blood pressure analysis,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],exercise test with hand held dynamometer
3680,NCT04810780,Primery Effectivness Endpoint,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3681,NCT06185465,Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B,Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm,2024-01-03,RECRUITING,INTERVENTIONAL,['NA'],
3682,NCT04150926,Insulin concentration,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA'],
3683,NCT04572165,Occurrence of first time malignant neoplasm of pancreas,,2021-01-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
3684,NCT03824002,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change from Baseline Pulse Wave Velocity at 3 and 9 months,2017-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3685,NCT05191160,Liver fat,Glucose tolerance - 2-hour plasma glucose (2h-PG),2021-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Adherence biomarkers - Objective biomarkers of SSBs (urinary fructose)
3686,NCT00272831,Fatal or severe bleeding,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3687,NCT02880592,Time to initial closure of diabetic foot ulcer,Incidence of adverse events,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
3688,NCT02716610,Maximum glucose infusion rate (GIRmax),Bioavailability,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3689,NCT01396941,Insulin sensitivity,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
3690,NCT04823208,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
3691,NCT06318442,Difference in Glucose tolerance,Difference in insulin sensitivity,2024-04-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Tissue specific changes in AMPK determined from adipose and muscle biopsies
3692,NCT00312780,Reduction in albumin excretion relative to creatinine,Pharmacokinetics and renal elimination,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3693,NCT00850239,"Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.",• Demonstrate changes in fasting plasma glucose,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
3694,NCT05083013,Need for ventilatory support,Incidence of other complications,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3695,NCT01101867,Mean Glucose,"1,5-anhydroglucitol Change",2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3696,NCT04657783,Major adverse cardiovascular events (MACE),All cause mortality,2020-06-10,RECRUITING,OBSERVATIONAL,['NA'],
3697,NCT05440591,Carotid Femoral Pulse Wave Velocity,Advanced glycation end products,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
3698,NCT02402933,Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events Through the Nasal Score Questionnaire,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Blood Glucose Level Over Time
3699,NCT00922649,Number of daily basal rates at Week 16,Change from baseline to week 16 in Patient Reported Outcomes (PROs),2008-02-01,COMPLETED,INTERVENTIONAL,['NA'],
3700,NCT04332302,Genotyping of HLA (rs2854275),Change from Baseline Balance at 12 weeks,2020-01-15,UNKNOWN,INTERVENTIONAL,['NA'],
3701,NCT00042458,- To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.,- To examine the pattern of daily insulin use over the course of the study.,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3702,NCT05691738,Falling Risk,Diaposan (Vibration) Evaluation,2022-10-03,COMPLETED,INTERVENTIONAL,['NA'],
3703,NCT04902638,Hyperglycaemia time,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
3704,NCT02694796,Achievement of Physical activity recommendations,Captured physical activity,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
3705,NCT02429024,A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.,OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Healthcare efficiency survey by the HCP
3706,NCT01076478,To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.,To assess the safety of Cilostazol therapy.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3707,NCT05644730,Primary Efficacy Outcome,Percent Time in the Desired Control Range,2022-11-08,RECRUITING,INTERVENTIONAL,['NA'],Glucose readings from CGM's versus from blood
3708,NCT02347709,Measure the degree of loss of epidermal nerve fibers near a lower extremity diabetic wound using Intra-epidermal Nerve Fiber Density analysis.,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA'],
3709,NCT03370497,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3710,NCT04279587,Change in Hemoglobin A1c,Change in Behavioral Pediatrics Feeding Assessment,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3711,NCT00278980,Change in sensory nerve conduction velocity from baseline to 6 mo of treatment,- Safety and tolerability of C-peptide,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3712,NCT00915200,Urinary Albumin excretion,tolerance and safety,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3713,NCT04619303,Difference in best corrected visual acuity change between treatment arms,Adverse Events,2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3714,NCT05628090,Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month,Proportion of patients on Toujeo® who switched to other therapy at the end of 6th month,2022-11-30,COMPLETED,OBSERVATIONAL,['NA'],
3715,NCT01150955,Metabolic parameters,Pathways of substrate metabolism.,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
3716,NCT02451436,Sleep Duration,hs-CRP,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
3717,NCT00734591,Rate of Primary Lung Cancer Mortality,Rate of Primary Lung Cancer Diagnosis,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
3718,NCT02299050,Glucose Metabolism During Mixed Meal Tolerance Test,Arterial Stiffness (AS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3719,NCT03447080,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,2017-06-02,COMPLETED,INTERVENTIONAL,['NA'],
3720,NCT02089438,Postprandial glucose,Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3721,NCT01707784,Markers of stress,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
3722,NCT01054118,GLP-1 levels after a standard meal,Assess incremental glucose changes after a meal tolerance test (MTT),2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
3723,NCT01841697,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment,2013-06-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
3724,NCT00599885,Comparison of telmisartan and valsartan on neointima volume with IVUS at 8 months after zotarolimus-eluting stent implantation.,"Comparison of telmisartan and valsartan on the levels of RBP-4 and inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
3725,NCT04745780,Glycated hemoglobin,Hypoglycemic events,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],
3726,NCT01469104,Change in plasma glucose concentration,Change in serum insulin concentrations,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
3727,NCT00819091,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18,Change From Baseline in Fasting Plasma Glucose at Week 12,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3728,NCT06237322,Blood Glucose Measurement taken with alternate PPG software device,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3729,NCT01912170,Fasting insulin,"birth weight, length of children",2013-08,UNKNOWN,INTERVENTIONAL,['NA'],"blood lipids, inflammatory markers"
3730,NCT01542242,Hemoglobin A1C,Total Body Adipose Tissue Distribution (whole body Computed Tomography),2012-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
3731,NCT02440061,β-cell function (DI-meal),,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3732,NCT03629704,28 day prognosis,Incidence of hypoglycemia,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA'],
3733,NCT02159638,Difference between the two CGM systems compared to capillary glucose value,Evaluation of two CGM systems from questionnaire,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
3734,NCT02561130,Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group,Number of Participants With Severe Hypoglycemic Episodes,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3735,NCT04554199,Cognitive function assessment in controlled type 2 diabetic patients wearing RPD.,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3736,NCT04787952,The potential associations between BAT activity and transcriptome profile,The potential associations between BAT activity and fT4 concentrations,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],
3737,NCT06079463,Beck Anxiety Scale,World Health Organization Quality of Life Scale,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3738,NCT02696252,"proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL",,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
3739,NCT01047982,difference in HOMA values,"incidence of pregnancy complications: hypertension, preterm delivery. macrosomia, shoulder dystocia, etc.",2010-03,COMPLETED,INTERVENTIONAL,['NA'],
3740,NCT05512871,Mobile health application feasibility,Change in intake of meals,2022-09-19,COMPLETED,INTERVENTIONAL,['NA'],
3741,NCT03958838,Change from Baseline HbA1c and at 12 months,Change in Peer Support Engagement and Health Care Utilization and 12 months,2019-05-25,COMPLETED,INTERVENTIONAL,['NA'],
3742,NCT00608439,Total Symptom Score,Quantitative Sensory Test,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3743,NCT05921019,the Brief Pain Inventory-Short Form,Nerve conduction velocity (NCV),2022-08-31,RECRUITING,INTERVENTIONAL,['NA'],
3744,NCT02274740,Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min),Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
3745,NCT05571878,"The change in brain imaging outcomes, measuring brain insulin resistance, following intranasal insulin or placebo challenges, compared between the participants with depression and healthy controls.",Correlation between brain insulin resistance with cognitive functioning at baseline and 6-month study follow up,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],"Correlation between brain insulin resistance, and hepatic and visceral adiposity"
3746,NCT00817778,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3747,NCT05424965,Activity of Wnt signaling pathway in placental tissue,,2018-03-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3748,NCT01493258,Change in CERSG Knowledge Score from baseline to 24-hr and to 6-month follow up,CERSG Acceptance,2010-08,WITHDRAWN,INTERVENTIONAL,['NA'],
3749,NCT02744300,Weight loss,Number of participants with either: a HbA1c value greater than or equal to 5.7; or a 2 hour value on a 75 g oral glucose tolerance test of greater than or equal to 140,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
3750,NCT04427189,Change of HbA1c level,DKA rate,2008-04,RECRUITING,OBSERVATIONAL,['NA'],
3751,NCT00970723,"The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.",Comparison of blood pressure in each group at one year,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
3752,NCT02524938,Change in estimated glomerular filtration rate (eGFR),Change in 8hydroxy 2'deoxyguanoside (8OhdG),2016-06-01,TERMINATED,INTERVENTIONAL,['NA'],
3753,NCT01155050,Change in Waist Circumference,Change in Fasting Plasma Glucose,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
3754,NCT03444142,Blood pressure,Waist Circumference,2017-11-17,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3755,NCT03102424,Change in HbA1c values to evaluate of the effect of DW1330,Change from baseline in OAD drugs description,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline of inflammatory biomarkers
3756,NCT04914819,Number of Participants Losing 5 Percent or More of Weight From Baseline to 16-week Follow-up,Intervention Arm: Number of Weeks With Daily Data Reporting for at Least 5 of 7 Days,2021-06-18,COMPLETED,INTERVENTIONAL,['NA'],
3757,NCT03338517,Ulcer surface area,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA'],
3758,NCT05601583,Total Scan Time,,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],
3759,NCT03273140,Better Sense of Coherence,Better Quality of life,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3760,NCT01024218,Device preference,Comparison of the frequency of adverse events (needle stick injuries),2004-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3761,NCT03904485,Assessment of myocardial injury,,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
3762,NCT06124586,effect of an immediate (within first 48h) PTA intervention on microbiome composition,Effect of the immediate PTA intervention on related complications,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
3763,NCT00537264,Health-related quality of life outcomes,,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
3764,NCT05529589,Change of visual acuity,B-mode ultrasound imaging,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],
3765,NCT00985114,Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline.,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
3766,NCT02039245,Plasma concentration of metformin following the dose of 2 CANA/MET XR FDC tablets,Percentage of participants with adverse events as a measure of safety and tolerability,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3767,NCT00357955,"Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg",,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
3768,NCT06077708,Periodontal Clinical Parameters,Biochemical Data,2022-08-23,COMPLETED,INTERVENTIONAL,['NA'],
3769,NCT03355040,number of Neonatal death,Number of Anal sphincter tear for the patient,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],
3770,NCT00725036,Long term pulmonary safety profiles,Treatment satisfaction,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3771,NCT05433415,Change from Block Kids 2004 Food Frequency Questionnaire (BKFFQ) at 12 and 24 weeks,Change fron Quality of Mother Interaction at 12 and 24 weeks,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],Change from Weight Efficacy Lifestyle Questionnaire at 12 and 24 weeks
3772,NCT03770767,Birth weight standard deviation score,"Neonatal morbidity (neonatal hypoglycaemia, jaundice, respiratory distress and duration of stay in neonatal intensive care unit) and infant morbidity evaluated as hospitalization during the first 3 months of life (after discharge in the neonatal period)",2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3773,NCT00184613,Variation in morning FPG,Variation of pre-dinner plasma glucose collected in hospital on the last 3 days,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3774,NCT03819634,Time to Infusion Set Failure,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA'],
3775,NCT04905628,Dexcom Continuous Glucose Monitoring (CGM) System Performance,System Related Adverse Device Effects,2021-07-08,UNKNOWN,OBSERVATIONAL,['NA'],
3776,NCT01787903,Time spent in the euglycemic range,Changes in hypoglycemia awareness score,2013-02,COMPLETED,INTERVENTIONAL,['NA'],RT-CGM satisfaction
3777,NCT00966407,"Genotype for specific genes related to obesity, metabolic syndrome, and/or type 2 diabetes; Fasting serum biomarkers; Hand grip strength, muscle strength of upper and lower extremities; Fitness measurements; Body composition measures",Perception of physical fitness; Relationship between physiological measures and genotype variation,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
3778,NCT02667964,FGF-21 change after physical activity,,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
3779,NCT01623882,Percentage of wounds closed,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],
3780,NCT00723853,"Biochemical markers (glucose tolerance, lipid panel, insulin, hemoglobin A-1-C)","Cost Assessment (costs incurred to attend meetings, eat healthier, exercise more)",2008-04,COMPLETED,INTERVENTIONAL,['NA'],
3781,NCT02097316,"Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4",Time spent in the strict glycemic area 80-140 mg / dl,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Time spent above 180mg/dl;
3782,NCT03258918,Percentage of participants who achieve weight loss goal,Study attrition,2017-09-11,COMPLETED,INTERVENTIONAL,['NA'],Change in physical symptoms
3783,NCT00960661,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30,Minor Hypoglycemia Rate Per Year,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3784,NCT03734887,Change of Medication Adherence Rate,Program Acceptability assessed by a random sub-sample of interviews,2019-10-31,TERMINATED,INTERVENTIONAL,['NA'],
3785,NCT01319656,Evaluation of effects,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
3786,NCT04881019,Gylcemic response profiles,,2021-06-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3787,NCT03028506,large for gestational age infants,,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
3788,NCT01055626,Differences in body fat,Differences in cardiovascular risk factors,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
3789,NCT03191396,Change in HbA1c,Change in Pulse Rate,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
3790,NCT06013228,Fatigue,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],
3791,NCT01188863,Half-life of the drug in plasma,Glucagon-like Peptide 1,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3792,NCT01662921,show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus,Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Compare incidence of primary cesarean section
3793,NCT06213337,Development of foot care self-efficacy in diabetic patients,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3794,NCT04183413,Systolic blood pressure among adults with hypertension,"21. Knowledge on diabetes and hypertension among adults with diabetes, prediabetes, or hypertension",2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3795,NCT01338376,HbA1c,The incidence of Hypoglycemia,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3796,NCT04041375,Change in Diabetes Distress Screening Scale (DDS17),Change in Use of community resources,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],Change in Use of VHA resources
3797,NCT05510583,"Assessment of the non-inferiority of the occurrence of maternal, fetal, and neonatal complications for patients of both groups",Comparison of the rate of patients put on insulin in both groups,2022-08-02,COMPLETED,OBSERVATIONAL,['NA'],
3798,NCT06125561,oral health-related quality of life,Clinical attachment loss,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],
3799,NCT04723134,Number of Wounds with Complete Healing,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
3800,NCT05427682,Plasma concentrations of rongliflozin,Incidence of Adverse Events [safety],2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],
3801,NCT03916601,(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax),Assessment of PD parameter: Time to GIRmax (GIR-tmax),2017-12-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
3802,NCT01353937,Quality of Life,cEPCs by FACS analysis,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3803,NCT03195153,"Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug",,2017-03-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3804,NCT01485913,"Compare the intermediate evolution of the HbA1c (3, 6 and 12 months)","Compare the evolution of the bio-clinical parameters at 3.6, and 12 months: weight, BMI, blood pressure, waist measurement",2011-07-01,COMPLETED,INTERVENTIONAL,['NA'],
3805,NCT05831059,Numeric Rating Scale,,2022-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3806,NCT01235026,Plasmatic Interleukin-6 (IL-6),Plasmatic usCRP,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],
3807,NCT03766256,Choice of evidence-based diabetes prevention (lifestyle change or metformin),Decisional conflict,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3808,NCT02992431,15D,visits to physician,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
3809,NCT04577274,Change from baseline Insulin at 240 minutes,Creatinine concentration analysis,2020-11-04,COMPLETED,INTERVENTIONAL,['NA'],
3810,NCT01349374,"Nothing will be measured, the aim of the study is the obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines.",,2011-01,TERMINATED,INTERVENTIONAL,['NA'],
3811,NCT01382264,Improved glycemic control as determined by A1C in a population of patients with inadequately controlled type 2 diabetes mellitus.,Satisfaction with treatment and quality of life.,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
3812,NCT02947503,Development of T2D and obesity during Phase C,Secondary outcome measures phase C,2019-11-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
3813,NCT00843609,"Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).",Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
3814,NCT04094194,LDL-cholesterol (randomized and non-randomized controlled trials),Incident Stroke (Prospective Cohort Studies),2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
3815,NCT03118336,epicardial adipose tissue volume,myocardial PCr/ATP ratio,2017-06-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
3816,NCT03080337,Compliance with glucose testing over time,Cost-effectiveness (dollars per hour),2017-03-17,TERMINATED,INTERVENTIONAL,['NA'],
3817,NCT01508806,Area under the Curve (AUC),Adverse events,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3818,NCT04971889,Change from Baseline HbA1c,Change from baseline Systolic Blood Pressure,2021-08-03,RECRUITING,INTERVENTIONAL,['NA'],Change from baseline Situational Obstacles to Dietary Adherence Questionnaire
3819,NCT01947556,T-BG≥10,T-INSAUC50%,2014-03,COMPLETED,INTERVENTIONAL,['NA'],time exogenous glucose requirement
3820,NCT01037647,VLDL-TG production and clearance rates,VLDL-TG subcutaneous adipose tissue storage,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
3821,NCT02750501,Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA),Plasma Composition (%) Ratio of n6/n3 Fatty Acids.,2016-07-20,COMPLETED,INTERVENTIONAL,['NA'],GI Symptoms
3822,NCT03878459,Decrease in HbA1c,insulin dose,2019-08-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
3823,NCT01472159,"Change in glycemic control, assessed by hemoglobin A1c","Change in psychosocial factors (e.g., self-efficacy, fear of hypoglycemia, quality of life, diabetes-specific family conflict, diabetes responsibility sharing, diabetes-specific burden, anxiety, depressive symptoms)",2011-10,COMPLETED,INTERVENTIONAL,['NA'],
3824,NCT06245980,Heart failure readmission,cardiovascular death,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],
3825,NCT05674799,BMI in early pregnancy,Glycemia in early pregnancy,2023-04-08,RECRUITING,INTERVENTIONAL,['NA'],Rate of neonatal hypoglycemia requiring treatment
3826,NCT00393770,Insulin sensitivity,Lipid profile.,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3827,NCT00673296,Interval between the treatment and clearing of premacular hemorrhage,"Snellen best-corrected visual acuity measurements, intraocular pressure, slit-lamp examination and non-contact lens biomicroscopic examination.",2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
3828,NCT01096940,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of simvastatin (including simvastatin acid) and vice versa by assessment of AUC(0-24) and Cmax.,"To evaluate the safety and tolerability of AZD1656 alone and in combination with simvastatin by assessments of adverse events, laboratory variables, electrocardiogram, blood pressure, pulse, results of physical examination, and weight.",2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3829,NCT06061861,6-month change in glycosylated hemoglobin level,Change in self-reported readiness to change,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
3830,NCT01905020,Percentage of time in target range,Number of hypoglycemic events requiring treatment,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3831,NCT03980353,Identification of community integration obstacles for children with type 1 diabetes,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3832,NCT01722266,Change in Mean Weekly Glucose Concentrations,Change in Glucagon Concentrations,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3833,NCT05612698,fasting plasma glucose,body composition (measured by bioimpedance),2023-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3834,NCT01165684,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32,Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes),2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3835,NCT01890993,Change in HbA1c (glycosylated haemoglobin),Change in systolic blood pressure,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
3836,NCT04218734,Change in HbA1c (%) from baseline to week 24,Change in body weight from baseline to week 12 and week 24,2020-01-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3837,NCT00431717,,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
3838,NCT01482481,HbA1c level,Body Mass Index (BMI),2008-01,COMPLETED,OBSERVATIONAL,['NA'],
3839,NCT00918879,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3840,NCT03341117,"Modification in the antioxidant enzymatic system activity (total antioxidant capacity, catalase, glutathione peroxidase , superoxide dismutase) in patients with type 2 diabetes after the administration of acetylsalicylic acid",Modification in fasting glucose in patients with type 2 diabetes after the administration of Acetylsalicylic acid,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3841,NCT02752828,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
3842,NCT04080596,AUClast,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
3843,NCT03025919,area under the ROC curve,sensitivity and specificity of screening,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
3844,NCT04461236,Change in whole-body protein metabolism in type 2 diabetic obese subjects,Changes in quality of life as measured by Short Form (36) Health Survey (SF36) in type 2 diabetics obese subjects,2019-05-30,UNKNOWN,INTERVENTIONAL,['NA'],Group differences in Bi-manual Coordination Task between type 2 diabetics and non-diabetic subjects
3845,NCT00770653,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.,Change From Baseline in Erythrocyte Deformability (60.00).,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3846,NCT04741685,TIR,Hypoglycemia perception 2,2021-02-15,COMPLETED,OBSERVATIONAL,['NA'],
3847,NCT02625649,Number of patients with HbA1c<48 mmol/mol.,Number of patients with two-step change from preoperative level on the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) scale,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
3848,NCT00813085,Comparison of change in diabetes quality of care between intervention and usual care group.,"Change in diabetes risk factor variables, satisfaction with care and technology, quality of life and health care utilization, health data privacy issues.",2002-04,COMPLETED,INTERVENTIONAL,['NA'],
3849,NCT00540462,"Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT.","Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy",2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3850,NCT02488785,Hemoglobin A1c,,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
3851,NCT03168867,Glycemic Control,Household Chaos (Self-reported),2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],
3852,NCT03169959,Maximum observed plasma concentration (Cmax),Laboratory assessments of urinalysis,2017-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3853,NCT03584217,Glomerular filtration rate (GFR),Renal perfusion,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Epigenetic profiling
3854,NCT02632292,In-stent late lumen loss,Anginal status assessed by the Seattle Angina Questionnaire,2016-01,TERMINATED,INTERVENTIONAL,['NA'],
3855,NCT04891159,"Adoption of a shared decision making measured by the total score obtained on the 9 items of the shared decision making questionnaire (SDM-Q-9), translated into French.",,2021-09,UNKNOWN,OBSERVATIONAL,['NA'],
3856,NCT05709444,"To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.",To measure the efficacy of SQ BMT in combination with RAAS inhibition therapy to achieve a <1.0 ml/min/year drop in eGFR after six months,2022-12-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
3857,NCT02161588,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs) recorded,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3858,NCT05716724,Change in glycated haemoglobin (HbA1c),Timing of intake of oral semaglutide as reported in patient diary,2023-01-25,COMPLETED,OBSERVATIONAL,['NA'],
3859,NCT00790530,Completion of dilated eye examination,Completion of microalbumin testing,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
3860,NCT01378117,Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy,Percent of Blood Glucose Readings Within Target Range Between 70 and 140 mg/dL Among the Three Groups After 24 Hrs of Randomized Treatment,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3861,NCT02432924,Change in physical activity level (PAL),QIntervention: Change in cardiovascular disease and type 2 diabetes risk,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
3862,NCT05666479,Accuracy of Real-Time Continuous Glucose Monitoring,Assess Irreversible Damage/Interference of Real-Time Continuous Glucose Monitoring Devices Caused by Electrocautery,2022-09-09,RECRUITING,OBSERVATIONAL,['NA'],
3863,NCT03577184,Change from baseline in Random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin,Number of participants who experienced an Adverse Event,2018-07,WITHDRAWN,OBSERVATIONAL,['NA'],
3864,NCT05965973,"Change in the expression of key genes in hepatic fibrogenesis including transforming growth factor beta 1, a-smooth muscle actin, type-1 collagen, connective tissue growth factor",Identify bacteria strains involved in the control of blood glucose such as C elegans.,2023-06-09,RECRUITING,INTERVENTIONAL,['NA'],
3865,NCT04163055,The rate of CWH of DFUs will be estimated as a proportion and compared between the two groups using a chi square test. The superiority of AF-guided intervention (Arm 2) will be established if the null hypothesis is rejected.,Quality of Life improvement due to the device as assessed Diabetic Foot Ulcer Scale,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3866,NCT05962372,Cardiometabolic Improvement Score (CIS),Change in self-efficacy score,2024-04-16,RECRUITING,INTERVENTIONAL,['NA'],Change in social support score
3867,NCT03774095,Gastrointestinal tolerability,,2018-06-11,UNKNOWN,INTERVENTIONAL,['NA'],
3868,NCT03449654,Change in vascular inflammation,Carotid intima media thickness,2017-10-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Autonomic nervous system function
3869,NCT04701424,Time in the target glucose range (3.9 to 10.0 mmol/l),Total insulin dose,2020-12-16,COMPLETED,INTERVENTIONAL,['NA'],Percentage of time of CGM availability
3870,NCT03760068,Treatment Emergent Antibody Response (TEAR),Change in 7-point Self-monitored Blood Glucose (SMBG) Profile From Baseline,2018-11-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3871,NCT03520972,Change of glycosylated hemoglobin(HbA1c),Self-monitoring of blood glucose (SMBG),2018-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Blood lipid
3872,NCT02350374,"The individual variation of CHO amount at each main meal : Breakfast, Lunch, Snacks, Dinner",,2014-11-17,COMPLETED,INTERVENTIONAL,['NA'],
3873,NCT02779452,Change in neurodevelopment,Change in DHA level in cord blood,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
3874,NCT05110404,fasting lipid profile,,2021-12-25,COMPLETED,INTERVENTIONAL,['NA'],
3875,NCT04924686,NOD2 ligands in fecal and plasma,,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],
3876,NCT00001723,Change in BMI Standard Deviation Score,Effect of Race on Change in Weight (kg),1998-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3877,NCT02675335,mean ulcer size after a treatment period of 12 weeks,,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
3878,NCT02882737,"The primary endpoint is peak plasma glucose achieved within 2 hours after the 200 μg subcutaneous glucagon injection. In the primary analysis, the investigators will compare the peak plasma glucose after exercise and after resting.",The fused data from the two sensors.,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
3879,NCT00608387,Glycosylated hemoglobin (HbgA1c),Overall cost-effectiveness,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
3880,NCT04731272,Early-phase insulin secretion,Glucose tolerance,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
3881,NCT01512849,Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284,Clinical Laboratory Tests,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3882,NCT01524874,Change in mean serum 25-hydroxycholecalciferol concentration,Change in mean cardiometabolic risk factors,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
3883,NCT01485614,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),Participants With Worsening in Dental Status at Week 54,2012-02-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3884,NCT01883258,Change in vascular endothelial function,Change in maximal oxygen consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
3885,NCT00592670,Catecholamine measures,,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
3886,NCT03267264,Overall User Preference -Combined Groups,User Experience - Each Individual Study Group,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
3887,NCT03439345,Progression to referable diabetic retinopathy/maculopathy,Cost-effectiveness (incremental cost per QALY gained),2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4'],Minor and major non-traumatic lower limb amputation (minor [defined as distal to the ankle] or major [defined as through or proximal to the ankle])
3888,NCT02722239,Adverse Events,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
3889,NCT02906319,HbA1c levels,,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
3890,NCT00607867,Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline,Change in Fasting Triglycerides at 5 Weeks From Baseline,2008-04,TERMINATED,INTERVENTIONAL,['NA'],
3891,NCT01867216,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve (AUEC₀-₁₂) During Mixed Meal Tolerance Test at Day 28,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3892,NCT03681249,24H urine total protein,,2018-11-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3893,NCT04503551,Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52,Reported incidence of device deficiencies,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3894,NCT06082063,MACE + HHF,"Diabetic ketoacidosis, safety",2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Long term risk of DKA
3895,NCT05221359,Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the whole duration of the study (extension phase included),Quality of Life: Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire,2022-05-05,RECRUITING,INTERVENTIONAL,['NA'],
3896,NCT00035984,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3897,NCT02500485,The number of volunteers with adverse events as a measure of safety and tolerability.,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3898,NCT05915975,Change in Glycemic Control,Change in Diabetes Self-Management,2023-11-07,RECRUITING,INTERVENTIONAL,['NA'],
3899,NCT03734718,Blood glucose,Number of symptomatic hypoglycemic events,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],
3900,NCT05936203,Insulin doses delivered,,2023-01-11,COMPLETED,INTERVENTIONAL,['NA'],
3901,NCT03468283,hemoglobin A1c levels,the Problem Areas in Diabetes,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],
3902,NCT05104437,Neutralizing antibody level,Adverse events following vaccination,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3903,NCT00676741,Metabolic control measured as HbA1c,Number of adverse drug reactions (ADR),2008-02,COMPLETED,OBSERVATIONAL,['NA'],
3904,NCT05309057,Body weight,Markers of inflammation - CRP,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3905,NCT02298192,Change From Baseline in HbA1c,Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
3906,NCT05093569,to determine the accuracy of K'Watch Release 0.x CGM system glucose readings at day 1 as compared to standard references.,Safety of the K'Watch system characterizing device-related pain intensity (Visual Analogue Scale scores from 0-10) recorded during the study.,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA'],
3907,NCT02501746,Change in Systolic Blood Pressure,Change in cardiovascular disease (CVD) risk Score,2017-02-06,COMPLETED,INTERVENTIONAL,['NA'],
3908,NCT03150199,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],Change in Hemoglobin A1c
3909,NCT04667143,Mean change from baseline in HbA1c at Week 24,,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3910,NCT00138606,Change from baseline in HbA1c at 52 weeks,Change from baseline in mean daily number of insulin injections at 52 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3911,NCT01864174,"Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation",Percent of Participants With HbA1c < 7%,2013-06-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
3912,NCT05630417,Blood Parameters Follow-up Form,Blood Parameters Follow-up Form,2022-03-15,COMPLETED,INTERVENTIONAL,['NA'],
3913,NCT03761615,Percentage of Time in Range Glucose Levels 63-140 mg/dL as Determined by CGM,Carbohydrate Consumption Over Last 2 Weeks of Third Trimester,2018-11-13,COMPLETED,OBSERVATIONAL,['NA'],Cesarean Delivery
3914,NCT03928379,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline in Fasting Plasma Insulin,2019-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
3915,NCT03958591,the proportions of treatment simplification,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3916,NCT00974272,Triglyceride concentration in serum,"serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function",2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3917,NCT05396378,Increase of blood glucose following the oral glucose dose,Maternal subjective well being after oral glucose dose during the preoperative fasting period,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3918,NCT01154413,Reduction in hypo/hyperglycemia episodes,"Lower mean glycemia, reduced time of stay in hospital",2007-12,COMPLETED,INTERVENTIONAL,['NA'],
3919,NCT00191178,Instruments used/tests performed:hand held computers to rate a series of 13 symptoms;hand held computers to administer a series of cognitive-motor performance tests;blood glucose testing,"blood glucose rate of change;eight-point self-monitored blood glucose profile;episodes of hypoglycemia, including episodes of severe hypoglycemia",2003-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3920,NCT06318611,Chronotype,Glycemic control,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],
3921,NCT02430870,Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 2,AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 2,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3922,NCT00343343,Deposition of sterile air depositions.,Amount of backflow,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3923,NCT00315952,"To perform positron emission tomography (PET) imaging of [18F]-fluoro-deoxy-glucose (FDG) uptake by muscle, following administration of a single dose of inhaled compared to infused insulin in volunteers with type 1 diabetes",To determine overnight rates of glucose production and plasma glucose after a single pre-dinner dose of inhaled compared to IV infused insulin in volunteers with type 1 diabetes,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3924,NCT02749435,Mean Change from baseline to Month 6 in HbA1c,Proportion of patients in both cohorts who intensify antihyperglycaemic treatment from Visit 1,2016-05-03,TERMINATED,OBSERVATIONAL,['NA'],Change from baseline to Month 6 in Morisky 8-item scale (adherence)
3925,NCT01486888,Maximum serum insulin concentration (Cmax),Adverse events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3926,NCT04001283,Metabolic protein expression in cardiac biopsies and vascular offcuts,,2013-01-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3927,NCT02079805,Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12),Number of Participants With Treatment-Emergent Adverse Events,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3928,NCT03766854,"AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state","GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state",2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3929,NCT03549845,Healthcare Utilization Composite - Change in CVD-related emergency department visits and hospitalizations,Participant experience of the CHAP intervention,2018-09-17,COMPLETED,INTERVENTIONAL,['NA'],Cardiovascular Risk - Change in diabetes risk score
3930,NCT01096277,Endothelial function,Effect on EPCs,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3931,NCT04215328,Weight change between groups,Changes in gut hormone levels,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3932,NCT03249077,Weight,HbA1c (24-month for digital DPP),2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],Motivation for continuing
3933,NCT02084654,First-phase insulin response,glucose lowering effect,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],insulin-mediated glucose uptake (insulin sensitivity)
3934,NCT01304836,Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation,Change from Baseline in HbA1C levels,2011-01-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
3935,NCT03740074,App utility,Personal Activity Intelligence (PAI) Score,2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
3936,NCT03318601,Correlation between copetine and other biomarkers,Copetine concentrations,2016-05-09,UNKNOWN,INTERVENTIONAL,['NA'],
3937,NCT04186195,Children's type 1 diabetes glycemic control,Parent's type 1 diabetes glycemic status,2020-11-03,COMPLETED,OBSERVATIONAL,['NA'],
3938,NCT03064347,Difference in AUC of GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,Difference in Peak GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,2017-02-22,COMPLETED,INTERVENTIONAL,['NA'],
3939,NCT03774511,Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),Visceral adipose fat,2017-07-09,COMPLETED,INTERVENTIONAL,['NA'],
3940,NCT03817749,Glucose control,Change from baseline caspase-1 activation at 14 days,2019-02-06,COMPLETED,INTERVENTIONAL,['NA'],
3941,NCT03977727,1-Hour Change in Postprandial Plasma Glucose (PPG),Pump Occlusions,2019-06-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3942,NCT06336486,Visual Analog Scale(VAS),36-Item Short Form Health Survey(SF-36),2018-12-04,COMPLETED,INTERVENTIONAL,['NA'],
3943,NCT06146322,Food intake,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3944,NCT02634333,Change in Visual Acuity From Baseline,Development of PDR and/or DME (Whichever Came First),2016-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3945,NCT01588418,Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism,Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3946,NCT02123563,plaque and gingival indices,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3947,NCT01429818,%ΔMBF,Adverse effects,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3948,NCT04499820,density of the deep capillary plexus in optical coherence tomography angiography (OCTA),Diet questionnaire,2020-06-26,RECRUITING,INTERVENTIONAL,['NA'],
3949,NCT03594344,Intact skin with no abnormal openings at the site of primary amputation,The Foot and Ankle Ability Measure (FAAM),2018-07-04,RECRUITING,INTERVENTIONAL,['NA'],
3950,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 36,Number of Participants Having an 'Other' Adverse Event,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3951,NCT00006165,,,na,COMPLETED,INTERVENTIONAL,['NA'],
3952,NCT04878393,Number of adverse event (AEs),Number of serious adverse reactions (SARs),2021-04-30,COMPLETED,OBSERVATIONAL,['NA'],
3953,NCT06121856,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood,,2023-02-07,COMPLETED,OBSERVATIONAL,['NA'],
3954,NCT06160063,Evaluation of Literacy Scale for Acute Complications of Diabetesfor Children with Type 1 Diabetes (8-12 years),,2023-01-16,COMPLETED,INTERVENTIONAL,['NA'],
3955,NCT05773495,Change in Diabetic Screening Rate,Follow Up Rate For In-Person Eye Care Among Screen Positives,2024-03-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
3956,NCT03010475,Area under the rosuvastatin plasma concentration-time curve,Maximum observed rosuvastatin plasma concentration,2017-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3957,NCT01825148,pancreatic uptake of radiolabeled Exendin,,2012-12,COMPLETED,OBSERVATIONAL,['NA'],
3958,NCT02230488,Prevent <31 day readmission,improve overall glycemic management,2014-09,TERMINATED,INTERVENTIONAL,['NA'],Patient satisfaction
3959,NCT02250222,Number of participants with one or more drug related adverse events or serious adverse events,PK profile (maximum concentration (Cmax) of LGD-6972 after repeat oral doses in NHS and in subjects with T2DM,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Change from baseline in fasting plasma active and total GLP-1 measured during an OGTT on Day 14 of treatment with LGD-6972 at 0.5, 1, 1.5, 2, 3, and 4 hours post-glucose load in one dose group of subjects with T2DM"
3960,NCT05035082,Change in Glycosylated hemoglobin A1c (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score",2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
3961,NCT03914326,"Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke",Time to first occurrence of a severe hypoglycaemic episode,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3962,NCT00544934,glycated albumimin concentration,urine albumin,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3963,NCT01223560,,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
3964,NCT04618406,Change in the number of wound complications,Number of participants requiring re-amputation,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3965,NCT04346524,Maternal complications during pregnancy,Fetal complications during pregnancy,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
3966,NCT00892151,Number of Participants Rated Successful (<=3) at Performing Specific Tasks,Number of Participants Who Rated Clarity and Usefulness of User Instructions as >=3,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
3967,NCT03490136,Prevalence of type 2 diabetes,Changes in dietary habits,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
3968,NCT02174562,"Percent of Participants With Improvement in Hemoglobin A1c by 0.5%""",Adherence as Measured By Percentage of Doses Taken as Prescribed,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
3969,NCT00870454,Mean of the last 7 daily average diabetic peripheral neuropathy (DPN) pain scores,The mean of the last 7 Daily Sleep Interference scores.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3970,NCT03811470,All cancers,Cost-effectiveness,2017-05-31,RECRUITING,OBSERVATIONAL,['NA'],
3971,NCT01685502,Decrease rate of HbA1c,Body weight,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
3972,NCT01805245,Diabetes Distress,Mean Night Diastolic Ambulatory Blood Pressure,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Mindfulness
3973,NCT04190160,The Diabetes Treatment Satisfaction (DTSQ),Cognitive function (MMSE),2018-11-19,COMPLETED,INTERVENTIONAL,['NA'],
3974,NCT05247437,Changes in weight from baseline (week 0) to posttreatment (week 9),Changes in the scores on the Weight loss self-efficacy scale,2022-02-19,UNKNOWN,INTERVENTIONAL,['NA'],
3975,NCT03091686,Participants' intentions to reduce occupational sitting time,Participants confidence to reduce occupational sitting time,2017-08-17,COMPLETED,INTERVENTIONAL,['NA'],
3976,NCT01910727,Change in percent of total calories from fat from baseline through 12 months follow-up,Increased numbers of individuals having been screen for diabetes between baseline and 12 months follow-up,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
3977,NCT02744963,Appropriate medicine adherence,Healthcare costs including medication costs,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],Count of healthcare encounters
3978,NCT05015894,"AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose","Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose",2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
3979,NCT00700622,Change From Baseline in HbA1c to Week 16,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
3980,NCT02291874,Fasting plasma glucose,"Adverse events (AEs), vital signs, and laboratory tests",2014-10-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3981,NCT02856113,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in CD26 (CD8+T Cells) Surface Antigen Levels at Weeks 26 and 52,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3982,NCT00931372,Area under the insulin secretion curve,Area under the insulin secretion curve,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3983,NCT05544266,"Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods",,2020-09-30,RECRUITING,OBSERVATIONAL,['NA'],
3984,NCT01413035,To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3985,NCT04234373,Effect of a low-carb dietary intervention on glycemic control as defined by blood glucose level at 2h after an oral glucose tolerance test.,Effect of a low-carb dietary intervention on liver fat fraction as measured with MRI,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],
3986,NCT01163591,"The optimal eZscan unit to detect the presence of diabetic nephropathy as defined by eGFR and ACR using ROC analysis, sensitivity and specificity values.","A prediction algorithm using age, sex, body mass index and eZcan score will be developed to predict eGFR as continuous and categorical variables using Cox regression analysis.",2009-01,COMPLETED,OBSERVATIONAL,['NA'],
3987,NCT03119142,Adherence to the Mediterranean diet,Inflammation,2017-05-02,COMPLETED,OBSERVATIONAL,['NA'],
3988,NCT01121276,Area under the blood glucose concentration-time curve,Area under the blood glucose concentration-time curve,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3989,NCT00095446,Treatment satisfaction with insulin pump therapy,infusion set in-use times,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3990,NCT03922022,Rate of recruitment,EQ-5D-5L,2019-05-21,COMPLETED,INTERVENTIONAL,['NA'],
3991,NCT05392959,the longitudinal change of the Index of Microvascular Resistance (IMR).,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],
3992,NCT02065349,"Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)","Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6",2014-02-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
3993,NCT01566006,proteinuria,,2012-04,UNKNOWN,INTERVENTIONAL,['NA'],
3994,NCT00349362,The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin.,The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone.,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3995,NCT03448367,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,2018-02-27,TERMINATED,OBSERVATIONAL,['NA'],
3996,NCT02506972,Incremental area under the blood glucose response curve,Time to baseline,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
3997,NCT06327191,"To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.",,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3998,NCT04240652,Diabetic macular edema,Albumin-creatinine-ratio (mg/mmol),2018-06-05,RECRUITING,OBSERVATIONAL,['NA'],
3999,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2,Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Findings (Last Observation Carried Forward {LOCF]),2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4000,NCT05949281,Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L),Safety-related events,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction
4001,NCT00118976,albuminuria,Tertiary: differences in response to treatment in patients with different ACE/ID and other renin angiotensin system genotypes.,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
4002,NCT04277598,Wound area reduction after 4 weeks treatment with APO-2,Evaluation of Quality of Life: questionnaire,2020-10-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4003,NCT00609986,Acute/Active Rejection,Severe Hyperglycemia,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
4004,NCT01456650,Change in plasma fasting glucose,HbA1c levels,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
4005,NCT00554671,Hemoglobin A1c,Health-care Costs to the VHA,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
4006,NCT02747277,Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers,,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
4007,NCT03740698,% Time in Target Range Defined as 3.9-10mmol/l,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA'],
4008,NCT02162212,Arm elevation.,"Disability of the Arm, Shoulder, and Hand (DASH) questionnaire",2014-09,COMPLETED,INTERVENTIONAL,['NA'],
4009,NCT05067270,"Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas",,2021-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
4010,NCT04753099,parental competence with managing child's care,,2020-10-09,COMPLETED,INTERVENTIONAL,['NA'],
4011,NCT00484419,Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint,Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean),2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4012,NCT05427084,TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta,Change in monocyte marker expression,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4013,NCT03766334,Average blood glucose fluctuations at endpoint and baseline,Waist circumference(endpoint)-Waist circumference(baseline),2018-12-05,WITHDRAWN,INTERVENTIONAL,['NA'],
4014,NCT05386927,Urine metabolomics,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
4015,NCT05597709,Analysis of risk factors for clinical outcomes in patients with T2DM,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
4016,NCT02701569,Glycated hemoglobin,Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Depressive symptoms as measured by the Beck's Depression Inventory
4017,NCT05231174,AUROC of the self-evaluation tool,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
4018,NCT00231023,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
4019,NCT02756117,Change in plasma 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),Change in urinary 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
4020,NCT01145599,"Identify ""progressors""","Identify correlations between ""progressors"" and study outcomes.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
4021,NCT02131272,Change in HbA1c (Glycosylated Haemoglobin),Incidence of Adverse Events (AEs),2014-06-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
4022,NCT04430608,Time In Range (TIR) for blood glucose,Course of hospital stay.,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],
4023,NCT03661684,AUC for glucose during OGTT,AUC for Insulin during OGTT,2016-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4024,NCT00933881,Improvement in heart rate control post-GDM,Improvement in SDB post-GDM,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
4025,NCT01051089,"HbA1c, serum adipokine levels",VO2max,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
4026,NCT04613700,Duration of ad libitum meal,Gallbladder motility,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],
4027,NCT00477204,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4028,NCT01525238,Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin,Number of Participants With Marked Urinalysis Abnormalities,2012-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4029,NCT02063321,Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema,Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy),2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
4030,NCT00703989,prostacyclin synthase activity,,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
4031,NCT04642534,Correlation of in vitro circadian parameters (amplitude and magnitude) with clinical metabolic health outcomes (body weight),"Glucose excursion (time-in-range, coefficient of variation)",2020-02-12,COMPLETED,OBSERVATIONAL,['NA'],Metabolomic parameters of energy metabolism
4032,NCT01708096,Insulin sensitivity,Weight reduction,2009-10,COMPLETED,INTERVENTIONAL,['NA'],Insulin signaling and glucose transport in skeletal muscle
4033,NCT04758364,gait speed,,2021-02-20,COMPLETED,OBSERVATIONAL,['NA'],
4034,NCT00934414,To compare the relative bioavailability and bioeffect of TI Inhalation Powder in subjects with type 2 diabetes who smoke and who do not smoke to determine relative insulin bioavailability,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
4035,NCT00042471,Effect of varying needle length on bioavailability of Pramlintide,Effect of varying needle length on safety and tolerability of Pramlintide,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4036,NCT05619198,Percentage of time spent in sensor-derived time in range (3.9-10.0 mmol/L) during and after a bout of exercise,Physical activity level assessed by Actigraph GT3x,2022-12-19,RECRUITING,INTERVENTIONAL,['NA'],
4037,NCT04460885,Change in HbA1c,"Time spent > 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6",2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
4038,NCT05297110,rate of fasting glycemia level reduction,rate of adverse effects,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4039,NCT01257464,Insulin release,Incretin Response,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
4040,NCT01365507,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4041,NCT01185496,,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
4042,NCT06192940,Insulin Injection,Acute Diabetes Events,2024-03-28,RECRUITING,OBSERVATIONAL,['NA'],
4043,NCT02420392,Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion,Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
4044,NCT01653899,To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant,2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4045,NCT01677104,skin blood flow,,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
4046,NCT03890991,Diabetes self-care activities measured using the Revised Summary of Diabetes Self-care Activities,Proportion of participants who adhere to yearly eye and foot screening,2019-02-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4047,NCT01669473,Medication adherence,"Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol.",2013-06,COMPLETED,INTERVENTIONAL,['NA'],
4048,NCT01934608,Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure,"Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.",2013-09,COMPLETED,INTERVENTIONAL,['NA'],
4049,NCT03027934,Aggregation Response,Reticulated Platelet Reactivity Index (PRI),2017-08-28,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4050,NCT04322240,measurement of Compound Muscle Action Potential (CMAP) distal latency,,2020-04-02,COMPLETED,INTERVENTIONAL,['NA'],
4051,NCT05822349,change in anxiety level,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],
4052,NCT06224803,Concentration of HbA1c,Concentration of Blood Sugar,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],
4053,NCT00536965,HbA1c profile,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
4054,NCT02913703,Effect of preprandial ghrelin on glucose tolerance,Effect of preprandial ghrelin on insulin sensitivity (as measured by Matsuda index),2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4055,NCT04776239,Post-PCI coronary artery endothelial function as assessed via FFR,Number of participants with Target Vessel Failure,2021-08-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4056,NCT04035044,Analytical verification of Allegro - Urine Albumin comparison,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
4057,NCT00006068,,,na,UNKNOWN,INTERVENTIONAL,['NA'],
4058,NCT01840982,"1. Glycemic index(GI) 2. Glucose, insulin AUC(incremental area under the curve) 3. C-peptide","Homeostatic model assessment-insulin resistance(HOMA-IR), quantitative insulin sensitivity check index(QUICKI), Insulinogenic index(IGI)",2010-10,COMPLETED,INTERVENTIONAL,['NA'],
4059,NCT04495972,Insulin sensitivity,Level of 2-hour blood glucose Area Under the Curve (AUC),2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
4060,NCT06057454,Measurement of adverse events from the date of the first dose through 12 weeks of R-5280 tolerance,Measurement of clinical activity and to determine the gut microbiome profile in youth with recently diagnosed Type 1 Diabetes,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
4061,NCT04267367,Change in HbA1c level,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],
4062,NCT00854984,The obstacles to providing access and support to a generic online self help computerised cognitive behavioural therapy (CBT) programme for such patients.,"A change in depression (BDI-2), anxiety , social function (WASAS), quality of life (Euroqol 5D) or illness perception (IPQ-R) from participation in a self help programme.",2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
4063,NCT02192450,Symptomatic nocturnal hypoglycaemia,Quality of life incl. pre-depression scale,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4064,NCT00447382,Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies,Adverse Events,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4065,NCT04565418,Change in 24 rhythm in whole-body energy metabolism (fat oxidation),Change in 24h rhythm in serum cholesterol,2021-01-26,COMPLETED,INTERVENTIONAL,['NA'],
4066,NCT00857376,This study will provide information on the effect of a dose range of ALA on oxidative stress biomarkers.,To determine whether ALA improves vascular function through its effects on oxidative stress,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
4067,NCT04761016,Blood pressure,Medication use,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4068,NCT06119737,Thyroid Stimulating Hormone,,2021-05-02,COMPLETED,INTERVENTIONAL,['NA'],
4069,NCT00823953,serum fructosamine at end of trial phase in each of the groups,"Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase",2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
4070,NCT01941290,Target Lesion Failure (TLF),Clinical Procedure Success,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
4071,NCT00522158,,,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
4072,NCT00121641,A1C Changes From Baseline at Week 24 - Open Label Cohort,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Changes From Baseline in Heart Rate During the ST + LT Period - Open Label Cohort
4073,NCT04420507,the gut and oral microbiome of healthy pregnant women,The glucose level during pregnancy,2017-05-15,COMPLETED,OBSERVATIONAL,['NA'],
4074,NCT03354806,Foot tissue oxygenation on day 2,Foot tissue oxygenation in hyperaemia-induced condition on day 2,2018-06,WITHDRAWN,INTERVENTIONAL,['NA'],
4075,NCT05960565,Area under the glucose curve,Pharmacokinetics of glucagon,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
4076,NCT03999385,Change in diabetes self-management,Change in Eating Disorder Symptomatology,2019-06-24,UNKNOWN,INTERVENTIONAL,['NA'],
4077,NCT02178787,To Compare Profiles of TCD-blood Flow Velocities (TCD_BFV).,To Compare Profiles of UTlight Blood Flow (UT_BF) and Regional Oximetry (UT_Ox).,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
4078,NCT04109235,Change in HbA1C,Physical Activity (minutes per week),2020-02-13,RECRUITING,INTERVENTIONAL,['NA'],
4079,NCT04653961,Sensor glucose percentage of time in hyperglycemia above 250 mg/dl,Number of Serious Adverse Events,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],The amount of bolus insulin dose
4080,NCT04073524,Level of quality of life - total score,Level of self perceived stress,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
4081,NCT01963663,Serum concentration of YKL-40,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
4082,NCT03319784,Change in blood glucose level,American Shoulder and Elbow Surgeon (ASES) Shoulder Score,2018-09-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4083,NCT04269070,Change in 2-hour postprandial area-under-the-curve blood glucose at 2 weeks,Change in baseline workplace stepping time at 2 weeks,2021-03-25,COMPLETED,INTERVENTIONAL,['NA'],Change in central aortic diastolic and systolic blood pressure at 2 weeks
4084,NCT00891943,"Changes in weight, waist circumference and percent body fat at 12 months.","BMI, blood pressure, resting heart rate; obesity and weight related quality of life, Rosenberg measure of self-esteem changes at 12 months.",2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
4085,NCT04230382,OGTT,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA'],S-Magnesium
4086,NCT05864183,comparison between the measurement of HbA1c in normal non prediabetics and prediabetics at Sohag university hospital .,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA'],
4087,NCT01520831,Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes,"t½, terminal half-life",1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
4088,NCT01464437,To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin,Adverse events,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
4089,NCT01607294,assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes,"assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
4090,NCT00445003,Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks,Change in Optical Coherence Tomography Retinal Volume,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4091,NCT04484779,Total and Domain Specific Score of the mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients,Likelihood of Site to Recommend the IIM System,2020-07-14,COMPLETED,INTERVENTIONAL,['NA'],
4092,NCT05620927,Impaired awareness of hypoglycemia (IAH) - Clarke's Questionnaire,occurrence of cognitive impairment,2022-11-24,RECRUITING,OBSERVATIONAL,['NA'],
4093,NCT04181424,Glycemic control (HbA1c),Blood Pressure,2019-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4094,NCT03499704,Mean Change from Baseline in HbA1c at Week 26,Number of Participants who Achieved an HbA1c Goal Target of Less than (<) 6.5 Percent (%) at Week 26,2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
4095,NCT00276939,Hemoglobin A1c,Dietary Acceptability,2003-09,COMPLETED,INTERVENTIONAL,['NA'],
4096,NCT05845242,"Correlation of the above features with the chance of developing ulcers (Risk 0, Risk 1, Risk 2 and Risk 3).","Assessing the practical needs for transferring measurements to a different environment (e.g., home) by interviewing the clinicians involved in the consortium.",2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
4097,NCT04308291,Time in range (TIR),Glycemic parameters changes,2021-02-15,COMPLETED,OBSERVATIONAL,['NA'],
4098,NCT03437044,P2Y12 Reaction Units (PRU),Platelet Reactivity Index (PRI),2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
4099,NCT03266952,Incidence of Stroke,Scoring cognitive impairment,1993-01,COMPLETED,OBSERVATIONAL,['NA'],Incidence of diabetes
4100,NCT00771004,Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.,Time course of Adiponectin Laboratory Procedure.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
4101,NCT00369148,glycohemoglobin,blood pressure,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
4102,NCT04515758,Participant and Instructor Age,Change in Exercise-related Self-Efficacy,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4103,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Health status and quality of life
4104,NCT05031871,AUC0-inf：Area under the curve from time 0 to infinity；,ADA：anti-drug antibody,2021-09-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4105,NCT04470635,Vascular endothelial growth factor level,Thiol/disulphide measurement,2020-07-25,COMPLETED,OBSERVATIONAL,['NA'],
4106,NCT04495114,Preoperative glucose,,2017-08-31,COMPLETED,INTERVENTIONAL,['NA'],
4107,NCT05165693,Glucose positive area under the curve (AUC),Insulin Concentrations,2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],Sensory Questionnaire
4108,NCT01361594,Hospital Mortality,Cerebrovascular Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4109,NCT00435786,,,na,COMPLETED,OBSERVATIONAL,['NA'],
4110,NCT01383304,"Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke",Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death,2007-11,UNKNOWN,OBSERVATIONAL,['NA'],Genotype according to pre-specified genetic single nucleotide polymorphisms (SNPs)
4111,NCT00516958,"To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers",To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4112,NCT05452525,AUClast,,2022-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
4113,NCT05147883,Score of Quality of Life,Depression,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
4114,NCT04234867,time to development of DKA,time to decrease of ph level,2022-05-18,TERMINATED,INTERVENTIONAL,['PHASE1'],
4115,NCT03923114,Pituitary uptake of Ga-68-NODAGA-exendin,Metabolic status (ACTH),2019-05-23,UNKNOWN,INTERVENTIONAL,['NA'],
4116,NCT04948931,Spielberger State-Trait Anxiety Scale (STAI),,2021-07-28,COMPLETED,INTERVENTIONAL,['NA'],
